TTD - Therapeutic Targets Database Full Data Download File Title - Drug to disease mapping with ICD identifiers Version 8.1.01 (2021.11.08) Provided by IDRB Lab of Innovative Drug Reasearch and Bioinformatics College of Pharmaceutical Sciences Zhejiang University https://idrblab.org/ Provided by BIDD BioInformatic and Drug Design Group Department of Pharmacy National Unviersity of Singapore http://bidd.nus.edu.sg/ Any question about data provided here, please contact with: Dr. Zhou (zhou_ying@zju.edu.cn) and Dr. Zhang (zhangyintao@zju.edu.cn) -------------------------------------------------------------------------------------------------------- Abbreviations: TTDDRUID TTD Drug ID DRUGNAME Drug Name INDICATI Indication Disease entry ICD-11 Clinical status -------------------------------------------------------------------------------------------------------- TTDDRUID D00ABE DRUGNAME ALD-301 INDICATI Ischemia [ICD-11: 8B10-8B11] Phase 2 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 2 TTDDRUID D00ABO DRUGNAME KW-2449 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D00ABW DRUGNAME Opterone INDICATI Hormone deficiency [ICD-11: 5A61.1] Discontinued in Phase 1 TTDDRUID D00ACC DRUGNAME ND1251 INDICATI Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1 TTDDRUID D00ACH DRUGNAME HMR-4004 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D00ACP DRUGNAME Anti-HER-2 mab-FcgR2- FcgR4 fusion proteins INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00ADV DRUGNAME THF carbapenems INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Terminated TTDDRUID D00AEQ DRUGNAME Hydroxyprogesterone INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D00AES DRUGNAME Dicopp INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D00AEV DRUGNAME Oxothiazolidine carboxylate INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D00AHT DRUGNAME PRAME antigen-specific cancer immunotherapeutic INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Metastatic melanoma [ICD-11: 2E2Z] Phase 1 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D00AHV DRUGNAME SKL-PD INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D00AIS DRUGNAME AP-11014 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00AIZ DRUGNAME SND-159 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D00AJI DRUGNAME PF-4480682 INDICATI Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 2 TTDDRUID D00AJS DRUGNAME AIK11 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D00AKL DRUGNAME Immunose FLU INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D00AKQ DRUGNAME O-desulfated heparin INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D00AKR DRUGNAME AMG 479 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D00AKV DRUGNAME F-351 INDICATI Liver disease [ICD-11: DB90-BD99] Phase 2 TTDDRUID D00AKY DRUGNAME SK&F-S-106203 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D00ALE DRUGNAME H1N1 pandemic influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D00ALJ DRUGNAME Placental expanded stem cell therapy INDICATI Peripheral vascular disease [ICD-11: BD4Z] Phase 2 TTDDRUID D00AMQ DRUGNAME Ethanol INDICATI Cystitis [ICD-11: GC00] Approved INDICATI Chronic pain [ICD-11: MG30] Approved TTDDRUID D00ANG DRUGNAME Erythropoietin-transfected autologous cell therapy INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 1/2 TTDDRUID D00AOJ DRUGNAME Docosanol INDICATI Herpes simplex virus infection [ICD-11: 1F00] Approved TTDDRUID D00AQP DRUGNAME Ribavirin + interferon alfa-2a INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D00AQV DRUGNAME COTI-4A INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Investigative TTDDRUID D00AQY DRUGNAME IDDB-41331 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D00ARN DRUGNAME Tyloxapol INDICATI Cystic fibrosis [ICD-11: CA25] Terminated TTDDRUID D00ARS DRUGNAME MER-3001 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D00ASJ DRUGNAME Typherix INDICATI Salmonella infection [ICD-11: 1A09] Approved TTDDRUID D00ASX DRUGNAME PJ-015 INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D00AUC DRUGNAME (99M)-TC-CPI INDICATI Diagnostic imaging [ICD-11: N.A.] Phase 2 TTDDRUID D00AUM DRUGNAME AQU-010 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D00AUX DRUGNAME MSDC-0602 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D00AUZ DRUGNAME Thiolated chitosan nanoparticle theophylline INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D00AVG DRUGNAME GX-110E INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D00AVH DRUGNAME VEN100 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D00AWA DRUGNAME WIN-63759 INDICATI Emphysema [ICD-11: CA21] Terminated TTDDRUID D00AWT DRUGNAME Propericiazine INDICATI Psychiatric disorder [ICD-11: 6E8Z] Approved TTDDRUID D00AXG DRUGNAME SMT-14224 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D00AXJ DRUGNAME Miconazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D00AXT DRUGNAME MDC-922 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00AXZ DRUGNAME CAP-22 INDICATI Diabetic angiopathy [ICD-11: BD53.Y] Investigative TTDDRUID D00AYA DRUGNAME BMS-188797 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D00AYW DRUGNAME HMS5552 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D00BBB DRUGNAME MetPril INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D00BCG DRUGNAME Goserelin INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D00BCP DRUGNAME Chlorpropamide INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Approved TTDDRUID D00BCS DRUGNAME INT-0015/2008 INDICATI Panic disorder [ICD-11: 6B01] Investigative TTDDRUID D00BCZ DRUGNAME XGP-610 INDICATI Reperfusion injury [ICD-11: ND56.Z] Investigative TTDDRUID D00BDC DRUGNAME Morniflumate INDICATI Otitis media [ICD-11: AA80-AB0Z] Approved TTDDRUID D00BHL DRUGNAME EC20 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 TTDDRUID D00BIY DRUGNAME CGP-48369 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D00BJV DRUGNAME BMS-986207 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D00BKV DRUGNAME SB 418790 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D00BLL DRUGNAME Fesoterodine fumarate INDICATI Overactive bladder [ICD-11: GC50.0] Approved TTDDRUID D00BLS DRUGNAME AZD0284 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 1 TTDDRUID D00BMF DRUGNAME MK-4827 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Ewing sarcoma [ICD-11: 2B52] Phase 1 TTDDRUID D00BMM DRUGNAME Dismutase mimetics INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00BND DRUGNAME BF-1 INDICATI Cluster headache [ICD-11: 8A81.0] Phase 1 INDICATI Migraine [ICD-11: 8A80] Phase 1 TTDDRUID D00BOY DRUGNAME CP-18770 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D00BPE DRUGNAME AVE-1642 INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D00BPH DRUGNAME COVA322 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1/2a TTDDRUID D00BTW DRUGNAME UC-781 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D00BTZ DRUGNAME CT-003230 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D00BUO DRUGNAME MM-141 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D00BUR DRUGNAME ICA-17043 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Constitutional neutropenia [ICD-11: 4B00.0] Discontinued in Phase 2 TTDDRUID D00BVB DRUGNAME Men Quad TT INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 3 TTDDRUID D00BVF DRUGNAME IP-889 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 3 TTDDRUID D00BVJ DRUGNAME NHS-IL 12 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00BVS DRUGNAME Tanezumab INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 3 INDICATI Chronic low back pain [ICD-11: MG30.02] Phase 3 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 3 INDICATI Cancer related pain [ICD-11: MG30] Phase 3 TTDDRUID D00BWF DRUGNAME AGN-XX/YY INDICATI Fibromyalgia [ICD-11: MG30.01] Phase 2 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID D00BXK DRUGNAME Pyrazole derivative 39 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D00BXZ DRUGNAME M-402 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00BYM DRUGNAME Volasertib INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 TTDDRUID D00BZJ DRUGNAME Trumenba INDICATI Meningitis [ICD-11: 1D01] Approved TTDDRUID D00BZO DRUGNAME HL-035 INDICATI Syndrome X [ICD-11: 5C53.4] Investigative TTDDRUID D00BZS DRUGNAME Gimatecan INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D00BZZ DRUGNAME PF-4603629 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D00CBP DRUGNAME DTPw-HBV/Hib INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3 TTDDRUID D00CBY DRUGNAME CEL-021 INDICATI Interstitial cystitis [ICD-11: GC00.3] Investigative TTDDRUID D00CCI DRUGNAME Benoxaprofen INDICATI Inflammation [ICD-11: 1A00-CA43.1] Withdrawn from market TTDDRUID D00CED DRUGNAME HG-1097 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00CEE DRUGNAME Tetraxim INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D00CEG DRUGNAME D-43787 INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D00CEI DRUGNAME CM-2501 INDICATI Poison intoxication [ICD-11: NE6Z] Preclinical TTDDRUID D00CFB DRUGNAME Zeniplatin INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 2 TTDDRUID D00CFU DRUGNAME RO-4840700 INDICATI Schizophrenia [ICD-11: 6A20] Investigative TTDDRUID D00CGH DRUGNAME RO-23-7553 INDICATI Prostate disease [ICD-11: GA91] Phase 1 TTDDRUID D00CGU DRUGNAME IMS INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1 TTDDRUID D00CGX DRUGNAME DV-1179 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Phase 1 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Discontinued in Phase 1 TTDDRUID D00CIF DRUGNAME EMD-503982 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D00CIT DRUGNAME Regavirumab INDICATI Cytomegalovirus infection [ICD-11: 1D82] Discontinued in Preregistration TTDDRUID D00CLC DRUGNAME SLV-338 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D00CLM DRUGNAME NIP-004 INDICATI Thrombocytopenia [ICD-11: 3B64] Phase 1 TTDDRUID D00CMA DRUGNAME VVZ-172 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D00CMC DRUGNAME BP-9906 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00CMV DRUGNAME ABT-102 INDICATI Chronic pain [ICD-11: MG30] Phase 1 TTDDRUID D00COH DRUGNAME Biaryl mannoside derivative 24 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D00COJ DRUGNAME Inclisiran INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Phase 3 TTDDRUID D00CPQ DRUGNAME RemoSynch INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 TTDDRUID D00CQI DRUGNAME Indatuximab ravtansine INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D00CQL DRUGNAME N-8295 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D00CQQ DRUGNAME TGFK09SD INDICATI Hypoactive sexual desire dysfunction [ICD-11: HA00] Phase 2 TTDDRUID D00CQW DRUGNAME TNP-351 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D00CRQ DRUGNAME Phenylate derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D00CSA DRUGNAME LFF-269 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D00CSQ DRUGNAME Triclosan INDICATI Malaria [ICD-11: 1F40-1F45] Approved INDICATI Trypanosomiasis [ICD-11: 1D51-1F53] Investigative INDICATI Infection of P. falciparum [ICD-11: 1F40] Investigative TTDDRUID D00CTS DRUGNAME Lubiprostone INDICATI Chronic idiopathic constipation [ICD-11: DC32] Approved TTDDRUID D00CTZ DRUGNAME MEDI9929 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D00CVJ DRUGNAME Neu-P11 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Dementia [ICD-11: 6D80-6D86] Phase 2 TTDDRUID D00CVT DRUGNAME TD-6301 INDICATI Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 1 TTDDRUID D00CZT DRUGNAME Solanezumab INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D00DAE DRUGNAME Carboxyamidotriazole orotate INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D00DAU DRUGNAME LCP-3301 INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D00DBE DRUGNAME CI-1018 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D00DBH DRUGNAME NPS 1776 INDICATI Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 2 TTDDRUID D00DBO DRUGNAME Pipamperone INDICATI Insomnia [ICD-11: 7A00-7A0Z] Phase 1/2 TTDDRUID D00DBU DRUGNAME SA-IGIV INDICATI Staphylococcus infection [ICD-11: 1B5Y] Discontinued in Phase 2 TTDDRUID D00DCY DRUGNAME OraTest INDICATI Oral cancer [ICD-11: 2B6E] Approved TTDDRUID D00DDR DRUGNAME G3139 + Thalidomide INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D00DEF DRUGNAME Lisdexamfetamine INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved TTDDRUID D00DFP DRUGNAME KBP-5074 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1/2 TTDDRUID D00DHM DRUGNAME SDZ-208911 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Investigative TTDDRUID D00DHT DRUGNAME Mammalian sterile 20-like kinase 1 gene eluting stent INDICATI Artery stenosis [ICD-11: BD52] Investigative TTDDRUID D00DIB DRUGNAME Anti-CD33 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D00DIM DRUGNAME Monohydroxyethylrutoside INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D00DJC DRUGNAME CJX-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00DKK DRUGNAME Isotretinoin INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D00DPJ DRUGNAME Amezinium INDICATI Hypotension [ICD-11: BA20-BA21] Approved TTDDRUID D00DPP DRUGNAME CYCLOPLATAM INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D00DQX DRUGNAME Motesanib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 3 TTDDRUID D00DRA DRUGNAME KA-20X INDICATI Gastrointestinal cancer [ICD-11: 2C11] Investigative TTDDRUID D00DRL DRUGNAME MK-2461 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1/2 TTDDRUID D00DSD DRUGNAME GLI-5021 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D00DSG DRUGNAME PF-05313261 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D00DSN DRUGNAME Sepcidin INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D00DSV DRUGNAME Polynoma-1 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D00DTP DRUGNAME ZP-006 INDICATI Pharyngitis [ICD-11: CA02.Z] Investigative TTDDRUID D00DXC DRUGNAME Macrocycle derivative 13 INDICATI Cell proliferative disorder [ICD-11: FB86] Patented TTDDRUID D00DXH DRUGNAME LYS-6KAKT1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00DYI DRUGNAME Benzothiazole analog 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D00DYK DRUGNAME Lunacalcipol INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D00DYN DRUGNAME Botulinum neurotoxin vaccine INDICATI Botulism [ICD-11: 1A11] Phase 1 TTDDRUID D00DZN DRUGNAME Beclamide INDICATI Psychiatric disorder [ICD-11: 6E8Z] Approved TTDDRUID D00EBH DRUGNAME ICI-170809 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D00ECB DRUGNAME CD-349 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D00ECO DRUGNAME SIB-1553A INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2 TTDDRUID D00EEL DRUGNAME Gaboxadol INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D00EEP DRUGNAME E-3309 INDICATI Helicobacter infection [ICD-11: DA42-DA63] Discontinued in Phase 1 TTDDRUID D00EFD DRUGNAME C-21191 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D00EFO DRUGNAME Interferon alpha-2b INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D00EGN DRUGNAME ETX-9101 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D00EGU DRUGNAME PACAP38 INDICATI Nerve injury [ICD-11: ND56.4] Phase 1 TTDDRUID D00EGV DRUGNAME Monoamine derivative 2 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D00EHX DRUGNAME TT-301 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D00EIB DRUGNAME Ha-1a INDICATI Sepsis [ICD-11: 1G40-1G41] Approved INDICATI Congestive heart failure [ICD-11: BD10] Approved INDICATI Atrial fibrillation [ICD-11: BC81.3] Approved TTDDRUID D00EIL DRUGNAME CG-103065 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00EJP DRUGNAME GSK2339345 INDICATI Cough [ICD-11: MD12] Phase 2 TTDDRUID D00EKM DRUGNAME Virapt INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D00EMB DRUGNAME GSK-1247446A INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D00EML DRUGNAME Q-Vax INDICATI Coxiella infection [ICD-11: 1C33] Terminated TTDDRUID D00ENU DRUGNAME CAB-101 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D00ENY DRUGNAME L-Glutamic Acid INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D00EPS DRUGNAME PMID18163548C4 INDICATI Reperfusion injury [ICD-11: ND56.Z] Clinical trial INDICATI Myocardial ischemia [ICD-11: BA6Z] Clinical trial TTDDRUID D00EPT DRUGNAME E7850 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D00EQD DRUGNAME PN-277 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D00EQL DRUGNAME Tazemetostat INDICATI Follicular lymphoma [ICD-11: 2A80] Approved INDICATI Malignant rhabdoid tumour [ICD-11: 2A00.1Y] Phase 2 INDICATI Brain and central nervous system tumour [ICD-11: 2A00.11] Phase 2 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2 INDICATI Synovial sarcoma [ICD-11: 2B5A] Phase 1 TTDDRUID D00EQY DRUGNAME KTN3379 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00ERV DRUGNAME Gallopamil INDICATI Asthma [ICD-11: CA23] Phase 2 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D00ESH DRUGNAME DCVax-Liver INDICATI Liver cancer [ICD-11: 2C12] Phase 1/2 TTDDRUID D00ETS DRUGNAME Hexobarbital INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D00EUL DRUGNAME PMID28270021-Compound-WO2016054807Example82 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D00EVP DRUGNAME Simenepag isopropyl INDICATI Ocular hypertension [ICD-11: 9C61.01] Phase 2 TTDDRUID D00EWR DRUGNAME Fidarestat INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 3 TTDDRUID D00EXZ DRUGNAME PB-357 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00EYC DRUGNAME F-7TG INDICATI Hemophilia [ICD-11: 3B10.0] Phase 1 TTDDRUID D00EYF DRUGNAME PEGylated insulin INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D00EZE DRUGNAME Panamesine INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 2 TTDDRUID D00EZO DRUGNAME TC-2216 INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 1 TTDDRUID D00FAW DRUGNAME CL-508 INDICATI Vomiting [ICD-11: MD90] Investigative TTDDRUID D00FBC DRUGNAME KHK-6188 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D00FBM DRUGNAME LP-2307 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D00FCW DRUGNAME ViaScint INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Preregistration TTDDRUID D00FDD DRUGNAME INT-0020 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Phase 1 TTDDRUID D00FEA DRUGNAME GRL-0036A INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D00FGO DRUGNAME Melphalan INDICATI Multiple myeloma [ICD-11: 2A83] Approved INDICATI Intrahepatic cholangiocarcinoma [ICD-11: 2C12.10] Phase 3 TTDDRUID D00FGR DRUGNAME Miltefosine INDICATI Leishmaniasis [ICD-11: 1F54] Approved INDICATI Visceral leishmaniasis [ICD-11: 1F54.0] Phase 2 TTDDRUID D00FGV DRUGNAME Carbinoxamine INDICATI Vasomotor/allergic rhinitis [ICD-11: CA08] Approved TTDDRUID D00FGW DRUGNAME Anthrax transdermal vaccine INDICATI Anthrax [ICD-11: 1B97] Phase 1 TTDDRUID D00FGY DRUGNAME PF-755616 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D00FHI DRUGNAME Zabiciprilat INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D00FHR DRUGNAME MGCD-0103 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D00FIO DRUGNAME Anti-CD20-CAR-transduced T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D00FIV DRUGNAME Leukotoxin INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D00FIX DRUGNAME Agalsidase beta INDICATI Fabry disease [ICD-11: 5C56.01] Approved TTDDRUID D00FJC DRUGNAME Nuvanil INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D00FJH DRUGNAME N-acylpiperidine ether derivative 4 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D00FJQ DRUGNAME Leucine + metformin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D00FJS DRUGNAME KRH-2731 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D00FMK DRUGNAME SDZ-LAV-694 INDICATI Actinic keratosis [ICD-11: EK90.0] Phase 1 TTDDRUID D00FMQ DRUGNAME FX-300 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D00FMV DRUGNAME Putrescine INDICATI Burn and burn infection [ICD-11: ND90-NE2Z] Discontinued in Phase 2 TTDDRUID D00FMW DRUGNAME TIM ETEC vaccine INDICATI Diarrhea [ICD-11: ME05.1] Phase 2 TTDDRUID D00FOR DRUGNAME NBI-80649 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D00FQP DRUGNAME LAGATIDE INDICATI Diarrhea [ICD-11: ME05.1] Discontinued in Phase 2 TTDDRUID D00FRX DRUGNAME CTA-056 INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D00FRY DRUGNAME BILD-1351 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Terminated TTDDRUID D00FSB DRUGNAME BIIB095 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D00FSS DRUGNAME SPD-452 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D00FSV DRUGNAME Phytonadione INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved INDICATI Vitamin K deficiency [ICD-11: 5B59] Approved TTDDRUID D00FUD DRUGNAME HRA-081025 INDICATI Contraception [ICD-11: QA21] Investigative TTDDRUID D00FWB DRUGNAME L-163017 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D00FXQ DRUGNAME IG-CN-023 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D00FYF DRUGNAME NVP-DPP728 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D00FYP DRUGNAME PG-36 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Terminated TTDDRUID D00FZA DRUGNAME ALD-805 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00FZH DRUGNAME Nest mesenchymal stem cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D00FZZ DRUGNAME PEG-FGF-21 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D00GAM DRUGNAME Beclanorsen INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID D00GAV DRUGNAME AR-2474 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D00GBG DRUGNAME Resp syncytial virus ig INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Approved TTDDRUID D00GBZ DRUGNAME CEQ-508 INDICATI Familial adenomatous polyposis [ICD-11: 2B90.Y] Phase 1/2 TTDDRUID D00GCA DRUGNAME MK-7288 INDICATI Excessive daytime sleepiness [ICD-11: MG42] Phase 1 TTDDRUID D00GDN DRUGNAME ML-03 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated TTDDRUID D00GEG DRUGNAME Ralfinamide INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 3 TTDDRUID D00GES DRUGNAME JD-5037 INDICATI Diabetic complication [ICD-11: 5A2Y] Preclinical INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D00GFU DRUGNAME BTma22 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D00GFV DRUGNAME Leridistim INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 2 TTDDRUID D00GHG DRUGNAME VAX-102 INDICATI Influenza A virus infection [ICD-11: 1E30] Phase 2 TTDDRUID D00GIR DRUGNAME DAC-060 INDICATI Keratosis [ICD-11: ED56] Phase 2 TTDDRUID D00GJK DRUGNAME Depigoid birch pollen extract vaccine INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Phase 2 TTDDRUID D00GKH DRUGNAME HG-1179 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00GLQ DRUGNAME 2LM20-4 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D00GLW DRUGNAME OM-294-DP INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00GNI DRUGNAME REGN-727 INDICATI Familial hypercholesterolemia [ICD-11: 5C80.00] Approved INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Approved TTDDRUID D00GNJ DRUGNAME Linaclotide INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved TTDDRUID D00GNK DRUGNAME LY293111 INDICATI Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 2 TTDDRUID D00GNN DRUGNAME P53 mdm-2-binding domain peptides INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00GOH DRUGNAME HepeX-B INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2 TTDDRUID D00GOS DRUGNAME Clocortolone INDICATI Rosacea [ICD-11: ED90.0] Approved TTDDRUID D00GOV DRUGNAME Nivolumab INDICATI Melanoma [ICD-11: 2C30] Approved INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved INDICATI Malignant pleural mesothelioma [ICD-11: 2C26.0] Phase 3 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 3 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Esophageal cancer [ICD-11: 2B70] Phase 3 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 3 INDICATI Central nervous system lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 1/2 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1 INDICATI Renal cell carcinoma [ICD-11: 2C90] Application submitted TTDDRUID D00GPQ DRUGNAME PF-03084014 INDICATI Desmoid tumour [ICD-11: 2F7C] Phase 3 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D00GPY DRUGNAME OMP-18R5 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00GXL DRUGNAME PBT-2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Huntington disease [ICD-11: 8A01.10] Phase 2 TTDDRUID D00GZW DRUGNAME ONO-2506 INDICATI Stroke [ICD-11: 8B20] Phase 2/3 INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D00GZY DRUGNAME AT1001 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D00HAN DRUGNAME IM23 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D00HAP DRUGNAME Dapagliflozin/metformin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D00HBE DRUGNAME AZD0914 INDICATI Neisseria gonorrhoeae infection [ICD-11: 1A7Z] Phase 3 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D00HBF DRUGNAME CAB-103 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00HBR DRUGNAME AIKO-150 INDICATI Opioid dependence [ICD-11: 6C43.2Z] Phase 1 TTDDRUID D00HCQ DRUGNAME Capecitabine INDICATI Colorectal cancer [ICD-11: 2B91.Z] Approved INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D00HDB DRUGNAME AC-105 INDICATI Spinal cord injury [ICD-11: ND51.2] Phase 2 TTDDRUID D00HDC DRUGNAME MCP-204 INDICATI Bladder disease [ICD-11: DC11-DC1Z] Investigative TTDDRUID D00HDH DRUGNAME Molecule 22 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D00HDK DRUGNAME PGX-5188 INDICATI Bipolar disorder [ICD-11: 6A60] Preclinical TTDDRUID D00HDU DRUGNAME Moexipril INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D00HDZ DRUGNAME Wharton's Jelly-Mesenchymal Stem Cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D00HEA DRUGNAME Transcobalamin (vitamin B12) receptor-targeting mabTCR23-saporin conjugate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00HEN DRUGNAME Rotavirus vaccine, Lanzhou Institute of Biological Products INDICATI Rotavirus infection (Diarrhoea) [ICD-11: ME05.1] Approved TTDDRUID D00HFD DRUGNAME E-6080 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D00HGB DRUGNAME Niflumic Acid INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D00HGF DRUGNAME ERYTHRITOL INDICATI Neurological disorder [ICD-11: 6B60] Phase 2/3 TTDDRUID D00HGY DRUGNAME Insulin B chain vaccine INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D00HHP DRUGNAME CP-111905 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D00HHS DRUGNAME Pseudoephedrine INDICATI Nasal congestion [ICD-11: MD11.9] Approved TTDDRUID D00HHU DRUGNAME AFO-18 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID D00HIC DRUGNAME Pseudomonas aeruginosa vaccine INDICATI Pseudomonas infection [ICD-11: 1B92] Discontinued in Phase 1 TTDDRUID D00HMQ DRUGNAME Ormaplatin INDICATI leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 1 TTDDRUID D00HMZ DRUGNAME TV1-Kidney-1 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 TTDDRUID D00HNB DRUGNAME Clodronate INDICATI Hypercalcaemia [ICD-11: 5B91.0] Approved TTDDRUID D00HNK DRUGNAME RHb1.1 INDICATI Anemia [ICD-11: 3A00-3A9Z] Terminated TTDDRUID D00HNQ DRUGNAME TDI-0051 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D00HPD DRUGNAME Moxetumomab pasudotox INDICATI Hairy cell leukaemia [ICD-11: 2A82.2] Approved INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D00HPK DRUGNAME Naftifine INDICATI Dermatomycosis [ICD-11: EA60] Approved TTDDRUID D00HPX DRUGNAME ON-04 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D00HQB DRUGNAME TX-MSD INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D00HQE DRUGNAME Ty800 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 2 TTDDRUID D00HSK DRUGNAME Algenpantucel-L INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 TTDDRUID D00HTO DRUGNAME Apomine INDICATI Osteopetrosis [ICD-11: LD24.10] Phase 2 TTDDRUID D00HTT DRUGNAME XE-9 INDICATI Transplant rejection [ICD-11: NE84] Terminated TTDDRUID D00HTY DRUGNAME PGF2alpha INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Clinical trial TTDDRUID D00HUZ DRUGNAME NDDP INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D00HWO DRUGNAME Cyclacillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D00HYD DRUGNAME CDT-fenofibrate INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 1 TTDDRUID D00HYF DRUGNAME H5N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D00HYK DRUGNAME AFN-1252 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 2 TTDDRUID D00HZA DRUGNAME YPEG-Somatropin INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Phase 1 TTDDRUID D00HZO DRUGNAME GS-497C INDICATI Lung cancer [ICD-11: 2C25.0] Investigative TTDDRUID D00HZV DRUGNAME Trimipramine INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved TTDDRUID D00IAH DRUGNAME Hemiacidrin INDICATI Urolithiasis [ICD-11: GB7Z] Approved TTDDRUID D00IBN DRUGNAME Piroxicam INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D00ICD DRUGNAME SH-529 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Phase 2 TTDDRUID D00ICM DRUGNAME Naltiazem hydrochloride INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D00ICY DRUGNAME FP-187 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D00IDP DRUGNAME Emdogain INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D00IDR DRUGNAME Phenylalanine hydroxylase INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D00IDV DRUGNAME CRTX-070 INDICATI Allergic rhinitis [ICD-11: CA08.0] Investigative TTDDRUID D00IEB DRUGNAME DRL-21994 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative TTDDRUID D00IFH DRUGNAME INO-1400 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00IFQ DRUGNAME MVT-1075 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00IFR DRUGNAME AZD1208 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00IJM DRUGNAME EPI-A0001 INDICATI Friedreich's ataxia [ICD-11: 8A03.10] Phase 2 TTDDRUID D00IJQ DRUGNAME Zatosetron maleate INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 3 TTDDRUID D00IKH DRUGNAME Hexylcarbamoyl fluorouracil INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Withdrawn from market TTDDRUID D00IKI DRUGNAME PF-04895162 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 1 TTDDRUID D00INM DRUGNAME Occlusin INDICATI Liver cancer [ICD-11: 2C12] Preclinical TTDDRUID D00IOS DRUGNAME CYT-017-IL17Qb INDICATI Multiple sclerosis [ICD-11: 8A40] Terminated TTDDRUID D00IPW DRUGNAME CGP-47969A INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D00IQH DRUGNAME RQ-00000007 (oral) INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D00IQV DRUGNAME Homspera INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D00IRU DRUGNAME E-5842 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D00ISN DRUGNAME MT-1303 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D00ITC DRUGNAME PRT4445 INDICATI Bleeding disorder [ICD-11: GA20-GA21] Phase 3 TTDDRUID D00ITG DRUGNAME Clinafloxacin INDICATI Pneumonia [ICD-11: CA40] Terminated TTDDRUID D00IUD DRUGNAME K-832 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D00IUG DRUGNAME Levobunolol INDICATI Open-angle glaucoma [ICD-11: 9C61] Approved TTDDRUID D00IVF DRUGNAME Murepavadin INDICATI Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 3 TTDDRUID D00IVN DRUGNAME Navicixizumab INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 1 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1 TTDDRUID D00IWE DRUGNAME RP-6000 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D00IWL DRUGNAME PolyHeme INDICATI Blood forming organ disorder [ICD-11: JB64.1] Phase 3 TTDDRUID D00IXM DRUGNAME DR-3001 INDICATI Urinary incontinence [ICD-11: MF50.2] Phase 3 TTDDRUID D00IXN DRUGNAME GS-6637 INDICATI Substance use disorder [ICD-11: 6C4Z] Phase 1 TTDDRUID D00IYB DRUGNAME Maraciclatide INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D00IYM DRUGNAME AEZS-127 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D00IZD DRUGNAME DVC1-0101 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 2 TTDDRUID D00IZW DRUGNAME BM-13.1188 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D00IZY DRUGNAME DCN01 INDICATI Ocular infection [ICD-11: 1F00.1] Phase 2 TTDDRUID D00JAU DRUGNAME Irbesartan INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D00JBM DRUGNAME UR-5908 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D00JCA DRUGNAME NewGam INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 3 TTDDRUID D00JCB DRUGNAME CD19/CD22 CAR T cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D00JDJ DRUGNAME AX-024 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D00JDL DRUGNAME MGD006 INDICATI Acute myeloid lymphoma [ICD-11: 2A80] Phase 1 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D00JDP DRUGNAME AMX-213 INDICATI Cachexia [ICD-11: MG20] Investigative TTDDRUID D00JED DRUGNAME AN-2898 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D00JFE DRUGNAME ARN-810 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D00JFN DRUGNAME MDC-917 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00JGL DRUGNAME D-4476 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Preclinical TTDDRUID D00JIV DRUGNAME PF-4989216 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00JIX DRUGNAME IKH-25 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00JJG DRUGNAME RAP101 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D00JJW DRUGNAME RH 1 INDICATI Discovery agent [ICD-11: N.A.] Phase 1 TTDDRUID D00JJZ DRUGNAME LaViv INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 TTDDRUID D00JKJ DRUGNAME HS-P1 INDICATI Pancreatic cancer [ICD-11: 2C10] Investigative TTDDRUID D00JME DRUGNAME SMT-14400 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D00JMG DRUGNAME HRA-081035 INDICATI Contraception [ICD-11: QA21] Investigative TTDDRUID D00JMY DRUGNAME AMP-224 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D00JNL DRUGNAME Tenilsetam INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D00JNT DRUGNAME HCV-086 INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 1 TTDDRUID D00JQA DRUGNAME Benzimidazole derivative 3 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D00JQE DRUGNAME BAY-60-5521 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 1 TTDDRUID D00JQQ DRUGNAME RX-465 INDICATI Sarcoma [ICD-11: 2A60-2C35] Terminated TTDDRUID D00JRA DRUGNAME Asenapine INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D00JRD DRUGNAME PGF2ALPHA-IE INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 3 TTDDRUID D00JRS DRUGNAME Lopinavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D00JSG DRUGNAME Fluoratec INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Terminated TTDDRUID D00JVC DRUGNAME ATB-429 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D00JVR DRUGNAME Azelastine INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Approved TTDDRUID D00JWL DRUGNAME LEX-028 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D00JWN DRUGNAME Allogeneic human dental pulp stem cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D00JXV DRUGNAME INCB-10820 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D00JZD DRUGNAME GSK2321138A INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D00JZS DRUGNAME Anti-FGFR1 mab program INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00JZX DRUGNAME EP-012637 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D00KCR DRUGNAME Enkastim-iv INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00KDQ DRUGNAME Anti-CEA CAR-T cells INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 INDICATI Peritoneal metastasis [ICD-11: 2D91] Phase 1 TTDDRUID D00KEF DRUGNAME Org-2766 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 3 TTDDRUID D00KFB DRUGNAME Dextromethorphan Polistirex INDICATI Dry cough [ICD-11: MD12] Approved TTDDRUID D00KGB DRUGNAME Abagovomab INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2/3 TTDDRUID D00KGI DRUGNAME IVN-201 INDICATI Allergy [ICD-11: 4A80-4A85] Phase 1 TTDDRUID D00KHD DRUGNAME TAK-128 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 TTDDRUID D00KHI DRUGNAME Anti-PSMA CAR-T cell therapy INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00KHM DRUGNAME Pimozide INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D00KIE DRUGNAME Ensaculin hydrochloride INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D00KIU DRUGNAME MKC-242844 INDICATI Lymphoma [ICD-11: 2A80-2A86] Investigative TTDDRUID D00KJO DRUGNAME MUT-056399 INDICATI Methicillin-resistant staphylococci infection [ICD-11: 1A00-1A09] Preclinical TTDDRUID D00KKD DRUGNAME PMID26651364-Compound-5 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D00KLH DRUGNAME KR-6346 INDICATI Stomach ulcer [ICD-11: DA60.Z] Terminated TTDDRUID D00KLP DRUGNAME Immune globulin + albumin INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D00KMI DRUGNAME CEP-37309 INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D00KML DRUGNAME SYN004 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00KMQ DRUGNAME OI362GT INDICATI Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 1 TTDDRUID D00KNI DRUGNAME BI-853520 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00KOV DRUGNAME Monatepil maleate INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Preregistration TTDDRUID D00KQN DRUGNAME PEGylated pitrakinra INDICATI Asthma [ICD-11: CA23] Phase 2 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D00KQT DRUGNAME FR-129169 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D00KRE DRUGNAME Olsalazine INDICATI Ulcerative colitis [ICD-11: DD71] Approved TTDDRUID D00KRT DRUGNAME Indocyanine green INDICATI Gastrointestinal disease [ICD-11: DE2Z] Approved TTDDRUID D00KSU DRUGNAME MT-274 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D00KTN DRUGNAME PMID25666693-Compound-121 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D00KTV DRUGNAME Salirasib INDICATI Lung cancer [ICD-11: 2C25.0] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 1/2 TTDDRUID D00KUD DRUGNAME ADL 10-0101 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D00KVE DRUGNAME Cutamesine INDICATI Major depressive disorder [ICD-11: 6A70.3] Preclinical TTDDRUID D00KVO DRUGNAME Albendazole INDICATI Worm infection [ICD-11: 1F90.Z] Approved TTDDRUID D00KVX DRUGNAME LP-261 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00KWA DRUGNAME Recainam INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D00KWF DRUGNAME PYN-9 INDICATI Ileus [ICD-11: DA93.0] Preclinical TTDDRUID D00KXO DRUGNAME Ciraparantag INDICATI Harmful effects of drugs, medicaments or biological substances [ICD-11: NE60] Phase 2 TTDDRUID D00KXQ DRUGNAME LF-13-0491c INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D00LAA DRUGNAME VA-118020 INDICATI Respiratory disease [ICD-11: CB40] Investigative TTDDRUID D00LBD DRUGNAME Metazosin INDICATI Cardiac disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3 TTDDRUID D00LCT DRUGNAME Symakalim INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D00LDI DRUGNAME UPA-targeted oncolytic Sendai virus INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00LFB DRUGNAME Ritodrine INDICATI Premature labour [ICD-11: JB00] Approved TTDDRUID D00LGA DRUGNAME NN-8226 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D00LGR DRUGNAME TP-0903 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00LHF DRUGNAME GS-9219 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D00LHI DRUGNAME BAY 794980 INDICATI Discovery agent [ICD-11: N.A.] Phase 2 TTDDRUID D00LJF DRUGNAME INT0001/2004 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D00LLI DRUGNAME Candistat-G INDICATI Candidiasis [ICD-11: 1F23] Discontinued in Phase 2 TTDDRUID D00LMA DRUGNAME Heteroaryl-carboxamide derivative 4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D00LMR DRUGNAME AP-006 INDICATI Pulmonary disease [ICD-11: 1B10-1F85] Investigative TTDDRUID D00LMY DRUGNAME RO-5212651 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D00LNW DRUGNAME Selinexor INDICATI Multiple myeloma [ICD-11: 2A83] Phase 3 INDICATI Liposarcoma [ICD-11: 2B59] Phase 3 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D00LOB DRUGNAME RWJ-671818 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D00LPZ DRUGNAME Vapill INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D00LRP DRUGNAME PRS-080 INDICATI Anaemia [ICD-11: 3A90] Phase 1/2 TTDDRUID D00LSD DRUGNAME SERX-1 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D00LSI DRUGNAME Vidofludimus INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D00LSQ DRUGNAME PMID26815044-Compound-126 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D00LSW DRUGNAME VA-111913 INDICATI Dysmenorrhea [ICD-11: GA34.3] Phase 2 TTDDRUID D00LVA DRUGNAME Dianicline INDICATI Tobacco dependence [ICD-11: 6C4A.2] Discontinued in Phase 3 TTDDRUID D00LWD DRUGNAME AF-3473 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D00LWF DRUGNAME P-1075 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D00LWR DRUGNAME BVT-A INDICATI Acromegaly [ICD-11: 5A60.0] Preclinical TTDDRUID D00LWS DRUGNAME Ataprost INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 3 TTDDRUID D00LWX DRUGNAME Promegapoietin INDICATI Bone marrow transplantation [ICD-11: QB63.6] Terminated TTDDRUID D00LXB DRUGNAME Panaecin INDICATI Lung infection [ICD-11: CA4Z] Investigative TTDDRUID D00LXD DRUGNAME Omega interferon INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2 TTDDRUID D00LYE DRUGNAME GC-003 INDICATI Neutropenia [ICD-11: 4B00.0] Investigative TTDDRUID D00LYW DRUGNAME BW-1003C87 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D00LZM DRUGNAME CP1 INDICATI Cough [ICD-11: MD12] Investigative TTDDRUID D00LZO DRUGNAME CZC-19091 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D00LZY DRUGNAME AA-184 INDICATI Kidney injury [ICD-11: NB92.0] Investigative TTDDRUID D00MAM DRUGNAME AMG-JAK2-01 INDICATI Myeloproliferative syndrome [ICD-11: 2A22] Investigative TTDDRUID D00MAN DRUGNAME GRC-6211 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D00MBR DRUGNAME Iratumumab INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 TTDDRUID D00MBY DRUGNAME AAD-2004 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D00MCA DRUGNAME BB-PTH 1-84 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D00MCY DRUGNAME REC2615 INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative TTDDRUID D00MDP DRUGNAME Prinomastat INDICATI Lung cancer [ICD-11: 2C25.0] Approved INDICATI Brain cancer [ICD-11: 2A00] Discontinued in Phase 3 TTDDRUID D00MET DRUGNAME Recombinant uteroglobin INDICATI Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Investigative TTDDRUID D00MEV DRUGNAME Sch-45752 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D00MFA DRUGNAME Aspartame INDICATI Poison intoxication [ICD-11: NE6Z] Investigative TTDDRUID D00MFY DRUGNAME GPI-3000 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D00MGO DRUGNAME PMID28270021-Compound-WO2016054807Example1 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D00MHP DRUGNAME SR-2640 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D00MIF DRUGNAME JTP-4761 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D00MIN DRUGNAME Propylthiouracil INDICATI Hyperthyroidism [ICD-11: 5A02] Approved TTDDRUID D00MIX DRUGNAME CP-114271 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D00MJI DRUGNAME Emactuzumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00MLJ DRUGNAME Pyrazole derivative 61 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D00MLQ DRUGNAME Protosufloxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D00MLW DRUGNAME Triheptanoin INDICATI Long-chain fatty acid oxidation disorder [ICD-11: BC43.10] Approved INDICATI Genetic epileptic syndromes with variable age of onset [ICD-11: 8A61.4Y] Phase 3 TTDDRUID D00MLX DRUGNAME Abacavir/dolutegravir/lamivudine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D00MMV DRUGNAME Enoticumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D00MNG DRUGNAME HIV gp41 vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D00MPX DRUGNAME JX-1395 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00MQS DRUGNAME PD-165167 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D00MRH DRUGNAME MDPTQ INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D00MSP DRUGNAME FR-149581 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D00MTG DRUGNAME SAR279356 INDICATI Serious infection [ICD-11: 1H0Z] Phase 2 TTDDRUID D00MUC DRUGNAME CD19 CAR-T cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D00MVK DRUGNAME Ro-48-8391 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D00MWE DRUGNAME UX-004 INDICATI Lysosomal storage disease [ICD-11: 5C56.Z] Investigative TTDDRUID D00MXN DRUGNAME MK-3207 INDICATI Migraine [ICD-11: 8A80] Phase 2 TTDDRUID D00MYQ DRUGNAME Protriptyline INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D00MYT DRUGNAME Thiopental INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D00MYW DRUGNAME NS-018 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 1/2 TTDDRUID D00MZC DRUGNAME LTX-100 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D00MZK DRUGNAME FK-788 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D00NAX DRUGNAME Promazine INDICATI Psychomotor agitation [ICD-11: MB23.M] Approved TTDDRUID D00NBF DRUGNAME GM06 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 TTDDRUID D00NBJ DRUGNAME Remetinostat INDICATI Basal cell carcinoma [ICD-11: 2C32] Phase 2 INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2 TTDDRUID D00NBW DRUGNAME ONCOS-102 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 INDICATI Melanoma [ICD-11: 2C30] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00NEL DRUGNAME BI-754091 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00NGN DRUGNAME Sabeluzole INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 3 TTDDRUID D00NIV DRUGNAME ATYR-1920 INDICATI Genetic disease [ICD-11: 8E02] Investigative TTDDRUID D00NJE DRUGNAME SFc INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D00NJJ DRUGNAME Mezlocillin INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D00NJL DRUGNAME Clofoctol INDICATI Bronchitis [ICD-11: CA20] Approved TTDDRUID D00NKB DRUGNAME Triamterene INDICATI Congestive heart failure [ICD-11: BD10] Approved INDICATI Edema [ICD-11: MG29] Approved INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D00NNC DRUGNAME Etidronic acid INDICATI Paget's disease [ICD-11: FB85] Approved TTDDRUID D00NNI DRUGNAME ASP-3652 INDICATI Overactive bladder [ICD-11: GC50.0] Phase 2 TTDDRUID D00NOL DRUGNAME MK-0536 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D00NOP DRUGNAME OBP-401 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D00NOY DRUGNAME BetaRx INDICATI Type-1 diabetes [ICD-11: 5A10] Investigative TTDDRUID D00NPE DRUGNAME MMP-408 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D00NPO DRUGNAME ABT-199 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3 TTDDRUID D00NPP DRUGNAME Zanamivir INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D00NPT DRUGNAME Minodronate INDICATI Osteoporosis [ICD-11: FB83.0] Approved TTDDRUID D00NSD DRUGNAME XL-820 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D00NSM DRUGNAME CM-GLP-1 INDICATI Brain injury [ICD-11: NA07.Z] Discontinued in Phase 1/2 TTDDRUID D00NTR DRUGNAME Histoplasmin INDICATI Histoplasma infection [ICD-11: 1F2A.Z] Approved TTDDRUID D00NTW DRUGNAME BIBR-363 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D00NUG DRUGNAME Olokizumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D00NUO DRUGNAME IDP-122 INDICATI Plaque psoriasis [ICD-11: EA90.0] Application submitted TTDDRUID D00NVM DRUGNAME SNS-595 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D00NVO DRUGNAME Flezelastine INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D00NVX DRUGNAME Forasartan INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D00NWT DRUGNAME GR-213487 INDICATI Cystic fibrosis [ICD-11: CA25] Discontinued in Phase 2 TTDDRUID D00NWV DRUGNAME Ypeginterferon alfa-2a INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3 TTDDRUID D00NXM DRUGNAME GSK-2251052 INDICATI Urinary tract infection [ICD-11: GC08] Phase 2 TTDDRUID D00NXT DRUGNAME Xmab 5871 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 INDICATI IgG4 related disease [ICD-11: 4A43.0] Phase 2 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1/2 TTDDRUID D00NYJ DRUGNAME Varlitinib INDICATI Metastatic biliary tract neoplasms [ICD-11: 2C14-2C17] Phase 2/3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D00NYL DRUGNAME AAV2/8-CBA-hSMN1 INDICATI Spinal muscular atrophy [ICD-11: 8B61] Investigative TTDDRUID D00NZL DRUGNAME LY2603618 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D00OAB DRUGNAME APX-007 INDICATI Bone metastases [ICD-11: 2D50] Investigative TTDDRUID D00OAU DRUGNAME GW-328267 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 1 TTDDRUID D00OAY DRUGNAME Lenampicillin hci INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D00OCB DRUGNAME CCT-018159 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D00ODY DRUGNAME PMID25666693-Compound-95 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D00OEG DRUGNAME RhTPO INDICATI Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Discontinued in Phase 3 TTDDRUID D00OFV DRUGNAME Asperlicin INDICATI Gastrointestinal disease [ICD-11: DE2Z] Investigative TTDDRUID D00OGX DRUGNAME Anapsos INDICATI Atopic dermatitis [ICD-11: EA80] Approved TTDDRUID D00OHP DRUGNAME PRO-GR-300 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D00OJL DRUGNAME QBP1 mimetics INDICATI Huntington disease [ICD-11: 8A01.10] Investigative TTDDRUID D00OKK DRUGNAME PC4708 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D00OLY DRUGNAME PMID25666693-Compound-149 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D00OMJ DRUGNAME SJ-BRV INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D00ONE DRUGNAME CWF-0710 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D00OON DRUGNAME CAB-AXL-ADC INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D00OOZ DRUGNAME E-7107 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00OPX DRUGNAME Fostamatinib disodium INDICATI Thrombocytopenia [ICD-11: 3B64] Phase 3 TTDDRUID D00ORZ DRUGNAME BMS-824393 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D00OTH DRUGNAME P-979 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D00OTL DRUGNAME Vernakalant INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 3 TTDDRUID D00OTM DRUGNAME LY3022855 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00OTQ DRUGNAME Proximab INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D00OTT DRUGNAME ISIS 1570 INDICATI Lleum inflammation [ICD-11: 1A40.0] Approved TTDDRUID D00OVC DRUGNAME EVT-201 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Phase 2 TTDDRUID D00OVE DRUGNAME PF-06650808 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00OVU DRUGNAME Suvorexant INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D00OWU DRUGNAME RBP-8000 INDICATI Cocaine addiction [ICD-11: 6C45.2] Phase 2 TTDDRUID D00OXP DRUGNAME Bb21217 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D00OYC DRUGNAME Motolimid INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D00OYQ DRUGNAME Imisopasem manganese INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D00OZC DRUGNAME THX-TS01 INDICATI Tourette syndrome [ICD-11: 8A05.00] Phase 3 TTDDRUID D00PBI DRUGNAME SUVN-501 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D00PBS DRUGNAME Allogeneic NK cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D00PBX DRUGNAME GDC-0199 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D00PDG DRUGNAME CORT-108297 INDICATI Weight gain [ICD-11: MG43.6] Discontinued in Phase 1/2 TTDDRUID D00PDQ DRUGNAME Kuzbanian INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00PEH DRUGNAME Eltrombopag INDICATI Thrombocytopenia [ICD-11: 3B64] Approved INDICATI Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Phase 3 TTDDRUID D00PEN DRUGNAME MGD007 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 1 TTDDRUID D00PFW DRUGNAME AZD4818 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D00PGA DRUGNAME ALS-AAV9 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D00PGF DRUGNAME RV-1088 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D00PHK DRUGNAME Carboxylic acid derivative 1 INDICATI Neoplasm [ICD-11: 2A00-2F9Z] Patented INDICATI Angiogenesis disorder [ICD-11: BE2Z] Patented TTDDRUID D00PIE DRUGNAME Banoxantrone INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Discontinued in Phase 1 TTDDRUID D00PJJ DRUGNAME FK-614 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D00PJK DRUGNAME SRI-21009 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00PJY DRUGNAME Prosorba INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D00PLV DRUGNAME Nitroprusside INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D00PLX DRUGNAME MystiLol INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D00PMA DRUGNAME CL-246738 INDICATI Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2 TTDDRUID D00PMB DRUGNAME VGX-3100 INDICATI Cervical Intraepithelial neoplasia [ICD-11: 2E66.1] Phase 3 INDICATI Dysplasia [ICD-11: LB30-LD2F] Phase 3 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 2 INDICATI Vulvar squamous intraepithelial lesion [ICD-11: 2E66.1] Phase 2 INDICATI Vulvar intraepithelial neoplasia [ICD-11: 2E67.10] Phase 2 TTDDRUID D00PNU DRUGNAME TGN-1412 INDICATI Autoimmune diabetes [ICD-11: 5A10] Discontinued in Phase 1 TTDDRUID D00POS DRUGNAME DL-017 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 TTDDRUID D00PPV DRUGNAME Siderophore-conjugated monocarbams INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D00PQS DRUGNAME NE-2 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D00PRI DRUGNAME Edetate calcium disodium INDICATI Toxicity [ICD-11: N.A.] Approved TTDDRUID D00PSG DRUGNAME NOX-100 INDICATI Hypotension [ICD-11: BA20-BA21] Phase 2 TTDDRUID D00PTZ DRUGNAME Dasiprotimut-T INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 3 TTDDRUID D00PUT DRUGNAME BT-016 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D00PXQ DRUGNAME Fananserin INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D00PYP DRUGNAME NBI-37582 INDICATI Depression [ICD-11: 6A70-6A7Z] Terminated INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D00PZH DRUGNAME AC-187 INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D00PZK DRUGNAME APD-405 INDICATI Vomiting [ICD-11: MD90] Discontinued in Phase 2 TTDDRUID D00QAQ DRUGNAME Terpenoid schweinfurthins INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00QAX DRUGNAME PF-708093 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical TTDDRUID D00QBV DRUGNAME DD7 INDICATI Acute respiratory distress syndrome [ICD-11: CB00] Investigative INDICATI Myocardial reperfusion injury [ICD-11: NB31] Investigative INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D00QCB DRUGNAME SRI-62-834 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D00QCV DRUGNAME MG-401 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00QCX DRUGNAME SCP-123 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D00QDJ DRUGNAME Trametinib INDICATI Metastatic melanoma [ICD-11: 2E2Z] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D00QEP DRUGNAME Inotuzumab ozogamicin INDICATI Acute lymphocytic leukaemia [ICD-11: 2B33.3] Approved INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved TTDDRUID D00QET DRUGNAME Montelukast INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D00QEZ DRUGNAME PMID25666693-Compound-60 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D00QFV DRUGNAME GR-DD1 INDICATI Liver cancer [ICD-11: 2C12] Investigative TTDDRUID D00QFY DRUGNAME YM533 INDICATI Chronic renal failure [ICD-11: GB61.Z] Discontinued in Phase 3 TTDDRUID D00QGB DRUGNAME O-2442 INDICATI Cocaine addiction [ICD-11: 6C45.2] Investigative TTDDRUID D00QGV DRUGNAME Human interferon alpha oral INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D00QHT DRUGNAME AK-295 INDICATI Cerebral infarction [ICD-11: 8B11.5Z] Terminated TTDDRUID D00QIJ DRUGNAME Huntingtin gene antisense INDICATI Huntington disease [ICD-11: 8A01.10] Preclinical TTDDRUID D00QIK DRUGNAME PS-519 INDICATI Ischemia-reperfusion injury [ICD-11: DB98.B] Terminated TTDDRUID D00QJL DRUGNAME Influvac TC INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D00QKI DRUGNAME SCH-527123 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00QKL DRUGNAME T2c-003 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 1/2 TTDDRUID D00QKS DRUGNAME BMS-954561 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 TTDDRUID D00QLG DRUGNAME Lovaxin M INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D00QNW DRUGNAME Laropiprant/niacin/ simvastatin combination INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 3 TTDDRUID D00QOF DRUGNAME ORG-13011 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 2 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 INDICATI Major depressive disorder [ICD-11: 6A70.3] Application submitted TTDDRUID D00QOG DRUGNAME F-2833 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D00QOH DRUGNAME OCT-SG815 INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D00QOJ DRUGNAME 99mTc-RP-128 INDICATI Diagnostic imaging [ICD-11: N.A.] Phase 2 TTDDRUID D00QTA DRUGNAME A-058 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D00QTL DRUGNAME MDDR 184045 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D00QTU DRUGNAME TH-1320 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00QUJ DRUGNAME AM-3005 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D00QUZ DRUGNAME TTP-814 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1/2 TTDDRUID D00QVT DRUGNAME ATN-161 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 TTDDRUID D00QVY DRUGNAME Resorcinol compound 23 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D00QWK DRUGNAME CLL1-specific gene-engineered T cells INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D00QWU DRUGNAME BMS-779788 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 1 TTDDRUID D00QXB DRUGNAME WT1 peptide vaccine INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2 TTDDRUID D00QXV DRUGNAME BMS-181101 INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2 TTDDRUID D00QZJ DRUGNAME Growth hormone INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Investigative TTDDRUID D00RAM DRUGNAME Bone Marrow-Derived Mesenchymal Stem Cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D00RCI DRUGNAME Teduglutide INDICATI Short bowel syndrome [ICD-11: KB89.1] Approved TTDDRUID D00RDI DRUGNAME OPN-401 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D00RDO DRUGNAME PMID26651364-Compound-116 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D00RFZ DRUGNAME PSI-6130 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Terminated TTDDRUID D00RGF DRUGNAME GCC-4401 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D00RGX DRUGNAME RG7876 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00RIB DRUGNAME RG-201 INDICATI Acquired immune deficiency syndrome [ICD-11: 1C62.3] Discontinued in Phase 1 TTDDRUID D00RIK DRUGNAME B7/CD28 costimulatory proteins INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D00RJA DRUGNAME VX-148 INDICATI Psoriasis vulgaris [ICD-11: EA90] Patented TTDDRUID D00RJB DRUGNAME Rilopirox INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 2 TTDDRUID D00RJE DRUGNAME Pancopride INDICATI Nausea [ICD-11: MD90] Phase 3 TTDDRUID D00RJJ DRUGNAME Ganirelix INDICATI Ovulation dysfunction [ICD-11: 5A80] Approved TTDDRUID D00RMC DRUGNAME BIBX-1382 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 TTDDRUID D00RMD DRUGNAME FK-960 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D00RNB DRUGNAME IQB-9302 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D00ROR DRUGNAME CYNK-001 cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D00ROV DRUGNAME FK-041 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D00ROY DRUGNAME Adjustable basal insulin INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D00RPV DRUGNAME EPB-200 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D00RQQ DRUGNAME ASP-1120 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D00RQW DRUGNAME Biaryl mannoside derivative 8 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D00RRU DRUGNAME BIIB037 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D00RSK DRUGNAME GW-406381 INDICATI Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 3 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 3 TTDDRUID D00RTC DRUGNAME Vicinium INDICATI Bladder cancer [ICD-11: 2C94] Phase 3 TTDDRUID D00RTU DRUGNAME 227Th-rituximab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00RWQ DRUGNAME CX157 INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 2 TTDDRUID D00RWU DRUGNAME FT-301 INDICATI Muscle wasting disease [ICD-11: 8E4A.3] Investigative TTDDRUID D00RWW DRUGNAME Fexinidazole INDICATI Trypanosomiasis [ICD-11: 1D51-1F53] Phase 2/3 TTDDRUID D00RXR DRUGNAME AC-253 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D00RYA DRUGNAME SB-1578 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00RYU DRUGNAME IPH-2102 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D00RZA DRUGNAME EPB-500 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D00SBD DRUGNAME Recoflavone INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2 TTDDRUID D00SBN DRUGNAME Perhexiline INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D00SBU DRUGNAME PF614 INDICATI Chronic pain [ICD-11: MG30] Phase 1 TTDDRUID D00SBX DRUGNAME ZL006 INDICATI Fear-related disorder [ICD-11: 6B0Z] Investigative TTDDRUID D00SEB DRUGNAME Enalapril INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D00SFN DRUGNAME TUCARESOL INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 2 TTDDRUID D00SFY DRUGNAME BI-44847 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D00SGD DRUGNAME Pentacel INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D00SHQ DRUGNAME Bromperidol INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D00SHS DRUGNAME Human hemoglobin INDICATI Blood transfusion [ICD-11: QB98] Phase 3 TTDDRUID D00SIA DRUGNAME ARQ-171 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00SIR DRUGNAME CS-461 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D00SIZ DRUGNAME RG6180 INDICATI Metastatic melanoma [ICD-11: 2E2Z] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00SJE DRUGNAME Secobarbital INDICATI Intractable insomnia [ICD-11: 7A00] Approved TTDDRUID D00SJN DRUGNAME HLL1-Fab-A3B3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00SJX DRUGNAME NK-110 INDICATI Muscle wasting disease [ICD-11: 8E4A.3] Investigative TTDDRUID D00SKM DRUGNAME TT12 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1 INDICATI Oropharyngeal cancer [ICD-11: 2B6A] Phase 1 TTDDRUID D00SKS DRUGNAME GS-8374 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D00SLY DRUGNAME Umeclidinium INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D00SMC DRUGNAME PAN-22 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative TTDDRUID D00SML DRUGNAME NMHSS1-1 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Investigative TTDDRUID D00SMU DRUGNAME Lenti-D INDICATI Adrenoleukodystrophy [ICD-11: 8A44.1] Phase 3 TTDDRUID D00SNY DRUGNAME TDI-0057 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D00SOZ DRUGNAME DE-117 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 3 TTDDRUID D00SPK DRUGNAME E-4021 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2 TTDDRUID D00SQN DRUGNAME HBI-8000 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Registered INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Registered INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 1/2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1/2 TTDDRUID D00SRE DRUGNAME HPMPA prodrugs INDICATI Cytomegalovirus infection [ICD-11: 1D82] Investigative TTDDRUID D00SSZ DRUGNAME OBP-801 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00STJ DRUGNAME Enocitabine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D00STL DRUGNAME Nilotinib INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Approved TTDDRUID D00STZ DRUGNAME Mam-05.200 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D00SUK DRUGNAME Tonapofylline INDICATI Acute and chronic heart failure [ICD-11: BD1Z] Phase 2 TTDDRUID D00SVK DRUGNAME PMID25684022-Compound-WO2011137219 37(4-6) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D00SVP DRUGNAME PF-4455242 INDICATI Bipolar disorder [ICD-11: 6A60] Phase 1 TTDDRUID D00SVU DRUGNAME Y-25130 INDICATI Nausea and vomiting [ICD-11: MD90] Approved TTDDRUID D00SWN DRUGNAME MS-806 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D00SWQ DRUGNAME Mitoglitazone INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D00SYV DRUGNAME GSK2618960 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 INDICATI Sjogren syndrome [ICD-11: 4A43.20] Phase 1 TTDDRUID D00TAP DRUGNAME Helivax INDICATI Helicobacter infection [ICD-11: DA42-DA63] Discontinued in Phase 1 TTDDRUID D00TBD DRUGNAME PHA-665752 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00TBI DRUGNAME Imidazole derivative 7 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D00TBJ DRUGNAME PF-271836 INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative TTDDRUID D00TBS DRUGNAME SPIRU-211 INDICATI Constipation [ICD-11: DD91.1] Investigative TTDDRUID D00TCM DRUGNAME Yellow fever vaccine INDICATI Yellow fever virus infection [ICD-11: 1D47] Approved TTDDRUID D00TED DRUGNAME JNJ-54728518 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D00TEN DRUGNAME TV-1390 INDICATI Multiple sclerosis [ICD-11: 8A40] Preclinical TTDDRUID D00TGR DRUGNAME Citric acid, magnesium oxide, sodium picosulfate INDICATI Crohn disease [ICD-11: DD70] Approved TTDDRUID D00THA DRUGNAME QLT-091001 INDICATI Restless legs syndrome [ICD-11: 7A80] Phase 2 INDICATI Leber congenital amaurosis [ICD-11: 9B70] Phase 1 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Phase 1 TTDDRUID D00THG DRUGNAME DE-105 INDICATI Corneal disease [ICD-11: 9A78.Z] Phase 2 TTDDRUID D00THJ DRUGNAME 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 3 INDICATI Skin disease [ICD-11: EA00-EM0Z] Patented INDICATI Muscular wasting [ICD-11: 8C7Y] Patented TTDDRUID D00TIG DRUGNAME RG3806 INDICATI Acromegaly [ICD-11: 5A60.0] Preregistration TTDDRUID D00TJV DRUGNAME RP-3120 INDICATI Respiratory tract inflammation [ICD-11: CA07] Investigative TTDDRUID D00TJX DRUGNAME Albinterferon alfa-2b INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3 TTDDRUID D00TKC DRUGNAME NCP-004 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D00TLD DRUGNAME RIG-200 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D00TLM DRUGNAME PRUVANSERIN INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 2 TTDDRUID D00TLN DRUGNAME Cyproheptadine INDICATI Rhinitis [ICD-11: FA20] Approved TTDDRUID D00TLP DRUGNAME Simeprevir INDICATI Chronic HCV-1 infection [ICD-11: 1E51.1] Approved TTDDRUID D00TMK DRUGNAME Dengvaxia INDICATI Dengue fever [ICD-11: 1D2Z] Phase 2 TTDDRUID D00TMQ DRUGNAME Azetidine-1-carboxamide derivative 3 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D00TNC DRUGNAME S-8510 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D00TNZ DRUGNAME Enadenotucirev INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00TPC DRUGNAME MAT-401 INDICATI Aspergillosis [ICD-11: 1F20] Investigative TTDDRUID D00TPI DRUGNAME Nalidixic Acid + Ampicillin INDICATI Typhoid fever [ICD-11: 1A07] Investigative TTDDRUID D00TPQ DRUGNAME VT-384 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D00TPW DRUGNAME FST-201 INDICATI Otitis externa [ICD-11: AA00-AA13] Phase 3 TTDDRUID D00TQN DRUGNAME JTK-003 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2 TTDDRUID D00TRL DRUGNAME REV-598 INDICATI Carcinoid syndrome [ICD-11: 5B10] Terminated TTDDRUID D00TRV DRUGNAME Besifloxacin INDICATI Ocular inflammation [ICD-11: 9C61.24] Approved TTDDRUID D00TTS DRUGNAME Human chorionic gonadotropin INDICATI Heart disease [ICD-11: BA41-BA42] Terminated TTDDRUID D00TUP DRUGNAME Vitreosolve INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Phase 3 TTDDRUID D00TUR DRUGNAME LY2495655 INDICATI Disuse muscle atrophy [ICD-11: 8B61] Phase 2 TTDDRUID D00TVI DRUGNAME SR-58894A INDICATI Gastrointestinal disease [ICD-11: DE2Z] Terminated TTDDRUID D00TXL DRUGNAME AAV2-hFIX16 INDICATI Factor IX deficiency [ICD-11: 3B11] Phase 1 TTDDRUID D00TYI DRUGNAME TG-3030 INDICATI Nicotine dependence [ICD-11: 6C4A.2] Investigative TTDDRUID D00TYP DRUGNAME KIN-4064 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00TYR DRUGNAME Anti-tubulin agents INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00UAE DRUGNAME Bavituximab INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Asthma [ICD-11: CA23] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 TTDDRUID D00UBK DRUGNAME L-159689 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D00UBX DRUGNAME TNX-355 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D00UCC DRUGNAME ABT-518 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D00UCW DRUGNAME CEREBROCRAST INDICATI Nerve injury [ICD-11: ND56.4] Discontinued in Phase 1 TTDDRUID D00UDP DRUGNAME Terameprocol INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D00UEC DRUGNAME ASP3662 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D00UEG DRUGNAME LY288513 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D00UEQ DRUGNAME Etomoxir INDICATI Heart failure [ICD-11: BD10-BD13] Terminated TTDDRUID D00UET DRUGNAME SAR-407899 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 INDICATI Microvascular angina [ICD-11: BA86] Phase 2 TTDDRUID D00UFZ DRUGNAME AMG 745 INDICATI Muscle atrophy [ICD-11: FB32.Y] Phase 2 TTDDRUID D00UGC DRUGNAME HSC660 INDICATI Alopecia [ICD-11: ED70] Phase 1/2 TTDDRUID D00UGX DRUGNAME Cenplacel-L INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D00UGY DRUGNAME Natural killer cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D00UHK DRUGNAME KI-0905 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D00UJF DRUGNAME Dextran INDICATI Thrombosis [ICD-11: DB61-GB90] Approved TTDDRUID D00UKN DRUGNAME Mesenchymal stromal cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D00ULY DRUGNAME KAI-9803/ BMS-875944 INDICATI Reperfusion injury [ICD-11: ND56.Z] Phase 2 TTDDRUID D00UMJ DRUGNAME NM-007-LENK INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D00UNK DRUGNAME Coltuximab ravtansine INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D00UOQ DRUGNAME PAT-SC1 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2 TTDDRUID D00UOR DRUGNAME Desirudin INDICATI Deep vein thrombosis [ICD-11: BD71] Approved TTDDRUID D00UOZ DRUGNAME MEDI-491 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1 TTDDRUID D00UPU DRUGNAME RPR-107836 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D00UQF DRUGNAME GW4064 INDICATI Hepatic fibrosis [ICD-11: DB93.0] Preclinical TTDDRUID D00UQW DRUGNAME RG7741 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00URZ DRUGNAME LG-740 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2 TTDDRUID D00USF DRUGNAME Trazodone INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D00USS DRUGNAME Cholera vaccine INDICATI Vibrio cholerae infection [ICD-11: 1A00] Approved TTDDRUID D00USX DRUGNAME CEFMATILEN HYDROCHLORIDE HYDRATE INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3 TTDDRUID D00UTD DRUGNAME Nedaplatin INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved TTDDRUID D00UUL DRUGNAME N8-GP INDICATI Factor VIII deficiency [ICD-11: 3B10] Phase 3 TTDDRUID D00UVA DRUGNAME Carfilzomib INDICATI Multiple myeloma [ICD-11: 2A83] Approved INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D00UVU DRUGNAME Lipoteichoic acid INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D00UWY DRUGNAME RT-001 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 INDICATI Friedreich's ataxia [ICD-11: 8A03.10] Phase 1/2 TTDDRUID D00UXT DRUGNAME Acetrizoate Sodium INDICATI Radiographic contrast medium [ICD-11: N.A.] Approved TTDDRUID D00UYB DRUGNAME Anti-DLL-4 mab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00UYE DRUGNAME Meperidine INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D00UYR DRUGNAME IMC-1 INDICATI Fibromyalgia [ICD-11: MG30.01] Phase 2 TTDDRUID D00UZR DRUGNAME Palbociclib INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D00VAJ DRUGNAME ORBOFIBAN INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 3 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3 TTDDRUID D00VBT DRUGNAME ZK 304709 INDICATI Advanced solid tumour [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D00VCH DRUGNAME F-98214 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D00VCZ DRUGNAME HGT-2610 INDICATI Leukodystrophy [ICD-11: 8A44] Investigative TTDDRUID D00VFE DRUGNAME Saralasin Acetate INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D00VFH DRUGNAME PXS-25 INDICATI Fibrosis [ICD-11: GA14-GC01] Phase 1 TTDDRUID D00VFM DRUGNAME RWJ-49968 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D00VGP DRUGNAME XGP-215 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00VJC DRUGNAME Peg. Adrenomedullin INDICATI Lung disease [ICD-11: CA60-CA8Z] Phase 1 TTDDRUID D00VKK DRUGNAME VPI-2690B INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID D00VLF DRUGNAME HCV/MF59 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1/2 TTDDRUID D00VMA DRUGNAME Vatreptacog alfa (activated) INDICATI Bleeding disorder [ICD-11: GA20-GA21] Phase 3 TTDDRUID D00VMY DRUGNAME P-3378 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00VNH DRUGNAME ZK-200775 INDICATI Coronary artery disease [ICD-11: BA80] Phase 1 TTDDRUID D00VOE DRUGNAME Myoblast cell transplantation INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 1 TTDDRUID D00VOF DRUGNAME TNF-PEG-20 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00VPT DRUGNAME SB222200 INDICATI Schizoaffective disorder [ICD-11: 6A21] Preclinical INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D00VPU DRUGNAME SLV-323 INDICATI Gastric motility disorder [ICD-11: DA21] Discontinued in Phase 1 INDICATI Chemotherapy-induced nausea [ICD-11: MD90] Discontinued in Phase 1 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 1 TTDDRUID D00VPV DRUGNAME TAK-013 INDICATI Uterine fibroids [ICD-11: 2E86.0] Discontinued in Phase 2 TTDDRUID D00VQI DRUGNAME SQ-30741 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D00VQT DRUGNAME 99mTc-EC-DG INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D00VSQ DRUGNAME E-1455 INDICATI Schizophrenia [ICD-11: 6A20] Investigative TTDDRUID D00VUG DRUGNAME FF21101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D00VUL DRUGNAME Phenazopyridine INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D00VUN DRUGNAME TRX-818 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00VXZ DRUGNAME YT-1006 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D00VZF DRUGNAME Merbarone INDICATI Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 2 TTDDRUID D00VZZ DRUGNAME Allopregnanolone INDICATI Postpartum depression [ICD-11: 6E20.0] Approved INDICATI Depression [ICD-11: 6A70-6A7Z] Approved INDICATI Status epilepticus seizure [ICD-11: 8A66.1Y] Phase 3 INDICATI Essential tremor or related tremors [ICD-11: 8A04.1] Phase 2 TTDDRUID D00WAM DRUGNAME Hydroflumethiazide INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D00WBN DRUGNAME ALV-003 INDICATI Coeliac disease [ICD-11: DA95] Phase 2 TTDDRUID D00WCT DRUGNAME EVP-1001-1 INDICATI Heart disease [ICD-11: BA41-BA42] Phase 2 TTDDRUID D00WCX DRUGNAME Bezafibrate INDICATI Hyperlipidaemia [ICD-11: 5C80] Approved TTDDRUID D00WDM DRUGNAME BST-204 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00WDY DRUGNAME BMS-903452 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D00WEL DRUGNAME ABS-401 INDICATI Amnesia [ICD-11: MB21.1] Terminated TTDDRUID D00WEP DRUGNAME BLX-155 INDICATI Deep vein thrombosis [ICD-11: BD71] Investigative TTDDRUID D00WHC DRUGNAME MB-03966 INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Investigative TTDDRUID D00WHL DRUGNAME Juvidex INDICATI Sarcoidosis [ICD-11: 4B20.5] Phase 2 TTDDRUID D00WJC DRUGNAME DCDS0780A INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D00WJE DRUGNAME SUN-1334H INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2 TTDDRUID D00WKL DRUGNAME PSX-4206 INDICATI Pulmonary disease [ICD-11: 1B10-1F85] Investigative TTDDRUID D00WME DRUGNAME Conatumumab INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D00WMJ DRUGNAME CMC-001 INDICATI Liver cancer [ICD-11: 2C12] Phase 2 TTDDRUID D00WMK DRUGNAME Relvar/Breo INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D00WOT DRUGNAME CDP-850 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D00WOX DRUGNAME Human retinal pigment epithelial cell therapy INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 1/2 TTDDRUID D00WPT DRUGNAME ACV-1 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D00WPU DRUGNAME Sazetidine-A INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D00WUC DRUGNAME Histidase-PEG-20 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00WUF DRUGNAME Pregabalin INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D00WVI DRUGNAME AS-1907417 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D00WVW DRUGNAME YM443 INDICATI Functional dyspepsia [ICD-11: DD90.3] Approved TTDDRUID D00WWU DRUGNAME SMP-028 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D00WYV DRUGNAME V-3526 INDICATI Encephalitis virus infection [ICD-11: 1C83-1C84] Terminated TTDDRUID D00WZK DRUGNAME BC-3781 intravenous INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D00XBC DRUGNAME GSK-2239633 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D00XBH DRUGNAME MNLP-462a INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D00XCX DRUGNAME DIFLOMOTECAN INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D00XDN DRUGNAME Pyrazole derivative 40 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D00XEM DRUGNAME Beta-cyclodextrin conjugate derivative 3 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D00XEU DRUGNAME GSK-923295 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D00XEX DRUGNAME MN-201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00XFT DRUGNAME Pyrazole derivative 53 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D00XFY DRUGNAME ISIS 2922 + foscarnet 3' -azido-3'-deoxythymidine 2'-3'-dideoxycytidine INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D00XHD DRUGNAME Balofloxacin INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Approved TTDDRUID D00XIP DRUGNAME MVA-BN Brachyury INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00XKB DRUGNAME AZ-4217 INDICATI Rheumatoid arthritis [ICD-11: FA20] Clinical trial TTDDRUID D00XKE DRUGNAME PMID26651364-Compound-109 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D00XLE DRUGNAME PF-4764793 INDICATI Respiratory disease [ICD-11: CB40] Phase 1 TTDDRUID D00XMZ DRUGNAME Drug 1940029 INDICATI Acne vulgaris [ICD-11: ED80] Phase 1 TTDDRUID D00XNC DRUGNAME CAT-2200 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D00XND DRUGNAME PMA-511R INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D00XNW DRUGNAME AL-54478 INDICATI Ocular hypertension [ICD-11: 9C61.01] Phase 2 TTDDRUID D00XPA DRUGNAME L-759274 INDICATI Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 3 INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 3 TTDDRUID D00XPC DRUGNAME Halobetasol Propionate INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D00XPZ DRUGNAME ELB-WE-007 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D00XQK DRUGNAME HRC-102 INDICATI Reperfusion injury [ICD-11: ND56.Z] Terminated TTDDRUID D00XQO DRUGNAME MANOALIDE INDICATI Arthritis [ICD-11: FA20] Phase 2 TTDDRUID D00XRI DRUGNAME TJN-220 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D00XRK DRUGNAME BMS-182193 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D00XSP DRUGNAME S-35678 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D00XSQ DRUGNAME PGL-1001 INDICATI Female infertility [ICD-11: GA31.Z] Investigative TTDDRUID D00XTS DRUGNAME CR-3834 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D00XUN DRUGNAME Etidronate Disodium INDICATI Osteoporosis [ICD-11: FB83.0] Approved TTDDRUID D00XVE DRUGNAME BR6819 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 1 TTDDRUID D00XVL DRUGNAME ITI-214 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1/2 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 INDICATI Complete androgen insensitivity syndrome [ICD-11: LD2A.4] Phase 1 INDICATI Immune dysregulation [ICD-11: 4A01.2] Phase 1 TTDDRUID D00XWB DRUGNAME F-15845 INDICATI Angina pectoris [ICD-11: BA40] Phase 1 TTDDRUID D00XWD DRUGNAME Tegaserod INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved INDICATI Gastro-oesophageal reflux [ICD-11: DA22] Withdrawn from market INDICATI Dyspepsia [ICD-11: MD92] Withdrawn from market TTDDRUID D00XWF DRUGNAME RBX2660 INDICATI C. difficile infection [ICD-11: 1A04] Phase 3 TTDDRUID D00XXZ DRUGNAME N-acylpiperidine ether derivative 1 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D00XZP DRUGNAME UR-7198 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D00XZY DRUGNAME ORC-Vax INDICATI Vibrio cholerae infection [ICD-11: 1A00] Approved TTDDRUID D00YAH DRUGNAME E2730 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 1 TTDDRUID D00YAS DRUGNAME Q-102 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D00YBW DRUGNAME OXY-111A INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1/2 TTDDRUID D00YBZ DRUGNAME OC-10X INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 1 INDICATI Proliferative diabetic retinopathy [ICD-11: 9B71.01] Phase 1 TTDDRUID D00YCO DRUGNAME Pulvomycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D00YDN DRUGNAME CXR-1002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00YEO DRUGNAME NZ-1002 INDICATI Lysosomal storage disease [ICD-11: 5C56.Z] Terminated TTDDRUID D00YER DRUGNAME HM-78136B INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D00YEV DRUGNAME BAICALEIN INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D00YFP DRUGNAME RG7697 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D00YGA DRUGNAME SB-219994 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D00YJD DRUGNAME SEL-103 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D00YJI DRUGNAME EOS-013 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Investigative TTDDRUID D00YLF DRUGNAME Serpacwa INDICATI Poison intoxication [ICD-11: NE6Z] Approved TTDDRUID D00YLM DRUGNAME TRAXOPRODIL MESYLATE INDICATI Neurological disorder [ICD-11: 6B60] Phase 2 TTDDRUID D00YLW DRUGNAME Dolasetron INDICATI Nausea [ICD-11: MD90] Approved TTDDRUID D00YMM DRUGNAME SAR-215500 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D00YMN DRUGNAME AIKO-152 INDICATI Opioid dependence [ICD-11: 6C43.2Z] Investigative TTDDRUID D00YNJ DRUGNAME XB-387 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative TTDDRUID D00YNK DRUGNAME MGN-7455 INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative TTDDRUID D00YNY DRUGNAME VPC-94075 INDICATI Vascular disease [ICD-11: BE2Z] Investigative TTDDRUID D00YOV DRUGNAME MT-110 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00YOW DRUGNAME LM-1376 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D00YPR DRUGNAME CP-547632 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D00YQI DRUGNAME TRC105 INDICATI Hemangiosarcoma [ICD-11: 2B56.1] Phase 3 INDICATI Angiosarcoma [ICD-11: 2B56] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 2 INDICATI Peritoneal cancer [ICD-11: 2C51.Z] Phase 2 INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 2 INDICATI Soft tissue sarcoma [ICD-11: 2B57] Phase 2 INDICATI Gestational trophoblastic neoplasia [ICD-11: 2F33-2F76] Phase 2 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1 TTDDRUID D00YQZ DRUGNAME L-702958 INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Terminated TTDDRUID D00YRF DRUGNAME UCB-1277763 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D00YRS DRUGNAME PMID26815044-Compound-H INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D00YSJ DRUGNAME Tecadenoson INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 3 INDICATI Atrial fibrillation [ICD-11: BC81.3] Discontinued in Phase 3 TTDDRUID D00YTQ DRUGNAME BMS-345541 INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D00YTS DRUGNAME AVP-13546 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Investigative TTDDRUID D00YTX DRUGNAME OG-19 INDICATI Dementia [ICD-11: 6D80-6D86] Investigative TTDDRUID D00YUB DRUGNAME NT-3 INDICATI Constipation [ICD-11: DD91.1] Discontinued in Phase 2 TTDDRUID D00YUP DRUGNAME LT-3001 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 1 TTDDRUID D00YUQ DRUGNAME CART-19 T cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D00YVF DRUGNAME Exenatide INDICATI Type-2 diabetes [ICD-11: 5A11] Approved INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3 TTDDRUID D00YWH DRUGNAME Anti-MRSA INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D00YWL DRUGNAME BMS-936557 INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 2 TTDDRUID D00YWP DRUGNAME Nandrolone INDICATI Osteoporosis [ICD-11: FB83.0] Approved TTDDRUID D00YXA DRUGNAME PMID25666693-Compound-2 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D00YXG DRUGNAME Anti-mesothelin CAR transduced PBL INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1/2 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1/2 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 1/2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D00YXR DRUGNAME Foxy-5 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D00YXU DRUGNAME CCX-025 INDICATI Crohn disease [ICD-11: DD70] Phase 1 TTDDRUID D00YZA DRUGNAME Thiotepa INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D00YZD DRUGNAME Dolutegravir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D00YZP DRUGNAME EBS-A42 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D00ZBQ DRUGNAME TL-1892 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00ZBZ DRUGNAME OGX-427 + Paclitaxel INDICATI Lung cancer [ICD-11: 2C25.0] Investigative INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative INDICATI Bladder cancer [ICD-11: 2C94] Investigative INDICATI Ovarian cancer [ICD-11: 2C73] Investigative INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D00ZCN DRUGNAME Caspofungin INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D00ZCT DRUGNAME Fostemsavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D00ZDO DRUGNAME SELA-070 INDICATI Tobacco dependence [ICD-11: 6C4A.2] Phase 1 TTDDRUID D00ZEG DRUGNAME Umespirone INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1 TTDDRUID D00ZEN DRUGNAME Seasonal influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D00ZFC DRUGNAME WilVent INDICATI Pulmonary disease [ICD-11: 1B10-1F85] Investigative TTDDRUID D00ZFP DRUGNAME Estrone INDICATI Menopausal and postmenopausal disorder [ICD-11: GA30] Approved TTDDRUID D00ZFQ DRUGNAME H2N3 MO 2003/AA INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D00ZGA DRUGNAME Casopitant INDICATI Chemotherapy-induced nausea [ICD-11: MD90] Withdrawn from market TTDDRUID D00ZGE DRUGNAME Oncopurge INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D00ZGF DRUGNAME DA-6886 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 1 TTDDRUID D00ZGT DRUGNAME MMR vaccine INDICATI Rubella prophylaxis [ICD-11: 1F02] Phase 3 INDICATI Mumps virus infection [ICD-11: 1D80] Phase 3 INDICATI Measles [ICD-11: 1F03] Phase 3 TTDDRUID D00ZHM DRUGNAME Autologous adipose-derived stem cells INDICATI Anal fistula [ICD-11: DB50.1] Phase 2 TTDDRUID D00ZHR DRUGNAME Salmonella typhimurium A1-R INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00ZKC DRUGNAME CS-92 INDICATI Acquired immune deficiency syndrome [ICD-11: 1C62.3] Discontinued in Phase 2 TTDDRUID D00ZLC DRUGNAME NeuroCell-PD INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D00ZMN DRUGNAME Fluorofenidone INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D00ZMU DRUGNAME P28 cell penetrating peptide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Phase 1 TTDDRUID D00ZNP DRUGNAME HMR-1426 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 2 TTDDRUID D00ZNS DRUGNAME CDE-5110 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D00ZOF DRUGNAME Sodium lactate INDICATI Acidosis [ICD-11: 5C73] Approved TTDDRUID D00ZPR DRUGNAME Neucardin INDICATI Heart failure [ICD-11: BD10-BD13] Phase 3 INDICATI Chronic heart failure [ICD-11: BD1Z] Phase 2 TTDDRUID D00ZPT DRUGNAME BI-11634 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D00ZRO DRUGNAME Cyclic compound 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D00ZRS DRUGNAME TARP peptide vaccines INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D00ZTD DRUGNAME OZ277 INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D00ZUU DRUGNAME ONO-5334 INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2 TTDDRUID D00ZVM DRUGNAME BAY1129980 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00ZVS DRUGNAME Condoliase INDICATI Herniation disk [ICD-11: ND51.2] Phase 3 TTDDRUID D00ZWE DRUGNAME AT-007 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D00ZWG DRUGNAME NS-638 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D00ZXR DRUGNAME Heteroaryl-carboxamide derivative 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D00ZZB DRUGNAME Oxaborole INDICATI Leishmania infection [ICD-11: 1F54.0] Investigative TTDDRUID D00ZZH DRUGNAME BK-218 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D01AAH DRUGNAME CAR-T cells targeting CD22 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D01ACE DRUGNAME BF/PC-13 INDICATI Dermatitis [ICD-11: EA80-EA89] Investigative TTDDRUID D01ADH DRUGNAME Evitar INDICATI Wound healing [ICD-11: EL8Y] Phase 2 TTDDRUID D01ADL DRUGNAME Roledumab INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 2/3 TTDDRUID D01AEF DRUGNAME 3F8 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01AET DRUGNAME MPC-150-IM INDICATI Heart failure [ICD-11: BD10-BD13] Phase 3 TTDDRUID D01AFG DRUGNAME RG7414 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2 TTDDRUID D01AHI DRUGNAME Dance-501 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D01AHO DRUGNAME Abarelix INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D01AIM DRUGNAME HBsAG-HBIG complex INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3 TTDDRUID D01AIN DRUGNAME Fezakinumab INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D01AJM DRUGNAME YP-009 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D01AJY DRUGNAME Baclofen INDICATI Multiple sclerosis [ICD-11: 8A40] Approved INDICATI Fragile X syndrome [ICD-11: LD55] Phase 3 TTDDRUID D01AKK DRUGNAME ALXN1101 INDICATI Molybdenum cofactor deficiency [ICD-11: 5B5K.A] Phase 2/3 TTDDRUID D01AKU DRUGNAME MCP-201 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D01ALJ DRUGNAME BV-6481 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D01ALP DRUGNAME MBC-31 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D01ANE DRUGNAME EB-1,2,3 mab INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D01AQT DRUGNAME Terconazole INDICATI Candidiasis [ICD-11: 1F23] Approved TTDDRUID D01ARG DRUGNAME DB-900 INDICATI Type-2 diabetes [ICD-11: 5A11] Investigative TTDDRUID D01ARU DRUGNAME DST-2970 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D01ASM DRUGNAME NPC-15199 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 2 TTDDRUID D01ATS DRUGNAME LEO-90110 INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D01AUL DRUGNAME L-697639 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D01AVF DRUGNAME SAR-106881 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Investigative TTDDRUID D01AXB DRUGNAME Duloxetine INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D01AXK DRUGNAME Antibodie derivative 10 INDICATI Neoplasm [ICD-11: 2A00-2F9Z] Patented INDICATI Angiogenesis disorder [ICD-11: BE2Z] Patented TTDDRUID D01AXT DRUGNAME NP-50301 INDICATI Eye disorder [ICD-11: 9A01-9A0Z] Discontinued in Phase 2 TTDDRUID D01AYF DRUGNAME ND-1.1 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D01AYJ DRUGNAME Terbinafine INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved INDICATI Onychomycosis [ICD-11: EE12.1] Phase 2 TTDDRUID D01AYP DRUGNAME Bromo benzyl ether derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D01AYX DRUGNAME AZD3293 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2/3 TTDDRUID D01AZG DRUGNAME Risperidone INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D01AZP DRUGNAME BNC-105 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 2 TTDDRUID D01BAU DRUGNAME SPN-812 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2 TTDDRUID D01BBB DRUGNAME VM-1500 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2/3 TTDDRUID D01BBR DRUGNAME Dezinamide INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 2 TTDDRUID D01BDY DRUGNAME Axomadol INDICATI Back pain [ICD-11: ME84.Z] Phase 2 TTDDRUID D01BEX DRUGNAME PRS-060 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D01BFA DRUGNAME BIK-381 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Investigative TTDDRUID D01BGU DRUGNAME UX-002 INDICATI Lysosomal storage disease [ICD-11: 5C56.Z] Investigative TTDDRUID D01BHC DRUGNAME BTA-929 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D01BIQ DRUGNAME Human embryonic stem cell-derived motor neuron progenitors INDICATI Neuromuscular disease [ICD-11: 8C6Y] Investigative TTDDRUID D01BJK DRUGNAME Mimovax INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D01BJO DRUGNAME GABA mimetics INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D01BJS DRUGNAME HL-028 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D01BOD DRUGNAME Pro-Islet INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D01BOE DRUGNAME 44-Bu INDICATI Heart arrhythmia [ICD-11: BC65] Investigative TTDDRUID D01BPF DRUGNAME Avitriptan INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 3 TTDDRUID D01BPP DRUGNAME EC0225 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01BQC DRUGNAME Cefonicid INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D01BQJ DRUGNAME TCV-295 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D01BQK DRUGNAME Carbamide peroxide INDICATI Ear disease [ICD-11: AA0Y-AC0Z] Approved TTDDRUID D01BRD DRUGNAME SGN-CD123A INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D01BRX DRUGNAME IMM-252 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D01BUS DRUGNAME CA9-ADC INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D01BUT DRUGNAME LXT-101 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D01BVI DRUGNAME V-101 INDICATI Erythema [ICD-11: ME64.0] Phase 2 TTDDRUID D01BWJ DRUGNAME Tyrophostins INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01BYB DRUGNAME Adenosine triphosphate INDICATI Malnutrition [ICD-11: 5B50-5B71] Approved INDICATI Heart disease [ICD-11: BA41-BA42] Phase 2 INDICATI Bradycardia [ICD-11: MC81.1] Discontinued in Phase 2 TTDDRUID D01BZP DRUGNAME Tuberculosis therapy, Ithemba INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D01BZR DRUGNAME IC-041 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D01CAH DRUGNAME Mesenchymal stem cells INDICATI Epidermolysis bullosa [ICD-11: EC3Z] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01CAJ DRUGNAME AZD-3342 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D01CBE DRUGNAME Ygalo INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D01CBG DRUGNAME SRP-5051 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D01CBK DRUGNAME OSE2101 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID D01CBU DRUGNAME FG-020318 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01CBV DRUGNAME C-5997 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D01CDE DRUGNAME BIMU-1 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 1 TTDDRUID D01CEG DRUGNAME P-1736 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D01CEQ DRUGNAME CER-227185 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Discontinued in Phase 1/2 TTDDRUID D01CFL DRUGNAME Benzothiazoline derivative 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D01CFQ DRUGNAME LB-2.1 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D01CGV DRUGNAME LY-2599506 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D01CHD DRUGNAME RG6061 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01CHI DRUGNAME VR315 INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D01CIB DRUGNAME SAR164653 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D01CIN DRUGNAME STF-62247 INDICATI Renal cell carcinoma [ICD-11: 2C90] Investigative TTDDRUID D01CJB DRUGNAME Novovac-M1 INDICATI Melanoma [ICD-11: 2C30] Terminated TTDDRUID D01CJY DRUGNAME FR-146687 INDICATI Prostate disease [ICD-11: GA91] Phase 2 TTDDRUID D01CKY DRUGNAME Ecabet sodium INDICATI Ulcer [ICD-11: CA02-CB40] Approved INDICATI Xerophthalmia [ICD-11: 5B55.Y] Phase 2 TTDDRUID D01CLK DRUGNAME CHGN111 INDICATI Skin infection [ICD-11: 1F28-1G0Z] Investigative TTDDRUID D01CNB DRUGNAME E6201 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D01CND DRUGNAME PMID26651364-Compound-114 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D01CNV DRUGNAME PL-611 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D01COH DRUGNAME ZP-010 INDICATI Bronchitis [ICD-11: CA20] Investigative TTDDRUID D01CON DRUGNAME IGIV3I Grifols INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D01CQJ DRUGNAME KLS-HPV INDICATI Cervical cancer [ICD-11: 2C77.0] Investigative TTDDRUID D01CRB DRUGNAME L-Tyrosine INDICATI Malnutrition [ICD-11: 5B50-5B71] Approved TTDDRUID D01CTR DRUGNAME Plasminogen INDICATI Congenital plasminogen activator inhibitor type 1 deficiency [ICD-11: 3B50.1] Phase 2/3 INDICATI Hypoplasminogenemia [ICD-11: DA0D.3] Phase 2/3 TTDDRUID D01CUC DRUGNAME BCMA CAR T cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D01CUO DRUGNAME TTI-621 INDICATI Melanoma [ICD-11: 2C30] Phase 1 INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 1 INDICATI Mycosis fungoides [ICD-11: 2B01] Phase 1 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01CXJ DRUGNAME PAC-113 INDICATI Oral candidiasis [ICD-11: 1F23.0] Phase 2 TTDDRUID D01CXW DRUGNAME MEDI0680 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01CYA DRUGNAME Bendamustine hydrochloride INDICATI leukaemia [ICD-11: 2A60-2B33] Approved TTDDRUID D01CYK DRUGNAME ME1100 INDICATI Bacterial pneumonia [ICD-11: CA40.0] Phase 1 TTDDRUID D01CYT DRUGNAME ELND-002 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D01CYW DRUGNAME PK-236 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D01CZH DRUGNAME Chanllergen INDICATI Allergy [ICD-11: 4A80-4A85] Approved TTDDRUID D01DAD DRUGNAME CJ-13610 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D01DAW DRUGNAME Bifeprunox INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 3 TTDDRUID D01DBF DRUGNAME APIT INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01DBQ DRUGNAME Teniposide INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved TTDDRUID D01DCJ DRUGNAME GRNOPC-1 INDICATI Spinal cord injury [ICD-11: ND51.2] Phase 1 TTDDRUID D01DDN DRUGNAME SCH-900271 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 2 TTDDRUID D01DGN DRUGNAME Ethiodized oil INDICATI Lymphatic disease [ICD-11: BD9Z] Approved TTDDRUID D01DGZ DRUGNAME ABBV-2222 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 TTDDRUID D01DIM DRUGNAME CLL442 INDICATI Cutaneous squamous cell carcinoma [ICD-11: 2C30] Phase 1/2 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1/2 TTDDRUID D01DJA DRUGNAME TSK-204 INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D01DJI DRUGNAME PHY-906 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 TTDDRUID D01DLT DRUGNAME Encapsulated live cells converting ifosfamide INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D01DMT DRUGNAME Dendrogenin A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01DNH DRUGNAME PMID25666693-Compound-150 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D01DOY DRUGNAME GR-127607 INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 1 TTDDRUID D01DPC DRUGNAME Ribavirin + interferon alfa-2b INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D01DPD DRUGNAME KW-6055 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1 TTDDRUID D01DQI DRUGNAME Parvovirus H-1 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Investigative TTDDRUID D01DQR DRUGNAME AIR-Epinephrine INDICATI Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 1 TTDDRUID D01DRE DRUGNAME SOM-0002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01DRL DRUGNAME RGH-2721 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Terminated TTDDRUID D01DSP DRUGNAME Cephapirin INDICATI Sepsis [ICD-11: 1G40-1G41] Approved TTDDRUID D01DTO DRUGNAME AOB102 INDICATI Eczema [ICD-11: EA80-EA89] Phase 2 TTDDRUID D01DTQ DRUGNAME PXS-2076 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D01DVR DRUGNAME NT-001 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D01DVX DRUGNAME DPC-333 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated INDICATI Inflammatory bowel disease [ICD-11: DD72] Terminated TTDDRUID D01DXI DRUGNAME PF-06290510 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 2 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D01EAG DRUGNAME MDDR 287569 INDICATI Urinary incontinence [ICD-11: MF50.2] Investigative TTDDRUID D01EBJ DRUGNAME 4991W93 INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 2 TTDDRUID D01ECN DRUGNAME MVA-BN DF INDICATI Flavivirus infection [ICD-11: 1C80] Preclinical TTDDRUID D01EDJ DRUGNAME CSE-1034 INDICATI Nosocomial infection [ICD-11: PL10] Phase 3 TTDDRUID D01EDO DRUGNAME GW-250495 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D01EDS DRUGNAME SL-65.1498 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D01EFO DRUGNAME CGP-53716 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D01EHI DRUGNAME Live attenuated H1N1 pandemic influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D01EJG DRUGNAME RG6100 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D01EJJ DRUGNAME JTE-051 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 INDICATI Allergy [ICD-11: 4A80-4A85] Phase 1 TTDDRUID D01EKN DRUGNAME RAV-12 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01EKQ DRUGNAME Ferrous Citrate, Fe-59 INDICATI Iron deficiency [ICD-11: 5B5K.0] Approved TTDDRUID D01ELU DRUGNAME VSN-16R INDICATI Muscle spasm [ICD-11: MB47.3] Phase 2 TTDDRUID D01EMD DRUGNAME Ovarian dendritic cell-based vaccine INDICATI Peritoneal cancer [ICD-11: 2C51.Z] Phase 1/2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 TTDDRUID D01EPO DRUGNAME ABIO 09-01 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D01EPP DRUGNAME EL-715 INDICATI Osteoporosis [ICD-11: FB83.0] Terminated TTDDRUID D01EQG DRUGNAME Azapropazone INDICATI Inflammation [ICD-11: 1A00-CA43.1] Withdrawn from market TTDDRUID D01ERE DRUGNAME ASP4345 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 TTDDRUID D01ESB DRUGNAME YM-992 INDICATI Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 2 TTDDRUID D01ESC DRUGNAME BBT-009 INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D01ESJ DRUGNAME Luzindole INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Terminated TTDDRUID D01EUF DRUGNAME BMS 275291 INDICATI Kaposi sarcoma [ICD-11: 2B57] Discontinued in Phase 3 INDICATI Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 3 TTDDRUID D01EUO DRUGNAME Ragweed extract INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 3 TTDDRUID D01EVP DRUGNAME Resorcinol compound 17 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D01EWC DRUGNAME CR-2991 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D01EXG DRUGNAME AMG 224 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D01EXL DRUGNAME RNF43-721 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D01EXY DRUGNAME BN-AO-014 INDICATI Atrophy [ICD-11: 9A2Y-9C40] Preclinical TTDDRUID D01EYI DRUGNAME Umbilical Cord Mesenchymal Stem Cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01EYM DRUGNAME BB-2275 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D01EYR DRUGNAME ImmunoVEX-timelan INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 TTDDRUID D01EZA DRUGNAME EC-8042 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01EZY DRUGNAME JTP-2724 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D01FBO DRUGNAME H5N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2 TTDDRUID D01FBP DRUGNAME Vanutide cridificar INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D01FBS DRUGNAME ALF-5755 INDICATI Liver failure [ICD-11: DB99.7] Phase 2 TTDDRUID D01FCK DRUGNAME Teglicar INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D01FCY DRUGNAME Engineered hnCD16 iNK Cell INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D01FDL DRUGNAME Dabelotine INDICATI Cognitive impairment [ICD-11: 6D71] Phase 3 TTDDRUID D01FDN DRUGNAME NAL-GLU INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2/3 TTDDRUID D01FEC DRUGNAME Rusalatide acetate INDICATI Diabetic foot ulcer [ICD-11: BD54] Discontinued in Phase 2 TTDDRUID D01FFA DRUGNAME (+-)-tetrahydropalmatine INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved INDICATI Irritability [ICD-11: MB24] Approved INDICATI Analgesia [ICD-11: MB40.8] Approved TTDDRUID D01FFC DRUGNAME OPB-51602 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01FFG DRUGNAME Antistasin INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2 TTDDRUID D01FGR DRUGNAME Diphenhydramine INDICATI Meniere disease [ICD-11: AB31.0] Approved TTDDRUID D01FHL DRUGNAME AGN-150998 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 2 TTDDRUID D01FJA DRUGNAME UC-2024 INDICATI Premenstrual syndrome [ICD-11: GA34.40] Investigative TTDDRUID D01FJN DRUGNAME BAY-1006451 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D01FJT DRUGNAME Bucillamine INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved TTDDRUID D01FLN DRUGNAME LX-2932 INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D01FME DRUGNAME HNK-20 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Terminated TTDDRUID D01FQR DRUGNAME Ocaperidone INDICATI Schizoaffective disorder [ICD-11: 6A21] Phase 2 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 1b TTDDRUID D01FQV DRUGNAME Dichloroacetate sodium INDICATI Pulmonary hypertension [ICD-11: BB01] Phase 1 TTDDRUID D01FRK DRUGNAME LA-N8 INDICATI Factor VIII deficiency [ICD-11: 3B10] Investigative TTDDRUID D01FRP DRUGNAME APC-0013 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01FSX DRUGNAME REGN5093 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D01FTK DRUGNAME PN-403 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D01FTU DRUGNAME EQ-317 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D01FUB DRUGNAME AZD8529 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2 TTDDRUID D01FUC DRUGNAME Exatecan INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D01FUL DRUGNAME Balapiravir INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D01FWE DRUGNAME Certiva INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D01FWR DRUGNAME MPL-containing Pollinex allergy desensitization vaccine INDICATI Melanoma [ICD-11: 2C30] Preregistration TTDDRUID D01FXD DRUGNAME SCH-351591 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D01FYA DRUGNAME PU-H71 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 1 TTDDRUID D01FYX DRUGNAME Andes-1537 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01FZX DRUGNAME LEO 22811 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D01FZZ DRUGNAME GDC0310 INDICATI Chronic pain [ICD-11: MG30] Phase 1 TTDDRUID D01GAG DRUGNAME PV-921 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01GAZ DRUGNAME 123I-DRM-106 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D01GBV DRUGNAME CDD-190 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D01GBY DRUGNAME Desloratadine INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D01GCT DRUGNAME AZM-090 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D01GCY DRUGNAME NNC-26-0762 INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Terminated TTDDRUID D01GDB DRUGNAME Tat Oyi-Cys22 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D01GDH DRUGNAME XR-9051 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D01GDO DRUGNAME Cytoporins INDICATI Respiratory tract infection [ICD-11: CA45] Preclinical TTDDRUID D01GEB DRUGNAME ROXINDOLE INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 2 TTDDRUID D01GEK DRUGNAME PMID25666693-Compound-133 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D01GEO DRUGNAME Telomestatin INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D01GFU DRUGNAME ADCON(R) INDICATI Wound healing [ICD-11: EL8Y] Discontinued in Phase 3 TTDDRUID D01GFX DRUGNAME OSI-906 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D01GGB DRUGNAME SL-301 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01GHV DRUGNAME RANBEZOLID HYDROCHLORIDE INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical TTDDRUID D01GIF DRUGNAME BM-113 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D01GIG DRUGNAME RepliVec INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01GIW DRUGNAME S3 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D01GNW DRUGNAME NGN-9076 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D01GOY DRUGNAME AV-GBM-1 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 2 TTDDRUID D01GPA DRUGNAME Gepon INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D01GQD DRUGNAME EZN-3042 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01GQO DRUGNAME Mesenchymal stem cell therapy, ischemic-tolerant stem cells INDICATI Acute myocardial infarction [ICD-11: BA41] Phase 1 TTDDRUID D01GSA DRUGNAME C-0334578 INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Investigative TTDDRUID D01GSE DRUGNAME E-10030 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 2 TTDDRUID D01GTB DRUGNAME ZD-2767 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D01GTC DRUGNAME TAK-041 INDICATI XY disorder of sex development due to androgen resistance [ICD-11: LD2A.4] Phase 1 TTDDRUID D01GUS DRUGNAME Udenafil INDICATI Erectile dysfunction [ICD-11: HA01.1] Approved TTDDRUID D01GVC DRUGNAME GP-3269 INDICATI Convulsion [ICD-11: 8A68.Z] Phase 1 TTDDRUID D01GVM DRUGNAME Lemuteporfin INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D01GXB DRUGNAME Combinations SAR245409 / MSC1936369B SAR245408/SAR256212 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01GXL DRUGNAME REP8839 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D01GYK DRUGNAME Succimer INDICATI Metal intoxication [ICD-11: NE60] Approved TTDDRUID D01GYT DRUGNAME Fosfomycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D01HAT DRUGNAME CD19.CAR-aNKT cells INDICATI B-cell small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 1 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 INDICATI Myeloid leukaemia [ICD-11: 2B33.1] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D01HBE DRUGNAME RHIZOXIN INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D01HBG DRUGNAME Apadoline INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D01HDP DRUGNAME SLV 306 INDICATI Acute decompensated heart failure [ICD-11: BD1Z] Phase 2 TTDDRUID D01HED DRUGNAME PMID25666693-Compound-158 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D01HEN DRUGNAME HBDt.Fc INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01HFP DRUGNAME HL-160 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01HGI DRUGNAME TGSC01AA(4) INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D01HGT DRUGNAME Anti-CD22 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D01HHD DRUGNAME Fovepta INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 3 TTDDRUID D01HHH DRUGNAME CHR-4125 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01HHJ DRUGNAME HTU-PA INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1/2 TTDDRUID D01HJQ DRUGNAME Aminoazetidine derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D01HKL DRUGNAME ABT-335 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Approved TTDDRUID D01HKZ DRUGNAME TSR-011 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D01HLF DRUGNAME ATI-0810 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01HLO DRUGNAME PF-05190457 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D01HNL DRUGNAME Allantoin INDICATI Vulnerary [ICD-11: ND56.Z] Approved TTDDRUID D01HOI DRUGNAME MT-503 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01HOL DRUGNAME Autologous idiotypic cancer vaccine INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D01HOT DRUGNAME X-072-NAB INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D01HPI DRUGNAME DLX-0110 INDICATI Neuropathic pain [ICD-11: 8E43.0] Terminated TTDDRUID D01HPP DRUGNAME ECFCs INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D01HPY DRUGNAME Melphalan flufenamide INDICATI Multiple myeloma [ICD-11: 2A83] Approved INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 INDICATI Plasma cell myeloma [ICD-11: 2A83.1] Phase 1/2 TTDDRUID D01HQJ DRUGNAME Dialyzable leukocyte cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01HQQ DRUGNAME Bone morphogenetic protein-4 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Investigative TTDDRUID D01HQU DRUGNAME AK107 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01HRJ DRUGNAME JEBIK V INDICATI Japanese encephalitis virus infection [ICD-11: 1C85] Approved TTDDRUID D01HRR DRUGNAME Domitroban INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Preregistration TTDDRUID D01HRU DRUGNAME SBR-759 INDICATI Hypophosphatasia [ICD-11: 5C64.3] Phase 3 TTDDRUID D01HSA DRUGNAME HG-1154 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D01HTH DRUGNAME Aptiganel HCl INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Investigative TTDDRUID D01HTJ DRUGNAME FG-65155 INDICATI Reperfusion injury [ICD-11: ND56.Z] Investigative TTDDRUID D01HTL DRUGNAME Vinorelbine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D01HTS DRUGNAME MIP-1231 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01HVC DRUGNAME MTD-102 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01HVE DRUGNAME ICI-D-1542 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D01HVM DRUGNAME 99mTc-DI-DD3B6/22-80B3 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D01HVR DRUGNAME SAV-001 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID D01HVT DRUGNAME Ribociclib Succinate INDICATI Hormone receptor positive and HER2-negative advanced or metastatic breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D01HVZ DRUGNAME TD-8954 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1/2 TTDDRUID D01HWK DRUGNAME AA-10044 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D01HXA DRUGNAME AUS-131 INDICATI Hot flushes [ICD-11: GA30] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1/2 TTDDRUID D01HXN DRUGNAME TRL-382 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D01HYQ DRUGNAME IONIS-GCCRRX INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D01HZQ DRUGNAME VP-102 INDICATI Molluscum contagiosum infection [ICD-11: 1E76] Phase 3 INDICATI Common wart [ICD-11: 1E80] Phase 2 TTDDRUID D01IBO DRUGNAME BCX-1470 INDICATI Bleeding disorder [ICD-11: GA20-GA21] Discontinued in Phase 1 TTDDRUID D01ICI DRUGNAME Remdesivir INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Approved INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 1 TTDDRUID D01ICU DRUGNAME Conjugated estrogens b INDICATI Hormone replacement therapy [ICD-11: 8E01] Approved TTDDRUID D01ICY DRUGNAME AVE-0657 INDICATI Cheyne-stokes respiration [ICD-11: MD11.Y] Phase 2 TTDDRUID D01IDE DRUGNAME E-5324 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D01IDQ DRUGNAME IPH-1101 INDICATI Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 2 TTDDRUID D01IDW DRUGNAME SKI-O-703 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D01IED DRUGNAME BVD-523 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D01IEM DRUGNAME Pneumovax 23 INDICATI Otitis media [ICD-11: AA80-AB0Z] Approved TTDDRUID D01IGH DRUGNAME SERA5-targeted malaria vaccine INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1 TTDDRUID D01IGZ DRUGNAME Napabucasin INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Gastrointestinal cancer [ICD-11: 2C11] Phase 1/2 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 INDICATI Recurring respiratory infection [ICD-11: CA07-CA45] Phase 1/2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D01IHR DRUGNAME AC-1202 INDICATI Memory loss [ICD-11: MB21.1Z] Phase 2 TTDDRUID D01IHV DRUGNAME AD-0027 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01IJJ DRUGNAME MV-NIS INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Bladder cancer [ICD-11: 2C94] Phase 1 INDICATI Medulloblastoma [ICD-11: 2A00.10] Phase 1 INDICATI Urothelial carcinoma [ICD-11: 2C92.0] Phase 1 TTDDRUID D01IJL DRUGNAME FR-182877 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D01IJM DRUGNAME LY3164530 INDICATI Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01IKM DRUGNAME HB-adipose-derived mesenchymal stem cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01ILA DRUGNAME GNbAC-1 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D01ILJ DRUGNAME Celvapan INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D01ILP DRUGNAME CNT0-3157 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D01IMN DRUGNAME VLA15-101 INDICATI Lyme disease [ICD-11: 1C1G] Phase 1 TTDDRUID D01IPI DRUGNAME Gemopatrilat INDICATI Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2 TTDDRUID D01IPT DRUGNAME AGS-v INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 1 TTDDRUID D01IRG DRUGNAME Bictegravir, emtricitabine and tenofovir alafenamide INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D01IRW DRUGNAME Bermoprofen INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Preregistration TTDDRUID D01ISE DRUGNAME Bimakalim INDICATI Angina pectoris [ICD-11: BA40] Phase 2 TTDDRUID D01ITB DRUGNAME TV1001sr INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 2 TTDDRUID D01IUD DRUGNAME PRT-20 INDICATI Duchenne dystrophy [ICD-11: 8C70] Investigative TTDDRUID D01IUS DRUGNAME Mapracorat INDICATI Ocular disease [ICD-11: 1F00.1Z] Phase 3 TTDDRUID D01IVE DRUGNAME Lobeline INDICATI Substance use disorder [ICD-11: 6C4Z] Phase 2 TTDDRUID D01IWJ DRUGNAME Fluticasone furoate/ fluticasone propionate INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D01IWS DRUGNAME Inulin INDICATI Measure kidney function [ICD-11: MG02] Approved TTDDRUID D01IXD DRUGNAME Finafloxacin INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D01IYQ DRUGNAME TAK-201 INDICATI Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 2 TTDDRUID D01IZE DRUGNAME Recombinant botulinum toxin vaccine INDICATI Yersinia infection [ICD-11: 1B93] Phase 2 TTDDRUID D01JCT DRUGNAME CD19-CAR T Cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial TTDDRUID D01JEI DRUGNAME F-50003 INDICATI Parainfluenza virus infection [ICD-11: 1D9Y] Terminated TTDDRUID D01JEO DRUGNAME Brevenal INDICATI Cystic fibrosis [ICD-11: CA25] Investigative TTDDRUID D01JEU DRUGNAME Memantine INDICATI Alzheimer disease [ICD-11: 8A20] Approved TTDDRUID D01JFM DRUGNAME AC-170 INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Phase 3 TTDDRUID D01JFT DRUGNAME Dipivefrin INDICATI Chronic open-angle glaucoma [ICD-11: 9C61.0] Approved TTDDRUID D01JGE DRUGNAME Netupitant/palonosetron INDICATI Chemotherapy-induced nausea [ICD-11: MD90] Phase 3 TTDDRUID D01JGG DRUGNAME Sodelglitazar INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D01JGV DRUGNAME Ajmalicine INDICATI Circulatory disorder [ICD-11: BE2Z] Approved TTDDRUID D01JHN DRUGNAME CR-3124 INDICATI Substance use disorder [ICD-11: 6C4Z] Terminated TTDDRUID D01JIA DRUGNAME L-glutamine INDICATI Short bowel syndrome [ICD-11: KB89.1] Approved TTDDRUID D01JIO DRUGNAME ZK-91587 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D01JKV DRUGNAME MK-8266 INDICATI Essential hypertension [ICD-11: BA00] Phase 1 TTDDRUID D01JLH DRUGNAME RESP-3000 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D01JLO DRUGNAME Tat-NR2B9c INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 3 INDICATI Stroke [ICD-11: 8B20] Phase 3 TTDDRUID D01JMC DRUGNAME Lorcaserin INDICATI Obesity [ICD-11: 5B81] Approved INDICATI Drug abuse [ICD-11: 6C4G.1Z] Phase 1 TTDDRUID D01JMX DRUGNAME INS-1 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 2 TTDDRUID D01JNE DRUGNAME Lexibulin INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D01JOA DRUGNAME D-1927 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D01JOJ DRUGNAME RX-77368 INDICATI Dementia [ICD-11: 6D80-6D86] Discontinued in Phase 2 TTDDRUID D01JPA DRUGNAME TRC102 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01JPJ DRUGNAME PTC-725 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D01JQJ DRUGNAME Iodinated glycerol INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D01JRF DRUGNAME SPD-453 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D01JSG DRUGNAME SBL-109 INDICATI Escherichia coli infection [ICD-11: 1A03] Investigative TTDDRUID D01JSI DRUGNAME PF-06863135 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D01JSO DRUGNAME VM-505 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D01JTL DRUGNAME KM-023 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D01JTW DRUGNAME PEV3A INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2 TTDDRUID D01JUF DRUGNAME Phentolamine INDICATI Dermal necrosis [ICD-11: MC85] Approved TTDDRUID D01JWH DRUGNAME SAN-134 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 1 TTDDRUID D01JYT DRUGNAME INT-0022 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 1 TTDDRUID D01KCE DRUGNAME BLB-750 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Registered TTDDRUID D01KDM DRUGNAME GTP-004 INDICATI Myasthenia gravis [ICD-11: 8C6Y] Phase 1 TTDDRUID D01KER DRUGNAME ARX-8203 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D01KGP DRUGNAME IPL 550,260 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D01KHH DRUGNAME Cyclobenzaprine INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D01KHW DRUGNAME CZEN-002 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 2 TTDDRUID D01KHX DRUGNAME Rilmakalim INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D01KIC DRUGNAME ORV-116E INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D01KIS DRUGNAME CGP-53437 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D01KIU DRUGNAME PRE-084 INDICATI Aging skin [ICD-11: EE40] Terminated TTDDRUID D01KIY DRUGNAME EPI-0031 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Investigative TTDDRUID D01KJM DRUGNAME KST-401 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01KJZ DRUGNAME Pyrazole derivative 4 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D01KKB DRUGNAME PW-2101 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Preregistration TTDDRUID D01KKE DRUGNAME GW876008 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 2 TTDDRUID D01KKI DRUGNAME SGN-CD33A INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D01KKM DRUGNAME House dust mite allergy vaccine INDICATI Allergic rhinitis [ICD-11: CA08.0] Terminated TTDDRUID D01KKQ DRUGNAME Raltitrexed INDICATI Rectal adenocarcinoma [ICD-11: 2B92] Approved TTDDRUID D01KMR DRUGNAME Neramexane INDICATI Cancer related pain [ICD-11: MG30] Phase 2 TTDDRUID D01KMW DRUGNAME BMS-830216 INDICATI Obesity [ICD-11: 5B81] Phase 1 TTDDRUID D01KMY DRUGNAME MK-8342 INDICATI Contraception [ICD-11: QA21] Phase 2 TTDDRUID D01KNA DRUGNAME Diamyd INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D01KNO DRUGNAME CTA1-3M2e-DD INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D01KNY DRUGNAME LCB-2183 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D01KOA DRUGNAME Selpercatinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved INDICATI Thyroid cancer [ICD-11: 2D10] Approved INDICATI Colon cancer [ICD-11: 2B90.Z] Phase 1/2 TTDDRUID D01KPS DRUGNAME IP-112 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preregistration TTDDRUID D01KPV DRUGNAME Fexofenadine INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D01KQA DRUGNAME Nalbuphine INDICATI Pain [ICD-11: MG30-MG3Z] Approved INDICATI Prurigo nodularis [ICD-11: EC91.0] Phase 2/3 INDICATI Uremic pruritus [ICD-11: EC90.10] Phase 2/3 TTDDRUID D01KQW DRUGNAME ID-93/GLA-SE INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Phase 2 TTDDRUID D01KRQ DRUGNAME EMC-0901 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D01KSL DRUGNAME REGN3048 + REGN3051 mabs INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Discontinued in Phase 1 TTDDRUID D01KSO DRUGNAME Synthetic peptide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01KTG DRUGNAME HDM201 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Liposarcoma [ICD-11: 2B59] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01KTN DRUGNAME Cefcapene pivoxil INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D01KWB DRUGNAME AD-313 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated TTDDRUID D01KWJ DRUGNAME VX-150 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D01KWK DRUGNAME Hydroxychloroquine + azithromycin + ivermectin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D01KXE DRUGNAME Influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D01KYG DRUGNAME INA-115E INDICATI Cytomegalovirus infection [ICD-11: 1D82] Investigative TTDDRUID D01KYP DRUGNAME APL-130277 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 3 TTDDRUID D01KZC DRUGNAME Minopafant INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2 TTDDRUID D01KZV DRUGNAME MIQ-004 INDICATI Brain cancer [ICD-11: 2A00] Investigative TTDDRUID D01LAC DRUGNAME MOFEGILINE INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 3 TTDDRUID D01LAP DRUGNAME ISIS 2922 + Ganciclovir INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D01LAX DRUGNAME Poloxafuse-R INDICATI Ischemia [ICD-11: 8B10-8B11] Investigative TTDDRUID D01LBD DRUGNAME Haw-AD-14 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D01LBI DRUGNAME LIV-1205 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01LCC DRUGNAME PF-4217903 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01LEO DRUGNAME LJJ-10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01LES DRUGNAME MEGF0444A INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 2 TTDDRUID D01LFA DRUGNAME ARX-201 INDICATI Growth failure [ICD-11: LD2F.1Y] Discontinued in Phase 2 TTDDRUID D01LFC DRUGNAME Mutant ras vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01LFH DRUGNAME Curmucin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01LFN DRUGNAME S. mutans Replacement Therapy INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D01LFQ DRUGNAME DWP-438 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01LGQ DRUGNAME PMID25666693-Compound-103 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D01LMM DRUGNAME BLY719 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01LNG DRUGNAME Balicatib INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2 TTDDRUID D01LNP DRUGNAME Samarium-153-DOTMP INDICATI Bone cancer [ICD-11: 2B5Z] Investigative TTDDRUID D01LOE DRUGNAME LY2963016 INDICATI Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 3 TTDDRUID D01LPK DRUGNAME MGX-006 INDICATI Vomiting [ICD-11: MD90] Discontinued in Preregistration TTDDRUID D01LPX DRUGNAME Linotroban INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D01LQC DRUGNAME P45 INDICATI Alopecia [ICD-11: ED70] Discontinued in Phase 2 TTDDRUID D01LQZ DRUGNAME TG-4023 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D01LRH DRUGNAME Sibopirdine INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D01LRM DRUGNAME SBC-014 INDICATI Neutropenia [ICD-11: 4B00.0] Phase 2 TTDDRUID D01LSB DRUGNAME MEMP1972A INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D01LSY DRUGNAME Atovaquone + azithromycin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01LUH DRUGNAME SP-30 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D01LUS DRUGNAME Mesoglycan INDICATI Cerebrovascular disease [ICD-11: 8B2Z] Approved TTDDRUID D01LVE DRUGNAME CPI-0610 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 3 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Myelodysplastic neoplasm [ICD-11: 2A60] Phase 1/2 INDICATI Myeloproliferative neoplasm [ICD-11: 2A20] Phase 1/2 TTDDRUID D01LVM DRUGNAME PMA-BB10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01LWE DRUGNAME EGFRvIII CAR T cells INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D01LWO DRUGNAME TM-601 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01LXD DRUGNAME Semagacestat INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D01LXG DRUGNAME KC-11425 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D01LXZ DRUGNAME DWJ-206 INDICATI Stomach ulcer [ICD-11: DA60.Z] Investigative TTDDRUID D01LYX DRUGNAME Eptastigmine INDICATI Cognitive impairment [ICD-11: 6D71] Phase 3 TTDDRUID D01LZB DRUGNAME Anti-HM1.24 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D01LZC DRUGNAME SDZ-GLI-328 INDICATI Genetic disease [ICD-11: 8E02] Terminated TTDDRUID D01MAU DRUGNAME AZD-1446 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D01MBM DRUGNAME LPO-1010DR INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Investigative TTDDRUID D01MBV DRUGNAME SB-207266A INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 2 TTDDRUID D01MCB DRUGNAME HTERT plasmid DNA cancer vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01MDH DRUGNAME Conjugated stigmines INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D01MDT DRUGNAME Tizanidine INDICATI Spasm [ICD-11: MB47.3] Approved TTDDRUID D01MDX DRUGNAME TRBC1 INDICATI Anaplastic large cell lymphoma [ICD-11: 2A90.A] Phase 1/2 INDICATI Angioimmunoblastic T-cell Lymphoma [ICD-11: 2A90.9] Phase 1/2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 INDICATI Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 1/2 TTDDRUID D01MFA DRUGNAME Infusible platelet membrane INDICATI Bleeding disorder [ICD-11: GA20-GA21] Discontinued in Phase 2 TTDDRUID D01MFG DRUGNAME Cholera EPVaccine INDICATI Vibrio cholerae infection [ICD-11: 1A00] Investigative TTDDRUID D01MFK DRUGNAME DFU INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D01MGA DRUGNAME Alatrofloxacin mesylate INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D01MGV DRUGNAME WC-3048 INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Phase 3 TTDDRUID D01MHI DRUGNAME Coluracetam INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D01MHL DRUGNAME T-2307 INDICATI Mycoses [ICD-11: 1F2Z] Phase 1 TTDDRUID D01MHT DRUGNAME BBT-046 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01MIP DRUGNAME SU5614 INDICATI Airway inflammation [ICD-11: CA05] Terminated TTDDRUID D01MJT DRUGNAME MGN-2677 INDICATI Artery stenosis [ICD-11: BD52] Investigative TTDDRUID D01MKD DRUGNAME Phenylalanine derivative 1 INDICATI Glioma [ICD-11: 2A00.0] Patented TTDDRUID D01MMB DRUGNAME Extrothyroxine INDICATI Hyperlipoproteinemia [ICD-11: 5C80] Approved TTDDRUID D01MMG DRUGNAME BBT-015 INDICATI Neutropenia [ICD-11: 4B00.0] Investigative TTDDRUID D01MML DRUGNAME MLN9708 INDICATI Amyloidosis [ICD-11: 5D00] Approved INDICATI Multiple myeloma [ICD-11: 2A83] Approved TTDDRUID D01MND DRUGNAME EU-C-001 INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D01MNK DRUGNAME BS-194 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01MNV DRUGNAME HER-2VAX INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1 TTDDRUID D01MPE DRUGNAME S-2150 INDICATI Angina pectoris [ICD-11: BA40] Phase 2 TTDDRUID D01MPX DRUGNAME PC-190723 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D01MQH DRUGNAME Vepalimomab INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1/2 TTDDRUID D01MQP DRUGNAME SECTA belomycin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D01MSB DRUGNAME Hydroxychloroquine + azithromycin + tocilizumab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01MSJ DRUGNAME Veronate INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3 TTDDRUID D01MSP DRUGNAME PMID30107136-Compound-Example3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D01MSZ DRUGNAME RM-4865 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D01MTY DRUGNAME Mefloquine + azithromycin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01MUR DRUGNAME Brinzolamide INDICATI Open-angle glaucoma [ICD-11: 9C61] Approved TTDDRUID D01MUW DRUGNAME Antineoplaston AS2-1 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D01MVK DRUGNAME CV-787 INDICATI Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 2 TTDDRUID D01MVO DRUGNAME ARG201 INDICATI Diffuse systemic sclerosis [ICD-11: 4A42.1] Phase 2 INDICATI Systemic sclerosis [ICD-11: 4A42] Phase 2 TTDDRUID D01MWF DRUGNAME GTx-878 INDICATI Prostate hyperplasia [ICD-11: GA90] Investigative TTDDRUID D01MXG DRUGNAME GLP-1 receptor PAM INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D01MXK DRUGNAME 2PX INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D01MXV DRUGNAME Etilefrine INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Withdrawn from market TTDDRUID D01MYJ DRUGNAME WT-4869 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID D01MYN DRUGNAME LY-2523199 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D01MZJ DRUGNAME LR3001 INDICATI Myeloid leukaemia [ICD-11: 2B33.1] Phase 2 TTDDRUID D01MZT DRUGNAME FGFR2-ADC INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D01NAM DRUGNAME ELB-139 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D01NAP DRUGNAME MM-151 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01NBX DRUGNAME RS-2135 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D01NCC DRUGNAME Factor-VIIa-XTEN INDICATI Hemophilia [ICD-11: 3B10.0] Investigative TTDDRUID D01NCH DRUGNAME Lufironil INDICATI Liver cirrhosis [ICD-11: DB93.1] Phase 2 TTDDRUID D01NCS DRUGNAME TOL-463 INDICATI Bacterial vaginosis [ICD-11: MF3A] Phase 2 INDICATI Vaginal disease [ICD-11: GA1Y] Phase 1 TTDDRUID D01NDF DRUGNAME AVN 101 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 TTDDRUID D01NDN DRUGNAME SNG-8006 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D01NEC DRUGNAME GSK2141795 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D01NFK DRUGNAME FP-1069 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D01NGB DRUGNAME ADC-1001 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D01NGH DRUGNAME Multi-envelope HIV vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D01NGT DRUGNAME RG-7185 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D01NIR DRUGNAME Radotinib INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 3 TTDDRUID D01NJE DRUGNAME ED45 INDICATI Acute respiratory distress syndrome [ICD-11: CB00] Investigative INDICATI Myocardial reperfusion injury [ICD-11: NB31] Investigative INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D01NJI DRUGNAME Mepyramine maleate INDICATI Headache [ICD-11: 8A80-8A84] Approved INDICATI Allergy [ICD-11: 4A80-4A85] Approved TTDDRUID D01NJT DRUGNAME Esreboxetine INDICATI Fibromyalgia [ICD-11: MG30.01] Discontinued in Phase 2 TTDDRUID D01NJW DRUGNAME PMID26815044-Compound-31 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D01NKF DRUGNAME LY-1-100 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D01NKS DRUGNAME Mefloquine + azithromycin + tocilizumab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01NKW DRUGNAME P2B-001 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D01NLB DRUGNAME Ziconotide INDICATI Pain [ICD-11: MG30-MG3Z] Approved INDICATI Traumatic brain injury [ICD-11: NA07.Z] Phase 1/2 TTDDRUID D01NMN DRUGNAME ALORACETAM INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D01NNL DRUGNAME Phosphonate INDICATI leukaemia [ICD-11: 2A60-2B33] Terminated TTDDRUID D01NOI DRUGNAME IPH-1201 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D01NPK DRUGNAME PTH-CBD INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D01NQM DRUGNAME Lasmiditan INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D01NSM DRUGNAME TST-10088 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01NTH DRUGNAME Ruthenium-based complexes INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01NTO DRUGNAME Meningitis B INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Approved TTDDRUID D01NTQ DRUGNAME SAR127963 INDICATI Traumatic brain injury [ICD-11: NA07.Z] Phase 1 TTDDRUID D01NTR DRUGNAME NTF-1836 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D01NTX DRUGNAME Mifamurtide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D01NUG DRUGNAME GSK870086 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D01NUR DRUGNAME ASTX660 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01NWV DRUGNAME Granexin gel INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 3 INDICATI Radiation syndrome [ICD-11: NF00] Phase 3 INDICATI Keloidal surgical scar [ICD-11: EL50.0] Phase 2 TTDDRUID D01NXF DRUGNAME Mydicar INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D01NXX DRUGNAME SAR-126119 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1 TTDDRUID D01NYQ DRUGNAME Drug 2696274 INDICATI Metachromatic leukodystrophy [ICD-11: 5C56.02] Phase 2 TTDDRUID D01NZH DRUGNAME ABBV-323 INDICATI Crohn disease [ICD-11: DD70] Phase 1 TTDDRUID D01NZT DRUGNAME Prohibitin-TP-01 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D01OBM DRUGNAME MEDl-559 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1/2 TTDDRUID D01ODC DRUGNAME TA-106 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D01ODT DRUGNAME Sophorolipid isoforms INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01ODU DRUGNAME BAY-35-3377 INDICATI Otitis media [ICD-11: AA80-AB0Z] Phase 3 TTDDRUID D01OFY DRUGNAME LAS-31180 INDICATI Heart failure [ICD-11: BD10-BD13] Terminated TTDDRUID D01OGL DRUGNAME Technetium Tc-99m Red Blood Cell Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D01OGV DRUGNAME POL-6014 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 1 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D01OHD DRUGNAME AMXT-1501 INDICATI Head and neck cancer [ICD-11: 2D42] Investigative TTDDRUID D01OIL DRUGNAME Gadobenate Dimeglumine INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D01OIR DRUGNAME AYX-1 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D01OKS DRUGNAME Axokine INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 3 TTDDRUID D01OLO DRUGNAME AS602868 INDICATI Multiple myeloma [ICD-11: 2A83] Discontinued in Phase 1 TTDDRUID D01OML DRUGNAME IoGen INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 3 TTDDRUID D01OMM DRUGNAME DeltaFLU-LAIV INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D01OMO DRUGNAME AdHSV-2 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Investigative TTDDRUID D01OMY DRUGNAME BHT-3034 INDICATI Myasthenia gravis [ICD-11: 8C6Y] Investigative TTDDRUID D01OOQ DRUGNAME FP-253-GDEPT INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D01OPV DRUGNAME Selenomethionine Se-75 INDICATI Diagnostic imaging [ICD-11: N.A.] Approved TTDDRUID D01OQQ DRUGNAME PMID30107136-Compound-Example50 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D01ORM DRUGNAME Mitonafide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D01OSN DRUGNAME Riferminogene pecaplasmid INDICATI Critical limb ischemia [ICD-11: BD4Y] Discontinued in Phase 3 TTDDRUID D01OUA DRUGNAME TJN-598 INDICATI Glomerulonephritis [ICD-11: 5D00.Y] Terminated TTDDRUID D01OUE DRUGNAME Betazole INDICATI Gastric secretory disorder [ICD-11: DD90] Approved TTDDRUID D01OVV DRUGNAME OVI-117 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01OWB DRUGNAME Immune globulin INDICATI Alzheimer disease [ICD-11: 8A20] Approved INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved INDICATI Immunodeficiency [ICD-11: 4A00-4A85] Approved INDICATI Bone marrow transplantation [ICD-11: QB63.6] Approved INDICATI Nervous system paraneoplastic or autoimmune disorders [ICD-11: 8E4A.1] Phase 3 INDICATI Pediatric cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Bacillus anthracis infection [ICD-11: 1G40] Phase 1 TTDDRUID D01OWJ DRUGNAME TG-1024 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D01OXH DRUGNAME ASP-7035 INDICATI Nocturia [ICD-11: MF55] Phase 2 TTDDRUID D01OXI DRUGNAME DTI-015 INDICATI Liver cancer [ICD-11: 2C12] Approved INDICATI Brain cancer [ICD-11: 2A00] Approved TTDDRUID D01OYR DRUGNAME AZD-9343 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 1 TTDDRUID D01OYS DRUGNAME Cyclolignan picropodophyllin INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D01OYX DRUGNAME N-acetylcysteine + fuzhenghuayu INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01PAR DRUGNAME Vitamin INDICATI Vitamin deficiency [ICD-11: 5B55-5B71] Approved TTDDRUID D01PBW DRUGNAME CB-839 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D01PBX DRUGNAME Biphenyl mannoside derivative 6 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D01PCB DRUGNAME VALERGEN-DS INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D01PCE DRUGNAME BCH-2687 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D01PFX DRUGNAME TDI-0065 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D01PGJ DRUGNAME PDM-08 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01PGR DRUGNAME SAR245409 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01PHK DRUGNAME PCL-016 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D01PIL DRUGNAME Remoxipride INDICATI Schizophrenia [ICD-11: 6A20] Withdrawn from market TTDDRUID D01PJR DRUGNAME Tocainide INDICATI Ventricular arrhythmias [ICD-11: BC71] Approved TTDDRUID D01PJZ DRUGNAME Cyclic peptidomimetic derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D01PKG DRUGNAME Fenofibrate/ simvastatin INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 3 TTDDRUID D01PLH DRUGNAME 7U85 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D01PLJ DRUGNAME PMID25666693-Compound-58 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D01PLN DRUGNAME Cefalotin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D01PLR DRUGNAME PF-04171327 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D01PNR DRUGNAME Gastrin 17C diphtheria toxoid conjugate INDICATI Pancreatic cancer [ICD-11: 2C10] Investigative TTDDRUID D01PQK DRUGNAME Ruxolitinib + simvastatin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01PQM DRUGNAME Vaccinia immune globulin INDICATI Vaccination [ICD-11: N.A.] Approved TTDDRUID D01PRH DRUGNAME APX-009 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01PSI DRUGNAME AM-3301 INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2 TTDDRUID D01PSY DRUGNAME SIG-005 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D01PTS DRUGNAME VG-101 INDICATI Menopause symptom [ICD-11: GA30.0] Phase 1/2 TTDDRUID D01PVV DRUGNAME KD3010 INDICATI Obesity [ICD-11: 5B81] Phase 1 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1 TTDDRUID D01PXH DRUGNAME NAM-NK cells + IL-2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D01PYH DRUGNAME PANFLUVAC INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D01PZD DRUGNAME Romiplostim INDICATI Thrombocytopenia [ICD-11: 3B64] Approved INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 TTDDRUID D01PZJ DRUGNAME BDNA-002 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D01QAR DRUGNAME LY-221068 INDICATI Arthritis [ICD-11: FA20] Terminated TTDDRUID D01QCY DRUGNAME OBP-AI1 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D01QGX DRUGNAME Lurasidone hydrochloride INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D01QIA DRUGNAME BL-1872 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D01QIN DRUGNAME Atorvastatin INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D01QIV DRUGNAME Prostaview INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D01QIX DRUGNAME Drug 2696275 INDICATI Wiskott-Aldrich syndrome [ICD-11: 3B62.0] Phase 2 TTDDRUID D01QKD DRUGNAME ATL-1101 INDICATI Psoriatic disorder [ICD-11: EA90] Preclinical TTDDRUID D01QKR DRUGNAME ALNESPIRONE INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D01QKZ DRUGNAME ABT-413 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01QLH DRUGNAME Amyl nitrite INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D01QLM DRUGNAME AAB-002 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 0 TTDDRUID D01QLP DRUGNAME Tarextumab INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D01QMC DRUGNAME LAI338 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D01QMK DRUGNAME Denintuzumab mafodotin INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 TTDDRUID D01QML DRUGNAME Carphenazine INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved INDICATI Schizophrenia [ICD-11: 6A20] Withdrawn from market TTDDRUID D01QNJ DRUGNAME KD-501 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D01QNO DRUGNAME LM-13765 INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D01QNR DRUGNAME PIM447 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 1 TTDDRUID D01QQC DRUGNAME Hematopoietic stem cell gene therapy INDICATI Wiskott-Aldrich syndrome [ICD-11: 3B62.0] Phase 1/2 TTDDRUID D01QQM DRUGNAME LAMIFIBAN INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 3 TTDDRUID D01QRF DRUGNAME IKS-04 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01QRG DRUGNAME RPR 200765A INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D01QSG DRUGNAME VTP-27999 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 TTDDRUID D01QSO DRUGNAME Buparlisib INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D01QTD DRUGNAME GT-038 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Investigative TTDDRUID D01QTJ DRUGNAME XEN901 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 1 TTDDRUID D01QUF DRUGNAME GW-3600 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D01QUS DRUGNAME Calcipotriol INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved TTDDRUID D01QWS DRUGNAME GM-CT-01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01QWT DRUGNAME Ramucirumab INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Bladder cancer [ICD-11: 2C94] Phase 3 TTDDRUID D01QXS DRUGNAME RX-0201N INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01QXW DRUGNAME CSL-324 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D01QXY DRUGNAME B7-2/GM-CSF INDICATI Dementia [ICD-11: 6D80-6D86] Phase 1 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01QYA DRUGNAME Diamine derivative 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D01QYQ DRUGNAME ATL-844 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D01RAE DRUGNAME Sonepiprazole INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D01RAN DRUGNAME LA-419 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D01RBK DRUGNAME Nisin INDICATI Bacillus anthracis infection [ICD-11: 1G40] Terminated TTDDRUID D01RBP DRUGNAME RE-024 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 3 TTDDRUID D01RBR DRUGNAME SGS742 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D01RCC DRUGNAME BMS-186318 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated TTDDRUID D01RCM DRUGNAME TAK-114 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 1 TTDDRUID D01RDR DRUGNAME AB569 INDICATI Pseudomonas infection [ICD-11: 1B92] Phase 1 TTDDRUID D01REE DRUGNAME DA-3031 INDICATI Neutropenia [ICD-11: 4B00.0] Phase 3 TTDDRUID D01REJ DRUGNAME VBY- 891 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D01RFF DRUGNAME Etoxazole INDICATI Pest attack [ICD-11: N.A.] Investigative TTDDRUID D01RFI DRUGNAME Ro-24-0238 INDICATI Sepsis [ICD-11: 1G40-1G41] Terminated TTDDRUID D01RHK DRUGNAME PMID26651364-Compound-5d INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D01RIT DRUGNAME Pyrazole derivative 20 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D01RKQ DRUGNAME SDZ-280-446 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D01RKY DRUGNAME VAG-624 INDICATI Acne vulgaris [ICD-11: ED80] Discontinued in Phase 1 TTDDRUID D01RLA DRUGNAME CYC-4068 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01RLG DRUGNAME RTU-007 INDICATI Diabetic cataract [ICD-11: 9B10.21] Approved TTDDRUID D01RLS DRUGNAME Allostrome INDICATI Arthropathy [ICD-11: FA11-FA38] Phase 1/2 TTDDRUID D01RLU DRUGNAME EG-016 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 1/2 TTDDRUID D01RNF DRUGNAME ZG-451 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01RNL DRUGNAME Lintuzumab INDICATI leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 2 TTDDRUID D01RNV DRUGNAME AMT-011 INDICATI Blood forming organ disorder [ICD-11: JB64.1] Phase 3 TTDDRUID D01RQN DRUGNAME DS-1971 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D01RQP DRUGNAME IGN002 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D01RQV DRUGNAME Eculizumab INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Approved TTDDRUID D01RRF DRUGNAME STA-5312 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01RSK DRUGNAME CDP-146 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D01RSW DRUGNAME Orazamide orotate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01RTO DRUGNAME Polyhydroxy benzamide derivative 4 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D01RUK DRUGNAME PMID25666693-Compound-104 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D01RVA DRUGNAME ADR-851 INDICATI Nausea and vomiting [ICD-11: MD90] Phase 1 TTDDRUID D01RVS DRUGNAME AZD5985 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D01RXW DRUGNAME Vaniprevir INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D01RYJ DRUGNAME OP-02 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01SAD DRUGNAME TT-115 INDICATI Coagulation defect [ICD-11: 3B10.0] Investigative TTDDRUID D01SAK DRUGNAME TL-14077 INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D01SAT DRUGNAME Bevantolol INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D01SAV DRUGNAME Oshadi D INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01SAY DRUGNAME Sipuleucel-T INDICATI Prostate cancer [ICD-11: 2C82.0] Approved INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3 TTDDRUID D01SBC DRUGNAME TSRI-265 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01SBP DRUGNAME Co-152791 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D01SCR DRUGNAME NPB-001-056 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1/2 TTDDRUID D01SEO DRUGNAME ICI-181037 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D01SFN DRUGNAME IC9-GD2-CD28-OX40 INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 1 TTDDRUID D01SGK DRUGNAME Opicapone INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D01SGM DRUGNAME FK-906 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D01SHJ DRUGNAME E7046 INDICATI Rectal adenocarcinoma [ICD-11: 2B92] Phase 1 TTDDRUID D01SHZ DRUGNAME Rucaparib INDICATI Ovarian cancer [ICD-11: 2C73] Approved TTDDRUID D01SIB DRUGNAME MK-6349 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D01SJC DRUGNAME Transdur-sufentanil INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D01SJS DRUGNAME AXL-1717 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01SJT DRUGNAME PF-562271 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01SKR DRUGNAME Lamivudine /maraviroc/zidovudine fixed-dose combination INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D01SKT DRUGNAME IONIS-SOD111RX INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 TTDDRUID D01SNU DRUGNAME P-BCMA-ALL01 INDICATI Multiple myeloma [ICD-11: 2A83] Preclinical TTDDRUID D01SNV DRUGNAME Recombinant human nerve growth factor INDICATI Neurotrophic keratitis [ICD-11: 9A74] Phase 2 TTDDRUID D01SNZ DRUGNAME VTS-270 INDICATI Niemann-pick disease [ICD-11: 5C56.0Y] Phase 3 TTDDRUID D01SPD DRUGNAME BAY-85-3934 INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 2 TTDDRUID D01SPI DRUGNAME CGRP INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D01SPJ DRUGNAME Litenimod INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D01SPW DRUGNAME VR647 INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D01SQI DRUGNAME POT-4 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 2 TTDDRUID D01SQP DRUGNAME HM-61713B INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01SRB DRUGNAME AAV2-hRPE65v2 INDICATI Ocular disease [ICD-11: 1F00.1Z] Phase 3 TTDDRUID D01SSK DRUGNAME MTRN-2696 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01SSL DRUGNAME AT-027 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01STB DRUGNAME Ramipril INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D01SUF DRUGNAME GP-1200 INDICATI Ulcerative colitis [ICD-11: DD71] Investigative TTDDRUID D01SUL DRUGNAME JNJ-10397049 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Investigative TTDDRUID D01SUO DRUGNAME EBC-46 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01SUY DRUGNAME BRU-83-92 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D01SVG DRUGNAME KA-10X INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01SVO DRUGNAME EIDD-1931 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D01SWJ DRUGNAME AVP-13748 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Investigative TTDDRUID D01SWK DRUGNAME Rafabegron INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D01SXE DRUGNAME F-18 T808 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D01SXG DRUGNAME ThermoStem INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D01SXH DRUGNAME CD20-CAR-T Cells INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID D01SXY DRUGNAME NVB-302 INDICATI Clostridium infection [ICD-11: 1A04] Phase 1 INDICATI C. difficile infection [ICD-11: 1A04] Phase 1 TTDDRUID D01SYU DRUGNAME Turofexorate isopropyl INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 1 TTDDRUID D01SZA DRUGNAME MR-1817 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D01TAQ DRUGNAME NLP-44 INDICATI Acne vulgaris [ICD-11: ED80] Investigative TTDDRUID D01TBJ DRUGNAME CMX-2043 INDICATI Myocardial reperfusion injury [ICD-11: NB31] Phase 2 INDICATI Cardiac disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D01TBL DRUGNAME HRGP INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01TBN DRUGNAME Ezlopitant INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 2 INDICATI Vomiting [ICD-11: MD90] Discontinued in Phase 2 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D01TCM DRUGNAME CEE-03-320 INDICATI Substance use disorder [ICD-11: 6C4Z] Terminated TTDDRUID D01TDY DRUGNAME Unacylated ghrelin INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D01TEA DRUGNAME DSC-127 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 3 TTDDRUID D01TGH DRUGNAME PF-572778 INDICATI Generalized anxiety disorder [ICD-11: 6B00] Terminated TTDDRUID D01THN DRUGNAME JTT-654 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D01THX DRUGNAME Factor viii INDICATI Hemophilia [ICD-11: 3B10.0] Approved TTDDRUID D01TIN DRUGNAME R-1458 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Terminated TTDDRUID D01TJM DRUGNAME CTCE-9908 INDICATI Sarcoma [ICD-11: 2A60-2C35] Phase 1/2 TTDDRUID D01TJV DRUGNAME K-103-PA INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D01TJY DRUGNAME GLPG-0187 INDICATI Bone metastases [ICD-11: 2D50] Phase 1 TTDDRUID D01TLV DRUGNAME EVT 401 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D01TMF DRUGNAME Latrodectus antivenin INDICATI Poison intoxication [ICD-11: NE6Z] Approved TTDDRUID D01TMK DRUGNAME GX-G6 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D01TMQ DRUGNAME Bupropion+naltrexone INDICATI Obesity [ICD-11: 5B81] Phase 3 TTDDRUID D01TMW DRUGNAME Tradjeta INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D01TNK DRUGNAME CAR-T cells targeting EpCAM INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 1 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 TTDDRUID D01TNW DRUGNAME Dapagliflozin INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D01TPU DRUGNAME AWD-160-275 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D01TQR DRUGNAME Nonoxynol-9 INDICATI Contraception [ICD-11: QA21] Approved TTDDRUID D01TRU DRUGNAME NFTA-105 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D01TSI DRUGNAME Ergotamine INDICATI Headache [ICD-11: 8A80-8A84] Approved TTDDRUID D01TVQ DRUGNAME Ibritumomab INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2 TTDDRUID D01TVR DRUGNAME Tagatose INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3 TTDDRUID D01TVT DRUGNAME FAS-115 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D01TWG DRUGNAME Rozanolixizumab INDICATI Myasthenia gravis [ICD-11: 8C6Y] Phase 2 TTDDRUID D01TYB DRUGNAME Basulin INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1 TTDDRUID D01UAD DRUGNAME PTX-022 INDICATI Flavivirus infection [ICD-11: 1C80] Phase 2 TTDDRUID D01UAM DRUGNAME Human and mouse gp100 DNA plasmid vaccines INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01UAU DRUGNAME CTP-543 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D01UBV DRUGNAME DXL-1215 INDICATI Endometriosis [ICD-11: GA10] Investigative TTDDRUID D01UBX DRUGNAME Aclarubicin INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved TTDDRUID D01UBY DRUGNAME JNJ-41443532 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D01UDR DRUGNAME Ro-25-0993 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D01UDS DRUGNAME CNV-2197944 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D01UFK DRUGNAME ATX-MS-1467 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D01UFN DRUGNAME Falecalcitrol INDICATI Hyperparathyroidism [ICD-11: 5A51] Approved TTDDRUID D01UFZ DRUGNAME REL-1017 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D01UGG DRUGNAME Sabarubicin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01UHA DRUGNAME MIS-416 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 INDICATI Bacillus anthracis infection [ICD-11: 1G40] Investigative TTDDRUID D01UHU DRUGNAME Pyriplatin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01UJK DRUGNAME AVE0897 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D01UJS DRUGNAME Rebelex INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Investigative TTDDRUID D01UKK DRUGNAME PF-06760805 INDICATI Streptococcus infection [ICD-11: 1B53] Phase 2 TTDDRUID D01ULX DRUGNAME CC-0651 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01UMT DRUGNAME Ro 31-7453 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01UNF DRUGNAME BAL-0019764 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Preclinical TTDDRUID D01UNS DRUGNAME Thalidomide + hormones INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01UPT DRUGNAME FA-70 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D01UTL DRUGNAME Desipramine INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D01UUD DRUGNAME Pitolisant INDICATI Excessive daytime sleepiness [ICD-11: MG42] Approved INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 TTDDRUID D01UUF DRUGNAME Rh-GDNF INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D01UUW DRUGNAME Trecetilide fumarate INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Investigative TTDDRUID D01UXC DRUGNAME Atenolol INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D01UXJ DRUGNAME Resminostat INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 TTDDRUID D01UXP DRUGNAME LASSBio-294 INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D01UXW DRUGNAME Morphine-6-glucuronide INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D01UYA DRUGNAME MEDI1341 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D01UZH DRUGNAME IQP-0528 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D01VAA DRUGNAME ACR-125 INDICATI Keratosis [ICD-11: ED56] Investigative TTDDRUID D01VAB DRUGNAME Alprenolol INDICATI Hypertension [ICD-11: BA00-BA04] Withdrawn from market TTDDRUID D01VAP DRUGNAME YM-430 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D01VCB DRUGNAME ACH-2928 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1 TTDDRUID D01VCE DRUGNAME Gadomelitol INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D01VCW DRUGNAME MEN-10690 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated TTDDRUID D01VDI DRUGNAME AVI-5126 INDICATI Coronary artery disease [ICD-11: BA80] Phase 2 TTDDRUID D01VEJ DRUGNAME Elapegademase INDICATI Adenosine deaminase defciency [ICD-11: 4A01.1] Approved INDICATI Immunodeficiency [ICD-11: 4A00-4A85] Phase 3 TTDDRUID D01VEV DRUGNAME Cannabinoids INDICATI Schizophrenia [ICD-11: 6A20] Investigative TTDDRUID D01VFQ DRUGNAME CGEN-855 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D01VHJ DRUGNAME Nitazoxanide INDICATI Diarrhea [ICD-11: DA90] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D01VJN DRUGNAME Olanzapine/fluoxetine combination INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D01VLT DRUGNAME ASP8232 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 1 TTDDRUID D01VMA DRUGNAME ITX-4520 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D01VMO DRUGNAME Flutrimazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D01VMZ DRUGNAME ARI-3037MO INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 INDICATI Hypertriglyceridemia [ICD-11: 5C80.1] Phase 2 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Phase 2 TTDDRUID D01VNL DRUGNAME JM-1232(-) INDICATI Anaesthesia [ICD-11: 9A78.6] Investigative TTDDRUID D01VNQ DRUGNAME AEM-18 INDICATI Familial hypercholesterolemia [ICD-11: 5C80.00] Investigative TTDDRUID D01VNT DRUGNAME COL-003 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Preregistration TTDDRUID D01VOJ DRUGNAME RTI-4229-982 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D01VPK DRUGNAME FK-453 INDICATI Renal failure [ICD-11: GB60-GB6Z] Discontinued in Phase 2 TTDDRUID D01VPR DRUGNAME BBR-3438 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Discontinued in Phase 2 TTDDRUID D01VQA DRUGNAME VAL BRO 03 INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 3 TTDDRUID D01VQM DRUGNAME CHR-5154 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D01VRQ DRUGNAME BAY-1902607 INDICATI Cough [ICD-11: MD12] Phase 2 TTDDRUID D01VSK DRUGNAME TR-14531 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D01VSR DRUGNAME Hepatitis C immune globulin INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3 TTDDRUID D01VTT DRUGNAME P-coumaric acid derivative 6 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D01VUE DRUGNAME BMS-182874 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D01VVL DRUGNAME PF-04523655 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 TTDDRUID D01VWB DRUGNAME IL-2/gene-modified lymphocytes INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 TTDDRUID D01VWD DRUGNAME HTI-101 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D01VWR DRUGNAME S-15261 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D01VZQ DRUGNAME LG-723 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D01WBD DRUGNAME Mibampator INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D01WBT DRUGNAME DYN-15 INDICATI Blindness [ICD-11: 9D90] Investigative TTDDRUID D01WCL DRUGNAME SLV 354 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D01WCW DRUGNAME KPPF-1 INDICATI Ulcerative colitis [ICD-11: DD71] Investigative TTDDRUID D01WFI DRUGNAME VG-FLU INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D01WHC DRUGNAME Leuvectin INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D01WJL DRUGNAME Aminosalicylic Acid INDICATI Pulmonary and extrapulmonary tuberculosis [ICD-11: 1B10.Z] Approved INDICATI Inflammatory bowel disease [ICD-11: DD72] Approved TTDDRUID D01WJM DRUGNAME D-26344 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D01WKE DRUGNAME Semapimod INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D01WKZ DRUGNAME Citarinostat INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D01WLB DRUGNAME Lu-AA39959 INDICATI Bipolar disorder [ICD-11: 6A60] Phase 2 TTDDRUID D01WLC DRUGNAME Metolazone INDICATI Edema [ICD-11: MG29] Approved INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D01WLE DRUGNAME MC-1101 INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Phase 2/3 TTDDRUID D01WMI DRUGNAME SP-1031C INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01WMJ DRUGNAME Copper INDICATI Contraception [ICD-11: QA21] Approved TTDDRUID D01WMO DRUGNAME Tularemia vaccine INDICATI Tularemia [ICD-11: 1B94] Phase 1 TTDDRUID D01WMW DRUGNAME RG7232 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Investigative TTDDRUID D01WOD DRUGNAME PF-4064900 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D01WQL DRUGNAME MPC-9528 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01WQO DRUGNAME BIRT 2584 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D01WQQ DRUGNAME ABT-981 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 TTDDRUID D01WSL DRUGNAME NPB-1 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D01WTV DRUGNAME HDL-200 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3 TTDDRUID D01WUA DRUGNAME Treprostinil INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Approved TTDDRUID D01WVJ DRUGNAME BIO-306 INDICATI Migraine [ICD-11: 8A80] Preclinical TTDDRUID D01WWD DRUGNAME KPS-0373 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D01WWN DRUGNAME Pyrazole derivative 57 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D01WXU DRUGNAME ZK-205367 INDICATI Coronary artery disease [ICD-11: BA80] Phase 2/3 TTDDRUID D01WYO DRUGNAME Hydroxychloroquine + nitazoxanide INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D01WYT DRUGNAME ASP3550 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D01WYV DRUGNAME Angiostatin/paclitaxel/carboplatin INDICATI Lung cancer [ICD-11: 2C25.0] Investigative TTDDRUID D01WZG DRUGNAME Creatine ALS-08 INDICATI Motor neurone disease [ICD-11: 8B60] Phase 3 TTDDRUID D01WZL DRUGNAME AVE-8112 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D01XAE DRUGNAME PRX-12239 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D01XAJ DRUGNAME CSL-425 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D01XAR DRUGNAME AP-521 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D01XBA DRUGNAME Raloxifene INDICATI Osteoporosis [ICD-11: FB83.0] Approved TTDDRUID D01XCL DRUGNAME Veratrum Viride Root INDICATI High blood pressure [ICD-11: BA00] Approved TTDDRUID D01XDL DRUGNAME Idarubicin INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved TTDDRUID D01XDO DRUGNAME VSSP INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D01XEC DRUGNAME Botulinum toxin recombinant vaccine INDICATI Botulism [ICD-11: 1A11] Preclinical TTDDRUID D01XEO DRUGNAME Debio-0824 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1b/2a INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 1 TTDDRUID D01XEQ DRUGNAME R348 INDICATI Psoriasis vulgaris [ICD-11: EA90] Terminated TTDDRUID D01XFZ DRUGNAME GPD-1116 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D01XGX DRUGNAME JTP-4819 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D01XHG DRUGNAME DENBUFYLLINE INDICATI Cognitive impairment [ICD-11: 6D71] Phase 3 TTDDRUID D01XHU DRUGNAME AN-207 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01XIF DRUGNAME Ivermectin + nitazoxanide INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D01XIK DRUGNAME Antimalarials INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D01XLM DRUGNAME Piperazine INDICATI Enterobiasis [ICD-11: 1F65] Approved INDICATI Ascariasis [ICD-11: 1F62] Approved TTDDRUID D01XMC DRUGNAME VTB-38543 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D01XMP DRUGNAME TG-D INDICATI Bone disease [ICD-11: FC0Z] Investigative TTDDRUID D01XMS DRUGNAME ENT-103 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D01XNB DRUGNAME Omeprazole INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Approved TTDDRUID D01XOD DRUGNAME Alpidem INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D01XPG DRUGNAME CAN-296 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D01XPY DRUGNAME L-citrulline INDICATI Acute lung injury [ICD-11: NB32.3] Phase 3 TTDDRUID D01XQQ DRUGNAME TT-30 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D01XRP DRUGNAME Simethicone INDICATI Dyspepsia [ICD-11: MD92] Approved TTDDRUID D01XTN DRUGNAME Epaxal INDICATI Hepatitis A virus infection [ICD-11: 1E50.0] Approved TTDDRUID D01XUE DRUGNAME Tedatioxetine INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 1 INDICATI Generalized anxiety disorder [ICD-11: 6B00] Phase 1 TTDDRUID D01XUG DRUGNAME ASP6432 INDICATI Lower urinary tract symptom [ICD-11: GB71] Discontinued in Phase 1 TTDDRUID D01XVF DRUGNAME Sirukumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 INDICATI Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 3 INDICATI Giant cell arteritis [ICD-11: 4A44.2] Phase 3 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D01XVK DRUGNAME Pyrazoline derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D01XVX DRUGNAME CC-220 INDICATI Sarcoidosis [ICD-11: 4B20.5] Phase 2 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D01XWG DRUGNAME Daunorubicin INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved INDICATI Kaposi sarcoma [ICD-11: 2B57] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01XXF DRUGNAME Modified SDF-1 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D01XYJ DRUGNAME Zidovudine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D01XZG DRUGNAME G1T28-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01YCF DRUGNAME 4SCAR-GD2 INDICATI Tumour [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D01YCX DRUGNAME YJRN-0904 INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D01YDF DRUGNAME Pibutidine INDICATI Ulcerative colitis [ICD-11: DD71] Discontinued in Phase 3 TTDDRUID D01YDH DRUGNAME GSK2981710 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D01YFR DRUGNAME DWJ-205 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D01YGD DRUGNAME ICO-25 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D01YGF DRUGNAME KF-15570 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D01YGY DRUGNAME UC-1011 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D01YHL DRUGNAME DasKloster 0039-01 INDICATI Asbestosis [ICD-11: CA60.2] Investigative TTDDRUID D01YHO DRUGNAME WP-1122 INDICATI Glioma [ICD-11: 2A00.0] Investigative TTDDRUID D01YIF DRUGNAME PAC1 INDICATI Anaplastic astrocytoma [ICD-11: 2A00.0] Phase 1 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D01YIO DRUGNAME JNJ-10311795 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D01YJR DRUGNAME IVN-birch INDICATI Allergic rhinitis [ICD-11: CA08.0] Investigative TTDDRUID D01YKI DRUGNAME ANX-510 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 TTDDRUID D01YKR DRUGNAME FCR001 INDICATI Organ transplant rejection [ICD-11: NE84] Phase 2 TTDDRUID D01YLA DRUGNAME NP-432 INDICATI Respiratory tract infection [ICD-11: CA45] Investigative TTDDRUID D01YLF DRUGNAME PTI-701 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D01YLK DRUGNAME Meningitis ACYW conj. INDICATI Meningitis [ICD-11: 1D01] Phase 1 TTDDRUID D01YOC DRUGNAME BMS-181100 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 3 TTDDRUID D01YQH DRUGNAME GM-CSF INDICATI Neurological disorder [ICD-11: 6B60] Approved TTDDRUID D01YQN DRUGNAME Levamisole Pill + Budesonide+Formoterol inhaler INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D01YSH DRUGNAME DV-7021 INDICATI Liver disease [ICD-11: DB90-BD99] Terminated TTDDRUID D01YSU DRUGNAME AG-PPC709 INDICATI Respiratory disease [ICD-11: CB40] Investigative TTDDRUID D01YTX DRUGNAME CBLC-4H10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01YVT DRUGNAME Colesevelam INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Approved TTDDRUID D01YVZ DRUGNAME GLYX-13 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 3 TTDDRUID D01YYP DRUGNAME Margetuximab INDICATI HER2-positive breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Gastrointestinal cancer [ICD-11: 2C11] Phase 2 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2 TTDDRUID D01YZF DRUGNAME CART-BCMA INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D01ZAQ DRUGNAME AZD5363 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01ZBF DRUGNAME E-1224 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 2 TTDDRUID D01ZCC DRUGNAME PMID26815044-Compound-118 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D01ZCL DRUGNAME ACT-N INDICATI Brain injury [ICD-11: NA07.Z] Preclinical TTDDRUID D01ZDQ DRUGNAME ACH-1095 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D01ZDR DRUGNAME FR-208419 INDICATI Dyspepsia [ICD-11: MD92] Terminated TTDDRUID D01ZEC DRUGNAME Cefacetrile INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D01ZEY DRUGNAME MDL-201112 INDICATI Colitis [ICD-11: 1A40.Z] Terminated TTDDRUID D01ZFK DRUGNAME Tuberculosis recombinant vaccine INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Phase 2 TTDDRUID D01ZFM DRUGNAME LNK-3248 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D01ZGH DRUGNAME JTK-853 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1 TTDDRUID D01ZGS DRUGNAME TGN-208 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01ZHB DRUGNAME Revusiran INDICATI Amyloidosis [ICD-11: 5D00] Phase 3 TTDDRUID D01ZHQ DRUGNAME MIM-A2 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D01ZII DRUGNAME Chlorpromazine INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D01ZJB DRUGNAME Autologous bone marrow-derived mesenchymal stem cells INDICATI Lateral sclerosis [ICD-11: 8B61] Phase 1 TTDDRUID D01ZJK DRUGNAME Ardeparin INDICATI Venous thrombosis [ICD-11: BA43] Approved INDICATI Deep vein thrombosis [ICD-11: BD71] Approved INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 3 INDICATI Venous thromboembolism [ICD-11: BD72] Phase 3 TTDDRUID D01ZJM DRUGNAME R-1479 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1 TTDDRUID D01ZJP DRUGNAME Lopinavir + ritonavir + hydoxychloroquine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D01ZKE DRUGNAME Biaryl mannoside derivative 21 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D01ZLI DRUGNAME CBR-2092 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D01ZLK DRUGNAME APX005M INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Brain cancer [ICD-11: 2A00] Phase 1 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Investigative TTDDRUID D01ZLL DRUGNAME Aom-0755 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D01ZLR DRUGNAME PF-05082566 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01ZLU DRUGNAME TAS-120 INDICATI Cholangiocarcinoma [ICD-11: 2C12.10] Phase 3 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D01ZMR DRUGNAME Calcineurin INDICATI T-cell mediated immune dysfunction [ICD-11: 4A01.1Y] Investigative TTDDRUID D01ZMS DRUGNAME PK1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01ZNH DRUGNAME IDAZOXAN HYDROCHLORIDE INDICATI Neurological disorder [ICD-11: 6B60] Phase 3 TTDDRUID D01ZNQ DRUGNAME TMC-310911 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D01ZOB DRUGNAME Terguride INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 TTDDRUID D01ZOG DRUGNAME Difluprednate INDICATI Ocular pain [ICD-11: MC18] Approved TTDDRUID D01ZPK DRUGNAME BA-207 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D01ZPT DRUGNAME ACTR087 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D01ZPY DRUGNAME FMP2.1/AS02A INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2 TTDDRUID D01ZQE DRUGNAME Metenkefalin + tridecactide INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D01ZQN DRUGNAME ALD-306 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D01ZRI DRUGNAME Axitinib INDICATI Renal cell carcinoma [ICD-11: 2C90] Approved TTDDRUID D01ZSO DRUGNAME Moclobemide INDICATI Depression [ICD-11: 6A70-6A7Z] Approved INDICATI Skin imperfections [ICD-11: EK71] Patented TTDDRUID D01ZSP DRUGNAME AAB-003/PF-05236812 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D01ZUA DRUGNAME Coenzyme Q10 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2 INDICATI Pancreatic tumour [ICD-11: 2C10] Phase 2 INDICATI Epidermolysis bullosa [ICD-11: EC3Z] Phase 1 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D01ZUV DRUGNAME GDC-0425 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D01ZVK DRUGNAME SCD-211 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D01ZWC DRUGNAME RPH-104 + olokizumab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D01ZWF DRUGNAME BPI-711001 INDICATI Hypoglycemia [ICD-11: 5A41] Investigative TTDDRUID D01ZXW DRUGNAME Lintitript INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 2 TTDDRUID D01ZYG DRUGNAME Alemtuzumab INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Approved INDICATI Multiple sclerosis [ICD-11: 8A40] Approved TTDDRUID D01ZZG DRUGNAME INV-311 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D02AAD DRUGNAME Biaryl mannoside derivative 31 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D02AAO DRUGNAME AZD-4877 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D02ABS DRUGNAME BMS-180560 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D02ADC DRUGNAME SDZ-MKS-492 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D02ADJ DRUGNAME Apolipoprotein E INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Terminated TTDDRUID D02ADM DRUGNAME Silibinin INDICATI Hepatic failure [ICD-11: DB99.7] Phase 2/3 TTDDRUID D02AEI DRUGNAME BM-13.1196 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D02AEW DRUGNAME Xenon Xe-127 INDICATI Diagnostic imaging [ICD-11: N.A.] Approved TTDDRUID D02AIM DRUGNAME Metoprine INDICATI Advanced cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D02AIN DRUGNAME AZD5718 INDICATI Coronary artery disease [ICD-11: BA80] Phase 2 TTDDRUID D02AIZ DRUGNAME BIL010t INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1/2 TTDDRUID D02ALD DRUGNAME NOLOMIROLE HYDROCHLORIDE INDICATI Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 3 TTDDRUID D02ALZ DRUGNAME ONO-3307 INDICATI Coagulation defect [ICD-11: 3B10.0] Phase 2 TTDDRUID D02AMG DRUGNAME HGS-1029 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02ANJ DRUGNAME NZ-107 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D02ANO DRUGNAME LY-2393910 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D02AOD DRUGNAME HF-0220 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D02AQL DRUGNAME AT-003 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02AQM DRUGNAME VAR-10300 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D02AQY DRUGNAME Actarit INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved TTDDRUID D02ARR DRUGNAME Dehydrocholic acid INDICATI Constipation [ICD-11: DD91.1] Approved TTDDRUID D02AUB DRUGNAME Bimosiamose INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2a INDICATI Psoriatic disorder [ICD-11: EA90] Phase 2a INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2a INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D02AUI DRUGNAME Technetium Tc-99m Mebrofenin Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D02AUY DRUGNAME MERS-five-helix bundle INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D02AVC DRUGNAME BMS-820132 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D02AWB DRUGNAME MERS-CoV-SDNA vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D02AWQ DRUGNAME AZD1419 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D02AXG DRUGNAME Testosterone undecanoate INDICATI Hypogonadism [ICD-11: 5A61.0] Approved TTDDRUID D02AXS DRUGNAME GSK406725 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D02AYL DRUGNAME Pretomanid INDICATI Tuberculosis [ICD-11: 1B10-1B14] Approved INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 3 TTDDRUID D02BAA DRUGNAME Patient-derived CD19- and CD22 specific CAR INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D02BAE DRUGNAME Synthetic conjugated estrogen INDICATI Vaginal disease [ICD-11: GA1Y] Phase 3 TTDDRUID D02BAW DRUGNAME MK-6325 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D02BBC DRUGNAME CL-329167 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D02BCY DRUGNAME CD19 CART INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D02BDL DRUGNAME Dibenzoylmethane INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02BGL DRUGNAME DHAC INDICATI Mesothelioma [ICD-11: 2C51.2] Discontinued in Phase 2 TTDDRUID D02BGU DRUGNAME Pyrido/pyrrolo-fused pyrimidine derivative 1 INDICATI Pain [ICD-11: MG30-MG3Z] Patented TTDDRUID D02BGZ DRUGNAME AXP-107-17 INDICATI Radiation syndrome [ICD-11: NF00] Investigative TTDDRUID D02BHP DRUGNAME Nacolomab tafenatox INDICATI Colorectal cancer [ICD-11: 2B91.Z] Terminated TTDDRUID D02BHW DRUGNAME IM19 CAR-T INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID D02BIY DRUGNAME DCVax-Direct INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D02BJN DRUGNAME Human liver progenitor cells INDICATI Liver cirrhosis [ICD-11: DB93.1] Investigative TTDDRUID D02BLD DRUGNAME Oprozomib INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 2 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D02BLO DRUGNAME Oxilan iohexol INDICATI Vascular disease [ICD-11: BE2Z] Approved TTDDRUID D02BMJ DRUGNAME ND-601 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D02BPX DRUGNAME NGM 282 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 INDICATI Primary biliary cirrhosis [ICD-11: DB96.1] Phase 2 TTDDRUID D02BQE DRUGNAME E7820 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D02BRJ DRUGNAME Vabicaserin INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 2 TTDDRUID D02BTZ DRUGNAME Twinrix INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D02BVQ DRUGNAME TGC-9 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02BVW DRUGNAME FF-10501-01 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1/2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID D02BWY DRUGNAME JNJ-64041757 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1/2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D02BYZ DRUGNAME ASP8273 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D02CAF DRUGNAME NOX-H94 INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 2 TTDDRUID D02CBD DRUGNAME J-30 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02CCA DRUGNAME GSK-172981 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D02CEO DRUGNAME SND-226 INDICATI Toxoplasmosis [ICD-11: 1F57] Investigative TTDDRUID D02CFP DRUGNAME Citicoline INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved TTDDRUID D02CFR DRUGNAME GW-559768X INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02CFV DRUGNAME Solubilized type 1 native bovine collagen INDICATI Scleroderma [ICD-11: 4A42] Phase 2 TTDDRUID D02CGC DRUGNAME Sorbinil INDICATI Diabetic cataract [ICD-11: 9B10.21] Terminated TTDDRUID D02CGY DRUGNAME Bifemelane INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D02CII DRUGNAME Abaloparatide INDICATI Postmenopausal osteoporosis [ICD-11: FB83.11] Approved TTDDRUID D02CJA DRUGNAME CM-2236 INDICATI Post-traumatic stress disorder [ICD-11: 6B40] Preclinical TTDDRUID D02CJX DRUGNAME Desoxycorticosterone Acetate INDICATI Discovery agent [ICD-11: N.A.] Approved TTDDRUID D02CKG DRUGNAME Diltiazem + niclosamide INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D02CKH DRUGNAME OPI-1002 INDICATI Acute kidney injury [ICD-11: GB60] Phase 2 TTDDRUID D02CKO DRUGNAME Anoro INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D02CKX DRUGNAME Carbimazole INDICATI Hyperthyroidism [ICD-11: 5A02] Approved TTDDRUID D02CLV DRUGNAME AdCh63 AMA1 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1/2 TTDDRUID D02CND DRUGNAME KI-0901 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02CNR DRUGNAME Anecortave acetate INDICATI Macular degeneration [ICD-11: 9B78.3] Approved TTDDRUID D02COS DRUGNAME IdB-1016 INDICATI Liver disease [ICD-11: DB90-BD99] Phase 2 TTDDRUID D02CPP DRUGNAME Vonoprazan INDICATI Helicobacter infection [ICD-11: DA42-DA63] Approved INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 3 TTDDRUID D02CQL DRUGNAME Adyvia INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D02CRM DRUGNAME KI-0907 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D02CTS DRUGNAME Ospemifene INDICATI Dyspareunia [ICD-11: GA12] Approved INDICATI Postmenopausal vaginal atrophy [ICD-11: GA30.2] Phase 3 TTDDRUID D02CTZ DRUGNAME LY433221 INDICATI Depression [ICD-11: 6A70-6A7Z] Investigative TTDDRUID D02CUN DRUGNAME NM504 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 0 TTDDRUID D02CVF DRUGNAME SynGEM INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Investigative TTDDRUID D02CWZ DRUGNAME AMBAZONE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02CXA DRUGNAME LG-912 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D02CXZ DRUGNAME PMID26815044-Compound-123 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D02CYL DRUGNAME MOR-208 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2/3 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 INDICATI B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D02CYR DRUGNAME Chromic phosphate P 32 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D02CZF DRUGNAME Aderbasib INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D02CZK DRUGNAME Karenitecin INDICATI Lung cancer [ICD-11: 2C25.0] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 TTDDRUID D02DBA DRUGNAME Helicobacter pylori vaccine INDICATI Helicobacter infection [ICD-11: DA42-DA63] Phase 1 TTDDRUID D02DEH DRUGNAME GM-602 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 2 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 TTDDRUID D02DES DRUGNAME Anakinra INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D02DEZ DRUGNAME GALE-301 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Endometrial cancer [ICD-11: 2C76] Phase 1/2 TTDDRUID D02DFJ DRUGNAME Biaryl mannoside derivative 10 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D02DGU DRUGNAME Tretinoin INDICATI Acne vulgaris [ICD-11: ED80] Approved INDICATI Acute promyelocytic leukaemia [ICD-11: 2A60.0] Approved TTDDRUID D02DHU DRUGNAME SKF-81297 INDICATI Parkinson disease [ICD-11: 8A00.0] Terminated TTDDRUID D02DJF DRUGNAME BAX-111 INDICATI Pain [ICD-11: MG30-MG3Z] Preregistration TTDDRUID D02DJG DRUGNAME LY-2189102 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D02DJR DRUGNAME AMG 167 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 1 TTDDRUID D02DJS DRUGNAME Iodoxamate Meglumine INDICATI Bile duct disease [ICD-11: LB20] Approved TTDDRUID D02DKD DRUGNAME Benzquinamide INDICATI Nausea [ICD-11: MD90] Approved TTDDRUID D02DLP DRUGNAME VOFOPITANT HYDROCHLORIDE INDICATI Vomiting [ICD-11: MD90] Phase 2 TTDDRUID D02DMQ DRUGNAME Eletriptan INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D02DMW DRUGNAME S-1360 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D02DNA DRUGNAME Cureskin INDICATI Sarcoidosis [ICD-11: 4B20.5] Approved TTDDRUID D02DOK DRUGNAME SJ-8002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02DOZ DRUGNAME ALKS 3831 INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 TTDDRUID D02DPA DRUGNAME Cimetidine INDICATI Acid-reflux disorder [ICD-11: DA22] Approved TTDDRUID D02DPP DRUGNAME MTHF INDICATI Cognitive impairment [ICD-11: 6D71] Phase 4 TTDDRUID D02DPU DRUGNAME Aniracetam INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved TTDDRUID D02DSD DRUGNAME Sodium Chromate Cr-51 INDICATI Hemorrhage [ICD-11: MG27] Approved TTDDRUID D02DSZ DRUGNAME Temocapril hydrochloride INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D02DTQ DRUGNAME PF-3893787 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D02DVB DRUGNAME AGN-191743 INDICATI Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 1 TTDDRUID D02DVK DRUGNAME CV-9201 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D02DWK DRUGNAME 2-hydroxyoleic acid INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1/2 TTDDRUID D02DWM DRUGNAME Amphotericin B INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved INDICATI Mycoses [ICD-11: 1F2Z] Investigative TTDDRUID D02DWN DRUGNAME AB-0440a INDICATI Bone disease [ICD-11: FC0Z] Investigative TTDDRUID D02DWX DRUGNAME Prostvac-VF INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D02DXC DRUGNAME SPN-803 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D02DXV DRUGNAME HAP aniline mustard INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02DYU DRUGNAME SC-75416 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D02DZI DRUGNAME MGN-8107 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D02DZK DRUGNAME LY3303560 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D02EAS DRUGNAME TBC 11251 (TBC) INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Withdrawn from market TTDDRUID D02ECG DRUGNAME Sodium pyruvate INDICATI Asthma [ICD-11: CA23] Phase 1/2 TTDDRUID D02EEJ DRUGNAME SCY-635 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D02EEK DRUGNAME J 591 Lu-177 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D02EFJ DRUGNAME MDAB-16 INDICATI Bone disease [ICD-11: FC0Z] Phase 2 TTDDRUID D02EGY DRUGNAME Aromatic hydrazine carboxyimidoamide derivative 6 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D02EHE DRUGNAME BI-730357 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 TTDDRUID D02EHV DRUGNAME Human neutral insulin INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D02EKI DRUGNAME Hydroxychloroquine + intravenous famotidine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D02EKO DRUGNAME PMID25666693-Compound-126 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D02ELN DRUGNAME HM-5016699 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02ELS DRUGNAME L-alanosine INDICATI Brain cancer [ICD-11: 2A00] Phase 2 TTDDRUID D02EMR DRUGNAME Cilomilast INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 3 INDICATI Bronchitis [ICD-11: CA20] Discontinued in Phase 3 INDICATI Emphysema [ICD-11: CA21] Discontinued in Phase 3 TTDDRUID D02ENG DRUGNAME BVT.2733 INDICATI Lupus [ICD-11: 4A40] Phase 3 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 3 INDICATI Myasthenia gravis [ICD-11: 8C6Y] Phase 2 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D02EOH DRUGNAME SGT-53 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02EOR DRUGNAME ABBV-399 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02EOS DRUGNAME CVX-241 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02EPS DRUGNAME Oralair grasses INDICATI Grass pollen hypersensitivity [ICD-11: 4B07] Approved INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Approved TTDDRUID D02EPW DRUGNAME Hydroxychloroquine + azithromycin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D02EQX DRUGNAME Hydroxychloroquine + camostat mesylate INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D02ERH DRUGNAME EP-2060 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D02ESK DRUGNAME GSK-732461 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D02ESL DRUGNAME ON-01210.Na INDICATI Radiation syndrome [ICD-11: NF00] Phase 1 INDICATI Acute radiation syndrome [ICD-11: NF00] Phase 1 TTDDRUID D02ESX DRUGNAME Neomedi INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D02ETJ DRUGNAME SIL-43 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02ETP DRUGNAME SOM-0420 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D02ETU DRUGNAME PMID28270021-Compound-WO2014152663 701 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D02ETY DRUGNAME SAR97276 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2 TTDDRUID D02EVF DRUGNAME Losartan/thioctic acid INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID D02EVL DRUGNAME TDT-077 INDICATI Postherpetic neuralgia [ICD-11: 1E91.5] Investigative TTDDRUID D02EVT DRUGNAME SAR-152954 INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Discontinued in Phase 1 TTDDRUID D02EWF DRUGNAME RiVax INDICATI Ricin poisoning [ICD-11: NE61] Phase 1 TTDDRUID D02EXB DRUGNAME Vero cell seasonal influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D02EXZ DRUGNAME Ferric maltol INDICATI Iron-deficiency anemia [ICD-11: 3A00] Approved INDICATI Onychomycosis [ICD-11: EE12.1] Phase 3 TTDDRUID D02EYG DRUGNAME Linagliptin INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D02EYZ DRUGNAME GSK2654909A INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 1 TTDDRUID D02EZM DRUGNAME Fospropofol disodium INDICATI Monitored anaesthesia care [ICD-11: N.A.] Approved TTDDRUID D02FAI DRUGNAME Pbi-shPDX-1 LP INDICATI Pancreatic cancer [ICD-11: 2C10] Investigative TTDDRUID D02FBG DRUGNAME UC-2029 INDICATI Premenstrual syndrome [ICD-11: GA34.40] Investigative TTDDRUID D02FCQ DRUGNAME Protokylol Hydrochloride INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D02FCU DRUGNAME MIV-210 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D02FDJ DRUGNAME Ioforminol INDICATI Pulmonary embolism [ICD-11: BB00] Phase 2 TTDDRUID D02FDZ DRUGNAME LCP-AtorFen INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2/3 TTDDRUID D02FEA DRUGNAME FENDILINE INDICATI Coronary artery disease [ICD-11: BA80] Withdrawn from market TTDDRUID D02FEJ DRUGNAME ODC-0501 INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 1/2 TTDDRUID D02FEM DRUGNAME Natamycin INDICATI Conjunctivitis [ICD-11: 9A60] Approved TTDDRUID D02FEV DRUGNAME S-8921 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D02FGG DRUGNAME AFM-21 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02FHP DRUGNAME RX-01-423 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical TTDDRUID D02FIC DRUGNAME JB-004/A INDICATI Inner ear disease [ICD-11: AB30-AB37] Phase 2 TTDDRUID D02FIJ DRUGNAME FK-224 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D02FLB DRUGNAME Sodium bicarbonate INDICATI Metabolic acidosis [ICD-11: 5C73] Approved TTDDRUID D02FNJ DRUGNAME AL-309 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D02FNU DRUGNAME Ipsapirone INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D02FPT DRUGNAME H5N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D02FTU DRUGNAME Recombinant follicle stimulating hormone INDICATI Female infertility [ICD-11: GA31.Z] Investigative TTDDRUID D02FTV DRUGNAME INGN-241 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D02FXK DRUGNAME Botulinum Toxin Type B INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D02FXU DRUGNAME Lapaquistat acetate INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 3 TTDDRUID D02FYE DRUGNAME TT-223 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D02FYI DRUGNAME Tozaride INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D02GAC DRUGNAME Clomocycline INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D02GDK DRUGNAME Cx-601 INDICATI Perianal fistula [ICD-11: DB50.1] Phase 3 TTDDRUID D02GDN DRUGNAME Berirab INDICATI Rabies [ICD-11: 1C82] Approved TTDDRUID D02GEC DRUGNAME Omalizumab INDICATI Asthma [ICD-11: CA23] Approved INDICATI Chronic idiopathic urticaria [ICD-11: EB00.1] Phase 2 TTDDRUID D02GFZ DRUGNAME Heparin-EGF-like factor INDICATI Gastrointestinal disease [ICD-11: DE2Z] Terminated TTDDRUID D02GGG DRUGNAME BLI-1100 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D02GIA DRUGNAME BL-7040 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2 TTDDRUID D02GIU DRUGNAME Cilastatin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D02GJE DRUGNAME CG-8840 INDICATI Bladder cancer [ICD-11: 2C94] Terminated TTDDRUID D02GJZ DRUGNAME Ioflupane i-123 INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D02GKJ DRUGNAME Monosialoganglioside INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved TTDDRUID D02GLD DRUGNAME MF-101 INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 3 TTDDRUID D02GMT DRUGNAME Org-7797 INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2 TTDDRUID D02GNH DRUGNAME Quinazoline derivative 9 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D02GNL DRUGNAME KMJ-372 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D02GOG DRUGNAME BY-963 INDICATI Myocardial disease [ICD-11: BC43.20] Approved TTDDRUID D02GPG DRUGNAME JNJ-42165279 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 INDICATI Social anxiety disorder [ICD-11: 6B04] Phase 2 TTDDRUID D02GRR DRUGNAME Oleclumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02GSA DRUGNAME RBx10558 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D02GTN DRUGNAME ZY-15106 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D02GTT DRUGNAME AR-XYZ INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D02GTV DRUGNAME Menomune INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D02GTY DRUGNAME Tamibarotene INDICATI T-cell leukaemia [ICD-11: 2A90] Phase 3 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2/3 TTDDRUID D02GUG DRUGNAME Ajmaline INDICATI Atrial fibrillation [ICD-11: BC81.3] Approved TTDDRUID D02GVH DRUGNAME PIRODAVIR INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2 TTDDRUID D02GWF DRUGNAME PACTIMIBE INDICATI Arteriosclerosis [ICD-11: BD40] Phase 2/3 TTDDRUID D02GWJ DRUGNAME MCT-125 INDICATI Fatigue [ICD-11: MG22] Phase 2 TTDDRUID D02GYD DRUGNAME CDP-845 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D02HBB DRUGNAME AEZS-108 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 3 TTDDRUID D02HBI DRUGNAME Bmab-100 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02HBW DRUGNAME SCH-32615 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D02HCU DRUGNAME WEB-2347 INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D02HDG DRUGNAME AQX-1125 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D02HDP DRUGNAME V-1810 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02HED DRUGNAME Perphenazine INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D02HFD DRUGNAME Glutathione INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D02HFN DRUGNAME BFCR4350A INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D02HHM DRUGNAME SGN-CD19B INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D02HJR DRUGNAME SID-530 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D02HKC DRUGNAME MUC1-Poly-ICLC INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D02HKL DRUGNAME Suriclone INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Preregistration TTDDRUID D02HLL DRUGNAME RQ-00317076 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D02HNF DRUGNAME Radium-223 chloride INDICATI Prostate cancer [ICD-11: 2C82.0] Approved INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D02HNG DRUGNAME MK-0752 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D02HPF DRUGNAME Biaryl mannoside derivative 9 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D02HPI DRUGNAME FGI-103-723 INDICATI Ebola virus infection [ICD-11: 1D60.0] Investigative TTDDRUID D02HQR DRUGNAME Anti-HBs human mab INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D02HRD DRUGNAME KLS-0611 INDICATI Xerophthalmia [ICD-11: 5B55.Y] Phase 2 TTDDRUID D02HSB DRUGNAME Cabazitaxel INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D02HTD DRUGNAME GS-9451 INDICATI Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D02HUB DRUGNAME Nestorone INDICATI Endometriosis [ICD-11: GA10] Phase 3 TTDDRUID D02HUU DRUGNAME FluPro INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D02HUW DRUGNAME SAR-548304 INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 1 TTDDRUID D02HUY DRUGNAME Debio 0827 INDICATI Chronic pain [ICD-11: MG30] Phase 1 TTDDRUID D02HVW DRUGNAME Zibotentan INDICATI Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 3 TTDDRUID D02HWP DRUGNAME CHLOROXINE INDICATI Erythema [ICD-11: ME64.0] Approved TTDDRUID D02HWR DRUGNAME PV-1019 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02HXS DRUGNAME Bufexamac INDICATI Dermatitis [ICD-11: EA80-EA89] Approved TTDDRUID D02HYK DRUGNAME Chondroitin INDICATI Cataract [ICD-11: 9B10] Approved TTDDRUID D02IAR DRUGNAME Nov-038 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D02IBS DRUGNAME INH-001 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D02IBU DRUGNAME Oritavancin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Terminated TTDDRUID D02IBX DRUGNAME Pyrrolo[2,3-b]pyridine derivative 3 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D02ICI DRUGNAME VIT-45 INDICATI Iron-deficiency anemia [ICD-11: 3A00] Approved TTDDRUID D02IHW DRUGNAME Nepafenac INDICATI Osteoarthritis [ICD-11: FA00-FA05] Approved TTDDRUID D02IIE DRUGNAME Penicillin V Potassium INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D02IIL DRUGNAME KOSN1559 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02IIM DRUGNAME FCX-013 INDICATI Scleroderma [ICD-11: 4A42] Phase 1 TTDDRUID D02IIW DRUGNAME Faropenem INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Approved TTDDRUID D02IJA DRUGNAME Tau-binding PET tracer INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D02IJP DRUGNAME CLX-0900 INDICATI Hyperlipidaemia [ICD-11: 5C80] Terminated TTDDRUID D02IKD DRUGNAME HG-1245 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02IKF DRUGNAME M9831 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02IKQ DRUGNAME Hepatitis B DNA vaccine INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1 TTDDRUID D02ILI DRUGNAME ZP-G-CSF INDICATI Neutropenia [ICD-11: 4B00.0] Investigative TTDDRUID D02IND DRUGNAME CBI-006 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02INX DRUGNAME TD-1211 INDICATI Opioid-induced constipation [ICD-11: DB32.1] Phase 2 TTDDRUID D02INZ DRUGNAME BABIM INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D02IOC DRUGNAME CP154,526 INDICATI Depression [ICD-11: 6A70-6A7Z] Investigative TTDDRUID D02IOH DRUGNAME Alphaprodine INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D02IPI DRUGNAME CTA-002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D02IQY DRUGNAME Ergoloid mesylate INDICATI Alzheimer disease [ICD-11: 8A20] Approved TTDDRUID D02IRD DRUGNAME Megesterol acetate INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D02IRL DRUGNAME IDX375 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2 TTDDRUID D02ISP DRUGNAME SKI-2034R INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D02ITL DRUGNAME AV-201 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D02IUD DRUGNAME Sodium Fluoride F-18 INDICATI Bone related disease [ICD-11: FB82-FB85] Approved INDICATI Osteoporosis [ICD-11: FB83.0] Approved TTDDRUID D02IUO DRUGNAME CORT-113083 INDICATI Weight gain [ICD-11: MG43.6] Investigative TTDDRUID D02IWC DRUGNAME AZD2624 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2 TTDDRUID D02IYC DRUGNAME IMP-701 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02IZN DRUGNAME ON-123 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02JAY DRUGNAME Stannsoporfin INDICATI Neonatal hyperbilirubinemia [ICD-11: KA87] Phase 2 TTDDRUID D02JBI DRUGNAME SAL-200 INDICATI Bacteremia [ICD-11: 1A73] Phase 2 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 1 TTDDRUID D02JDL DRUGNAME Porfimer Sodium INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved TTDDRUID D02JDN DRUGNAME IFN-alpha INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 TTDDRUID D02JEW DRUGNAME GSK-2130579A INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D02JFF DRUGNAME ISIS 16518 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02JGD DRUGNAME SKL-10406 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 1 TTDDRUID D02JHW DRUGNAME ANG-2864 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02JIB DRUGNAME Ro-25-2016 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D02JIF DRUGNAME EDP-19 INDICATI Brain cancer [ICD-11: 2A00] Investigative TTDDRUID D02JIN DRUGNAME 264W94 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D02JIS DRUGNAME Iobenguane I-123 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Approved TTDDRUID D02JKY DRUGNAME TD-9855 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 INDICATI Orthostatic hypotension [ICD-11: BA21] Phase 1 TTDDRUID D02JMI DRUGNAME SLV-310 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2 TTDDRUID D02JMU DRUGNAME Tasquinimod INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D02JMZ DRUGNAME Recombinant human keratinocyte growth factor-2 INDICATI Wound healing [ICD-11: EL8Y] Phase 1 TTDDRUID D02JNC DRUGNAME BCMA CAR-T INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D02JND DRUGNAME ADC-3680 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D02JNM DRUGNAME Desonide INDICATI Atopic dermatitis [ICD-11: EA80] Approved TTDDRUID D02JNX DRUGNAME OxycoDex INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D02JNY DRUGNAME BIBN-140 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D02JOA DRUGNAME Phenylisoserine derivatives SK80 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical TTDDRUID D02JOH DRUGNAME BMS-708163 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D02JOI DRUGNAME EPI-3905 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Investigative TTDDRUID D02JQB DRUGNAME PMID25666693-Compound-140 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D02JRD DRUGNAME VT-310 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D02JRT DRUGNAME 111In-imciromab pentetate INDICATI Myocardial infarction [ICD-11: BA41-BA43] Approved TTDDRUID D02JUM DRUGNAME METIAPRIL INDICATI Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2 TTDDRUID D02JVX DRUGNAME Resorcinol compound 7 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D02JWA DRUGNAME Flomoxef sodium INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D02JWN DRUGNAME STNM-01 INDICATI Pyloric stenosis [ICD-11: DA40.0] Investigative TTDDRUID D02JXG DRUGNAME SB-265610 INDICATI Asthma [ICD-11: CA23] Phase 2 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D02JYA DRUGNAME Raxibacumab INDICATI Anthrax [ICD-11: 1B97] Approved TTDDRUID D02JYT DRUGNAME GSK2654911A INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 1 TTDDRUID D02JYY DRUGNAME Indium In-111 Oxyquinoline INDICATI Diagnostic radiopharmaceutical [ICD-11: N.A.] Approved TTDDRUID D02JZJ DRUGNAME ETS-6218 INDICATI Fibromyalgia [ICD-11: MG30.01] Phase 2 TTDDRUID D02KAF DRUGNAME GT-2203 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D02KAU DRUGNAME PF-03882845 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Terminated TTDDRUID D02KAW DRUGNAME CDP-7657 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 TTDDRUID D02KBD DRUGNAME Mebutamate INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D02KBE DRUGNAME Ad-OC-hsvTK/valacyclovir INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D02KBO DRUGNAME Ciprokiren INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D02KCV DRUGNAME Iothalamate INDICATI Arthropathy [ICD-11: FA11-FA38] Approved TTDDRUID D02KEL DRUGNAME AVO113 INDICATI Malignant glioma [ICD-11: 2A00.0] Phase 2 TTDDRUID D02KEW DRUGNAME Levamisole + isoprinosine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D02KEY DRUGNAME SPP-676 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D02KFP DRUGNAME Invert sugar INDICATI Nutritional deficiency [ICD-11: 5B50-5B71] Approved TTDDRUID D02KIE DRUGNAME Cimetropium bromide INDICATI Spasm [ICD-11: MB47.3] Approved INDICATI Gastric motility disorder [ICD-11: DA21] Approved TTDDRUID D02KII DRUGNAME Vaqta INDICATI Hepatitis A virus infection [ICD-11: 1E50.0] Approved TTDDRUID D02KIU DRUGNAME Etonogestrel INDICATI Contraception [ICD-11: QA21] Approved TTDDRUID D02KJX DRUGNAME Betain anhydrous INDICATI Inborn homocystinuria [ICD-11: 5C50] Approved TTDDRUID D02KKA DRUGNAME MK-1775 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02KKQ DRUGNAME BAM-1110 INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2 TTDDRUID D02KLD DRUGNAME BVT-74316 INDICATI Obesity [ICD-11: 5B81] Phase 1 TTDDRUID D02KLE DRUGNAME P-536 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D02KLW DRUGNAME DIZOCILPINE INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D02KMG DRUGNAME Milveterol INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D02KMO DRUGNAME Pinacidil INDICATI High blood pressure [ICD-11: BA00] Approved TTDDRUID D02KOF DRUGNAME Lomefloxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D02KOY DRUGNAME RotaTeq INDICATI Rotavirus infection (Diarrhoea) [ICD-11: ME05.1] Approved TTDDRUID D02KPJ DRUGNAME UCART19 INDICATI Burkitt cell leukaemia [ICD-11: 2A85.6] Phase 1 TTDDRUID D02KQE DRUGNAME ON-09300 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D02KRI DRUGNAME Epristeride INDICATI Hirsutism [ICD-11: ED72] Phase 3 TTDDRUID D02KRS DRUGNAME Amantadine INDICATI Influenza A virus infection [ICD-11: 1E30] Approved TTDDRUID D02KSP DRUGNAME Tislelizumab INDICATI Hodgkin lymphoma [ICD-11: 2B30] Approved INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 TTDDRUID D02KTA DRUGNAME DER-45-EV INDICATI Rosacea [ICD-11: ED90.0] Phase 2 TTDDRUID D02KTG DRUGNAME CGEN-25068 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D02KUO DRUGNAME Cenegermin INDICATI Neurotrophic keratitis [ICD-11: 9A74] Approved TTDDRUID D02KVT DRUGNAME TUSC2/FUS1 gene therapy INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D02KXE DRUGNAME Aom-0811 INDICATI Premature ejaculation [ICD-11: HA03.0Z] Investigative TTDDRUID D02KXW DRUGNAME HE3286 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D02KYP DRUGNAME AC-101 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D02KZI DRUGNAME L-786392 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D02LAP DRUGNAME Oxymera INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D02LBK DRUGNAME ARRY-797 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 INDICATI Dilated cardiomyopathy [ICD-11: BC43.0] Phase 2 TTDDRUID D02LCI DRUGNAME TA-5493 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1 TTDDRUID D02LCL DRUGNAME T-5224 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D02LCR DRUGNAME Tiapride INDICATI Alcohol dependence [ICD-11: 6C40.2] Approved INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D02LCT DRUGNAME ARTELINIC ACID INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D02LDN DRUGNAME Magnesium Sulfate INDICATI Acute pain [ICD-11: MG31] Approved TTDDRUID D02LDV DRUGNAME Thiamine Hydrochloride INDICATI Wernicke-Korsakoff Syndrome [ICD-11: 5B5A.1] Approved INDICATI Thiamine deficiency [ICD-11: 5B5A] Approved TTDDRUID D02LHR DRUGNAME INDORAMIN INDICATI Hypertension [ICD-11: BA00-BA04] Withdrawn from market TTDDRUID D02LIY DRUGNAME Euro-Celtique 2 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D02LJR DRUGNAME Methenamine INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D02LJW DRUGNAME Tirbanibulin INDICATI Actinic keratosis [ICD-11: EK90.0] Approved INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D02LMR DRUGNAME Adva-27a INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02LNU DRUGNAME CART22-65s cells and huCART19 Cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D02LOB DRUGNAME JIN-2013 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D02LPF DRUGNAME Altretamine INDICATI Ovarian cancer [ICD-11: 2C73] Approved TTDDRUID D02LPY DRUGNAME A-623 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2/3 TTDDRUID D02LQA DRUGNAME TTH 03-001 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D02LRQ DRUGNAME Cycrimine INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D02LSR DRUGNAME SNK-882 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 TTDDRUID D02LTL DRUGNAME Dermatan sulfate INDICATI Deep vein thrombosis [ICD-11: BD71] Approved TTDDRUID D02LUP DRUGNAME RN-1005 INDICATI Sarcoidosis [ICD-11: 4B20.5] Terminated TTDDRUID D02LVZ DRUGNAME Darbepoetin alfa INDICATI Anemia [ICD-11: 3A00-3A9Z] Approved TTDDRUID D02LWU DRUGNAME Pralatrexate INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Peripheral T-cell lymphoma [ICD-11: 2A90.C] Approved TTDDRUID D02LYH DRUGNAME PMI-004 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Preclinical TTDDRUID D02LZB DRUGNAME Demecolcine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D02MBM DRUGNAME Mosquirix malaria recombinant vaccine INDICATI Parkinson disease [ICD-11: 8A00.0] Preregistration INDICATI Malaria [ICD-11: 1F40-1F45] Preregistration TTDDRUID D02MBN DRUGNAME SD-6010 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 3 TTDDRUID D02MBO DRUGNAME EPICOAT cancer vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D02MFC DRUGNAME 62Cu-ATSM INDICATI Hypoxia [ICD-11: MD11.1] Phase 1 TTDDRUID D02MFK DRUGNAME Affinitak + Cisplatin INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative TTDDRUID D02MGH DRUGNAME Pneumococcal vaccine INDICATI Streptococcus infection [ICD-11: 1B53] Approved TTDDRUID D02MHD DRUGNAME NPC-16570 INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D02MHE DRUGNAME CVS-1123 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 1 TTDDRUID D02MLA DRUGNAME AXP-107-08 INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D02MLN DRUGNAME ChAdOx1 nCoV-19 vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D02MLO DRUGNAME WT1-targeted autologous dendritic cell vaccine INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D02MLW DRUGNAME Ibutilide INDICATI Atrial fibrillation [ICD-11: BC81.3] Approved TTDDRUID D02MMF DRUGNAME FP-1097 INDICATI Urinary incontinence [ICD-11: MF50.2] Phase 2 TTDDRUID D02MMG DRUGNAME Pyrimidine derivative 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D02MMP DRUGNAME VX-500 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D02MNY DRUGNAME ON-01135 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D02MPT DRUGNAME MAGE-A3 immunotherapeutic INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D02MQL DRUGNAME RWJ-61907 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D02MRN DRUGNAME Golotimod INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 2 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 2 TTDDRUID D02MRX DRUGNAME ONO-4059 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID D02MSG DRUGNAME AcVx-25 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D02MTK DRUGNAME AT-008 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D02MUA DRUGNAME PF-06439535 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02MVA DRUGNAME NI-0701 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D02MVG DRUGNAME AMG-548 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D02MXT DRUGNAME MK-2894 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D02MYI DRUGNAME CAR-T Cells targeting PSCA INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D02MZD DRUGNAME AMG 876 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D02MZY DRUGNAME Cefpiramide INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D02NBY DRUGNAME LACTIN-V INDICATI Urinary tract infection [ICD-11: GC08] Phase 2/3 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D02NDC DRUGNAME GSK-2202083A INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D02NDP DRUGNAME PMID26651364-Compound-7a INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D02NDV DRUGNAME Levovist INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D02NEH DRUGNAME Ibutamoren INDICATI Fibromyalgia [ICD-11: MG30.01] Approved TTDDRUID D02NEZ DRUGNAME IMX-942 INDICATI Mucositis [ICD-11: CA00] Preclinical TTDDRUID D02NFA DRUGNAME A-68828 INDICATI Kidney disease [ICD-11: GC2Z] Terminated TTDDRUID D02NFE DRUGNAME Anti-CD19 CART Cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D02NGR DRUGNAME MK-499 INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2 TTDDRUID D02NHD DRUGNAME Ragaglitazar INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D02NHW DRUGNAME GSK-264220A INDICATI Coagulation defect [ICD-11: 3B10.0] Clinical trial TTDDRUID D02NHY DRUGNAME PLADD INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D02NIP DRUGNAME ITASETRON INDICATI Nausea [ICD-11: MD90] Phase 1 TTDDRUID D02NJA DRUGNAME Fomepizole INDICATI Athylene glycol or methanol poisoning [ICD-11: NE61] Approved TTDDRUID D02NJE DRUGNAME PEK fusion protein vaccine INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1 TTDDRUID D02NJK DRUGNAME MDR-03030 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D02NMG DRUGNAME SLV-332 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Preclinical TTDDRUID D02NMJ DRUGNAME Meningococcal B vaccine INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Approved TTDDRUID D02NMO DRUGNAME FR-79620 INDICATI Diabetic complication [ICD-11: 5A2Y] Preclinical INDICATI Obesity [ICD-11: 5B81] Preclinical INDICATI Eating disorder [ICD-11: 6B82] Preclinical TTDDRUID D02NMR DRUGNAME SFX-01 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Subarachnoid hemorrhage [ICD-11: 8B01] Phase 2 TTDDRUID D02NNN DRUGNAME CBP-501 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02NNV DRUGNAME VX-745 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D02NNZ DRUGNAME 1,2,4-triazole derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D02NOC DRUGNAME Cotara INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D02NSF DRUGNAME Oxymorphone INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D02NSS DRUGNAME CART-22 cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D02NTO DRUGNAME Tolnaftate INDICATI Dermatophytosis [ICD-11: 1F28.2] Approved INDICATI Jock itch [ICD-11: 1F28.3] Approved TTDDRUID D02NTS DRUGNAME JNJ-39393406 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 2 INDICATI Tobacco dependence [ICD-11: 6C4A.2] Phase 2 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 1 TTDDRUID D02NUS DRUGNAME MB-314 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02NUT DRUGNAME KU-60019 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Clinical trial TTDDRUID D02NVF DRUGNAME M-241247 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D02NXM DRUGNAME GSK2110183 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D02NXQ DRUGNAME NXL-105 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D02NXR DRUGNAME S-117957 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D02NYA DRUGNAME Anti-Ebola mAb INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 1/2 TTDDRUID D02NYK DRUGNAME Pifithrin-alpha INDICATI Toxicity [ICD-11: N.A.] Terminated TTDDRUID D02NZF DRUGNAME NZ-17000 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D02NZO DRUGNAME Amlodipine/ irbesartan fixed-dose combination INDICATI Hypertension [ICD-11: BA00-BA04] Phase 3 TTDDRUID D02OAH DRUGNAME PMID25666693-Compound-5 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D02OAV DRUGNAME Chloral hydrate INDICATI Alcohol dependence [ICD-11: 6C40.2] Approved TTDDRUID D02OBU DRUGNAME Valpentin INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D02OBW DRUGNAME Aminoazetidine derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D02OCD DRUGNAME NIBR-785 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D02OCF DRUGNAME AZD-8294 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Terminated TTDDRUID D02OEP DRUGNAME CWF-07pre03 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D02OGQ DRUGNAME APD INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D02OHR DRUGNAME SC-57666 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D02OIP DRUGNAME OP-05 INDICATI Liver cancer [ICD-11: 2C12] Investigative TTDDRUID D02OJC DRUGNAME Xaliproden INDICATI Juvenile idiopathic arthritis [ICD-11: FA24] Phase 3 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 INDICATI Lateral sclerosis [ICD-11: 8B61] Discontinued in Phase 3 INDICATI Peripheral sensory neuropathies [ICD-11: LD27.3] Discontinued in Phase 3 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 3 TTDDRUID D02OJN DRUGNAME Ru-41740 INDICATI Recurring respiratory infection [ICD-11: CA07-CA45] Approved TTDDRUID D02OLJ DRUGNAME N-acylpiperidine ether derivative 7 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D02ONA DRUGNAME AUTO3 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2 TTDDRUID D02ONK DRUGNAME Y-20024 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Terminated TTDDRUID D02ONR DRUGNAME RG7686 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 TTDDRUID D02ONT DRUGNAME 5-FP INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02OOB DRUGNAME PRX-12205 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D02ORJ DRUGNAME H1N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D02ORS DRUGNAME YKP-GI INDICATI Constipation [ICD-11: DD91.1] Phase 2 TTDDRUID D02OTH DRUGNAME FR-115427 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D02OTK DRUGNAME CH-4051 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D02OYJ DRUGNAME rMERS-CoV-E vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D02OZE DRUGNAME Digoxin INDICATI Heart failure [ICD-11: BD10-BD13] Approved INDICATI Arrhythmia [ICD-11: BC9Z] Approved INDICATI Congestive cardiac insufficiency [ICD-11: BD1Z] Approved TTDDRUID D02OZK DRUGNAME Obatoclax INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D02OZT DRUGNAME DCR-MYC INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 TTDDRUID D02OZY DRUGNAME Metharbital INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D02PAH DRUGNAME Bendroflumethiazide INDICATI High blood pressure [ICD-11: BA00] Approved TTDDRUID D02PAJ DRUGNAME UR-9650 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D02PAW DRUGNAME TLC-388 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D02PCR DRUGNAME Spectinomycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D02PGP DRUGNAME PU3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02PHE DRUGNAME AZD9668 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 INDICATI Bronchiectasis [ICD-11: CA24] Phase 2 TTDDRUID D02PIH DRUGNAME HO-221 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1 TTDDRUID D02PIN DRUGNAME GR-94839 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D02PIO DRUGNAME Benralizumab INDICATI Asthma [ICD-11: CA23] Approved INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3 TTDDRUID D02PJA DRUGNAME Hydriodic acid iodine-125 INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D02PKV DRUGNAME Human recombinant factor VIIa INDICATI Factor IX deficiency [ICD-11: 3B11] Investigative TTDDRUID D02PMO DRUGNAME Topotecan INDICATI Ovarian cancer [ICD-11: 2C73] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D02PMT DRUGNAME Nagrestipen INDICATI Bone marrow transplantation [ICD-11: QB63.6] Phase 1 TTDDRUID D02PNH DRUGNAME COL-171 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Preclinical TTDDRUID D02PNP DRUGNAME AGN-214868 INDICATI Overactive bladder [ICD-11: GC50.0] Phase 2 TTDDRUID D02POH DRUGNAME TA-7906 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D02PPN DRUGNAME Methylphenidate INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved INDICATI Traumatic brain injury [ICD-11: NA07.Z] Phase 4 TTDDRUID D02PQB DRUGNAME ATX-101 INDICATI Obesity [ICD-11: 5B81] Phase 3 TTDDRUID D02PSS DRUGNAME RG1577 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D02PSZ DRUGNAME A-74498 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D02PTD DRUGNAME IDC-7181 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical TTDDRUID D02PTI DRUGNAME AST-005 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D02PVS DRUGNAME KUR-213 INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D02PWM DRUGNAME Dyphylline INDICATI Acute bronchial asthma [ICD-11: CA23] Approved TTDDRUID D02PXP DRUGNAME CIGB-370 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02PYB DRUGNAME SDZ-GPI-562 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D02PYM DRUGNAME QAK-423 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1 TTDDRUID D02PYN DRUGNAME SR 16234 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D02QAO DRUGNAME IPP-203101 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D02QBJ DRUGNAME TIPLASININ INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D02QBT DRUGNAME AZETIRELIN INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D02QCD DRUGNAME DEXMETHYLPHENIDATE HYDROCHLORIDE INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved TTDDRUID D02QCM DRUGNAME Calcitonin Human INDICATI Paget's disease [ICD-11: FB85] Approved INDICATI Postmenopausal osteoporosis [ICD-11: FB83.11] Phase 3 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D02QDQ DRUGNAME QAX-576 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D02QFW DRUGNAME NNZ-2566 INDICATI Fragile X syndrome [ICD-11: LD55] Phase 2 INDICATI Rett syndrome [ICD-11: LD90.4] Phase 2 INDICATI Traumatic brain injury [ICD-11: NA07.Z] Phase 2 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D02QGM DRUGNAME CGS-26529 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D02QHJ DRUGNAME Intratect INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved TTDDRUID D02QJE DRUGNAME PMID25666693-Compound-23 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D02QJH DRUGNAME Fluocinolone Acetonide INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D02QLH DRUGNAME PTL-43401 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02QLQ DRUGNAME SRD-174 INDICATI Pruritus [ICD-11: EC90] Phase 2 TTDDRUID D02QMQ DRUGNAME S-3578 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D02QND DRUGNAME GF-011802-00 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D02QOL DRUGNAME XMetD INDICATI Hypoglycemia [ICD-11: 5A41] Investigative TTDDRUID D02QPR DRUGNAME Manganese Chloride INDICATI Overactive bladder [ICD-11: GC50.0] Approved TTDDRUID D02QQB DRUGNAME A-216546 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D02QQE DRUGNAME NKTR 214 INDICATI Melanoma [ICD-11: 2C30] Phase 3 INDICATI Sarcoma [ICD-11: 2A60-2C35] Phase 2 INDICATI Bladder cancer [ICD-11: 2C94] Phase 1/2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D02QQT DRUGNAME Quattvaxem INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D02QQV DRUGNAME ACAM-1000 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 3 TTDDRUID D02QUB DRUGNAME GM-CT-02 INDICATI Hepatic fibrosis [ICD-11: DB93.0] Investigative TTDDRUID D02QWJ DRUGNAME EREMOMYCIN INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D02QWK DRUGNAME SHP647 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 3 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D02QXI DRUGNAME ST-04 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Investigative TTDDRUID D02QYY DRUGNAME LY01005 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D02QZL DRUGNAME PNQX INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D02QZR DRUGNAME LY-545694 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D02RAI DRUGNAME ABX-PTH INDICATI Parathyroid disease [ICD-11: 5A50-5A5Z] Terminated TTDDRUID D02RAU DRUGNAME KRP-297 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 INDICATI Hyperlipidaemia [ICD-11: 5C80] Terminated TTDDRUID D02RBB DRUGNAME SUPERVAX INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D02RBQ DRUGNAME NG-2 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Investigative TTDDRUID D02RBR DRUGNAME Nitazoxanide + ivermectin + chloroquine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D02RCV DRUGNAME BVF-247 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D02RDC DRUGNAME NV.XOD.09 INDICATI Brain cancer [ICD-11: 2A00] Investigative TTDDRUID D02RDE DRUGNAME JTV-605 INDICATI Dysmenorrhea [ICD-11: GA34.3] Terminated TTDDRUID D02RDX DRUGNAME XP-23829 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 TTDDRUID D02RED DRUGNAME DCVax-Brain INDICATI Brain cancer [ICD-11: 2A00] Phase 3 TTDDRUID D02REJ DRUGNAME JNJ-17216498 INDICATI Narcolepsy [ICD-11: 7A20] Phase 2 TTDDRUID D02REM DRUGNAME DPI-221 INDICATI Urinary incontinence [ICD-11: MF50.2] Investigative TTDDRUID D02REO DRUGNAME TDI-0050 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D02RGZ DRUGNAME MKC-204 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D02RHC DRUGNAME ET190 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D02RHU DRUGNAME SF-111 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D02RHV DRUGNAME PROXODOLOL INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 2 TTDDRUID D02RIV DRUGNAME Hydroxystilbamidine Isethionate INDICATI Blastomycosis [ICD-11: 1F22] Approved TTDDRUID D02RJY DRUGNAME PHA-739358 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D02RKG DRUGNAME MORAb-004 INDICATI Sarcoma [ICD-11: 2A60-2C35] Phase 2 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 2 TTDDRUID D02RLS DRUGNAME R-1554 INDICATI Overactive bladder [ICD-11: GC50.0] Terminated TTDDRUID D02RNJ DRUGNAME SK&F-104662 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D02RNR DRUGNAME LB-100 INDICATI Astrocytoma [ICD-11: 2A00.0Y] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02RNS DRUGNAME Oglufanide INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3 TTDDRUID D02ROU DRUGNAME ASP-1707 INDICATI Endometriosis [ICD-11: GA10] Phase 2 TTDDRUID D02RPK DRUGNAME Z 360 INDICATI Discovery agent [ICD-11: N.A.] Phase 2 TTDDRUID D02RPO DRUGNAME BMS-986249 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02RPP DRUGNAME TPI ASM8 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D02RQT DRUGNAME Tenidap INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D02RQU DRUGNAME Pravastatin INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Approved TTDDRUID D02RRX DRUGNAME SILTENZEPINE INDICATI Stomach disease [ICD-11: DA43-DA4Y] Phase 1 TTDDRUID D02RSN DRUGNAME Levofloxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D02RSY DRUGNAME ADVM-022 INDICATI Wet age-related macular degeneration [ICD-11: 9B78.3Z] Phase 3 TTDDRUID D02RUO DRUGNAME ONO-8815Ly INDICATI Miscarriage [ICD-11: JA00.0] Terminated TTDDRUID D02RUZ DRUGNAME A-922500 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative TTDDRUID D02RVC DRUGNAME PPI-383 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D02RVE DRUGNAME TA-7552 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2 TTDDRUID D02RVN DRUGNAME Selurampanel INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 2 TTDDRUID D02RXG DRUGNAME Nalfurafine hcl INDICATI Uremic pruritus [ICD-11: EC90.10] Approved TTDDRUID D02RXJ DRUGNAME Ribavirin + lopinavir + ritonavir + interferon beta-1b INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D02RYE DRUGNAME AMA-237 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D02RZC DRUGNAME ASC-JMX2 INDICATI Prostate hyperplasia [ICD-11: GA90] Investigative TTDDRUID D02RZL DRUGNAME AZD4769 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D02SAC DRUGNAME Anti-CD123 CAR-T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D02SAK DRUGNAME 2NTX-99 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D02SBQ DRUGNAME Urofollitropin INDICATI Female infertility [ICD-11: GA31.Z] Approved TTDDRUID D02SDC DRUGNAME Inactine INDICATI Anemia [ICD-11: 3A00-3A9Z] Discontinued in Phase 3 TTDDRUID D02SDY DRUGNAME NaBen INDICATI Schizophrenia [ICD-11: 6A20] Phase 2/3 TTDDRUID D02SES DRUGNAME Peptide analog 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D02SEU DRUGNAME PT-107 INDICATI Sarcoma [ICD-11: 2A60-2C35] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D02SGL DRUGNAME PMID26815044-Compound-49 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D02SGT DRUGNAME OM-197-MP-AC INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02SHI DRUGNAME M8891 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02SJB DRUGNAME Imidazopyridazine derivative 8 INDICATI Pain [ICD-11: MG30-MG3Z] Patented INDICATI Inflammation [ICD-11: 1A00-CA43.1] Patented TTDDRUID D02SJG DRUGNAME VT-362 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D02SJN DRUGNAME VBP INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D02SKA DRUGNAME FCE-22716 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D02SKQ DRUGNAME PMID29334795-Compound-28 INDICATI Histamine H3-associated disorder [ICD-11: NE61] Patented TTDDRUID D02SLV DRUGNAME CB-1922 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D02SME DRUGNAME INO-4885 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D02SMV DRUGNAME Herpes simplex virus therapy INDICATI Herpes simplex virus infection [ICD-11: 1F00] Preclinical TTDDRUID D02SNE DRUGNAME NeuGene INDICATI Bacillus anthracis infection [ICD-11: 1G40] Investigative TTDDRUID D02SNJ DRUGNAME SPD602 INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 2 TTDDRUID D02SNQ DRUGNAME Pyrazole derivative 8 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D02SNY DRUGNAME WF-10 INDICATI Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 2 TTDDRUID D02SOL DRUGNAME GF-15 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02SPX DRUGNAME IDX899 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D02SRB DRUGNAME BPL-001 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D02SSR DRUGNAME Methylene blue + vitamin C + N-acetyl cysteine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D02SSV DRUGNAME ALN-RSV02 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Investigative TTDDRUID D02STG DRUGNAME ONO-4232 INDICATI Acute heart failure [ICD-11: BD10-BD13] Phase 1 TTDDRUID D02STN DRUGNAME ABIRATERONE INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D02SUB DRUGNAME SWT-06101 INDICATI Fibromyalgia [ICD-11: MG30.01] Phase 1 TTDDRUID D02SUP DRUGNAME TT-114 INDICATI Coagulation defect [ICD-11: 3B10.0] Investigative TTDDRUID D02SUR DRUGNAME L-697,661 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D02SVQ DRUGNAME HBI-3000 INDICATI Heart arrhythmia [ICD-11: BC65] Phase 2 INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 1 TTDDRUID D02SWB DRUGNAME Grass pollen-derived peptides INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Phase 1/2 TTDDRUID D02SXZ DRUGNAME S-707106 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D02SYQ DRUGNAME Sm-14 INDICATI Schistosomiasis [ICD-11: 1F86] Phase 1 TTDDRUID D02SYV DRUGNAME Lenzilumab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1 TTDDRUID D02SZF DRUGNAME 18F-SMIBR-K5 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02TAB DRUGNAME CJ-50300 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 3 TTDDRUID D02TBI DRUGNAME Carbenicillin INDICATI Infection of the upper and lower urinary tract [ICD-11: GC08] Approved TTDDRUID D02TBU DRUGNAME CIGB-552 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02TDV DRUGNAME ZK-001 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1/2 TTDDRUID D02TGD DRUGNAME Netoglitazone INDICATI Non-alcoholic fatty liver disease [ICD-11: DB92] Phase 2 TTDDRUID D02TGF DRUGNAME Apolipoprotein E-derived peptides INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D02TGN DRUGNAME XMT-1536 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02TGW DRUGNAME GE-20372A INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D02THB DRUGNAME SKF-96067 INDICATI Peptic ulcer [ICD-11: DA61] Discontinued in Phase 3 TTDDRUID D02TIK DRUGNAME HP-184 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D02TIY DRUGNAME Monoamine derivative 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D02TJS DRUGNAME Dicumarol INDICATI Thrombosis [ICD-11: DB61-GB90] Approved INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved TTDDRUID D02TJT DRUGNAME MK-8109 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 TTDDRUID D02TKX DRUGNAME Sac-0601 INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Investigative TTDDRUID D02TLD DRUGNAME AMT-050 INDICATI Cholesterol metabolism disorder [ICD-11: 5C8Z] Terminated TTDDRUID D02TLO DRUGNAME Ifosfamide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D02TMO DRUGNAME 177Lu-AMBA INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D02TNS DRUGNAME TMC-353121 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Preclinical TTDDRUID D02TNW DRUGNAME VR179 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 TTDDRUID D02TOI DRUGNAME Tricyclic phytocannabinoid derivative 2 INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented TTDDRUID D02TOK DRUGNAME IL-2 mimetic peptides INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02TOS DRUGNAME AMSH INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative TTDDRUID D02TQE DRUGNAME TA-102 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D02TQO DRUGNAME Vitamin E INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D02TSJ DRUGNAME Promethazine + sumatriptan INDICATI Migraine [ICD-11: 8A80] Phase 2 TTDDRUID D02TTF DRUGNAME YM-90K INDICATI Convulsion [ICD-11: 8A68.Z] Discontinued in Phase 2 TTDDRUID D02TTL DRUGNAME Debio 0932 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02TTP DRUGNAME TDI-0015 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D02TUL DRUGNAME PF-06651600 INDICATI Alopecia [ICD-11: ED70] Phase 2/3 INDICATI Asthma [ICD-11: CA23] Phase 2 INDICATI Crohn disease [ICD-11: DD70] Phase 1 TTDDRUID D02TVU DRUGNAME HTERT vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02TWR DRUGNAME BIIB080 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1/2 INDICATI Dementia [ICD-11: 6D80-6D86] Phase 1/2 TTDDRUID D02TXV DRUGNAME TRN-157 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D02TYL DRUGNAME HER-801 INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Phase 2 TTDDRUID D02TYV DRUGNAME DPS-102 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D02TZB DRUGNAME T2 18C3 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D02UAR DRUGNAME DiffGAM INDICATI Diarrhea [ICD-11: ME05.1] Discontinued in Phase 2 TTDDRUID D02UBC DRUGNAME MEDI6383 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02UCW DRUGNAME PA-2794 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D02UDO DRUGNAME PMID26651364-Compound-9d INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D02UFG DRUGNAME Metaproterenol Sulfate INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D02UFQ DRUGNAME TAK-285 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02UGL DRUGNAME TR-Flu INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D02UIC DRUGNAME SSR-128428 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D02UIE DRUGNAME ZK-91296 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D02UJD DRUGNAME PD-143188 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 2 TTDDRUID D02UJG DRUGNAME ISIS-387898 INDICATI Huntington disease [ICD-11: 8A01.10] Investigative TTDDRUID D02UJQ DRUGNAME TM-400 INDICATI Bone marrow transplantation [ICD-11: QB63.6] Investigative TTDDRUID D02UJS DRUGNAME PMID30107136-Compound-Example49 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D02UKX DRUGNAME CAP1-6D INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D02ULG DRUGNAME CP-4033 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02ULU DRUGNAME Semaglutide INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D02UMF DRUGNAME KT6-971 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Phase 2 TTDDRUID D02UNP DRUGNAME IMA-901 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 3 TTDDRUID D02UOE DRUGNAME Miltirone INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D02UOZ DRUGNAME NB-001 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 TTDDRUID D02UPI DRUGNAME AGS-6MF INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02UQG DRUGNAME RDEA-436 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D02UQU DRUGNAME ABS-301 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D02URD DRUGNAME SAR425899 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D02URM DRUGNAME Rezafungin INDICATI Candidiasis [ICD-11: 1F23] Phase 3 TTDDRUID D02URS DRUGNAME Potassium iodide INDICATI Thyrotoxicosis [ICD-11: 5A02] Approved TTDDRUID D02URX DRUGNAME KamRAB INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2/3 TTDDRUID D02USE DRUGNAME Heterocyclic derivative 15 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D02USG DRUGNAME P-2745 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1 TTDDRUID D02UVT DRUGNAME Dolutegravir + abacavir sulphate + lamivudine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D02UWX DRUGNAME OT-440 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D02UXK DRUGNAME MBX-3254 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D02UYB DRUGNAME Patisiran INDICATI Hereditary amyloidosis [ICD-11: 5D00.2] Approved INDICATI Amyloidosis [ICD-11: 5D00] Approved INDICATI Amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3 INDICATI Transthyretin familial amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3 TTDDRUID D02UYM DRUGNAME SB414 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 1 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D02VBF DRUGNAME BI-D1870 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Preclinical TTDDRUID D02VBL DRUGNAME EMZ701 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D02VCJ DRUGNAME Metrizamide INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Approved TTDDRUID D02VCK DRUGNAME FLUPAROXAN INDICATI Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 3 TTDDRUID D02VER DRUGNAME Radavirsen INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D02VFB DRUGNAME Miproxifene INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3 TTDDRUID D02VFC DRUGNAME Cefoxitin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D02VFK DRUGNAME PPRT-152 INDICATI Major depressive disorder [ICD-11: 6A70.3] Terminated TTDDRUID D02VHE DRUGNAME A-72055 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D02VIF DRUGNAME OLT1177 gel INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D02VIP DRUGNAME SB-267268 INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 1 TTDDRUID D02VIT DRUGNAME Arbidol INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D02VJP DRUGNAME Cobicistat INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D02VJY DRUGNAME Biricodar INDICATI Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 2 TTDDRUID D02VKC DRUGNAME NBQX INDICATI Neurological disorder [ICD-11: 6B60] Phase 1 TTDDRUID D02VLT DRUGNAME CholeraGarde cholera vaccine live attenuated INDICATI Vibrio cholerae infection [ICD-11: 1A00] Phase 2 TTDDRUID D02VLX DRUGNAME Beractant INDICATI Neonatal respiratory distress [ICD-11: CB04.2] Approved TTDDRUID D02VMC DRUGNAME RP-1000 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D02VMJ DRUGNAME TRICLABENDAZOLE INDICATI Helminth infection [ICD-11: 1F90.0] Approved TTDDRUID D02VNY DRUGNAME Pleodrug INDICATI Peripheral neuropathy [ICD-11: 8C0Z] Investigative TTDDRUID D02VOJ DRUGNAME RWJ-51204 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Preclinical TTDDRUID D02VPS DRUGNAME Anti-FGFR2 humanized mab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02VPX DRUGNAME Calcidiol INDICATI Vitamin D deficiency [ICD-11: 5B57] Approved TTDDRUID D02VQU DRUGNAME STF-31 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02VRN DRUGNAME KT-1 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D02VSP DRUGNAME MK-7655 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D02VTB DRUGNAME BAY1193397 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 2 TTDDRUID D02VUL DRUGNAME AIKO-151 INDICATI Opioid dependence [ICD-11: 6C43.2Z] Investigative TTDDRUID D02VUX DRUGNAME PF-217830 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2 INDICATI Bipolar disorder [ICD-11: 6A60] Discontinued in Phase 2 TTDDRUID D02VYE DRUGNAME Opdivo + Yervoy INDICATI Esophageal cancer [ICD-11: 2B70] Phase 3 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 3 INDICATI Urothelial carcinoma [ICD-11: 2C92.0] Phase 3 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D02VZP DRUGNAME Flesinoxan INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3 TTDDRUID D02WAB DRUGNAME Diloxanide INDICATI Parasitic infection [ICD-11: 1D0Y-1G2Z] Approved TTDDRUID D02WCI DRUGNAME Pirfenidone INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Approved TTDDRUID D02WDO DRUGNAME MGN-1333 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D02WEL DRUGNAME VG-106 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D02WEU DRUGNAME ApoCell INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1/2 TTDDRUID D02WFK DRUGNAME Cycloserine INDICATI Tuberculosis [ICD-11: 1B10-1B14] Approved INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved INDICATI Obsessive compulsive disorder [ICD-11: 6B20] Phase 2 TTDDRUID D02WFN DRUGNAME MK-7622 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D02WGD DRUGNAME LOR-220 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D02WGN DRUGNAME YM-114 INDICATI Nausea [ICD-11: MD90] Discontinued in Phase 2 TTDDRUID D02WGY DRUGNAME Eprotirome INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3 TTDDRUID D02WHY DRUGNAME Rubidium chloride Rb82 INDICATI Coronary artery disease [ICD-11: BA80] Approved TTDDRUID D02WII DRUGNAME TR-14035 INDICATI Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1 TTDDRUID D02WIW DRUGNAME Dexbrompheniramine INDICATI Hay fever [ICD-11: CA08.00] Approved TTDDRUID D02WJB DRUGNAME PMID26815044-Compound-124 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D02WLS DRUGNAME Onyvax-105 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 1 TTDDRUID D02WMX DRUGNAME CR-6261 INDICATI Influenza A virus infection [ICD-11: 1E30] Phase 2 TTDDRUID D02WQR DRUGNAME GSK-008A INDICATI Gynecological disease [ICD-11: GA6Z] Investigative TTDDRUID D02WQZ DRUGNAME Aprosulate sodium INDICATI Coagulation defect [ICD-11: 3B10.0] Discontinued in Phase 1 TTDDRUID D02WRE DRUGNAME ATS-907 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D02WRV DRUGNAME OrthoDerm INDICATI Musculoskeletal disorder [ICD-11: FA00-FC0Z] Phase 2 TTDDRUID D02WSB DRUGNAME CRS-207 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 TTDDRUID D02WST DRUGNAME Unfractionated heparin INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 3 TTDDRUID D02WSY DRUGNAME CVX-060 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D02WUC DRUGNAME Fenquizone INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D02WUW DRUGNAME PLD-177 INDICATI Allergic rhinitis [ICD-11: CA08.0] Terminated TTDDRUID D02WVT DRUGNAME E-3810 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D02WWT DRUGNAME Aryl mannoside derivative 19 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D02XAC DRUGNAME MG-1102 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02XAS DRUGNAME SGM-1019 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 1 TTDDRUID D02XBN DRUGNAME ZPL521 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 1/2 TTDDRUID D02XBW DRUGNAME Urea INDICATI Dermatological disease [ICD-11: DA24.Y] Approved TTDDRUID D02XBY DRUGNAME AGS-005 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Discontinued in Phase 1/2 TTDDRUID D02XEI DRUGNAME DCVax-Ovarian INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 INDICATI Brain cancer [ICD-11: 2A00] Phase 3 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D02XGC DRUGNAME PF-3864086 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D02XGF DRUGNAME H5N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Registered TTDDRUID D02XHD DRUGNAME KI-0805 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 3 TTDDRUID D02XHV DRUGNAME FluBlok INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D02XIY DRUGNAME Octreotide INDICATI Acromegaly [ICD-11: 5A60.0] Approved TTDDRUID D02XJI DRUGNAME Emedastine INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Approved TTDDRUID D02XJJ DRUGNAME LM11A-31 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1/2 TTDDRUID D02XJY DRUGNAME Midodrine INDICATI Orthostatic hypotension [ICD-11: BA21] Approved TTDDRUID D02XKK DRUGNAME FRM-0962 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D02XLI DRUGNAME LY-2979165 INDICATI Bipolar disorder [ICD-11: 6A60] Phase 1 TTDDRUID D02XMD DRUGNAME BGS-649 INDICATI Endometriosis [ICD-11: GA10] Phase 2 TTDDRUID D02XMM DRUGNAME Midaglizole INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D02XNH DRUGNAME C-linked disaccharide biphenyl mannoside derivative 6 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D02XNJ DRUGNAME CogniXan INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D02XNT DRUGNAME BMS-A INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D02XNW DRUGNAME VX-680 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D02XOK DRUGNAME Levomilnacipran INDICATI Fibromyalgia [ICD-11: MG30.01] Approved TTDDRUID D02XOM DRUGNAME HX-01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02XPI DRUGNAME Hydroxychloroquine + ivermectin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D02XSA DRUGNAME Stiripentol INDICATI Dravet syndrome [ICD-11: 8A61.11] Approved INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D02XSL DRUGNAME GlyT1 PET radiotracers INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D02XTN DRUGNAME RO5545965 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D02XTT DRUGNAME LV305 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 INDICATI Melanoma [ICD-11: 2C30] Phase 1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D02XUC DRUGNAME VF001 INDICATI Venous leg ulcer [ICD-11: BD74.3] Phase 2 TTDDRUID D02XUE DRUGNAME TDI-0106 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D02XUN DRUGNAME Trivalent seasonal influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D02XUY DRUGNAME AZ-1297442 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D02XVC DRUGNAME Phenylate derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D02XXF DRUGNAME BMN044 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D02XXN DRUGNAME Evacetrapib INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3 TTDDRUID D02XXQ DRUGNAME MEDl-557 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1 TTDDRUID D02XXT DRUGNAME Diphencyprone INDICATI Alopecia [ICD-11: ED70] Phase 2 TTDDRUID D02XXW DRUGNAME Allogeneic/autologous adult mesenchymal stem cell therapy INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 1/2 TTDDRUID D02XYA DRUGNAME Astuprotimut-R INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID D02XYB DRUGNAME SARIPIDEM INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D02XYT DRUGNAME Furopyridine derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D02XYW DRUGNAME CD19-directed CAR-T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D02YAD DRUGNAME Vivia-008 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02YAQ DRUGNAME GW-974 INDICATI Breast cancer [ICD-11: 2C60-2C65] Terminated TTDDRUID D02YBD DRUGNAME CAL-401 INDICATI Candidiasis [ICD-11: 1F23] Investigative TTDDRUID D02YBP DRUGNAME Mequitamium iodide INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D02YCH DRUGNAME Icodextrin INDICATI Kidney disease [ICD-11: GC2Z] Approved TTDDRUID D02YCL DRUGNAME SB-36131 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D02YEG DRUGNAME VBY-376 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D02YEO DRUGNAME NBTXR3 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D02YEY DRUGNAME FPL-62064 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 3 TTDDRUID D02YIP DRUGNAME AbGn-168 INDICATI Allergy [ICD-11: 4A80-4A85] Phase 2 TTDDRUID D02YIW DRUGNAME 5-(N,N-hexamethylene)-amiloride INDICATI Coronavirus infection [ICD-11: 1D92] Preclinical TTDDRUID D02YIZ DRUGNAME Erythromycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D02YKI DRUGNAME PF-04995274 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D02YNH DRUGNAME CP-809101 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D02YNI DRUGNAME OTX-015 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02YOQ DRUGNAME NUCB-1000 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 1 TTDDRUID D02YPG DRUGNAME Etomidate INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D02YPU DRUGNAME Pyridoxamine INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 3 INDICATI Diabetic kidney disease [ICD-11: GB61.Z] Phase 3 TTDDRUID D02YQB DRUGNAME MenQuadfi INDICATI Meningococcal infection [ICD-11: 1C1C] Approved TTDDRUID D02YQJ DRUGNAME B-5354a INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D02YRD DRUGNAME 4SCAR19 and 4SCAR70 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D02YRX DRUGNAME C-0333158 INDICATI Atopic dermatitis [ICD-11: EA80] Investigative TTDDRUID D02YSO DRUGNAME GX-C4 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D02YVM DRUGNAME Zicronapine INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 TTDDRUID D02YWD DRUGNAME B27PD INDICATI Uveitis [ICD-11: 9A96.Z] Phase 1/2 TTDDRUID D02YWE DRUGNAME EBP-1597 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D02YWM DRUGNAME BIO-500 INDICATI Radiation syndrome [ICD-11: NF00] Investigative TTDDRUID D02YWV DRUGNAME GR-159897 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D02YWW DRUGNAME IDM-1 INDICATI Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 3 TTDDRUID D02YXQ DRUGNAME GT-2016 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D02YYF DRUGNAME Bretylium INDICATI Ventricular fibrillation [ICD-11: BC71.1] Approved TTDDRUID D02YYS DRUGNAME BDNA-001 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D02YZK DRUGNAME RO-5303253 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D02ZAN DRUGNAME SparVax recombinant protective antigen anthrax vaccine INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 2 INDICATI Anthrax [ICD-11: 1B97] Phase 2 TTDDRUID D02ZAT DRUGNAME VGV-S INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D02ZBW DRUGNAME LC-150444 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D02ZCE DRUGNAME AD-337 INDICATI Chemotherapy-induced nausea [ICD-11: MD90] Phase 1 INDICATI Myalgia [ICD-11: FB56.2] Phase 1 INDICATI Fibromyalgia [ICD-11: MG30.01] Phase 1 TTDDRUID D02ZCM DRUGNAME Ad26.ENVA.01 HIV-1 recombinant vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D02ZEM DRUGNAME OBERADILOL MONOETHYL MALEATE INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D02ZGI DRUGNAME Secalciferol INDICATI Disorder of calcium metabolism [ICD-11: 5C64.5] Approved TTDDRUID D02ZHW DRUGNAME 177Lu-DOTA-octreotate INDICATI Melanoma [ICD-11: 2C30] Phase 3 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 3 TTDDRUID D02ZJI DRUGNAME Levalbuterol INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D02ZKB DRUGNAME WAY-126227 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D02ZKL DRUGNAME Reglixane INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D02ZKR DRUGNAME BCX-3408 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 INDICATI Gout [ICD-11: FA25] Phase 2 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D02ZLM DRUGNAME F-991 INDICATI Allergic skin disorder [ICD-11: 4A82] Discontinued in Phase 2 TTDDRUID D02ZMB DRUGNAME Urelumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D02ZMI DRUGNAME AA-29504 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D02ZNH DRUGNAME TT-310 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02ZPM DRUGNAME Anpirtoline INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D02ZPN DRUGNAME NN-414 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D02ZQN DRUGNAME PMID28270021-Compound-WO2013009582Example16 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D02ZQS DRUGNAME GSK269962A INDICATI Inflammation [ICD-11: 1A00-CA43.1] Clinical trial TTDDRUID D02ZSU DRUGNAME NS-49 INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2 TTDDRUID D02ZTJ DRUGNAME Sulfasalazine INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved TTDDRUID D02ZUG DRUGNAME Atogepant INDICATI Migraine [ICD-11: 8A80] Phase 2/3 TTDDRUID D02ZUO DRUGNAME Forodesine INDICATI B-cell acute lymphoblastic leukaemia [ICD-11: 2B33.3] Phase 1/2 INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1/2 TTDDRUID D02ZUT DRUGNAME TRP6-01 INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D02ZVY DRUGNAME Diphenyl purine derivative 4 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D02ZWG DRUGNAME SR-80027A INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D02ZWJ DRUGNAME EP-94 INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative TTDDRUID D02ZWO DRUGNAME DEF-201 INDICATI Ebola virus infection [ICD-11: 1D60.0] Investigative TTDDRUID D02ZWR DRUGNAME IMO-2134 INDICATI Allergy [ICD-11: 4A80-4A85] Preclinical INDICATI Asthma [ICD-11: CA23] Preclinical TTDDRUID D02ZXK DRUGNAME TJ003234 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D02ZXM DRUGNAME Thioguanine INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved TTDDRUID D02ZYI DRUGNAME IPP-201007 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D02ZYV DRUGNAME Biaryl mannoside derivative 15 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D02ZZC DRUGNAME NN-8630 INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Phase 2 TTDDRUID D02ZZG DRUGNAME LEO 43204 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 3 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 INDICATI Actinic keratosis [ICD-11: EK90.0] Phase 2 TTDDRUID D02ZZU DRUGNAME DM-CHOC-PEN INDICATI Brain cancer [ICD-11: 2A00] Phase 2 INDICATI Brain metastases [ICD-11: 2D50] Phase 2 TTDDRUID D03AAV DRUGNAME ProLindaun INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03ABH DRUGNAME Deriglidole INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D03ACE DRUGNAME ASP5094 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D03ACT DRUGNAME PRS-211375 iv INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D03AEG DRUGNAME CBI-008 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03AFF DRUGNAME JNJ-64007957 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D03AFX DRUGNAME CM-2397 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D03AGK DRUGNAME PF-05251749 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D03AJF DRUGNAME SPN-810 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3 TTDDRUID D03AJU DRUGNAME Osilodrostat INDICATI Cushing disease [ICD-11: 5A70] Approved TTDDRUID D03AKH DRUGNAME CER-001 INDICATI Acute coronary syndrome [ICD-11: BA41] Phase 2 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D03AKL DRUGNAME ATLIPROFEN METHYL ESTER INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D03ALS DRUGNAME VA-DIFTET INDICATI Clostridium infection [ICD-11: 1A04] Approved TTDDRUID D03AND DRUGNAME RAF265 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D03AOP DRUGNAME DS-8500 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D03APL DRUGNAME AS-1403 INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1 TTDDRUID D03APM DRUGNAME ABT-110 INDICATI Chronic pain [ICD-11: MG30] Phase 1 TTDDRUID D03AQZ DRUGNAME GMB-Vax INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D03ATI DRUGNAME ITV-2 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D03AUN DRUGNAME RG1512 INDICATI Acute coronary syndrome [ICD-11: BA41] Discontinued in Phase 2 TTDDRUID D03AVA DRUGNAME SNG-8033 INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D03AVS DRUGNAME SR13668 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03AXQ DRUGNAME Soluble FePPi INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 2 TTDDRUID D03AYQ DRUGNAME EB-1020 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2 TTDDRUID D03AZB DRUGNAME Neo-1528 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D03AZK DRUGNAME Sodium zirconium cyclosilicate INDICATI Hyperkalemia [ICD-11: 5C76] Approved TTDDRUID D03AZR DRUGNAME Berubicin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D03AZU DRUGNAME Org-31710 INDICATI Contraception [ICD-11: QA21] Discontinued in Phase 1 TTDDRUID D03AZY DRUGNAME PNU-177864 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D03BAC DRUGNAME Revacept INDICATI Arteriosclerosis [ICD-11: BD40] Phase 2 TTDDRUID D03BAY DRUGNAME N-acylpiperidine ether derivative 5 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D03BBU DRUGNAME Lucatumumab INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 TTDDRUID D03BCE DRUGNAME FPT-038 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D03BCV DRUGNAME Macrocycle derivative 6 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D03BDE DRUGNAME QRX-401 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Discontinued in Phase 1 TTDDRUID D03BDP DRUGNAME Triferic INDICATI Iron-deficiency anemia [ICD-11: 3A00] Approved TTDDRUID D03BFS DRUGNAME SPN-809 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 1 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D03BFU DRUGNAME Pradaxa INDICATI Stroke [ICD-11: 8B20] Phase 3 TTDDRUID D03BGG DRUGNAME ST-1141 INDICATI Functional bowel disorder [ICD-11: DD91] Phase 1 TTDDRUID D03BHM DRUGNAME R1507 INDICATI Graves ophthalmopathy [ICD-11: 9C82.3] Phase 2 TTDDRUID D03BHO DRUGNAME JTP-2942 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D03BHZ DRUGNAME AZD8186 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03BIH DRUGNAME DFN-15 INDICATI Migraine [ICD-11: 8A80] Phase 3 TTDDRUID D03BJX DRUGNAME Botulinum toxin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03BKN DRUGNAME MS201408-0005B INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03BKV DRUGNAME KML-001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03BLF DRUGNAME Triamcinolone INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D03BLG DRUGNAME AGS-009 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 TTDDRUID D03BMR DRUGNAME PRX-1 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D03BND DRUGNAME GFC-001 INDICATI Leishmania infection [ICD-11: 1F54.0] Investigative TTDDRUID D03BNF DRUGNAME IMGN632 INDICATI Blastic plasmacytoid dendritic cell neoplasm [ICD-11: 2A60.5] Phase 1/2 TTDDRUID D03BNU DRUGNAME XL-388 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D03BOZ DRUGNAME RS-130830 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2 TTDDRUID D03BPU DRUGNAME Hematological disease agents INDICATI Hematologic disease [ICD-11: 3C0Z] Investigative TTDDRUID D03BQD DRUGNAME NMS-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03BQP DRUGNAME Rebamipide INDICATI Peptic ulcer [ICD-11: DA61] Phase 3 TTDDRUID D03BRP DRUGNAME Aromatic hydrazine carboxyimidoamide derivative 5 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D03BSK DRUGNAME URC102 INDICATI Gout [ICD-11: FA25] Phase 2 TTDDRUID D03BTP DRUGNAME Fosfluridine tidoxil INDICATI Keratosis [ICD-11: ED56] Terminated TTDDRUID D03BVH DRUGNAME AWD-23-111 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D03BVW DRUGNAME V-419 INDICATI Generalized anxiety disorder [ICD-11: 6B00] Phase 3 INDICATI Poliovirus infection [ICD-11: 1C8Y] Application submitted TTDDRUID D03BWQ DRUGNAME ATN-658 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03BXU DRUGNAME LNK-754 INDICATI Bladder cancer [ICD-11: 2C94] Phase 1 TTDDRUID D03BYM DRUGNAME BAY1895344 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03BZN DRUGNAME Sodium taurocholate INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1/2 TTDDRUID D03BZS DRUGNAME MK-8655 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D03BZU DRUGNAME RG7802 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D03CAT DRUGNAME Cefteram pivoxil INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D03CBU DRUGNAME PHY-626 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03CCH DRUGNAME SK&F-95601 INDICATI Peptic ulcer [ICD-11: DA61] Terminated TTDDRUID D03CCY DRUGNAME XEL 001HP INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D03CDK DRUGNAME ASP-7147 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 2 TTDDRUID D03CEF DRUGNAME Desvenalfaxine succinate INDICATI Fibromyalgia [ICD-11: MG30.01] Approved TTDDRUID D03CFJ DRUGNAME NCX-701 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D03CFR DRUGNAME SEP-226332 INDICATI Obstructive sleep apnea [ICD-11: 7A41] Discontinued in Phase 1 TTDDRUID D03CGQ DRUGNAME AG-013958 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Phase 1/2 TTDDRUID D03CGS DRUGNAME CHF-3098 INDICATI Epilepsy [ICD-11: 8A60-8A68] Withdrawn from market TTDDRUID D03CHE DRUGNAME PF-251802 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D03CHM DRUGNAME MSC1936369B INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D03CHT DRUGNAME Fudosteine INDICATI Expectorant [ICD-11: MD10] Approved INDICATI Bronchitis [ICD-11: CA20] Approved TTDDRUID D03CIN DRUGNAME PTX-007011 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D03CJL DRUGNAME Droperidol INDICATI Nausea [ICD-11: MD90] Approved TTDDRUID D03CKP DRUGNAME DasKloster 0182-01 INDICATI Sarcoidosis [ICD-11: 4B20.5] Investigative TTDDRUID D03CKX DRUGNAME Cromafiban INDICATI Coronary artery disease [ICD-11: BA80] Discontinued in Phase 2 TTDDRUID D03CLP DRUGNAME Dendritic cell vaccine INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D03CMR DRUGNAME TER-16998 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D03CMZ DRUGNAME CAR-T cells targeting EGFRviii INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D03CNS DRUGNAME Cyclothiazide INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D03CNT DRUGNAME L-698532 INDICATI Neurological disorder [ICD-11: 6B60] Terminated TTDDRUID D03CNV DRUGNAME VMD-30283 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 1/2 TTDDRUID D03CPM DRUGNAME SLV-334 INDICATI Brain injury [ICD-11: NA07.Z] Phase 2 TTDDRUID D03CQE DRUGNAME Gatifloxacin INDICATI Respiratory tract infection [ICD-11: CA45] Approved TTDDRUID D03CQN DRUGNAME Chk1-A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03CTH DRUGNAME Biphenyl mannoside derivative 10 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D03CUF DRUGNAME Furazolidone INDICATI Diarrhea [ICD-11: ME05.1] Approved TTDDRUID D03CUS DRUGNAME CS-207 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D03CVT DRUGNAME ONC1-13B INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D03CVV DRUGNAME Anisperimus INDICATI Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2 TTDDRUID D03CWO DRUGNAME ENDG-3020 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D03CWX DRUGNAME MEM-1414 INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 1 TTDDRUID D03CYF DRUGNAME RVX-408 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D03CZE DRUGNAME VPZ-758 INDICATI Raynaud disease [ICD-11: BD42.0] Investigative TTDDRUID D03CZX DRUGNAME PMA-201 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D03DAP DRUGNAME Flecainide INDICATI Tachyarrhythmias [ICD-11: BC71] Approved INDICATI Paroxysmal atrial fibrillation [ICD-11: BC81.30] Phase 1 INDICATI Atrial fibrillation [ICD-11: BC81.3] Investigative TTDDRUID D03DAY DRUGNAME ITV-1 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D03DBW DRUGNAME Pretubulysin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03DDR DRUGNAME Quinine INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D03DEI DRUGNAME Sulfinpyrazone INDICATI Gout [ICD-11: FA25] Approved TTDDRUID D03DFY DRUGNAME NP-7557 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D03DHM DRUGNAME CCX507 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 1 TTDDRUID D03DHQ DRUGNAME CX-516 INDICATI Pervasive developmental disorder [ICD-11: 6A00-6A0Z] Phase 2/3 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2/3 TTDDRUID D03DIG DRUGNAME Codeine INDICATI Pain [ICD-11: MG30-MG3Z] Approved INDICATI Cough [ICD-11: MD12] Phase 1 TTDDRUID D03DII DRUGNAME Pollen allergen immunotherapy INDICATI Seasonal allergic rhinitis [ICD-11: CA08.01] Investigative TTDDRUID D03DJL DRUGNAME Indacaterol INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved INDICATI Asthma [ICD-11: CA23] Phase 4 TTDDRUID D03DJT DRUGNAME Bococizumab INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3 TTDDRUID D03DKR DRUGNAME GALAMUSTINE HYDROCHLORIDE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03DKV DRUGNAME RGB-286638 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D03DMB DRUGNAME GSK2894512 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D03DNI DRUGNAME Hepatitis C virus E2 protein vaccines INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Terminated TTDDRUID D03DOC DRUGNAME DCC-2909 INDICATI Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Investigative TTDDRUID D03DOW DRUGNAME SWT-05141 INDICATI Atopic dermatitis [ICD-11: EA80] Investigative TTDDRUID D03DPZ DRUGNAME INK128 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D03DQK DRUGNAME PEG-Hb/HS INDICATI Shock [ICD-11: MG40] Investigative TTDDRUID D03DRR DRUGNAME Noberastine INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D03DRW DRUGNAME UTIBAPRIL INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D03DSB DRUGNAME Trospectomycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Preregistration TTDDRUID D03DSR DRUGNAME Ambroxol INDICATI Bronchitis [ICD-11: CA20] Approved TTDDRUID D03DSX DRUGNAME SSR411298 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D03DTQ DRUGNAME PMX-700 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Investigative TTDDRUID D03DTU DRUGNAME BCL-5 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D03DTW DRUGNAME EHT-107 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03DUH DRUGNAME ACAM-FLU-A INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D03DUI DRUGNAME GBR 830 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D03DUY DRUGNAME BMS-833923 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1b TTDDRUID D03DVD DRUGNAME Norovirus virus-like particle vaccine INDICATI Norovirus infection [ICD-11: 1A23] Phase 1/2 TTDDRUID D03DVJ DRUGNAME Propylhexedrine INDICATI Obesity [ICD-11: 5B81] Approved TTDDRUID D03DVV DRUGNAME NC-1006 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D03DWZ DRUGNAME SNP-002 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D03DXN DRUGNAME Polyestradiol Phosphate INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D03DXS DRUGNAME Odapipam INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1 TTDDRUID D03DYB DRUGNAME AZD-0275 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated TTDDRUID D03DYT DRUGNAME K252a INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03DZK DRUGNAME WSBI-19711A INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D03EBK DRUGNAME HIV-specific STAR fusions INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D03EBV DRUGNAME JNS-001 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3 TTDDRUID D03EDD DRUGNAME VN/107-1 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D03EDQ DRUGNAME Vismodegib INDICATI Basal cell carcinoma [ICD-11: 2C32] Approved INDICATI Primitive neuroectodermal tumour medulloblastoma [ICD-11: 2A00.11] Phase 2 TTDDRUID D03EEA DRUGNAME PMID25666693-Compound-70 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D03EEH DRUGNAME Gadodiamide INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Approved TTDDRUID D03EER DRUGNAME Thyrotropin INDICATI Hypothyroidism [ICD-11: 5A00] Approved TTDDRUID D03EFD DRUGNAME KT-95 INDICATI Inflammatory bowel disease [ICD-11: DD72] Terminated TTDDRUID D03EHN DRUGNAME Avdoralimab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D03EHR DRUGNAME Lecimibide INDICATI Hyperlipidaemia [ICD-11: 5C80] Terminated TTDDRUID D03EIA DRUGNAME Anti-CD19-CAR T INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D03EIC DRUGNAME ZD-7349 INDICATI Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1 TTDDRUID D03EIG DRUGNAME C3BS-GQR-1 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Investigative TTDDRUID D03EIK DRUGNAME NV.RYM.09 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D03ELL DRUGNAME Amisulpride INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D03END DRUGNAME Insecticide INDICATI Pest attack [ICD-11: N.A.] Investigative TTDDRUID D03EOF DRUGNAME Meplazumab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D03EOT DRUGNAME Borocaptate sodium B 10 INDICATI Brain cancer [ICD-11: 2A00] Approved TTDDRUID D03EOZ DRUGNAME IMG-7289 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 1/2 TTDDRUID D03ERR DRUGNAME H1N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D03ESO DRUGNAME GW-3333 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Preclinical TTDDRUID D03ESU DRUGNAME Anti-SEB mabs INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D03ESW DRUGNAME Cetefloxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D03EWD DRUGNAME CTAP101 INDICATI Kidney disease [ICD-11: GC2Z] Preregistration TTDDRUID D03EXK DRUGNAME Povidone-iodine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D03EZB DRUGNAME AR-H047108 INDICATI Duodenal ulcer [ICD-11: DA63] Discontinued in Phase 2 TTDDRUID D03EZE DRUGNAME GSK2126458 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D03EZQ DRUGNAME AN-1006 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D03EZR DRUGNAME CMD-003 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D03FAP DRUGNAME A-75729 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D03FBV DRUGNAME PF-04950615 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Phase 3 TTDDRUID D03FCF DRUGNAME Novolimus INDICATI Artery stenosis [ICD-11: BD52] Approved TTDDRUID D03FDN DRUGNAME PMID26161824-Compound-69 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D03FDT DRUGNAME Phenolphthalein INDICATI Constipation [ICD-11: DD91.1] Withdrawn from market TTDDRUID D03FEO DRUGNAME Ipecac INDICATI Poison intoxication [ICD-11: NE6Z] Approved TTDDRUID D03FEP DRUGNAME Nanofibers INDICATI Myocardial infarction [ICD-11: BA41-BA43] Investigative TTDDRUID D03FFA DRUGNAME HB-AS02V INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3 TTDDRUID D03FFL DRUGNAME Chitosan-thiomer INDICATI Xerophthalmia [ICD-11: 5B55.Y] Phase 2 TTDDRUID D03FFY DRUGNAME AZD3355 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2 TTDDRUID D03FGI DRUGNAME Anti-LAG3 mAb INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D03FIE DRUGNAME AEZS-126 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03FIL DRUGNAME Insulin Zinc Susp Recombinant Human INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D03FIS DRUGNAME EDP-23 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03FKQ DRUGNAME Ultrase INDICATI Pancreatic malfunction [ICD-11: DC30-DC3Z] Approved TTDDRUID D03FLC DRUGNAME Lamotrigine INDICATI Bipolar disorder [ICD-11: 6A60] Approved INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D03FLT DRUGNAME CP-331684 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D03FNJ DRUGNAME Pipobroman INDICATI Refractory chronic myeloid leukaemia [ICD-11: 2A20] Approved TTDDRUID D03FON DRUGNAME Comvac5 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D03FOP DRUGNAME AMG 319 INDICATI Myeloid leukaemia [ICD-11: 2B33.1] Phase 1 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 1 TTDDRUID D03FOT DRUGNAME AMD-AAV7 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Investigative TTDDRUID D03FPA DRUGNAME APP-018 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D03FQY DRUGNAME PMID26815044-Compound-121 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D03FSF DRUGNAME PMID25666693-Compound-73 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D03FUG DRUGNAME Pegylated carboxyhemoglobin INDICATI Sickle-cell disorder [ICD-11: 3A51] Phase 2 TTDDRUID D03FUO DRUGNAME GDC-0834 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D03FVI DRUGNAME 97-139 INDICATI Cerebrovascular disease [ICD-11: 8B2Z] Discontinued in Phase 2 TTDDRUID D03FVR DRUGNAME GSK-1827771 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D03FVS DRUGNAME Salvicine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D03FXM DRUGNAME Protamine INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved TTDDRUID D03GAI DRUGNAME IR-103 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 3 TTDDRUID D03GAN DRUGNAME A-558693 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D03GAX DRUGNAME TAK-802 INDICATI Urinary dysfunction [ICD-11: GC2Z] Discontinued in Phase 2 TTDDRUID D03GAY DRUGNAME H-409/22 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2 TTDDRUID D03GCJ DRUGNAME Carteolol INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved TTDDRUID D03GCR DRUGNAME MK-8742 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3 TTDDRUID D03GET DRUGNAME Menadione INDICATI Vitamin K deficiency [ICD-11: 5B59] Approved INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D03GFC DRUGNAME AZD-7545 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D03GFZ DRUGNAME Thieno[3,2-c]pyridine-7-carboxamide derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D03GGN DRUGNAME RO-09-4889 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03GHR DRUGNAME C-myb INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D03GHV DRUGNAME PR1 peptide antigen vaccine INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 TTDDRUID D03GII DRUGNAME SR-26831 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D03GIV DRUGNAME SNP-001 INDICATI Epilepsy [ICD-11: 8A60-8A68] Investigative TTDDRUID D03GKP DRUGNAME FD-891 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D03GLK DRUGNAME Imidazole derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D03GLL DRUGNAME TSS-HIG INDICATI Endotoxic shock [ICD-11: 1G41] Investigative TTDDRUID D03GLM DRUGNAME BMS-210285 INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D03GNI DRUGNAME ISOQUINE INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1 TTDDRUID D03GNR DRUGNAME ANA-975 INDICATI Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 1 TTDDRUID D03GOI DRUGNAME Liraglutide INDICATI Type-2 diabetes [ICD-11: 5A11] Approved INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D03GOO DRUGNAME Fumaric acid INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 INDICATI Pustular palmoplantar psoriasis [ICD-11: EA90] Phase 3 TTDDRUID D03GOP DRUGNAME Imvamune smallpox vaccine INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved INDICATI Smallpox [ICD-11: 1E70] Phase 3 INDICATI Monkeypox virus infection [ICD-11: 1E71] Phase 3 TTDDRUID D03GPK DRUGNAME DA-9801 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 TTDDRUID D03GQC DRUGNAME PD-117596 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D03GQH DRUGNAME B-581 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D03GRD DRUGNAME AX-200 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D03GSN DRUGNAME KVD001 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 TTDDRUID D03GTO DRUGNAME C-Met/PD-L1 CAR-T Cell INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1 TTDDRUID D03GVC DRUGNAME Methyclothiazide INDICATI Edema [ICD-11: MG29] Approved INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D03GVG DRUGNAME NP-2 INDICATI Influenza A virus infection [ICD-11: 1E30] Phase 2 TTDDRUID D03GWV DRUGNAME ZP-002 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D03GWY DRUGNAME Ciglitazone INDICATI Pulmonary fibrosis [ICD-11: CB03.4] Preclinical TTDDRUID D03GXU DRUGNAME WIN-901 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D03GYK DRUGNAME Laropiprant+niacin INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Discontinued in Phase 3 TTDDRUID D03HAA DRUGNAME PMID30107136-Compound-Example45 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D03HAW DRUGNAME HemaMax INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 TTDDRUID D03HCZ DRUGNAME Propoxyphene Hydrochloride INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D03HDL DRUGNAME MK 8719 INDICATI Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 1 TTDDRUID D03HDP DRUGNAME ACEA-1416 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D03HDV DRUGNAME DWP-431 INDICATI Bone development disorder [ICD-11: FB86] Phase 3 TTDDRUID D03HFG DRUGNAME Fluvoxamine INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D03HGP DRUGNAME CTP-conjugated WT1 peptide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03HGW DRUGNAME AV-370 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03HHD DRUGNAME Pyrazoline derivative 4 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D03HHG DRUGNAME PMID26651364-Compound-121 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D03HHJ DRUGNAME GSK3174998 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03HIG DRUGNAME AVX-470 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 1 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 1 TTDDRUID D03HJK DRUGNAME Zithromax INDICATI Syphilis infection [ICD-11: 1A6Z] Approved TTDDRUID D03HJZ DRUGNAME AZ-11657312 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D03HKA DRUGNAME ZFP TF INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D03HKR DRUGNAME CDX-0158 INDICATI Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Tumour [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03HLK DRUGNAME PRT-060096 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D03HML DRUGNAME CD56-specific gene-engineered T cells INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D03HMM DRUGNAME ABS-201 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Investigative TTDDRUID D03HOP DRUGNAME HG-1220 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03HOT DRUGNAME BC-19 INDICATI Brain disease [ICD-11: 8C70-8E61] Investigative TTDDRUID D03HQE DRUGNAME CRT0066101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03HQR DRUGNAME SUN-44 INDICATI Nervous system disease [ICD-11: 8A00-8E7Z] Investigative TTDDRUID D03HSA DRUGNAME Actimab-A INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D03HSF DRUGNAME Ro-23-7777 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D03HSN DRUGNAME CNTO-1959 INDICATI Plaque psoriasis [ICD-11: EA90.0] Approved INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D03HSQ DRUGNAME GBR-401 INDICATI B-cell lymphoma [ICD-11: 2A86] Investigative TTDDRUID D03HSS DRUGNAME LG-1041 INDICATI Hunter syndrome [ICD-11: 5C56.31] Investigative TTDDRUID D03HTI DRUGNAME HMR-3787 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D03HTZ DRUGNAME LD201t1 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D03HUX DRUGNAME PCM-075 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03HVN DRUGNAME P-1 INDICATI Atopic dermatitis [ICD-11: EA80] Discontinued in Phase 3 TTDDRUID D03HVV DRUGNAME Efaproxyn INDICATI Lung cancer [ICD-11: 2C25.0] Phase 3 TTDDRUID D03HXO DRUGNAME NPS-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03HYQ DRUGNAME Ranolazine INDICATI Chronic/stable angina [ICD-11: BA40.1] Approved INDICATI Paroxysmal atrial fibrillation [ICD-11: BC81.30] Phase 2 TTDDRUID D03HYX DRUGNAME Mometasone INDICATI Skin allergy [ICD-11: 4A82] Approved TTDDRUID D03IBI DRUGNAME Levotofisopam INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D03ICO DRUGNAME AR-709 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D03ICS DRUGNAME NPT-500 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D03IDK DRUGNAME CEP-18050 INDICATI Lymphoma [ICD-11: 2A80-2A86] Investigative TTDDRUID D03IDU DRUGNAME Hydrogen peroxide INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Approved TTDDRUID D03IEB DRUGNAME Penecure INDICATI Onychomycosis [ICD-11: EE12.1] Investigative TTDDRUID D03IGB DRUGNAME BVT.28949 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2 TTDDRUID D03IGH DRUGNAME Darunavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3 TTDDRUID D03IHA DRUGNAME GT 1061 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D03IHD DRUGNAME Anti-CD22-CAR-transduced T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D03IIP DRUGNAME EP-3533 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Terminated TTDDRUID D03IJO DRUGNAME GS-9820 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 TTDDRUID D03IJZ DRUGNAME Recombinant botulinum toxin INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D03IKT DRUGNAME Paramethasone INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 3 TTDDRUID D03IKZ DRUGNAME HBP-347 INDICATI Autoimmune diabetes [ICD-11: 5A10] Discontinued in Phase 3 TTDDRUID D03ILU DRUGNAME D17.4 INDICATI Myasthenia gravis [ICD-11: 8C6Y] Investigative TTDDRUID D03IMU DRUGNAME TNFR1 NAM INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D03INC DRUGNAME Triplelastat INDICATI Kidney transplant rejection [ICD-11: NE84] Investigative TTDDRUID D03ING DRUGNAME Anrukinzumab INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D03INQ DRUGNAME Laevo-Bambuterol INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D03IOM DRUGNAME CART-19 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2/3 TTDDRUID D03IQD DRUGNAME PF-06480605 INDICATI Crohn disease [ICD-11: DD70] Phase 1 TTDDRUID D03IQH DRUGNAME EDG-006 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D03IQK DRUGNAME BC-821 INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D03IQP DRUGNAME Alpha-Helical lipopeptides LLS INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D03IRG DRUGNAME PNK-007 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D03ISE DRUGNAME PAFENOLOL INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D03ISJ DRUGNAME BMS-863233 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID D03ITZ DRUGNAME Aryl mannoside derivative 4 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D03IUD DRUGNAME Ceftolozane sulfate INDICATI Respiratory tract infection [ICD-11: CA45] Phase 4 TTDDRUID D03IUY DRUGNAME Estropipate INDICATI Hypogonadism [ICD-11: 5A61.0] Approved TTDDRUID D03IWT DRUGNAME NT-13317 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D03IXK DRUGNAME ME-344 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D03JAA DRUGNAME Glycodiazine INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D03JAF DRUGNAME Nrti INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D03JBI DRUGNAME PPI-03306 INDICATI Obstructive sleep apnea [ICD-11: 7A41] Investigative TTDDRUID D03JCA DRUGNAME MB-11055 INDICATI Fatty liver disease [ICD-11: DB92.Z] Phase 2 TTDDRUID D03JCT DRUGNAME M-110101 INDICATI Seborrhea [ICD-11: ED91.2] Investigative TTDDRUID D03JDA DRUGNAME Nu-3 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 1/2 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D03JFJ DRUGNAME PMID26651364-Compound-108 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D03JHJ DRUGNAME FK-352 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D03JIH DRUGNAME SSR-125180 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1 TTDDRUID D03JJY DRUGNAME GANTACURIUM CHLORIDE INDICATI Anaesthesia [ICD-11: 9A78.6] Phase 1/2 TTDDRUID D03JLR DRUGNAME PLX51107 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03JMF DRUGNAME IKI-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03JMN DRUGNAME AD-177 INDICATI Psoriasis vulgaris [ICD-11: EA90] Terminated TTDDRUID D03JNS DRUGNAME Peanut allergy vaccine INDICATI Peanut hypersensitivity [ICD-11: 4A83] Phase 1 TTDDRUID D03JOA DRUGNAME Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D03JPH DRUGNAME Isoxicam INDICATI Osteoarthritis [ICD-11: FA00-FA05] Withdrawn from market TTDDRUID D03JQR DRUGNAME RG-7273 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Discontinued in Phase 1 TTDDRUID D03JRA DRUGNAME Beta-lactam INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Investigative TTDDRUID D03JRG DRUGNAME VU0364739 INDICATI Coagulation defect [ICD-11: 3B10.0] Clinical trial TTDDRUID D03JRJ DRUGNAME NTE-122 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D03JRL DRUGNAME TDI-0102 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D03JRO DRUGNAME ADCI INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Phase 1 TTDDRUID D03JSJ DRUGNAME Mupirocin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D03JSO DRUGNAME ASP-2535 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1 TTDDRUID D03JSS DRUGNAME Tidembersat INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 1 TTDDRUID D03JTG DRUGNAME Fruquintinib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D03JTL DRUGNAME APVO414 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D03JUF DRUGNAME KRL-104 INDICATI Generalized anxiety disorder [ICD-11: 6B00] Phase 1 TTDDRUID D03JUM DRUGNAME Pentaxim INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D03JUN DRUGNAME Anti-IL31 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D03JWU DRUGNAME REC-01 INDICATI Acute myocardial infarction [ICD-11: BA41] Phase 1 TTDDRUID D03JXN DRUGNAME Recombinant anti-IgE Fabs INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D03JXR DRUGNAME NOSO-74 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D03JYD DRUGNAME Tnk-6123 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D03JZC DRUGNAME PF-06263507 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03JZD DRUGNAME Neurosolve INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Preclinical TTDDRUID D03KAC DRUGNAME XL147 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D03KAV DRUGNAME Biphenyl mannoside derivative 12 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D03KAY DRUGNAME Darunavir + ritonavir + oseltamivir + hydroxychloroquine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D03KDO DRUGNAME Prochymal INDICATI Graft-versus-host disease [ICD-11: 4B24] Phase 3 INDICATI Crohn disease [ICD-11: DD70] Phase 3 INDICATI Acute radiation syndrome [ICD-11: NF00] Phase 3 INDICATI Heart disease [ICD-11: BA41-BA42] Phase 3 TTDDRUID D03KEK DRUGNAME Artemisinin SP INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D03KFJ DRUGNAME TB-102 INDICATI Bleeding disorder [ICD-11: GA20-GA21] Investigative TTDDRUID D03KGH DRUGNAME Upamostat INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D03KHN DRUGNAME CLR-1404 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D03KHO DRUGNAME PF-05175157 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D03KHQ DRUGNAME DNA-Ad INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1/2 TTDDRUID D03KHX DRUGNAME MC-D11 INDICATI Norovirus infection [ICD-11: 1A23] Phase 1/2 TTDDRUID D03KIA DRUGNAME Cerivastatin INDICATI Hyperlipidaemia [ICD-11: 5C80] Approved INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D03KIK DRUGNAME AP-300 INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D03KIZ DRUGNAME RG7596 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 2 TTDDRUID D03KJP DRUGNAME Meningococcal CYW vaccine INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Terminated TTDDRUID D03KJS DRUGNAME Antalarmin INDICATI Depression [ICD-11: 6A70-6A7Z] Terminated TTDDRUID D03KJU DRUGNAME NV-04 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D03KJV DRUGNAME Ultramorph INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D03KLF DRUGNAME MDX-1203 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03KLU DRUGNAME CT-406 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D03KNZ DRUGNAME Monoamine derivative 3 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D03KOU DRUGNAME XPro-1595 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D03KOZ DRUGNAME Epalrestat INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Approved INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D03KPZ DRUGNAME Ciprofloxacin+dexamethasone INDICATI Otitis externa [ICD-11: AA00-AA13] Approved INDICATI Acute otitis media [ICD-11: AB00] Approved TTDDRUID D03KQF DRUGNAME Maprotiline INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved TTDDRUID D03KRF DRUGNAME Superoxide dismutase mimetics INDICATI Retinopathy [ICD-11: 9B71] Investigative TTDDRUID D03KST DRUGNAME KT2-962 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D03KTD DRUGNAME Chromomycin a3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D03KTE DRUGNAME LGD2941 INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 1 TTDDRUID D03KTK DRUGNAME TAK-937 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1 TTDDRUID D03KTU DRUGNAME BMS-561388 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D03KUB DRUGNAME Deslorelin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D03KVW DRUGNAME MDX-1411 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03KVY DRUGNAME BCT303 INDICATI Hypothyroidism [ICD-11: 5A00] Phase 2 TTDDRUID D03KWN DRUGNAME AZD-6703 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D03KWU DRUGNAME VRP-S vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D03KXY DRUGNAME Doxifluridine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D03KYG DRUGNAME Perindopril INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D03KYI DRUGNAME IMD-1622 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Investigative TTDDRUID D03KZM DRUGNAME Tolvaptan INDICATI Hyponatraemia [ICD-11: 5C72] Approved INDICATI Heart failure [ICD-11: BD10-BD13] Phase 3 TTDDRUID D03LAB DRUGNAME TBC-3711 INDICATI Hypotension [ICD-11: BA20-BA21] Phase 2 TTDDRUID D03LAI DRUGNAME MSB0010445 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D03LAL DRUGNAME RBBX-01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03LAV DRUGNAME MEDI0700 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 TTDDRUID D03LBD DRUGNAME G-115 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D03LCX DRUGNAME CCX-662 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03LFA DRUGNAME Allogeneic CART-19 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D03LFR DRUGNAME SB-756050 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D03LGG DRUGNAME Zucapsacin INDICATI Osteoarthritis [ICD-11: FA00-FA05] Approved TTDDRUID D03LGX DRUGNAME NI-105 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D03LGY DRUGNAME Divalproex sodium INDICATI Seizure disorder [ICD-11: 8A6Z] Approved TTDDRUID D03LIE DRUGNAME PAV-059 INDICATI Encephalitis virus infection [ICD-11: 1C83-1C84] Investigative TTDDRUID D03LJR DRUGNAME Sirolimus INDICATI Organ transplant rejection [ICD-11: NE84] Approved INDICATI Multiple myeloma [ICD-11: 2A83] Approved INDICATI Dutch elm disease [ICD-11: 8D64] Phase 1/2 TTDDRUID D03LKU DRUGNAME Spheramine INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D03LKV DRUGNAME BMN045 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D03LLL DRUGNAME PRX-12255 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D03LMK DRUGNAME IB-07A085 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D03LNM DRUGNAME TK-112690 INDICATI Mucositis [ICD-11: CA00] Investigative TTDDRUID D03LNN DRUGNAME IDX136 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Preclinical TTDDRUID D03LNV DRUGNAME Argotom-VAX INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D03LQC DRUGNAME APD-209 INDICATI Cachexia [ICD-11: MG20] Phase 2 TTDDRUID D03LQQ DRUGNAME Alinidine INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 3 TTDDRUID D03LRU DRUGNAME Alvespimycin hydrochloride INDICATI Refractory hematologic malignancy [ICD-11: 2A85.5] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D03LSO DRUGNAME SPD-418 INDICATI Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 1 TTDDRUID D03LTA DRUGNAME Haemophilus influenzae B vaccine INDICATI Haemophilus influenza [ICD-11: 1G40] Approved TTDDRUID D03LTO DRUGNAME Tigatuzumab INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Liver cancer [ICD-11: 2C12] Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D03LUF DRUGNAME CD137 CAR-T Cell INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D03LUN DRUGNAME Laronidase INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Approved TTDDRUID D03LWG DRUGNAME BGJ398 INDICATI Cholangiocarcinoma [ICD-11: 2C12.10] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D03LWO DRUGNAME Desirudin Recombinant INDICATI Coagulation defect [ICD-11: 3B10.0] Approved TTDDRUID D03LXH DRUGNAME GAI-122 INDICATI Liver disease [ICD-11: DB90-BD99] Investigative TTDDRUID D03LXJ DRUGNAME KB-2683 INDICATI Arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D03LZK DRUGNAME APS-3010 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03MAD DRUGNAME CP-800569 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D03MBU DRUGNAME SC-006 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03MCV DRUGNAME RB-006 INDICATI Vascular disease [ICD-11: BE2Z] Discontinued in Phase 3 INDICATI Coronary artery disease [ICD-11: BA80] Discontinued in Phase 3 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 3 TTDDRUID D03MDV DRUGNAME PAT-CSL1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03MDW DRUGNAME DS-7309 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D03MDY DRUGNAME PLX9486 INDICATI Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03MER DRUGNAME Endogenous human peptide LL-37 INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D03MEU DRUGNAME Pathogen-specific aAPCs vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D03MFQ DRUGNAME CHF-5074 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 TTDDRUID D03MFV DRUGNAME MNLP-18 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Preclinical TTDDRUID D03MGL DRUGNAME Tafamidis meglumine INDICATI Hereditary amyloidosis [ICD-11: 5D00.2] Approved INDICATI Transthyretin familial amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3 TTDDRUID D03MGV DRUGNAME ASP-5034 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D03MIN DRUGNAME M-0004 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 1 TTDDRUID D03MIP DRUGNAME SPI-256 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D03MIR DRUGNAME Doxazosin INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D03MKE DRUGNAME Resorcinol compound 15 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D03MLR DRUGNAME ADE-LAM INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D03MNN DRUGNAME SKI-758 INDICATI Ischemia [ICD-11: 8B10-8B11] Approved TTDDRUID D03MNS DRUGNAME ADL-7445 INDICATI Constipation [ICD-11: DD91.1] Discontinued in Phase 1 TTDDRUID D03MSF DRUGNAME Nerenone INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID D03MSN DRUGNAME HD-101 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D03MSV DRUGNAME PB-1023 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D03MTN DRUGNAME Mepolizumab INDICATI Severe asthma [ICD-11: CA23] Approved INDICATI Asthma [ICD-11: CA23] Phase 2/3 TTDDRUID D03MTY DRUGNAME LA22-radioimmunoconjugates INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03MUM DRUGNAME EDONENTAN HYDRATE INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Discontinued in Phase 2 TTDDRUID D03MUT DRUGNAME Calfactant INDICATI Acute lung injury [ICD-11: NB32.3] Approved TTDDRUID D03MWM DRUGNAME Oncolysin B INDICATI Bone marrow transplantation [ICD-11: QB63.6] Discontinued in Phase 2 TTDDRUID D03MWZ DRUGNAME Syntropin INDICATI Dwarfism [ICD-11: 5B11] Phase 1 TTDDRUID D03MXK DRUGNAME AT-406 INDICATI Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D03MYO DRUGNAME MGL-3196 INDICATI Familial hypercholesterolemia [ICD-11: 5C80.00] Phase 2 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 1 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Phase 1 TTDDRUID D03MYX DRUGNAME AM0010 INDICATI Pancreatic ductal carcinoma [ICD-11: 2C10.0] Phase 3 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D03MZJ DRUGNAME BUCINDOLOL INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 2/3 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D03MZQ DRUGNAME Sevelamer hydrochloride INDICATI Hypophosphatasia [ICD-11: 5C64.3] Approved TTDDRUID D03MZU DRUGNAME AHCQ INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D03NAW DRUGNAME Dulaglutide INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D03NCL DRUGNAME Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 3 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D03NDI DRUGNAME KCO-912 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D03NGH DRUGNAME Ramoplanin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3 TTDDRUID D03NHS DRUGNAME PCO371 INDICATI Hypoparathyroidism [ICD-11: 5A50] Phase 1 TTDDRUID D03NHW DRUGNAME Ofloxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D03NHZ DRUGNAME Engineered toxin bodies INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03NIW DRUGNAME B244 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D03NJN DRUGNAME PAT-SM5 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03NJY DRUGNAME SF1126 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1 TTDDRUID D03NLJ DRUGNAME FGI-106 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D03NLQ DRUGNAME ABT-957 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D03NLV DRUGNAME KDT-501 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D03NMM DRUGNAME AM-643 INDICATI Dermatological disease [ICD-11: DA24.Y] Investigative TTDDRUID D03NMQ DRUGNAME 131I-CLR-1404 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D03NOS DRUGNAME Rimiterol INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D03NPH DRUGNAME Quazepam INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D03NPI DRUGNAME Idecabtagene vicleucel INDICATI Multiple myeloma [ICD-11: 2A83] Approved TTDDRUID D03NPZ DRUGNAME NNC-22-0031 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Terminated TTDDRUID D03NTF DRUGNAME CWP-231 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03NTJ DRUGNAME Prolixin decanoate INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D03NVS DRUGNAME NC-003 INDICATI Myalgia [ICD-11: FB56.2] Phase 2 TTDDRUID D03NWC DRUGNAME SNG-8023 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D03NXS DRUGNAME GKT-04 INDICATI Angiogenesis disorder [ICD-11: BE2Z] Investigative TTDDRUID D03NZM DRUGNAME T-588 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Discontinued in Phase 2 TTDDRUID D03NZV DRUGNAME SC-236 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D03OBV DRUGNAME AS-1405 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D03OCG DRUGNAME FGF-21 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1/2 TTDDRUID D03ODX DRUGNAME IC-84 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D03OFA DRUGNAME Ro-09-1428 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D03OFF DRUGNAME Pioglitazone INDICATI Diabetic complication [ICD-11: 5A2Y] Approved INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D03OFN DRUGNAME NK-314 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03OGQ DRUGNAME AZD-7009 INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 2 TTDDRUID D03OIO DRUGNAME Anti-Mesothelin CAR-T cells INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03OIW DRUGNAME Kinetin INDICATI Skin photodamage [ICD-11: EJ40] Approved TTDDRUID D03OKG DRUGNAME FK-739 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D03OKS DRUGNAME DC-IL-12 DNA therapeutic INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D03OLA DRUGNAME L-745631 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D03OMK DRUGNAME DM-107 INDICATI Atopic dermatitis [ICD-11: EA80] Investigative TTDDRUID D03ONE DRUGNAME BL-6010 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D03ONX DRUGNAME CL-H02 INDICATI Headache [ICD-11: 8A80-8A84] Investigative TTDDRUID D03ONZ DRUGNAME MCS-18 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D03OPE DRUGNAME CL-284027 INDICATI Cardiac disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D03OPS DRUGNAME HR2P-M2 peptide INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D03OQI DRUGNAME Tozadenant INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D03OSE DRUGNAME GVAX INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D03OSG DRUGNAME MBX-8025 INDICATI Obesity [ICD-11: 5B81] Phase 2/3 INDICATI Familial hypercholesterolemia [ICD-11: 5C80.00] Phase 2 INDICATI Primary biliary cholangitis [ICD-11: DB96.1] Phase 2 TTDDRUID D03OSO DRUGNAME HT-61 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Investigative TTDDRUID D03OTH DRUGNAME Belagenpumatucel-L INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID D03OTX DRUGNAME PSP-D-GITRL INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03OVA DRUGNAME 8-chloro-adenosine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D03OVN DRUGNAME ReN-003 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Phase 1/2 INDICATI Retinopathy [ICD-11: 9B71] Investigative TTDDRUID D03OYY DRUGNAME MAR-531 INDICATI Hypoglycemia [ICD-11: 5A41] Investigative TTDDRUID D03PBT DRUGNAME DuP-983 INDICATI Pruritus [ICD-11: EC90] Terminated TTDDRUID D03PBW DRUGNAME PG-760564 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D03PCJ DRUGNAME MPI-461359 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D03PCP DRUGNAME NCT-400 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D03PDY DRUGNAME SB-332235 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D03PEF DRUGNAME Hedgehog labelled stem cells INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D03PGE DRUGNAME PG-2 INDICATI Fatigue [ICD-11: MG22] Approved TTDDRUID D03PGS DRUGNAME IONIS-TTRRX INDICATI Amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3 TTDDRUID D03PHU DRUGNAME Tetrazolast meglumine INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D03PIA DRUGNAME CB-183315 INDICATI Malignant carcinoid syndrome [ICD-11: 5B10] Phase 3 TTDDRUID D03PIR DRUGNAME Ceftezole INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D03PJP DRUGNAME Trenonacog alfa INDICATI Discovery agent [ICD-11: N.A.] Discontinued in Phase 3 TTDDRUID D03PKI DRUGNAME Geldanamycin INDICATI Peripheral nerve damage [ICD-11: ND56.4] Discontinued in Phase 2 INDICATI Kidney cancer [ICD-11: 2C90.0] Discontinued in Phase 2 TTDDRUID D03PKJ DRUGNAME MK-6186 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D03PLQ DRUGNAME Benzothiazole analog 3 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D03PLR DRUGNAME RemuneX INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3 INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 3 TTDDRUID D03PMB DRUGNAME PTI-601 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D03POY DRUGNAME ISIS-AR INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D03PQW DRUGNAME BAY 79-4620 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03PRC DRUGNAME K562/GM-CSF INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D03PRM DRUGNAME NST-141 INDICATI Pruritus [ICD-11: EC90] Phase 2 TTDDRUID D03PRV DRUGNAME BGC-20-1259 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D03PSA DRUGNAME 1,2,4-oxadiazole derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D03PSP DRUGNAME Panobacumab INDICATI Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 2 INDICATI Hospital-acquired pneumonia [ICD-11: CA40.Z] Phase 2 INDICATI Pseudomonas infection [ICD-11: 1B92] Phase 1/2 TTDDRUID D03PTH DRUGNAME Pyrantel INDICATI Worm infection [ICD-11: 1F90.Z] Approved TTDDRUID D03PTZ DRUGNAME BTS-73947 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1 TTDDRUID D03PUA DRUGNAME Siltuximab INDICATI Idiopathic multicentric Castlemans disease [ICD-11: 2A81.Y] approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D03PUG DRUGNAME Revax-TBE INDICATI Flavivirus infection [ICD-11: 1C80] Investigative TTDDRUID D03PVQ DRUGNAME EDP-420 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D03PVY DRUGNAME GlycoPEGylated erythropoietin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D03PWD DRUGNAME GMI-1271 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D03PXT DRUGNAME Altastaph INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 2 TTDDRUID D03PYA DRUGNAME Cyclohexyl carbamate derivative 3 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D03PYD DRUGNAME K-604 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 2 TTDDRUID D03PZY DRUGNAME PHER-O2 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D03PZZ DRUGNAME Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 7 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D03QAO DRUGNAME AZD-9742 INDICATI MRSA infection [ICD-11: 1D01.0Y] Phase 1 TTDDRUID D03QAQ DRUGNAME SN429 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D03QAS DRUGNAME E-758 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03QAW DRUGNAME PMID25666693-Compound-61 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D03QBL DRUGNAME Autologous idiotypic cancer vaccine INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D03QBS DRUGNAME Furazolidinone INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D03QBT DRUGNAME Golnerminogene pradenovac INDICATI Esophageal cancer [ICD-11: 2B70] Phase 3 TTDDRUID D03QBY DRUGNAME Anavip INDICATI Poison intoxication [ICD-11: NE6Z] Phase 3 TTDDRUID D03QCW DRUGNAME Interferon alfa-n1 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Approved TTDDRUID D03QEB DRUGNAME VGX-1027 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D03QEC DRUGNAME ASP4131 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative INDICATI Colorectal cancer [ICD-11: 2B91.Z] Investigative TTDDRUID D03QFN DRUGNAME Patrome INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D03QFO DRUGNAME SOR-N43 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D03QFY DRUGNAME PPLs INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D03QGB DRUGNAME JNJ-5207852 INDICATI Narcolepsy [ICD-11: 7A20] Investigative TTDDRUID D03QGM DRUGNAME Sulpiride INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D03QHC DRUGNAME KAF156 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2 TTDDRUID D03QHM DRUGNAME JNJ-64041809 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D03QHR DRUGNAME GFC-036 INDICATI Leishmania infection [ICD-11: 1F54.0] Investigative TTDDRUID D03QIE DRUGNAME Bicifadine INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 3 INDICATI Chronic low back pain [ICD-11: MG30.02] Phase 3 TTDDRUID D03QIP DRUGNAME fluciclovine F-18 INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D03QJA DRUGNAME GSK-812397 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D03QJL DRUGNAME Ibudilast INDICATI Castleman's disease [ICD-11: 4B2Y] Approved INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 INDICATI Methamphetamine dependence [ICD-11: 6C46.2] Phase 2 INDICATI Opioid dependence [ICD-11: 6C43.2Z] Phase 2 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D03QJN DRUGNAME DPC 423 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D03QKW DRUGNAME KUC-7483 INDICATI Overactive bladder [ICD-11: GC50.0] Phase 1 TTDDRUID D03QLG DRUGNAME CEP1347 INDICATI Asthma [ICD-11: CA23] Phase 2/3 TTDDRUID D03QMY DRUGNAME IDM-2101 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D03QNA DRUGNAME CIGB-845 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D03QNW DRUGNAME Hextend INDICATI Blood transfusion [ICD-11: QB98] Approved TTDDRUID D03QQP DRUGNAME BDNA-003 INDICATI Chlamydia infection [ICD-11: 1A81] Investigative TTDDRUID D03QRS DRUGNAME Triptorelin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 4 TTDDRUID D03QSC DRUGNAME NT-KC-005 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D03QSR DRUGNAME TP-20 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D03QSS DRUGNAME AMX0035 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 TTDDRUID D03QTB DRUGNAME NSD-551 INDICATI Brain cancer [ICD-11: 2A00] Terminated TTDDRUID D03QTM DRUGNAME Oncophage vitespen INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3 TTDDRUID D03QTP DRUGNAME CGP-52411 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D03QUJ DRUGNAME PYM-60001 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D03QVY DRUGNAME EZN-4482 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03QWG DRUGNAME Ad-IFN-alpha INDICATI Bladder cancer [ICD-11: 2C94] Phase 1 TTDDRUID D03QWO DRUGNAME Dexefaroxan INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2 TTDDRUID D03QWT DRUGNAME Doripenem INDICATI Urinary tract infection [ICD-11: GC08] Approved INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Phase 3 TTDDRUID D03QWZ DRUGNAME PP-099 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 TTDDRUID D03QXD DRUGNAME RXP-470 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D03QZB DRUGNAME F-1394 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D03QZJ DRUGNAME CC-122 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D03RCB DRUGNAME FGI-101-1A6 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D03RCJ DRUGNAME Sodium Succinate INDICATI Arthritis [ICD-11: FA20] Approved TTDDRUID D03RCP DRUGNAME NM-135 INDICATI Dermatitis [ICD-11: EA80-EA89] Discontinued in Phase 2 TTDDRUID D03RCV DRUGNAME D2A21 INDICATI Burn and burn infection [ICD-11: ND90-NE2Z] Phase 3 TTDDRUID D03RDQ DRUGNAME Gavilimomab INDICATI Graft-versus-host disease [ICD-11: 4B24] Phase 2/3 TTDDRUID D03RDS DRUGNAME Labetuzumab govitecan INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D03REC DRUGNAME KP-736 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D03RFK DRUGNAME GTP-200 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D03RGO DRUGNAME CP-331 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D03RHZ DRUGNAME MDL-27192 INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Phase 2 TTDDRUID D03RIO DRUGNAME GSK598809 INDICATI Drug abuse [ICD-11: 6C4G.1Z] Phase 2 TTDDRUID D03RIX DRUGNAME Sirukumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D03RJZ DRUGNAME Oxeglitazar INDICATI Gout [ICD-11: FA25] Phase 1 TTDDRUID D03RKC DRUGNAME EG-Vac INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03RLC DRUGNAME MOR-6292 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D03RLP DRUGNAME GT160-246 INDICATI Diarrhea [ICD-11: ME05.1] Phase 3 TTDDRUID D03RMN DRUGNAME 1069C INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03RNX DRUGNAME EPC-K1 INDICATI Nerve injury [ICD-11: ND56.4] Discontinued in Phase 2 TTDDRUID D03ROA DRUGNAME Tr-2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03ROX DRUGNAME Betaxolol INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D03RQW DRUGNAME Rostaporfin INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Basal cell carcinoma [ICD-11: 2C32] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03RSI DRUGNAME IMMLG-5521 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D03RSQ DRUGNAME Vivia-007 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03RTC DRUGNAME BMS-812204 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D03RTK DRUGNAME Trabectedin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 TTDDRUID D03RTR DRUGNAME INP-02 INDICATI HIV-associated dementia [ICD-11: 6D85.3] Investigative TTDDRUID D03RTS DRUGNAME Celecoxib INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D03RUL DRUGNAME AP5280 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1/2 TTDDRUID D03RVC DRUGNAME YH-4808 INDICATI Duodenal ulcer [ICD-11: DA63] Phase 2 TTDDRUID D03RXE DRUGNAME Biphenyl mannoside derivative 3 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D03RXS DRUGNAME TAK-831 INDICATI Friedreich's ataxia [ICD-11: 8A03.10] Phase 2 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D03RYJ DRUGNAME REL-1015 INDICATI Chronic pain [ICD-11: MG30] Phase 2 TTDDRUID D03RYN DRUGNAME Cytolin INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical TTDDRUID D03RYS DRUGNAME VNA-932 INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1 TTDDRUID D03RZM DRUGNAME Steroid hormone conjugates INDICATI Cachexia [ICD-11: MG20] Terminated TTDDRUID D03RZU DRUGNAME CNS-5788 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D03RZV DRUGNAME Tolazoline INDICATI Pulmonary hypertension [ICD-11: BB01] Approved TTDDRUID D03SCP DRUGNAME PNT-200 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03SDH DRUGNAME Siratiazem INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D03SFN DRUGNAME Elzasonan hydrochloride INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2 TTDDRUID D03SFU DRUGNAME TERTATOLOL INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D03SGF DRUGNAME WBZ-7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03SGR DRUGNAME Efalizumab INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved INDICATI Renal transplantation [ICD-11: NE84] Phase 2 TTDDRUID D03SHD DRUGNAME Myo-inositol INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D03SHI DRUGNAME Ro-5287373 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03SHM DRUGNAME PMID25666693-Compound-88 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D03SHP DRUGNAME GSK2849466 INDICATI Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 1 TTDDRUID D03SIA DRUGNAME OBI-1 INDICATI Factor VIII deficiency [ICD-11: 3B10] Phase 3 TTDDRUID D03SKC DRUGNAME KRP-104 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D03SKD DRUGNAME Oxycodone INDICATI Pain [ICD-11: MG30-MG3Z] Approved INDICATI Back pain [ICD-11: ME84.Z] Phase 3 TTDDRUID D03SKF DRUGNAME SC-124a INDICATI Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 3 TTDDRUID D03SKL DRUGNAME BAY 86-9766 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D03SKR DRUGNAME Clonidine INDICATI Hypertension [ICD-11: BA00-BA04] Approved INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 3 TTDDRUID D03SLK DRUGNAME SAR292833 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Investigative TTDDRUID D03SLO DRUGNAME OSU-2S INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03SMB DRUGNAME 2-18F-FE-5-Br-glyburide INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D03SNE DRUGNAME PMID27828716-Compound-BIO-acetoxime INDICATI Malignant glioma [ICD-11: 2A00.0] Patented TTDDRUID D03SQT DRUGNAME Q203 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Phase 1 TTDDRUID D03SRY DRUGNAME Estramustine INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D03SSE DRUGNAME Mechlorethamine INDICATI T-cell lymphoma [ICD-11: 2A90] Approved INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 3 TTDDRUID D03SSG DRUGNAME PA-10040 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D03SSH DRUGNAME AI-1008 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Investigative TTDDRUID D03STA DRUGNAME Darotropium INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D03STV DRUGNAME GSK-2197870A INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D03SUQ DRUGNAME Apilimod dimesylate INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D03SVG DRUGNAME GSK-2189242A INDICATI Pneumococcal infection [ICD-11: CA00-CA40] Phase 2 TTDDRUID D03SVX DRUGNAME Aliskiren INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D03SVZ DRUGNAME Yersinia pestis vaccine INDICATI Yersinia infection [ICD-11: 1B93] Terminated TTDDRUID D03SWH DRUGNAME PNU-142633 INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 2 TTDDRUID D03SXE DRUGNAME Betamethasone Valerate INDICATI Dermatological disease [ICD-11: DA24.Y] Approved TTDDRUID D03SXI DRUGNAME INCAGN1949 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D03SXQ DRUGNAME MDX-1140 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03SXS DRUGNAME LY-2875358 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D03SYC DRUGNAME LY-GSK-3i INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03SZK DRUGNAME VXM-01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03SZR DRUGNAME M-carboxycinnamic acid bishydroxamide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D03TAP DRUGNAME MCT-275 INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Investigative TTDDRUID D03TAT DRUGNAME Weight regulating human endocrine peptide INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D03TAY DRUGNAME VGX-3400 INDICATI Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 1 TTDDRUID D03TBD DRUGNAME BMS-986148 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03TBJ DRUGNAME GRT-6005 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 3 TTDDRUID D03TDB DRUGNAME TMB-358 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D03TDE DRUGNAME AC-4402 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D03TDK DRUGNAME Sulfonamide derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D03TDW DRUGNAME Thiopilocarpine INDICATI Cognitive impairment [ICD-11: 6D71] Phase 1 TTDDRUID D03TFJ DRUGNAME Benzimidazole INDICATI Cytomegalovirus Disease [ICD-11: 1D82] Investigative TTDDRUID D03TGB DRUGNAME MOD-1002 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D03TGJ DRUGNAME Sorivudine INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D03TIJ DRUGNAME Titanocene dichloride INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D03TIS DRUGNAME Brentuximab vedotin INDICATI Hodgkin lymphoma [ICD-11: 2B30] Approved TTDDRUID D03TJN DRUGNAME KOS-1803 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D03TKI DRUGNAME FM-201 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D03TME DRUGNAME Crotalidae fab INDICATI Venom poisoning [ICD-11: NE61] Approved TTDDRUID D03TNA DRUGNAME ABT-724 INDICATI Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2 TTDDRUID D03TNG DRUGNAME GCAN 101 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D03TOH DRUGNAME AC-0523 INDICATI Huntington disease [ICD-11: 8A01.10] Investigative TTDDRUID D03TPI DRUGNAME TV-1102 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D03TPR DRUGNAME Dextrothyroxine Sodium INDICATI High blood cholesterol level [ICD-11: 5C80.00] Approved TTDDRUID D03TQB DRUGNAME AU105 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2 TTDDRUID D03TRO DRUGNAME GRN-529 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D03TSR DRUGNAME Grass pollen immunotherapy INDICATI Allergy [ICD-11: 4A80-4A85] Phase 3 TTDDRUID D03TTQ DRUGNAME TRYPAN BLUE INDICATI Ophthalmic surgery injury [ICD-11: PK97] Approved TTDDRUID D03TTT DRUGNAME AR-00341677 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03TVE DRUGNAME FGF21-PKE Adnectin INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D03TVW DRUGNAME Stepronin INDICATI Bronchitis [ICD-11: CA20] Approved TTDDRUID D03TVY DRUGNAME OTI-030 INDICATI Knee injuries [ICD-11: NC9Z] Phase 2 TTDDRUID D03TWD DRUGNAME PMID30107136-Compound-Example4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D03TXW DRUGNAME CSP-9222 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03TXY DRUGNAME PMID28216367-compound-6d INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D03TYI DRUGNAME Aminophylline INDICATI Bronchial asthma [ICD-11: CA23] Approved INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D03TYJ DRUGNAME ATHX-105 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D03TYT DRUGNAME PF-03800130 INDICATI Bipolar disorder [ICD-11: 6A60] Investigative TTDDRUID D03TYY DRUGNAME Nicotine-Q INDICATI Tobacco dependence [ICD-11: 6C4A.2] Phase 2 TTDDRUID D03TZG DRUGNAME MGN-9103 INDICATI Cardiac failure [ICD-11: BD10-BD13] Investigative TTDDRUID D03UAO DRUGNAME MG-1105 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D03UBI DRUGNAME VALERGEN-DP INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D03UBW DRUGNAME Ficlatuzumab INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D03UDF DRUGNAME LOXO-195 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03UDW DRUGNAME AI-850 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03UEO DRUGNAME Clazakizumab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D03UFM DRUGNAME BMS-200980 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Preregistration TTDDRUID D03UFQ DRUGNAME Malaria vaccine INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D03UHV DRUGNAME ONO-4578 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03UIB DRUGNAME TOK-8801 INDICATI Arthritis [ICD-11: FA20] Phase 2 TTDDRUID D03UID DRUGNAME RJR-2403 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D03UIF DRUGNAME SA-6541 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D03UIW DRUGNAME Brontictuzumab INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D03UKI DRUGNAME Autologous dendritic cell vaccines INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03UKJ DRUGNAME Pazopanib + Tyverb/Tykerb INDICATI Inflammatory breast cancer [ICD-11: 2C62] Phase 2 TTDDRUID D03UMA DRUGNAME CNT0-0007 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 1 TTDDRUID D03UNN DRUGNAME L-689560 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated TTDDRUID D03UNT DRUGNAME Anti-CD19-CAR vector-transduced T cells INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial INDICATI B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Clinical trial INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Clinical trial INDICATI Follicular lymphoma [ICD-11: 2A80] Clinical trial INDICATI Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Clinical trial INDICATI Prolymphocytic leukaemia [ICD-11: 2A82.1] Clinical trial TTDDRUID D03UOG DRUGNAME P2B-004 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03UOT DRUGNAME Hydroquinone INDICATI Melasma [ICD-11: ED60.1] Approved TTDDRUID D03UQM DRUGNAME Retapamulin INDICATI Impetigo [ICD-11: 1B72] Approved TTDDRUID D03URV DRUGNAME HL-1172 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03USI DRUGNAME SL-87.0495 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 2 TTDDRUID D03UUL DRUGNAME APN01 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 1 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 TTDDRUID D03UVL DRUGNAME SSR-240612 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D03UVS DRUGNAME Gemcitabine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D03UVX DRUGNAME NOPPI INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03UWE DRUGNAME CAT-1904 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D03UXT DRUGNAME Recombinant house dust mite allergy desensitization injection INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D03UYI DRUGNAME TAK-427 INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2 TTDDRUID D03UZC DRUGNAME DS-1150b INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D03UZP DRUGNAME RG7888 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Urothelial carcinoma [ICD-11: 2C92.0] Phase 2 TTDDRUID D03VAR DRUGNAME Trecovirsen sodium INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D03VCF DRUGNAME Urtoxazumab INDICATI Escherichia coli infection [ICD-11: 1A03] Discontinued in Phase 2 TTDDRUID D03VCJ DRUGNAME NP-01 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D03VDA DRUGNAME PTL-303 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D03VDC DRUGNAME Talc INDICATI Pleural disease [ICD-11: CB27] Approved TTDDRUID D03VDX DRUGNAME CPD-0905 INDICATI Trypanosomiasis [ICD-11: 1D51-1F53] Investigative TTDDRUID D03VEZ DRUGNAME AD-439 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D03VFL DRUGNAME TOCOTRIENOL INDICATI Hyperlipidaemia [ICD-11: 5C80] Approved TTDDRUID D03VFV DRUGNAME IL1aQb INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D03VGD DRUGNAME PACIS INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D03VGW DRUGNAME GCR-1087 INDICATI Type-2 diabetes [ICD-11: 5A11] Preclinical INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D03VHI DRUGNAME HMR-3562 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D03VLG DRUGNAME DCB-WH1 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 2 TTDDRUID D03VLH DRUGNAME ColoAd1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D03VLO DRUGNAME CD1-TB INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D03VLS DRUGNAME Lu-AA37096 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D03VMW DRUGNAME HepaGam B INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D03VNB DRUGNAME NI-0801 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D03VNJ DRUGNAME Carperitide INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D03VNX DRUGNAME Pro-urokinase INDICATI Thrombin deficiency [ICD-11: 3B14.Z] Approved TTDDRUID D03VPC DRUGNAME Cilostazol INDICATI Intermittent claudication [ICD-11: BD40.00] Approved TTDDRUID D03VPJ DRUGNAME AN0128 INDICATI Psoriatic disorder [ICD-11: EA90] Phase 2 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D03VPM DRUGNAME DPV-001 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D03VRX DRUGNAME Albumin Iodinated Serum INDICATI Imaging [ICD-11: QA0B] Approved TTDDRUID D03VTN DRUGNAME TRIMOPROSTIL INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 3 TTDDRUID D03VUV DRUGNAME Adarotene ester derivative back-up compounds INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03VWB DRUGNAME MP-157 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 TTDDRUID D03VXG DRUGNAME Insulin Lyspro recombinant INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D03VXJ DRUGNAME Hydrochloric acid INDICATI Alkalosis [ICD-11: 5C74] Approved TTDDRUID D03VXP DRUGNAME PMID25666693-Compound-145 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D03VXQ DRUGNAME Oxetane 3,3-dicarboxamide compound 1 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Patented TTDDRUID D03VYZ DRUGNAME MRX-4 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D03VZH DRUGNAME Ethchlorvynol INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D03WAJ DRUGNAME Heptabarbital INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D03WAT DRUGNAME PRC-4016 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Phase 2 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D03WAU DRUGNAME Anamorelin INDICATI Carbohydrate metabolism disorder [ICD-11: 5C51.Z] Phase 3 TTDDRUID D03WAX DRUGNAME KST-301 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03WCJ DRUGNAME 4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D03WCT DRUGNAME LAS-189913 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D03WDN DRUGNAME BI-638683 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03WEX DRUGNAME Vortioxetine INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 3 TTDDRUID D03WFI DRUGNAME Heteroaryl-carboxamide derivative 9 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D03WGM DRUGNAME SOM-0888 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D03WHC DRUGNAME Nnrti INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D03WJB DRUGNAME Biphenyl mannoside derivative 25 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D03WLI DRUGNAME Technetium Tc-99m Pentetate Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D03WMK DRUGNAME AC-162352 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1 TTDDRUID D03WMT DRUGNAME ML-721 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03WMY DRUGNAME NPC-17731 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D03WMZ DRUGNAME MEDI5884 INDICATI Coronary artery disease [ICD-11: BA80] Phase 2 TTDDRUID D03WNG DRUGNAME CORT-125134 INDICATI Cushing disease [ICD-11: 5A70] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Alcohol dependence [ICD-11: 6C40.2] Clinical trial TTDDRUID D03WNN DRUGNAME RG-7010 INDICATI Motor neurone disease [ICD-11: 8B60] Phase 1 TTDDRUID D03WOG DRUGNAME Evinacumab INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Approved INDICATI Elevated C-reactive protein [ICD-11: MA14.15] Phase 2 INDICATI Familial hypercholesterolemia [ICD-11: 5C80.00] Phase 2 TTDDRUID D03WOQ DRUGNAME LY3127804 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03WOW DRUGNAME QS-21 INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D03WPA DRUGNAME Trovafloxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D03WPI DRUGNAME NC-190 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D03WPP DRUGNAME Necitumumab INDICATI Colorectal cancer [ICD-11: 2B91.Z] Approved TTDDRUID D03WQS DRUGNAME BMS-582664 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 TTDDRUID D03WRJ DRUGNAME Lisofylline INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D03WRN DRUGNAME AVT-02 UE INDICATI Skin infection [ICD-11: 1F28-1G0Z] Discontinued in Phase 2 TTDDRUID D03WSE DRUGNAME XomaZyme-Mel INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 2 TTDDRUID D03WTE DRUGNAME BT-301 INDICATI Periodontal disease [ICD-11: DA0C] Investigative TTDDRUID D03WTX DRUGNAME SBC-105 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D03WUH DRUGNAME YM-099 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D03WUU DRUGNAME Multivalent (HIVIS 07) DNA vaccine Derma Vax/ZetaJet INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical TTDDRUID D03WVP DRUGNAME IBU-PC INDICATI Inflammation associated with osteoarthritis [ICD-11: FA00-FA05] Preclinical INDICATI Pain [ICD-11: MG30-MG3Z] Preclinical TTDDRUID D03WWG DRUGNAME Elcatonin INDICATI Disorder of calcium metabolism [ICD-11: 5C64.5] Approved TTDDRUID D03WWW DRUGNAME Hepcidin INDICATI Hemochromatosis [ICD-11: 5C64.1Y] Phase 1 TTDDRUID D03WXL DRUGNAME Staphguard INDICATI Staphylococcus infection [ICD-11: 1B5Y] Investigative TTDDRUID D03WXM DRUGNAME C-linked disaccharide biphenyl mannoside derivative 4 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D03WYV DRUGNAME TAK-225 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D03WZJ DRUGNAME A33-Ac-225 INDICATI Colon cancer [ICD-11: 2B90.Z] Investigative TTDDRUID D03XAO DRUGNAME NVX-108 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D03XBB DRUGNAME DX-2400 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03XBT DRUGNAME Prostatix INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D03XCR DRUGNAME Simotaxel INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03XDD DRUGNAME OG-45 INDICATI Dementia [ICD-11: 6D80-6D86] Investigative TTDDRUID D03XDX DRUGNAME Tarazepide INDICATI Gastrointestinal disease [ICD-11: DE2Z] Discontinued in Phase 2 TTDDRUID D03XES DRUGNAME Eptazocine hbr INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D03XET DRUGNAME POD-003 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D03XEV DRUGNAME NDC-1187 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03XEY DRUGNAME Epstein-barr virus-specific immunotherapy INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Phase 2 TTDDRUID D03XFH DRUGNAME ACTR-BCMA INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D03XHD DRUGNAME A-11259 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D03XHS DRUGNAME ACT-178882 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D03XIH DRUGNAME ABS-103 INDICATI Bipolar disorder [ICD-11: 6A60] Terminated TTDDRUID D03XJP DRUGNAME Y-175L INDICATI Lupus [ICD-11: 4A40] Investigative TTDDRUID D03XLO DRUGNAME PEV-8 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D03XLX DRUGNAME CP-778875 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 2 TTDDRUID D03XOC DRUGNAME Trilostane INDICATI Cushing disease [ICD-11: 5A70] Approved TTDDRUID D03XRA DRUGNAME GSK2661380 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03XRZ DRUGNAME PF-05094037 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03XSJ DRUGNAME Buclizine INDICATI Nausea [ICD-11: MD90] Approved TTDDRUID D03XST DRUGNAME MC-207252 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Terminated TTDDRUID D03XSX DRUGNAME CEL-2000 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D03XTC DRUGNAME Esmolol INDICATI Acute supraventricular tachycardia [ICD-11: BC81] Approved TTDDRUID D03XTY DRUGNAME APR-246 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Bladder cancer [ICD-11: 2C94] Phase 1/2 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2 INDICATI Esophageal cancer [ICD-11: 2B70] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D03XUQ DRUGNAME ABS-212 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D03XYW DRUGNAME Fenoprofen INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D03XZP DRUGNAME IL-12 gene therapy INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D03XZT DRUGNAME Cyclic compound 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D03YAA DRUGNAME PMID27215781-Compound-28 INDICATI Endometriosis [ICD-11: GA10] Patented TTDDRUID D03YAS DRUGNAME ONO-AE1-437 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D03YBJ DRUGNAME DS-8895 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03YBQ DRUGNAME DNL151 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D03YCT DRUGNAME TVX-004 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D03YEG DRUGNAME REGN-910 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03YEM DRUGNAME CD19/CD22 CAR T-Cells INDICATI Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 INDICATI B-cell prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D03YET DRUGNAME Coal tar INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved TTDDRUID D03YFL DRUGNAME PMID25666693-Compound-71 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D03YGL DRUGNAME RHIgM22 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D03YGP DRUGNAME CC-8490 INDICATI Brain cancer [ICD-11: 2A00] Phase 1 TTDDRUID D03YGR DRUGNAME Cinacalcet INDICATI Hyperparathyroidism [ICD-11: 5A51] Approved INDICATI Kidney disease [ICD-11: GC2Z] Phase 3 TTDDRUID D03YGX DRUGNAME SP-D INDICATI Lung inflammation [ICD-11: CA40.Z] Investigative TTDDRUID D03YIT DRUGNAME CL-186659 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D03YIU DRUGNAME Danoprevir + ritonavir + interferon INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D03YIX DRUGNAME Pneumostem INDICATI Respiratory distress syndrome [ICD-11: CB00] Phase 2 INDICATI Bronchopulmonary dysplasia [ICD-11: KB29.0] Phase 1/2 TTDDRUID D03YJC DRUGNAME SKL-NP INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D03YJW DRUGNAME Fus-1 tumor suppressor gene therapy INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D03YJZ DRUGNAME SDZ-89-104 INDICATI Bone marrow transplantation [ICD-11: QB63.6] Terminated TTDDRUID D03YKE DRUGNAME FG-4592 INDICATI Kidney disease [ICD-11: GC2Z] Phase 3 INDICATI Anaemia [ICD-11: 3A90] Phase 3 TTDDRUID D03YKO DRUGNAME VT-346 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D03YKQ DRUGNAME AD-452 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D03YLN DRUGNAME CP-67015 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D03YLZ DRUGNAME Thiamphenicol INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D03YMD DRUGNAME RP-805 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D03YOS DRUGNAME Phenoxodiol INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 TTDDRUID D03YPL DRUGNAME RP-70676 INDICATI Hyperlipidaemia [ICD-11: 5C80] Terminated TTDDRUID D03YPR DRUGNAME HL-1983 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D03YSJ DRUGNAME NBI-29 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D03YSL DRUGNAME CAT-1000 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D03YSQ DRUGNAME SAR-405838 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03YVO DRUGNAME Methylnaltrexone bromide INDICATI Opioid-induced constipation [ICD-11: DB32.1] Approved INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D03YVR DRUGNAME Oxamflatin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D03YXI DRUGNAME PIKAMILONE INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D03YZJ DRUGNAME ALO-02 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D03ZAE DRUGNAME Peg-G-CSF INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D03ZBL DRUGNAME MMS-255 INDICATI Multiple sclerosis [ICD-11: 8A40] Terminated TTDDRUID D03ZBM DRUGNAME NPC-567 INDICATI Rhinitis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D03ZBN DRUGNAME Olprinone INDICATI Heart failure [ICD-11: BD10-BD13] Approved TTDDRUID D03ZBT DRUGNAME Crizotinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved TTDDRUID D03ZCG DRUGNAME CMV vaccine INDICATI Cytomegalovirus infection [ICD-11: 1D82] Discontinued in Phase 1 TTDDRUID D03ZCH DRUGNAME 4SCAR19 and 4SCAR20 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D03ZDX DRUGNAME SM-88 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2/3 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D03ZFG DRUGNAME Cerulenin INDICATI Weight loss [ICD-11: MG43.5] Approved TTDDRUID D03ZFN DRUGNAME Tromethamine INDICATI Acidosis [ICD-11: 5C73] Approved TTDDRUID D03ZGV DRUGNAME Co-60549 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D03ZHE DRUGNAME MDX-070 INDICATI Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 2 TTDDRUID D03ZHN DRUGNAME SL-65.1708 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1 TTDDRUID D03ZIK DRUGNAME MT-001 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Investigative TTDDRUID D03ZIP DRUGNAME LOAd703 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D03ZIS DRUGNAME PERFOSFAMIDE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D03ZJK DRUGNAME NNZ-3006 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D03ZKE DRUGNAME CS-003 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D03ZKM DRUGNAME UX-001 INDICATI Hereditary inclusion body myositis [ICD-11: 4A41.2] Phase 3 INDICATI Myopathy [ICD-11: 8C7Y] Phase 2 TTDDRUID D03ZLN DRUGNAME SEL-403 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D03ZLR DRUGNAME Apimostinel INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D03ZME DRUGNAME Darinaparsin INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Liver cancer [ICD-11: 2C12] Phase 2 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 2 INDICATI Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2 TTDDRUID D03ZMK DRUGNAME NTP-6009 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D03ZMY DRUGNAME AM-220 INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D03ZNK DRUGNAME Tc99-labeled 14F7 humanized mab INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D03ZOZ DRUGNAME PMID25666693-Compound-97 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D03ZPX DRUGNAME PRX-07034 INDICATI Obesity [ICD-11: 5B81] Phase 1 TTDDRUID D03ZPY DRUGNAME SQ-33351 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D03ZSA DRUGNAME BMS-986016 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03ZTE DRUGNAME Chenodiol INDICATI Cholelithiasis [ICD-11: DC11] Approved TTDDRUID D03ZVD DRUGNAME KW-4490 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D03ZVW DRUGNAME Vapiprost INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D03ZWR DRUGNAME APC-300 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D03ZXZ DRUGNAME XL-228 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D03ZYQ DRUGNAME Olokizumab INDICATI Rheumatoid arthritis [ICD-11: FA20] phase 3 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D03ZYZ DRUGNAME Prophylactic dengue fever vaccine INDICATI Flavivirus infection [ICD-11: 1C80] Phase 2 TTDDRUID D03ZZC DRUGNAME Vascugel INDICATI Peripheral vascular disease [ICD-11: BD4Z] Phase 1/2 TTDDRUID D03ZZH DRUGNAME SLV-313 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1 TTDDRUID D03ZZK DRUGNAME Fluocinonide INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D03ZZM DRUGNAME DMT310 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D03ZZX DRUGNAME 123I-MNI-420 INDICATI Huntington disease [ICD-11: 8A01.10] Phase 1 TTDDRUID D04AAN DRUGNAME Mesoridazine INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D04AAR DRUGNAME XB-513 INDICATI Cardiac failure [ICD-11: BD10-BD13] Terminated TTDDRUID D04AAW DRUGNAME Cidofovir INDICATI Cytomegalovirus infection [ICD-11: 1D82] Approved TTDDRUID D04ABS DRUGNAME CPH-102 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D04ACD DRUGNAME [111In]B3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04ACK DRUGNAME Anti-CD30 CAR T cells INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D04ACW DRUGNAME Alogliptin/metformin INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D04AEQ DRUGNAME V81444 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1/2 INDICATI Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04AGG DRUGNAME Favipiravir INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D04AGM DRUGNAME PRTT-100 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D04AHQ DRUGNAME LY3009120 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04AHY DRUGNAME HT-2157 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 1/2 TTDDRUID D04AIB DRUGNAME AZD1772//RDX5791 INDICATI Chronic kidney disease [ICD-11: GB61] Phase 2 TTDDRUID D04AIT DRUGNAME B-Lactams INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04AIV DRUGNAME Eteplirsen INDICATI Duchenne dystrophy [ICD-11: 8C70] Approved TTDDRUID D04AKG DRUGNAME SER-287 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 1 TTDDRUID D04ALI DRUGNAME FHT-CT4 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D04AMD DRUGNAME ZD-6126 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D04APR DRUGNAME Tirilazad mesylate INDICATI Subarachnoid hemorrhage [ICD-11: 8B01] Approved INDICATI Cataract [ICD-11: 9B10] Approved TTDDRUID D04APY DRUGNAME KC-11404 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D04AQH DRUGNAME Sermorelin INDICATI Pediatric growth disorder [ICD-11: FB86] Approved TTDDRUID D04ARO DRUGNAME PEV-4 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Investigative TTDDRUID D04ASA DRUGNAME X-083-NAB INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D04ASH DRUGNAME Leuprorelin acetate INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D04ASP DRUGNAME Influenza virus DNA vaccine INDICATI Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 1 TTDDRUID D04ATE DRUGNAME AT-009 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04ATM DRUGNAME Trimegestone INDICATI Hormone replacement therapy [ICD-11: 8E01] Approved TTDDRUID D04ATY DRUGNAME Bulleyaconitine A INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D04AUA DRUGNAME MIV-170 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D04AYH DRUGNAME ADE-CRAN INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D04AYZ DRUGNAME CSL-654 INDICATI Factor IX deficiency [ICD-11: 3B11] Phase 3 TTDDRUID D04AZM DRUGNAME ARQ 736 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04AZT DRUGNAME MEDI1814 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D04BBA DRUGNAME Thiazole carboxamide derivative 24 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D04BBT DRUGNAME Heterocyclic derivative 12 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D04BCB DRUGNAME Lobeglitazone INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D04BCW DRUGNAME Ketobemidone INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D04BEN DRUGNAME Amrubicin INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID D04BFC DRUGNAME CC-292 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 TTDDRUID D04BFI DRUGNAME LGD-4665 INDICATI Immune thrombocytopenic purpura [ICD-11: 3B64.13] Phase 2 TTDDRUID D04BFU DRUGNAME LIDORESTAT INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D04BFX DRUGNAME IPL-423 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D04BHS DRUGNAME Recombinant batroxobin INDICATI Blood forming organ disorder [ICD-11: JB64.1] Phase 2 TTDDRUID D04BHY DRUGNAME KP-27 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04BIG DRUGNAME SR-90067 INDICATI Hormone deficiency [ICD-11: 5A61.1] Discontinued in Phase 2 TTDDRUID D04BIY DRUGNAME NKTR-140 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D04BKO DRUGNAME Etripamil INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 INDICATI Paroxysmal supraventricular tachycardia [ICD-11: BC81.Z] Phase 2 TTDDRUID D04BKZ DRUGNAME Mangafodipir Trisodium INDICATI Magnetic resonance imaging of liver [ICD-11: ME21] Approved TTDDRUID D04BLE DRUGNAME A-3309 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 3 TTDDRUID D04BMR DRUGNAME AL-59640 INDICATI Xerophthalmia [ICD-11: 5B55.Y] Investigative TTDDRUID D04BNA DRUGNAME RF1V INDICATI Parasitic infection [ICD-11: 1D0Y-1G2Z] Phase 2 TTDDRUID D04BNB DRUGNAME Lenzilumab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D04BNP DRUGNAME Temazepam INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D04BOK DRUGNAME DiabeCell INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D04BOT DRUGNAME Dalotuzumab INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D04BPS DRUGNAME Naveglitazar INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D04BQR DRUGNAME Acecainide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3 TTDDRUID D04BQV DRUGNAME Isofagomine tartrate INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 2 TTDDRUID D04BRF DRUGNAME TA-101 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D04BRW DRUGNAME Five membered heterocyclic benzamide derivative 2 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D04BSV DRUGNAME L-377202 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D04BSZ DRUGNAME PD-0204318 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D04BUH DRUGNAME Cizolirtine INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D04BVL DRUGNAME IM19 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D04BVN DRUGNAME PDGF-BB INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 3 TTDDRUID D04BXA DRUGNAME Pyrazole derivative 32 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D04BXH DRUGNAME COTI-001 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Investigative TTDDRUID D04BXJ DRUGNAME ED-1812 INDICATI Pain [ICD-11: MG30-MG3Z] Preclinical TTDDRUID D04BXX DRUGNAME AN-019 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 2 TTDDRUID D04CBI DRUGNAME Oestradiol valerate and dienogest INDICATI Endometriosis [ICD-11: GA10] Approved INDICATI Contraception [ICD-11: QA21] Approved TTDDRUID D04CCK DRUGNAME MT-119 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04CCX DRUGNAME PMID30107136-Compound-Example14 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D04CDO DRUGNAME TAS-102 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 TTDDRUID D04CEY DRUGNAME PYM-50018 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Preclinical TTDDRUID D04CFL DRUGNAME SB 242784 INDICATI Arterial calcification [ICD-11: BD52.Y] Preclinical TTDDRUID D04CFW DRUGNAME Bacampicillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04CJE DRUGNAME ATF-936 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 1 TTDDRUID D04CJL DRUGNAME Ferric citrate INDICATI Chronic kidney disease [ICD-11: GB61] Approved TTDDRUID D04CJN DRUGNAME CTP-298 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D04CKB DRUGNAME IkT-001 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D04CKC DRUGNAME GPC3-CART cells INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 TTDDRUID D04CKG DRUGNAME SPI-2012 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D04CKR DRUGNAME CAL-103-R INDICATI Herpes simplex virus infection [ICD-11: 1F00] Investigative TTDDRUID D04CLH DRUGNAME PMID26048809-compound2 INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D04CLM DRUGNAME YM-758 INDICATI Angina pectoris [ICD-11: BA40] Phase 2 TTDDRUID D04CNX DRUGNAME Ro-25-1132 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D04CON DRUGNAME SL-89.0591 INDICATI Prostate disease [ICD-11: GA91] Discontinued in Phase 2 TTDDRUID D04CQK DRUGNAME MK-8521 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D04CQV DRUGNAME Cis-urocanic acid INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D04CRL DRUGNAME Glatiramer Acetate INDICATI Multiple sclerosis [ICD-11: 8A40] Approved TTDDRUID D04CRN DRUGNAME Atomoxetine INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved TTDDRUID D04CSZ DRUGNAME Menthol INDICATI Throat irritation [ICD-11: CA0Y] Approved TTDDRUID D04CTD DRUGNAME SNDX-6352 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04CTP DRUGNAME EP-200 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04CUZ DRUGNAME SRG INDICATI Neutropenia [ICD-11: 4B00.0] Investigative TTDDRUID D04CWI DRUGNAME Galidesivir INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D04CWS DRUGNAME Anti-M1 prime INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D04CXX DRUGNAME GNKG-168 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 TTDDRUID D04CYD DRUGNAME ONT-10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04DAL DRUGNAME LAS-41001 INDICATI Rosacea [ICD-11: ED90.0] Discontinued in Preregistration TTDDRUID D04DBA DRUGNAME BAG956 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Investigative TTDDRUID D04DDW DRUGNAME MK-49 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D04DFJ DRUGNAME Pulmonary insulin INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D04DFR DRUGNAME FX005 INDICATI Melanoma [ICD-11: 2C30] Phase 2/3 TTDDRUID D04DGE DRUGNAME SB-247853 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D04DHZ DRUGNAME CART-EGFR INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D04DJN DRUGNAME Dihydrotestosterone INDICATI Prostate hyperplasia [ICD-11: GA90] Phase 4 TTDDRUID D04DJS DRUGNAME ICI 118,551 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 INDICATI HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D04DKH DRUGNAME NAFTOPIDIL INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D04DKL DRUGNAME ALT-836 INDICATI Adult respiratory distress syndrome [ICD-11: CB00] Phase 2 TTDDRUID D04DLW DRUGNAME NA-1 neuroprotectant INDICATI Stroke [ICD-11: 8B20] Phase 2 TTDDRUID D04DMO DRUGNAME FR-194738 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Terminated TTDDRUID D04DMQ DRUGNAME Fabesetron INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 2 TTDDRUID D04DMZ DRUGNAME AVXS-101 INDICATI Spinal muscular atrophy [ICD-11: 8B61] Phase 3 TTDDRUID D04DNB DRUGNAME Xentuzumab INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D04DNL DRUGNAME ALN-FLU01 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Preclinical TTDDRUID D04DQO DRUGNAME ABBV-257 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D04DQP DRUGNAME ADRIAC-36 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04DQT DRUGNAME Ribavirin + interferon beta-1a INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D04DQZ DRUGNAME AZD-2327 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D04DSD DRUGNAME TEI-5178 INDICATI Nephritis [ICD-11: GB40] Phase 1 TTDDRUID D04DTH DRUGNAME Emapalumab INDICATI Primary haemophagocytic lymphohistiocytosis [ICD-11: 4A01.23] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D04DUF DRUGNAME Phenylsulfonyl derivative 2 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Patented TTDDRUID D04DUG DRUGNAME AAV-GUS INDICATI Genetic disease [ICD-11: 8E02] Terminated TTDDRUID D04DUH DRUGNAME PMI-005 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 1 TTDDRUID D04DUJ DRUGNAME S-2474 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D04DVA DRUGNAME HAp-IFN INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D04DVF DRUGNAME CHF-1522 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Terminated TTDDRUID D04DXA DRUGNAME Tofogliflozin INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D04DXN DRUGNAME Benzoyl peroxide INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D04DYA DRUGNAME SMTP-0 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04DYC DRUGNAME PF-06463922 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D04DYZ DRUGNAME ABT-839 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Terminated TTDDRUID D04DZD DRUGNAME Bidisomide INDICATI Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 3 TTDDRUID D04DZE DRUGNAME BRL 26830A INDICATI Obesity [ICD-11: 5B81] Terminated TTDDRUID D04EAT DRUGNAME MCS-110 INDICATI Bone metastases [ICD-11: 2D50] Phase 2 INDICATI Tenosynovial giant cell tumour [ICD-11: 2F7B] Phase 2 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D04EAZ DRUGNAME M102.4 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D04EDM DRUGNAME PMID25684022-Compound-US20120277229 41(1.3) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D04EET DRUGNAME West Nile virus vaccine INDICATI West nile virus infection [ICD-11: 1D46] Terminated TTDDRUID D04EFB DRUGNAME OP-03 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D04EFG DRUGNAME DD-3 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D04EFK DRUGNAME DDP-225 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 2 INDICATI Chronic functional vomiting [ICD-11: DD90.4] Discontinued in Phase 2 TTDDRUID D04EGR DRUGNAME 1-MNA INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2/3 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D04EGX DRUGNAME Cabergoline INDICATI Hyperprolactinaemia [ICD-11: 5A60.1] Approved TTDDRUID D04EHF DRUGNAME DAV-132 INDICATI Toxicity [ICD-11: N.A.] Investigative TTDDRUID D04EIF DRUGNAME LOXORIBINE INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 2 TTDDRUID D04EIL DRUGNAME YM-344031 INDICATI Asthma [ICD-11: CA23] Preclinical TTDDRUID D04EIX DRUGNAME AA-102 INDICATI Breast cancer [ICD-11: 2C60-2C65] Preclinical TTDDRUID D04EJG DRUGNAME SHR-1314 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 1/2 TTDDRUID D04ELD DRUGNAME Glassia INDICATI Emphysema [ICD-11: CA21] Approved TTDDRUID D04ELS DRUGNAME ISCAR INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D04EMB DRUGNAME IW-1973 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D04ENF DRUGNAME Gene therapy, retinopathy, INDICATI Retinopathy [ICD-11: 9B71] Investigative TTDDRUID D04ENK DRUGNAME TCV-309 INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2 TTDDRUID D04EOH DRUGNAME APC-003 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04EON DRUGNAME BAL-101553 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D04EPP DRUGNAME RTL-342m INDICATI Optic neuritis [ICD-11: 9C40.1] Investigative TTDDRUID D04EPS DRUGNAME ON-24160 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04EQF DRUGNAME MT-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04EQX DRUGNAME BIIB-098 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 TTDDRUID D04ERQ DRUGNAME CXD-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04ESH DRUGNAME PMID30107136-Compound-Example8 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D04ETV DRUGNAME Nemonaxacin INDICATI Methicillin-resistant staphylococci infection [ICD-11: 1A00-1A09] Phase 3 TTDDRUID D04EVE DRUGNAME VR876 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3 TTDDRUID D04EXW DRUGNAME A-Fizz INDICATI Anal fistula [ICD-11: DB50.1] Investigative TTDDRUID D04EXX DRUGNAME KBF-611 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D04EYC DRUGNAME Metaraminol INDICATI Hypotension [ICD-11: BA20-BA21] Approved TTDDRUID D04EYG DRUGNAME Ranibizumab INDICATI Hereditary hemorrhagic telangiectasia [ICD-11: LA90.00] Approved TTDDRUID D04EZI DRUGNAME Peru-15 pCTB INDICATI Diarrhea [ICD-11: ME05.1] Phase 1 TTDDRUID D04EZR DRUGNAME SIG-003 INDICATI Respiratory disease [ICD-11: CB40] Investigative TTDDRUID D04FAC DRUGNAME SHEF-1 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Investigative TTDDRUID D04FAI DRUGNAME SCIO-323 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Preclinical TTDDRUID D04FBR DRUGNAME Mycophenolate mofetil INDICATI Organ transplant rejection [ICD-11: NE84] Approved INDICATI Pemphigus vulgaris [ICD-11: EB40] Phase 3 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D04FDN DRUGNAME Palifosfamide INDICATI Soft tissue sarcoma [ICD-11: 2B57] Phase 2 TTDDRUID D04FFM DRUGNAME ADXS-HPV INDICATI Cervical Intraepithelial neoplasia [ICD-11: 2E66.1] Phase 2 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 2 TTDDRUID D04FFY DRUGNAME AMG-8563 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D04FGX DRUGNAME EP-302 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04FHB DRUGNAME R547 INDICATI Advanced solid tumour [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D04FHY DRUGNAME BL-7020 INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D04FIO DRUGNAME Aom-0871 INDICATI Transplant rejection [ICD-11: NE84] Investigative TTDDRUID D04FIP DRUGNAME Cyclodextrin INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 4 TTDDRUID D04FKX DRUGNAME D-3263 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04FMB DRUGNAME XK-469 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04FNQ DRUGNAME BIM23A760 INDICATI Acromegaly [ICD-11: 5A60.0] Phase 2 INDICATI Carcinoid syndrome [ICD-11: 5B10] Phase 2 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 3 TTDDRUID D04FNR DRUGNAME Mitumomab INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D04FOP DRUGNAME Ravulizumab INDICATI Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D04FPN DRUGNAME CD19 CAR-T lymphocytes INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 TTDDRUID D04FQD DRUGNAME PH-80 INDICATI Premenstrual syndrome [ICD-11: GA34.40] Phase 3 TTDDRUID D04FRB DRUGNAME CGP-13774 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D04FRL DRUGNAME PMID25666693-Compound-44 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D04FRU DRUGNAME LLG783 INDICATI Intermittent claudication [ICD-11: BD40.00] Phase 2 INDICATI Vascular systems peripheral arterial disorder [ICD-11: BD5Z] Phase 2 TTDDRUID D04FSD DRUGNAME TgAAG76 INDICATI Blindness [ICD-11: 9D90] Phase 1/2 TTDDRUID D04FTB DRUGNAME AR-H049020 INDICATI Type-1 diabetes [ICD-11: 5A10] Discontinued in Phase 1 TTDDRUID D04FVD DRUGNAME TGBA01AD INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 2 TTDDRUID D04FVU DRUGNAME Palonosetron INDICATI Nausea [ICD-11: MD90] Approved TTDDRUID D04FWP DRUGNAME AMG 157 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D04FXE DRUGNAME KW-3433 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D04FXS DRUGNAME Didox INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D04FXY DRUGNAME SMT-19969 INDICATI C. difficile infection [ICD-11: 1A04] Phase 3 TTDDRUID D04FYI DRUGNAME H pylori vaccine INDICATI Helicobacter infection [ICD-11: DA42-DA63] Terminated TTDDRUID D04FYL DRUGNAME Contusugene ladenovec INDICATI Oral cancer [ICD-11: 2B6E] Phase 3 INDICATI Liver metastasis [ICD-11: 2D80] Phase 1 TTDDRUID D04FYM DRUGNAME Genital herpes therapy INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 1 TTDDRUID D04FYU DRUGNAME DMP-444 INDICATI Coronary artery disease [ICD-11: BA80] Phase 3 TTDDRUID D04FYZ DRUGNAME Plevitrexed (R)-isomer INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2 TTDDRUID D04GAG DRUGNAME GBR 1342 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D04GBP DRUGNAME QR-010 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 1/2 TTDDRUID D04GBW DRUGNAME IC31 seasonal influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 INDICATI Influenza A virus infection [ICD-11: 1E30] Phase 1 TTDDRUID D04GCC DRUGNAME N-acylpiperidine ether derivative 6 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D04GCH DRUGNAME Bmab-200 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04GCV DRUGNAME APS-2010 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D04GDI DRUGNAME NP93-31 INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D04GEI DRUGNAME TAK-448 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D04GFO DRUGNAME MC-2001 INDICATI leukaemia [ICD-11: 2A60-2B33] Preclinical TTDDRUID D04GGA DRUGNAME StaphStop INDICATI MRSA infection [ICD-11: 1D01.0Y] Investigative TTDDRUID D04GGG DRUGNAME CD123/CLL1 CAR-T Cells INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2/3 TTDDRUID D04GGJ DRUGNAME WST-057 INDICATI Peripheral neuropathy [ICD-11: 8C0Z] Phase 1 TTDDRUID D04GGQ DRUGNAME MPC-0767 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04GIJ DRUGNAME Piperazine urea derivative 4 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented TTDDRUID D04GIO DRUGNAME Anti-CD19 and Anti-CD20 CAR-T Cells INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D04GJN DRUGNAME Megestrol INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D04GJX DRUGNAME ZD-9720 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D04GKL DRUGNAME RAXOFELAST INDICATI Ischemia [ICD-11: 8B10-8B11] Phase 2 TTDDRUID D04GKO DRUGNAME Cilazapril INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D04GKP DRUGNAME AS-902330 INDICATI Arthropathy [ICD-11: FA11-FA38] Phase 2 TTDDRUID D04GLJ DRUGNAME OCFENTANIL INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D04GMY DRUGNAME TD-5108 INDICATI Gastroparesis [ICD-11: DA41.00] Phase 2 TTDDRUID D04GNG DRUGNAME CC-90011 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04GNX DRUGNAME SHP615 INDICATI Seizure disorder [ICD-11: 8A6Z] Phase 2 TTDDRUID D04GPZ DRUGNAME Hyaluronidase (ovine) INDICATI Resorption of radiopaque agents [ICD-11: N.A.] Approved TTDDRUID D04GRB DRUGNAME THRX-198321 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D04GSA DRUGNAME DAU-6285 INDICATI Vomiting [ICD-11: MD90] Terminated TTDDRUID D04GSL DRUGNAME ImmuCyst INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Approved TTDDRUID D04GSV DRUGNAME TRICIRIBINE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D04GSY DRUGNAME Buserelin acetate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D04GTA DRUGNAME Pegsunercept INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D04GTW DRUGNAME ReSX-i INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D04GVN DRUGNAME PF-807925 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D04GWO DRUGNAME Otilimab INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D04GWY DRUGNAME Telinavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D04GXS DRUGNAME BL-1893 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D04GYO DRUGNAME Oxiconazole INDICATI Tinea pedis [ICD-11: 1F28.2] Approved TTDDRUID D04GZA DRUGNAME Gentian violet INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04GZS DRUGNAME Tempol INDICATI Spinal cord injury [ICD-11: ND51.2] Phase 2 TTDDRUID D04HAA DRUGNAME WL-276 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04HAF DRUGNAME LY-2624803 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Phase 2 TTDDRUID D04HBH DRUGNAME AM-3701 INDICATI Bone metastases [ICD-11: 2D50] Investigative TTDDRUID D04HBJ DRUGNAME IGFBP 2 variants INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04HBL DRUGNAME PMID30107136-Compound-Example59 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D04HCS DRUGNAME PMID25666693-Compound-93 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D04HDZ DRUGNAME GRN163 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D04HER DRUGNAME SOM-0999 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D04HEW DRUGNAME PMID26815044-Compound-32 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D04HHW DRUGNAME FK-011 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D04HIS DRUGNAME Varilrix INDICATI Varicella zoster virus infection [ICD-11: 1E91] Approved TTDDRUID D04HIZ DRUGNAME BO-653 INDICATI Artery stenosis [ICD-11: BD52] Discontinued in Phase 2 TTDDRUID D04HJE DRUGNAME AZ-01, PEGylated interferon-beta INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D04HLE DRUGNAME Vitaxin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D04HMD DRUGNAME Glyphosate INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D04HMK DRUGNAME Hi8 melanoma vaccine INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D04HMM DRUGNAME XP-20925 INDICATI Migraine [ICD-11: 8A80] Preclinical TTDDRUID D04HOT DRUGNAME LFG-316 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 2 TTDDRUID D04HQA DRUGNAME FIT-06 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D04HQC DRUGNAME SB-9200 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D04HQJ DRUGNAME AB-103 INDICATI Necrotizing soft tissue infection [ICD-11: 1B71] Phase 3 TTDDRUID D04HQT DRUGNAME proglumide INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D04HSH DRUGNAME IMGN289 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04HTL DRUGNAME ABX-0402 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D04HUC DRUGNAME mRNA-046 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04HVB DRUGNAME Panomifene INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D04HWK DRUGNAME IL-7/CD80-expressing allogeneic RCC-26 tumor cell vaccine INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1 TTDDRUID D04HXB DRUGNAME Meningitec INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04HXP DRUGNAME PN-2XXX INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Investigative TTDDRUID D04HXS DRUGNAME REC-15/3079 INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2 TTDDRUID D04HYR DRUGNAME XN-05 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04HZX DRUGNAME CCX-832 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 1 TTDDRUID D04IAJ DRUGNAME MVA62B INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D04IBA DRUGNAME Ellipravin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D04IBG DRUGNAME Infanrix-DTaP-IPV-Hep B INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D04IBI DRUGNAME ABX-301 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D04ICN DRUGNAME DuP-630 INDICATI Dermatitis [ICD-11: EA80-EA89] Terminated TTDDRUID D04IDT DRUGNAME Helicobacter vaccine INDICATI Helicobacter infection [ICD-11: DA42-DA63] Terminated TTDDRUID D04IEM DRUGNAME Nartograstim INDICATI Constitutional neutropenia [ICD-11: 4B00.0] Approved TTDDRUID D04IFD DRUGNAME GR-ARA1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04IFU DRUGNAME GSK835726 INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2 TTDDRUID D04IHB DRUGNAME RUTI INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2 TTDDRUID D04IIU DRUGNAME INDISULAM INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 TTDDRUID D04IJZ DRUGNAME Microplasmin INDICATI Eye disorder [ICD-11: 9A01-9A0Z] Phase 3 TTDDRUID D04IKF DRUGNAME 18F-LMI-1195 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D04IME DRUGNAME SCH-48461 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D04INP DRUGNAME Pixykine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D04IPX DRUGNAME WEHI-0103122 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04IQH DRUGNAME PF-655 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 TTDDRUID D04ITO DRUGNAME Rifaximin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04ITR DRUGNAME PMID26868298-compound-N3 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D04IUB DRUGNAME NT0202 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3 TTDDRUID D04IUQ DRUGNAME SonoRx INDICATI Gastrointestinal disease [ICD-11: DE2Z] Approved TTDDRUID D04IUY DRUGNAME APC-001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04IWZ DRUGNAME PT2.0 INDICATI Clostridium infection [ICD-11: 1A04] Investigative TTDDRUID D04IXD DRUGNAME IPH-2101 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D04IXJ DRUGNAME Bimetopyrole INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D04IXL DRUGNAME HCV vaccine INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 1 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D04JAB DRUGNAME Tcelna INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D04JAQ DRUGNAME FH-AAV8 INDICATI Familial hypercholesterolemia [ICD-11: 5C80.00] Investigative TTDDRUID D04JAT DRUGNAME PF-4427429 INDICATI Migraine [ICD-11: 8A80] Phase 1 TTDDRUID D04JCD DRUGNAME Six-membered heterocyclic benzamide derivative 6 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D04JCN DRUGNAME Pergolide INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D04JCT DRUGNAME AA-204 INDICATI Kidney disease [ICD-11: GC2Z] Investigative TTDDRUID D04JEE DRUGNAME Propranolol INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D04JFB DRUGNAME RX-20001 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D04JFG DRUGNAME BMS-986253 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D04JFT DRUGNAME KW-5139 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D04JGA DRUGNAME BMS-191095 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 1 TTDDRUID D04JHH DRUGNAME CAR-T cells targeting CD19 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D04JHN DRUGNAME Hydromorphone INDICATI Pain [ICD-11: MG30-MG3Z] Approved INDICATI Chronic pain [ICD-11: MG30] Phase 3 TTDDRUID D04JIE DRUGNAME SER-201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04JIM DRUGNAME UCB-35440 INDICATI Rhinitis [ICD-11: FA20] Phase 2 TTDDRUID D04JIS DRUGNAME OG-Cx-833 INDICATI Huntington disease [ICD-11: 8A01.10] Investigative TTDDRUID D04JJE DRUGNAME RP-66153 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D04JKE DRUGNAME Promostem INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D04JKG DRUGNAME TherAtoH INDICATI Hearing disorder [ICD-11: AB50-AB57] Investigative TTDDRUID D04JLW DRUGNAME AWD-72-011 INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D04JMG DRUGNAME CEQ-626 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D04JMI DRUGNAME Plasma derived human butyrylcholinesterase INDICATI Neurotoxicity [ICD-11: NE61] Phase 1 TTDDRUID D04JMQ DRUGNAME Flurithromycin ethylsuccinate INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04JNC DRUGNAME ZL-N-91 INDICATI Lung inflammation [ICD-11: CA40.Z] Investigative TTDDRUID D04JNI DRUGNAME GSK2245840 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D04JNZ DRUGNAME PROSTRATIN INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D04JOE DRUGNAME Placulumab INDICATI Sciatica [ICD-11: ME84.3] Phase 1/2 TTDDRUID D04JPJ DRUGNAME Lomustine INDICATI Brain cancer [ICD-11: 2A00] Approved TTDDRUID D04JPQ DRUGNAME PSN-101 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D04JQR DRUGNAME LY-367385 INDICATI Neurological disorder [ICD-11: 6B60] Terminated TTDDRUID D04JRK DRUGNAME P-1104 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D04JSE DRUGNAME MK-7725 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D04JSI DRUGNAME CAR-T cells targeting CD133 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Preclinical TTDDRUID D04JTD DRUGNAME PX-12 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D04JTX DRUGNAME BI-224436 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D04JTY DRUGNAME Thiolactomycin INDICATI Malaria [ICD-11: 1F40-1F45] Investigative INDICATI Urinary tract infection [ICD-11: GC08] Investigative TTDDRUID D04JVU DRUGNAME Long-acting IFN-alpha INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D04JVX DRUGNAME AKP-320 INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D04JYK DRUGNAME GC-1107 INDICATI Clostridium infection [ICD-11: 1A04] Phase 3 TTDDRUID D04JZD DRUGNAME Polyvalent crotalid antivenin ovine fab INDICATI Poison intoxication [ICD-11: NE6Z] Approved TTDDRUID D04JZH DRUGNAME PF-01247324 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D04JZP DRUGNAME Mazapertine succinate INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 2 TTDDRUID D04KAQ DRUGNAME Pivampicillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04KBL DRUGNAME Bevacizumab INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Approved INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 INDICATI Brain metastases [ICD-11: 2D50] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Application submitted TTDDRUID D04KBU DRUGNAME AIR-001 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D04KCT DRUGNAME Org-21465 INDICATI Anaesthesia [ICD-11: 9A78.6] Discontinued in Phase 1 TTDDRUID D04KEL DRUGNAME EV-086 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D04KFR DRUGNAME NVP-SAA164 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D04KGB DRUGNAME Anti-IFN-alpha human mabs INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D04KHH DRUGNAME CEFCANEL DALOXATE HYDROCHLORIDE INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3 TTDDRUID D04KHY DRUGNAME Spiroglumide INDICATI Stomach disease [ICD-11: DA43-DA4Y] Phase 2 INDICATI Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 1 TTDDRUID D04KIH DRUGNAME Ac-YVAD-FMK INDICATI Photocontact dermatitis [ICD-11: EK20] Patented INDICATI Irritant contact dermatitis [ICD-11: EK02] Patented INDICATI Allergic contact dermatitis [ICD-11: EK00] Patented TTDDRUID D04KJO DRUGNAME Formoterol INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D04KJT DRUGNAME ABT-333 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D04KKE DRUGNAME Diaziquone INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3 TTDDRUID D04KKX DRUGNAME QX-30002222 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D04KMO DRUGNAME CGP-35348 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D04KMP DRUGNAME SUVN-G3031 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 3 TTDDRUID D04KMQ DRUGNAME GSK3117391 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D04KNL DRUGNAME PG-545 INDICATI Ocular disease [ICD-11: 1F00.1Z] Phase 1 TTDDRUID D04KQF DRUGNAME Tubacin INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D04KRV DRUGNAME Iofolastat I-124 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D04KTI DRUGNAME LY3127804 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D04KTZ DRUGNAME Cloxacillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04KUJ DRUGNAME Purine derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D04KUK DRUGNAME Medium chain triglycerides INDICATI Lymphatic disease [ICD-11: BD9Z] Approved TTDDRUID D04KVA DRUGNAME BVI-007 INDICATI Thrombotic stroke [ICD-11: 8B20] Phase 1 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 1 TTDDRUID D04KVQ DRUGNAME BAY-86-9596 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04KWH DRUGNAME Des-Arg(9)-[Leu(8)]-BK INDICATI Depression [ICD-11: 6A70-6A7Z] Investigative TTDDRUID D04KWO DRUGNAME MEDl-551 INDICATI Scleroderma [ICD-11: 4A42] Phase 1 TTDDRUID D04KWY DRUGNAME RTI-336 INDICATI Cocaine addiction [ICD-11: 6C45.2] Phase 1 TTDDRUID D04KXF DRUGNAME CEFTRAZONAL BOPENTIL INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D04KYB DRUGNAME ASCJ-9 INDICATI Alopecia [ICD-11: ED70] Phase 2 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D04KYY DRUGNAME Allopurinol INDICATI Hyperuricaemia [ICD-11: 5C55.Y] Approved TTDDRUID D04KZH DRUGNAME FluBiovax INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D04KZN DRUGNAME CTP-354 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1 TTDDRUID D04KZS DRUGNAME PRO-045 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1/2 TTDDRUID D04KZY DRUGNAME Gilteritinib INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved TTDDRUID D04LAQ DRUGNAME Candoxatrilat INDICATI Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 1 TTDDRUID D04LBC DRUGNAME Iclaprim INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3 INDICATI Pneumonia [ICD-11: CA40] Phase 2 INDICATI Acute bacterial skin infection [ICD-11: 1C41] Application submitted TTDDRUID D04LBJ DRUGNAME ASOBAMAST INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D04LCQ DRUGNAME Tafluprost INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved TTDDRUID D04LCX DRUGNAME Vax-SPIRAL INDICATI Leptospira infection [ICD-11: 1B91] Approved TTDDRUID D04LDH DRUGNAME BZ6 INDICATI Ataxia-telangiectasia [ICD-11: 4A01.31] Investigative TTDDRUID D04LDK DRUGNAME TZP-202 INDICATI Dyspepsia [ICD-11: MD92] Preclinical TTDDRUID D04LEH DRUGNAME LTX-03 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D04LEK DRUGNAME GSK729327 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1 TTDDRUID D04LFG DRUGNAME CGP-25454A INDICATI Major depressive disorder [ICD-11: 6A70.3] Terminated TTDDRUID D04LFR DRUGNAME SAR404460 INDICATI Pre-sarcopenia [ICD-11: FB32.Y] Phase 1 TTDDRUID D04LGK DRUGNAME VRT-750018 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D04LHG DRUGNAME SP-SAP INDICATI Cancer related pain [ICD-11: MG30] Investigative TTDDRUID D04LHJ DRUGNAME Methscopolamine Bromide INDICATI Nausea and vomiting [ICD-11: MD90] Approved TTDDRUID D04LIH DRUGNAME AVI-6002 INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 1 TTDDRUID D04LIR DRUGNAME PD-159913 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D04LJB DRUGNAME NP-213 INDICATI Onychomycosis [ICD-11: EE12.1] Phase 2 TTDDRUID D04LKS DRUGNAME Ruxolitinib INDICATI High-risk myelofibrosis [ICD-11: 2A20.2] Approved INDICATI Essential thrombocythemia [ICD-11: 3B63.1Z] Approved INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 1/2 INDICATI Vitiligo [ICD-11: ED63.0] Phase 1/2 TTDDRUID D04LMJ DRUGNAME MMB-4 INDICATI Poison intoxication [ICD-11: NE6Z] Investigative TTDDRUID D04LMZ DRUGNAME X-22 INDICATI Smoking dependence [ICD-11: 6C4A.2] Phase 2 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 INDICATI Tobacco dependence [ICD-11: 6C4A.2] Phase 2 TTDDRUID D04LOR DRUGNAME BMS-919373 INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 2 TTDDRUID D04LPZ DRUGNAME SAB-301 INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Discontinued in Phase 1 TTDDRUID D04LQN DRUGNAME ELAD INDICATI Acute liver failure [ICD-11: DB91] Phase 3 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2/3 TTDDRUID D04LRQ DRUGNAME TDI-0059 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D04LRU DRUGNAME AHR-16462B INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D04LSD DRUGNAME ABT-239 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 1 TTDDRUID D04LSH DRUGNAME SAR101099 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Discontinued in Phase 1 TTDDRUID D04LTF DRUGNAME TLN-4601 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D04LTO DRUGNAME Steamchol INDICATI Gallstone [ICD-11: DC11.3] Investigative TTDDRUID D04LTQ DRUGNAME Buproprion+zonisamide INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D04LUG DRUGNAME BSP-C801 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D04LVK DRUGNAME Ceritinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved TTDDRUID D04LWT DRUGNAME GSK1440115 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D04LXB DRUGNAME Captisol-enabled Melphalan INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D04LYD DRUGNAME Azosemide INDICATI Edema [ICD-11: MG29] Approved TTDDRUID D04LZF DRUGNAME NVX-208 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 1/2 TTDDRUID D04MBK DRUGNAME AGS-67E INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Malignant lymphatic [ICD-11: 2A82] Phase 1 TTDDRUID D04MBQ DRUGNAME iPSC-derived RPE (autologous) INDICATI Wet age-related macular degeneration [ICD-11: 9B78.3Z] Phase 1 TTDDRUID D04MBS DRUGNAME BMS-182657 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D04MCY DRUGNAME BMS 650032 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D04MDJ DRUGNAME Cefdaloxime pentexil tosilate INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D04MDO DRUGNAME HuL2G7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04MEB DRUGNAME Antituberculosis agents INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D04MEM DRUGNAME ORMD-1001 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D04MFQ DRUGNAME Myotubularin INDICATI Myotonic dystrophy [ICD-11: 8C71.0] Investigative TTDDRUID D04MFW DRUGNAME DL-3 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D04MFY DRUGNAME AJ-3941 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D04MGD DRUGNAME Elpetrigine INDICATI Bipolar disorder [ICD-11: 6A60] Phase 1 TTDDRUID D04MGI DRUGNAME PF-821385 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical TTDDRUID D04MGU DRUGNAME Technetium (99m Tc) bicisate INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Approved TTDDRUID D04MGW DRUGNAME BI-836858 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D04MHP DRUGNAME AZP-2006 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D04MHV DRUGNAME Heterocyclic derivative 17 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D04MKJ DRUGNAME Renzapride INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 3 TTDDRUID D04MLE DRUGNAME GKA-23 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D04MLR DRUGNAME CD123-specific gene-engineered T cells INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D04MMJ DRUGNAME ADX-2 series INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D04MNL DRUGNAME SERM-3339 INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2 TTDDRUID D04MOF DRUGNAME Milveterol+Fluticasone INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D04MOZ DRUGNAME NB3178 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D04MPB DRUGNAME Bevirimat INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D04MPV DRUGNAME Pyrazole derivative 15 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D04MRA DRUGNAME BAY-73-7977 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1 TTDDRUID D04MRG DRUGNAME Stevioside INDICATI Sweetener [ICD-11: N.A.] Approved TTDDRUID D04MRQ DRUGNAME Irsogladine INDICATI Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Approved TTDDRUID D04MRX DRUGNAME Chondroitinase INDICATI Intervertebral disc displacement [ICD-11: FB1Y] Investigative TTDDRUID D04MSM DRUGNAME Carbamazepine INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved INDICATI Type-1 diabetes [ICD-11: 5A10] NDA filed INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 TTDDRUID D04MUQ DRUGNAME RiVax + TVax INDICATI Ricin poisoning [ICD-11: NE61] Phase 1 TTDDRUID D04MWJ DRUGNAME Methacholine Chloride INDICATI bronchial hyperreactivity [ICD-11: CB40] Approved INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D04MXN DRUGNAME CEP-32496 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D04MXO DRUGNAME BCX-5191 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D04MXV DRUGNAME VGV-L INDICATI Lyme disease [ICD-11: 1C1G] Investigative TTDDRUID D04MYC DRUGNAME NSC-625487 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D04MYG DRUGNAME Fenbunafide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04MYO DRUGNAME ABN-912 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D04MYS DRUGNAME LL-4218 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D04MZP DRUGNAME NI-0101 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D04MZR DRUGNAME Bucelipase alfa INDICATI Exocrine pancreatic insufficiency [ICD-11: DC35.1] Phase 3 TTDDRUID D04NAQ DRUGNAME Emricasan INDICATI Hepatic fibrosis [ICD-11: DB93.0] Phase 2 INDICATI Liver cirrhosis [ICD-11: DB93.1] Phase 2 TTDDRUID D04NBY DRUGNAME SPVF-2801-10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04NCC DRUGNAME PMID28350212-Compound-18 INDICATI Alzheimer disease [ICD-11: 8A20] Patented TTDDRUID D04NCJ DRUGNAME BMY-21950 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D04NCK DRUGNAME Streptokinase INDICATI Acute myocardial infarction [ICD-11: BA41] Phase 4 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Discontinued in Phase 3 TTDDRUID D04NDK DRUGNAME Oral human gammaglobulin INDICATI Juvenile idiopathic arthritis [ICD-11: FA24] Phase 2 INDICATI Clostridium infection [ICD-11: 1A04] Phase 2 TTDDRUID D04NDM DRUGNAME Paromomycin INDICATI Intestinal amebiasis [ICD-11: 1A36] Approved TTDDRUID D04NFB DRUGNAME DMP-963 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D04NHQ DRUGNAME HSV529 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 1 TTDDRUID D04NIZ DRUGNAME AMG 747 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D04NJP DRUGNAME TRF-1101 INDICATI Sickle-cell anaemia [ICD-11: 3A51] Phase 2 TTDDRUID D04NJS DRUGNAME SAR351034 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Phase 1 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D04NKJ DRUGNAME Alferon LDO INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Discontinued in Phase 2 TTDDRUID D04NMF DRUGNAME DISC-PRO INDICATI Herpes simplex virus infection [ICD-11: 1F00] Discontinued in Phase 1 TTDDRUID D04NMJ DRUGNAME PMID25553724-Compound-US2012830453910 INDICATI Immune System disease [ICD-11: 4A01-4B41] Patented TTDDRUID D04NNJ DRUGNAME ZANOTERONE INDICATI Prostate hyperplasia [ICD-11: GA90] Phase 3 TTDDRUID D04NNK DRUGNAME Recombinant therapeutic proteins INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04NOE DRUGNAME OTSGC-A24 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 TTDDRUID D04NPP DRUGNAME SLX-2101 INDICATI Raynaud disease [ICD-11: BD42.0] Discontinued in Phase 2 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 INDICATI Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2 TTDDRUID D04NPR DRUGNAME Lu AF35700 INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 TTDDRUID D04NPX DRUGNAME ZD-1611 INDICATI Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 1 TTDDRUID D04NQI DRUGNAME Amodiaquine INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D04NQZ DRUGNAME V502 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 1 TTDDRUID D04NRB DRUGNAME Cetilistat INDICATI Obesity [ICD-11: 5B81] Phase 3 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 3 TTDDRUID D04NRP DRUGNAME ALS-2135 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D04NRV DRUGNAME IMM-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D04NSW DRUGNAME S-12340 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D04NTJ DRUGNAME Glisoxepide INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Approved TTDDRUID D04NVG DRUGNAME Angiotensin (1-7) INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D04NVK DRUGNAME ShRNA molecule silencing DNAPK radiosensitizer INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D04NWP DRUGNAME DRAFLAZINE INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2 TTDDRUID D04NWU DRUGNAME ONO-4053 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D04NXG DRUGNAME PMID26651364-Compound-128 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D04NXL DRUGNAME Indibulin INDICATI Advanced sarcoma [ICD-11: 2A60-2C35] Phase 2 TTDDRUID D04NXQ DRUGNAME Pefloxacin INDICATI Gonococcal urethritis [ICD-11: 1A70.0Y] Approved TTDDRUID D04NXR DRUGNAME RO-16-8714 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1 TTDDRUID D04NYX DRUGNAME AP-15012 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04OBB DRUGNAME Pheniramine INDICATI Hay fever [ICD-11: CA08.00] Approved TTDDRUID D04OBS DRUGNAME ZP-013 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D04OCC DRUGNAME Org-9616 INDICATI Anaesthesia [ICD-11: 9A78.6] Discontinued in Phase 2 TTDDRUID D04OCO DRUGNAME AC-163954 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D04ODH DRUGNAME Gonadorelin INDICATI Hypothalamic hypogonadism [ICD-11: 5A61.2] Approved TTDDRUID D04ODO DRUGNAME GSK-256073 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D04ODQ DRUGNAME 447C88 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1 TTDDRUID D04OFR DRUGNAME MEDI8897 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2/3 TTDDRUID D04OFY DRUGNAME ABBV-321 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04OGH DRUGNAME SEL-068 INDICATI Smoking dependence [ICD-11: 6C4A.2] Phase 1 TTDDRUID D04OGP DRUGNAME HL-10 INDICATI Respiratory distress syndrome [ICD-11: CB00] Phase 3 TTDDRUID D04OGS DRUGNAME LIV-2008 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04OGZ DRUGNAME D-699126 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04OIF DRUGNAME TAK-259 INDICATI Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 1 TTDDRUID D04OIG DRUGNAME DSLIM INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04OJM DRUGNAME Human interleukin-2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 TTDDRUID D04OKJ DRUGNAME Garenoxacin INDICATI Endocarditis [ICD-11: BB40-BA42] Terminated TTDDRUID D04OLK DRUGNAME AST-1306 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04OMR DRUGNAME PF-04840082 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 1 TTDDRUID D04ONP DRUGNAME ALBIFYLLINE INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1 TTDDRUID D04OOC DRUGNAME FCE-20696 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Terminated TTDDRUID D04OPS DRUGNAME MDT-011 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D04OQU DRUGNAME ASP2408 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D04ORP DRUGNAME GMK INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D04OSA DRUGNAME AZD-3839 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D04OSE DRUGNAME Nifedipine INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D04OTH DRUGNAME SomaKit-TOC; gallium (68Ga) edotreotide INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2 TTDDRUID D04OTY DRUGNAME BFH-772 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D04OUP DRUGNAME NNI-AD INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D04OXD DRUGNAME Netivudine INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 3 TTDDRUID D04OXG DRUGNAME PMZ-2123 INDICATI Cerebral oedema in diabetic ketoacidosis [ICD-11: 8D60.1] Phase 1 TTDDRUID D04OXU DRUGNAME E-2078 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D04OYW DRUGNAME ST-06 INDICATI Injury [ICD-11: NA00-ND5Z] Investigative TTDDRUID D04OZL DRUGNAME Hu3S193 INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 2 TTDDRUID D04OZR DRUGNAME TTH 02-001 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D04PAF DRUGNAME ANA-04 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D04PAN DRUGNAME Perflubron INDICATI Contrast imaging [ICD-11: N.A.] Approved TTDDRUID D04PAU DRUGNAME GSK2245035 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D04PBH DRUGNAME CONTIGOSIDE B INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 2/3 TTDDRUID D04PBS DRUGNAME MC-3001 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Preclinical TTDDRUID D04PCT DRUGNAME PMID30107136-Compound-Example12 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D04PDI DRUGNAME CD19-targeted CAR-T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Clinical trial TTDDRUID D04PEI DRUGNAME BMS-509744 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D04PEO DRUGNAME IRT-101 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D04PER DRUGNAME XEN-402 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 INDICATI Vasodilatation of extremities [ICD-11: EG00] Phase 2 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D04PFD DRUGNAME TriMixDC INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D04PGB DRUGNAME Gpi-1046 INDICATI Parkinson disease [ICD-11: 8A00.0] Terminated TTDDRUID D04PGO DRUGNAME MDL-28133A INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D04PHC DRUGNAME Epinephrine INDICATI Allergy [ICD-11: 4A80-4A85] Approved TTDDRUID D04PIH DRUGNAME Novaferon INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D04PIU DRUGNAME CART-BCMA cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D04PKQ DRUGNAME Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Patented TTDDRUID D04PKR DRUGNAME Aviptadil INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D04PKX DRUGNAME PMID26651364-Compound-125 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D04PLC DRUGNAME FOV1101 INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Discontinued in Phase 2 TTDDRUID D04PLI DRUGNAME SR46349B INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 INDICATI Primary insomnia [ICD-11: 7A00] Phase 3 INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 3 TTDDRUID D04PMM DRUGNAME AZD1386 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2 INDICATI Esophagus sensitivity [ICD-11: DA2Y-DA2Z] Discontinued in Phase 2 TTDDRUID D04PMS DRUGNAME HER2 antigen-specific cancer immunotherapeutic INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D04PPE DRUGNAME VE-04051645 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04PPK DRUGNAME CER-522 INDICATI Aortic valve stenosis [ICD-11: BB70] Phase 1 TTDDRUID D04PSL DRUGNAME FINROZOLE INDICATI Prostate disease [ICD-11: GA91] Discontinued in Phase 2 TTDDRUID D04PUI DRUGNAME BT-062 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D04PUO DRUGNAME OPNT001 INDICATI Eating disorder [ICD-11: 6B82] Phase 2 TTDDRUID D04PVE DRUGNAME PDA-002 INDICATI Ulcer [ICD-11: CA02-CB40] Phase 2 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 2 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 INDICATI Peripheral neuropathy [ICD-11: 8C0Z] Phase 2 TTDDRUID D04PVN DRUGNAME SPI-376 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D04PWT DRUGNAME DP-b99 INDICATI Stroke [ICD-11: 8B20] Phase 3 TTDDRUID D04PXS DRUGNAME Amitifadine INDICATI Obesity [ICD-11: 5B81] Phase 3 INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 2 TTDDRUID D04QCY DRUGNAME Antineoplaston-A3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D04QFV DRUGNAME SNX-024 INDICATI Obesity [ICD-11: 5B81] Terminated TTDDRUID D04QFX DRUGNAME 1-TDC INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D04QFY DRUGNAME GTx-027 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04QHT DRUGNAME EDP-20 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04QIE DRUGNAME Pemafibrate INDICATI Hyperlipidemia [ICD-11: 5C80.Z] Approved INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 3 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3 TTDDRUID D04QIL DRUGNAME IMP-111 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04QJD DRUGNAME Valaciclovir INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D04QKU DRUGNAME RG-7090 INDICATI Fragile X syndrome [ICD-11: LD55] Phase 2 TTDDRUID D04QLL DRUGNAME hESC-derived RPE (MA09-hRPE) INDICATI Myopic macular degeneration [ICD-11: 9B75.Y] Phase 1/2 INDICATI Dry age-related macular degeneration [ICD-11: 9B75] Phase 1/2 INDICATI Stargardt disease [ICD-11: 9B70] Phase 1 TTDDRUID D04QLR DRUGNAME Dyclonine INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D04QNO DRUGNAME Symbicort INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D04QPA DRUGNAME AST-OPC1 INDICATI Spinal cord injury [ICD-11: ND51.2] Phase 1/2 TTDDRUID D04QPD DRUGNAME FV-100 INDICATI Varicella zoster virus infection [ICD-11: 1E91] Phase 3 TTDDRUID D04QQZ DRUGNAME AT132 INDICATI X-linked myotubular myopathy [ICD-11: 8C72] Phase 1/2 TTDDRUID D04QRG DRUGNAME Antineoplaston A-10 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D04QRX DRUGNAME Thiazole carboxamide derivative 27 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D04QSH DRUGNAME DW-167 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2/3 TTDDRUID D04QSJ DRUGNAME R0-93877 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved INDICATI Constipation [ICD-11: DD91.1] Approved TTDDRUID D04QST DRUGNAME Riboflavin INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D04QUG DRUGNAME A-101 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D04QUX DRUGNAME PF-446687 INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Phase 2 TTDDRUID D04QVK DRUGNAME 1,2,4-tri-substituted imidazoline derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D04QVN DRUGNAME FPL-64170 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D04QVZ DRUGNAME DAS181 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D04QWE DRUGNAME Levallorphan INDICATI Narcotic depression [ICD-11: 6A7Z] Approved TTDDRUID D04QWQ DRUGNAME VX-509 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2/3 TTDDRUID D04QWV DRUGNAME APX-008 INDICATI Bone metastases [ICD-11: 2D50] Investigative TTDDRUID D04QXF DRUGNAME Anti-CD3 monoclonal antibody INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D04QXG DRUGNAME SR 120819A INDICATI Eating disorder [ICD-11: 6B82] Terminated TTDDRUID D04QXK DRUGNAME KY-62 INDICATI Leishmania infection [ICD-11: 1F54.0] Terminated TTDDRUID D04QXW DRUGNAME ARC-069 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D04QYS DRUGNAME SNA-120 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 INDICATI Pruritus [ICD-11: EC90] Phase 2 TTDDRUID D04QZD DRUGNAME Eslicarbazepine INDICATI Seizure disorder [ICD-11: 8A6Z] Approved TTDDRUID D04QZI DRUGNAME Retosiban INDICATI Preterm labour [ICD-11: JB00] Phase 3 TTDDRUID D04RAT DRUGNAME BIIR-777 INDICATI Neurological disorder [ICD-11: 6B60] Preclinical TTDDRUID D04RBY DRUGNAME EX-201 INDICATI Mucositis [ICD-11: CA00] Investigative TTDDRUID D04RCG DRUGNAME MEN-10627 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D04RCT DRUGNAME CHF-3381 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D04RCZ DRUGNAME Immunosuppressant synthetic peptide INDICATI Autoimmune diabetes [ICD-11: 5A10] Approved TTDDRUID D04RDT DRUGNAME CEP-431 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D04RDW DRUGNAME CAR-T cells targeting Lewis-Y INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04REV DRUGNAME CDX-1307 INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 TTDDRUID D04RFE DRUGNAME AnervaX.DB INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Terminated TTDDRUID D04RFX DRUGNAME LFn-p24 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D04RGA DRUGNAME Dinoprost Tromethamine INDICATI Abortion [ICD-11: JA00] Approved TTDDRUID D04RHJ DRUGNAME RG7116 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04RJM DRUGNAME DW-941 INDICATI Coronavirus infection [ICD-11: 1D92] Investigative TTDDRUID D04RKH DRUGNAME APH-0911 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04RKW DRUGNAME 7-methylxanthine INDICATI Myopia [ICD-11: 9D00.0] Phase 2 TTDDRUID D04RLB DRUGNAME HPIV-1 vaccine INDICATI Parainfluenza virus infection [ICD-11: 1D9Y] Phase 1 TTDDRUID D04RLX DRUGNAME Tariquidar INDICATI Adrenocortical carcinoma [ICD-11: 2D11.Z] Discontinued in Phase 2 TTDDRUID D04RLY DRUGNAME Vindesine INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved TTDDRUID D04RMM DRUGNAME Clazakizumab INDICATI Crohn disease [ICD-11: DD70] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D04RMP DRUGNAME Co-111732 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D04RNG DRUGNAME CAR-T cells recognizing EpCAM INDICATI Melanoma [ICD-11: 2C30] Phase 1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D04RNN DRUGNAME SUN-101 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3 TTDDRUID D04RRZ DRUGNAME MEDI4736 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D04RSI DRUGNAME FAS1 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Preclinical TTDDRUID D04RSR DRUGNAME Crolibulin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D04RSZ DRUGNAME GI-13000 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D04RUA DRUGNAME WRR-276 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D04RUP DRUGNAME SDZ-NKT-343 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1 TTDDRUID D04RWV DRUGNAME INS1009 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1 TTDDRUID D04RXX DRUGNAME N-acylpiperidine ether derivative 2 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D04RYU DRUGNAME Digitalin INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D04RZD DRUGNAME Interferon Alfa-2b, Recombinant INDICATI Hairy cell leukaemia [ICD-11: 2A82.2] Approved TTDDRUID D04RZE DRUGNAME FluLaval INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved INDICATI Influenza A virus infection [ICD-11: 1E30] Approved TTDDRUID D04RZZ DRUGNAME A-5021 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2 TTDDRUID D04SBH DRUGNAME Zamifenacin INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 3 TTDDRUID D04SBI DRUGNAME H.P. Acthar Gel INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 TTDDRUID D04SBW DRUGNAME Hexavalent conjugate vaccine INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Phase 1 TTDDRUID D04SBX DRUGNAME Temafloxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Withdrawn from market TTDDRUID D04SDN DRUGNAME RWJ-3981 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D04SEJ DRUGNAME IW-9179 INDICATI Dyspepsia [ICD-11: MD92] Phase 2 TTDDRUID D04SFH DRUGNAME Medrysone INDICATI Eye inflammation [ICD-11: 9A02] Approved TTDDRUID D04SHH DRUGNAME TC-6499-12 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 2 TTDDRUID D04SHO DRUGNAME NMI-1182 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D04SIO DRUGNAME NGD-91-1 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D04SIU DRUGNAME MCD-386 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D04SJT DRUGNAME MB-11040 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D04SKM DRUGNAME CART-10 cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D04SLF DRUGNAME Bevacizumab + Trastuzumab INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D04SNL DRUGNAME Grippol Plus INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D04SOA DRUGNAME H1N1 pandemic influenza A vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D04SOS DRUGNAME BMS-181168 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D04SOU DRUGNAME MK-4074 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D04SPJ DRUGNAME AZD7624 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D04SPK DRUGNAME Seratrodast INDICATI Allergic asthma [ICD-11: CA23.0] Discontinued in Phase 3 TTDDRUID D04SQJ DRUGNAME EW-A-401 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Phase 1 TTDDRUID D04SQO DRUGNAME DEBIO 1562 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 TTDDRUID D04SRO DRUGNAME GRT-3983Y INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 TTDDRUID D04STQ DRUGNAME CBH-11 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Terminated TTDDRUID D04SUU DRUGNAME Thymosin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D04SUX DRUGNAME Recombinant birch pollen allergen INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D04SVB DRUGNAME FR-133605 INDICATI Arthritis [ICD-11: FA20] Terminated TTDDRUID D04SWF DRUGNAME FP-1302 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D04SWT DRUGNAME Anti-CD47 mab INDICATI Ischemia [ICD-11: 8B10-8B11] Investigative TTDDRUID D04SXL DRUGNAME APG-115 INDICATI Prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04SZA DRUGNAME P-3914 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D04SZG DRUGNAME COTI-219 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Investigative TTDDRUID D04TBC DRUGNAME OZ-439 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2 TTDDRUID D04TBW DRUGNAME C-Rx INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D04TCQ DRUGNAME J-775Y INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D04TDQ DRUGNAME Noscapine (narcotine) INDICATI Cough [ICD-11: MD12] Approved TTDDRUID D04TEF DRUGNAME Alpha-1 antitrypsin INDICATI Coagulation defect [ICD-11: 3B10.0] Phase 2 INDICATI Bacillus anthracis infection [ICD-11: 1G40] Phase 1/2 TTDDRUID D04TFE DRUGNAME CreaVax-HCC INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 TTDDRUID D04TFL DRUGNAME SGX203 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D04TGF DRUGNAME AZD-2927 INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 2 TTDDRUID D04TGU DRUGNAME MK-3901 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D04THK DRUGNAME AL0-212 INDICATI Critical limb ischemia [ICD-11: BD4Y] Investigative TTDDRUID D04THU DRUGNAME KP-624 INDICATI Hyperuricaemia [ICD-11: 5C55.Y] Investigative TTDDRUID D04TIJ DRUGNAME Namitecan INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04TIL DRUGNAME ANA773 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2a TTDDRUID D04TIT DRUGNAME Nowarta110 INDICATI Plantar wart [ICD-11: 1E80.1] Phase 1/2 TTDDRUID D04TIU DRUGNAME PMID25666693-Compound-154 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D04TJL DRUGNAME LAS-41004 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D04TJP DRUGNAME Totrombopag INDICATI Thrombocytopenia [ICD-11: 3B64] Discontinued in Phase 1 TTDDRUID D04TKP DRUGNAME L-748415 INDICATI Osteoporosis [ICD-11: FB83.0] Terminated TTDDRUID D04TKU DRUGNAME H1N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D04TLJ DRUGNAME Soblidotin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D04TLQ DRUGNAME Cyclic peptidomimetic derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D04TNT DRUGNAME ABT-639 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D04TPF DRUGNAME TDI-0054 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D04TPQ DRUGNAME Aganepag isopropyl INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2 TTDDRUID D04TPS DRUGNAME A-887755 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D04TPU DRUGNAME RO-5323441 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D04TQO DRUGNAME Tenapanor INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved INDICATI Kidney disease [ICD-11: GC2Z] Phase 2 INDICATI Constipation [ICD-11: DD91.1] Phase 2 TTDDRUID D04TQT DRUGNAME Barusiban INDICATI Androgen deficiency [ICD-11: 5A81.1] Phase 2 TTDDRUID D04TSO DRUGNAME UNBS-1450 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04TSV DRUGNAME CI-992 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D04TUN DRUGNAME HTI-1066 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04TXB DRUGNAME Ceplene/Peg-Intron/Rebetol INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D04TYP DRUGNAME RG7600 INDICATI Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 1 TTDDRUID D04TZA DRUGNAME PF-04957325 INDICATI Itching [ICD-11: 1F28-1G07] Investigative INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D04TZK DRUGNAME LNK-3186 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D04TZT DRUGNAME SDZ-280-636 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D04UAL DRUGNAME Clovoxamine INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved TTDDRUID D04UAZ DRUGNAME CTA-091 INDICATI Hyperparathyroidism [ICD-11: 5A51] Investigative TTDDRUID D04UBI DRUGNAME AB928 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04UFI DRUGNAME ImMucin INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D04UFY DRUGNAME UX-003 INDICATI Lysosomal storage disease [ICD-11: 5C56.Z] Phase 3 INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 3 TTDDRUID D04UHW DRUGNAME PMID25684022-Compound-WO2008079988 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D04UHX DRUGNAME HumaRAD-HN INDICATI Head and neck cancer [ICD-11: 2D42] Discontinued in Phase 1 TTDDRUID D04UKC DRUGNAME Riociguat INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Approved TTDDRUID D04UKJ DRUGNAME NP-61 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1 TTDDRUID D04UKP DRUGNAME Tenatumomab INDICATI Glioma [ICD-11: 2A00.0] Phase 3 TTDDRUID D04UME DRUGNAME BI-144807 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D04UNO DRUGNAME KUL-7211 INDICATI Neurogenic bladder dysfunction [ICD-11: GC01.4] Phase 1 TTDDRUID D04UNY DRUGNAME Anti-GD2 T-cells (1RG-CART) INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 1 TTDDRUID D04UOJ DRUGNAME PYN-7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D04UPJ DRUGNAME DasKloster 0247-01 INDICATI Pulmonary hypertension [ICD-11: BB01] Investigative TTDDRUID D04UPM DRUGNAME KBAB-401 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D04UPW DRUGNAME RWJ-68023 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 1 TTDDRUID D04UQF DRUGNAME Influvac tC cell culture-derived influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D04UQS DRUGNAME NXD-9062 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D04URO DRUGNAME Streptokinase INDICATI Pulmonary embolism [ICD-11: BB00] Approved TTDDRUID D04URZ DRUGNAME AVX-003 INDICATI Glomerulonephritis [ICD-11: 5D00.Y] Investigative TTDDRUID D04USC DRUGNAME Ergotidine INDICATI Respiratory allergy [ICD-11: 4A80] Approved TTDDRUID D04USK DRUGNAME H5N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Preclinical TTDDRUID D04UTH DRUGNAME Long-acting erythropoietin conjugate INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 1 TTDDRUID D04UTT DRUGNAME Olodaterol INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D04UUD DRUGNAME CC-401 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D04UUH DRUGNAME Lithium Carbonate INDICATI Manic depression disorder [ICD-11: 6A71] Approved TTDDRUID D04UWG DRUGNAME Autologous T-cell therapy INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D04UWU DRUGNAME Oraxol INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D04UXX DRUGNAME PD-158771 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D04UYT DRUGNAME CBLB-612 INDICATI Radiation syndrome [ICD-11: NF00] Investigative TTDDRUID D04UYY DRUGNAME AD5-10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04UZN DRUGNAME Pyrimethamine/sulfadoxine INDICATI Pneumocystis pneumonia [ICD-11: CA40.20] Approved TTDDRUID D04UZT DRUGNAME Quinestrol INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D04VAR DRUGNAME GSK-2136773 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Investigative TTDDRUID D04VBF DRUGNAME JNJ-38518168 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 TTDDRUID D04VCF DRUGNAME ADR58 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D04VCN DRUGNAME Bovactant INDICATI Pulmonary disease [ICD-11: 1B10-1F85] Approved TTDDRUID D04VCQ DRUGNAME CART33 cells INDICATI Myeloid leukaemia [ICD-11: 2B33.1] Phase 1/2 TTDDRUID D04VCS DRUGNAME Neocartilage INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D04VDY DRUGNAME L-741671 INDICATI Vomiting [ICD-11: MD90] Terminated TTDDRUID D04VEJ DRUGNAME Lymecycline INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04VFJ DRUGNAME Toremifene INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D04VFW DRUGNAME SAR-116242 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D04VGR DRUGNAME PMID27998201-Compound-9 INDICATI Rheumatoid arthritis [ICD-11: FA20] Patented TTDDRUID D04VGS DRUGNAME Selenium sulfide INDICATI Erythema [ICD-11: ME64.0] Approved TTDDRUID D04VGY DRUGNAME CYT-007-TNFQb INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 1/2 TTDDRUID D04VHB DRUGNAME RSV recombinant vaccine INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2 TTDDRUID D04VHK DRUGNAME CLR-3001 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D04VHL DRUGNAME MystiTears INDICATI Xerophthalmia [ICD-11: 5B55.Y] Investigative TTDDRUID D04VHQ DRUGNAME AVI-7012 INDICATI Junin virus infection [ICD-11: 1D6Y] Investigative TTDDRUID D04VHZ DRUGNAME Interferon-alpha 2b INDICATI Hairy cell leukaemia [ICD-11: 2A82.2] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D04VIP DRUGNAME 4030W92 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D04VIS DRUGNAME Andrographolide INDICATI Bacillary dysentery [ICD-11: 1A02] Approved TTDDRUID D04VJH DRUGNAME ACREOZAST INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D04VJQ DRUGNAME BVS857 INDICATI Insulin-resistant disorder [ICD-11: 5A44] Phase 1 TTDDRUID D04VKO DRUGNAME ATON-004 INDICATI Heavy metal poisoning [ICD-11: NE60] Discontinued in Phase 2 TTDDRUID D04VKS DRUGNAME Acrisorcin INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D04VLR DRUGNAME PA-161 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical TTDDRUID D04VMG DRUGNAME ELEMENE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04VMM DRUGNAME Encapsulated cancer cells INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D04VMT DRUGNAME Sotalol INDICATI Sinus rhythm disorder [ICD-11: BC9Y] Approved TTDDRUID D04VOE DRUGNAME AS-1402 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D04VOZ DRUGNAME TKM-ApoB INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Phase 4 TTDDRUID D04VPA DRUGNAME Moricizine INDICATI Arrhythmia [ICD-11: BC9Z] Approved INDICATI Heart arrhythmia [ICD-11: BC65] Withdrawn from market TTDDRUID D04VPP DRUGNAME ATI-1150 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04VQH DRUGNAME XEN-D0501 INDICATI Overactive bladder [ICD-11: GC50.0] Phase 2 TTDDRUID D04VRB DRUGNAME NeuVax INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D04VRN DRUGNAME MMR INDICATI Rubella prophylaxis [ICD-11: 1F02] Phase 3 INDICATI Mumps virus infection [ICD-11: 1D80] Phase 3 INDICATI Measles [ICD-11: 1F03] Phase 3 TTDDRUID D04VSI DRUGNAME Arbidol INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 4 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D04VSM DRUGNAME CS-8958 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D04VTV DRUGNAME SYN-114 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1 TTDDRUID D04VUM DRUGNAME CGEN-928 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D04VUY DRUGNAME RG-7166 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1 TTDDRUID D04VVD DRUGNAME TeloB-Vax INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D04VVL DRUGNAME Malaria next generation vaccine INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2 TTDDRUID D04VWJ DRUGNAME ARRY-520 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D04VWO DRUGNAME Recombinant soluble CD6 INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D04VXN DRUGNAME Moxalactam Disodium INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04VXS DRUGNAME ENT-102 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D04VZS DRUGNAME CTS-21166 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D04WBT DRUGNAME Act1 INDICATI Wound healing [ICD-11: EL8Y] Phase 3 TTDDRUID D04WBY DRUGNAME Menotropins INDICATI Female infertility [ICD-11: GA31.Z] Approved TTDDRUID D04WCA DRUGNAME AVP-7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04WCI DRUGNAME PAMAPIMOD INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D04WCJ DRUGNAME DV-100 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D04WCO DRUGNAME EPB-415 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D04WDA DRUGNAME CSL-412 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D04WDX DRUGNAME PJ34 INDICATI Coronavirus infection [ICD-11: 1D92] Preclinical TTDDRUID D04WFD DRUGNAME Nortriptyline INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D04WFL DRUGNAME Trastuzumab INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Application submitted INDICATI HER2-positive breast cancer [ICD-11: 2C60-2C65] Application submitted TTDDRUID D04WFV DRUGNAME Hepatitis B immune globulin INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D04WHM DRUGNAME G0-203-2c INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D04WHX DRUGNAME FP-21399 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D04WIE DRUGNAME Sirna-027 INDICATI Exudative age-related macular degeneration [ICD-11: 9B78.3Z] Phase 1/2 INDICATI Neovascular age-related macular degeneration [ICD-11: 9B78.3Z] Phase 1 TTDDRUID D04WIF DRUGNAME ISIS-GCGR INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Preclinical TTDDRUID D04WIG DRUGNAME CY-1747 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D04WJO DRUGNAME Talaporfin INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D04WLX DRUGNAME AIK-21 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D04WMR DRUGNAME Tepoxalin INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D04WNA DRUGNAME ART-237 INDICATI Arthropathy [ICD-11: FA11-FA38] Investigative TTDDRUID D04WOM DRUGNAME Seractide Acetate INDICATI Essential hypertension [ICD-11: BA00] Approved TTDDRUID D04WQJ DRUGNAME AMG-181 INDICATI Crohn disease [ICD-11: DD70] Phase 2 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 TTDDRUID D04WQT DRUGNAME RG7201 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D04WSK DRUGNAME 99mTc-ImmuRAID-LL1 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D04WSL DRUGNAME Cardiotoxin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04WTN DRUGNAME Oxabact INDICATI Hyperoxaluria [ICD-11: 5C51.2] Phase 3 TTDDRUID D04WUA DRUGNAME CP-101,606 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Investigative TTDDRUID D04WVI DRUGNAME M-17 E. Coli INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 3 TTDDRUID D04WVL DRUGNAME SF-1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1/2 TTDDRUID D04WVY DRUGNAME SPI-026 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 TTDDRUID D04WWG DRUGNAME S-1389 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D04WXG DRUGNAME DVC-LVS INDICATI Tularemia [ICD-11: 1B94] Phase 2 TTDDRUID D04WYX DRUGNAME Netarsudil INDICATI Open-angle glaucoma [ICD-11: 9C61] Approved INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2 TTDDRUID D04WZK DRUGNAME AZD-2858 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D04WZL DRUGNAME CART-meso cells INDICATI Pancreatic cancer [ICD-11: 2C10] Clinical trial TTDDRUID D04XAB DRUGNAME Autologous cancer vaccine INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D04XBU DRUGNAME ATL-104 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D04XCK DRUGNAME OMP-313M32 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04XCO DRUGNAME AZD-8848 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D04XDT DRUGNAME Delafloxacin Meglumine INDICATI Acute bacterial skin infection [ICD-11: 1C41] Approved INDICATI Skin infection [ICD-11: 1F28-1G0Z] Approved TTDDRUID D04XEG DRUGNAME Fenoterol INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D04XEO DRUGNAME ChelASE INDICATI Retina disorder [ICD-11: 9B70-9B7Z] Discontinued in Phase 1 TTDDRUID D04XEQ DRUGNAME Imetelstat INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2/3 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Essential thrombocythemia [ICD-11: 3B63.1Z] Phase 2 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 2 TTDDRUID D04XGT DRUGNAME Benznidazole INDICATI Chagas disease [ICD-11: IF53] Approved INDICATI Trypanosomiasis [ICD-11: 1D51-1F53] Approved TTDDRUID D04XGU DRUGNAME Crestor/TriLipix INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Approved TTDDRUID D04XIA DRUGNAME Meningococcus B vaccine INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Terminated TTDDRUID D04XIO DRUGNAME Dutogliptin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D04XIV DRUGNAME Mesenchymal precursor cell INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D04XJE DRUGNAME REM-001 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D04XJG DRUGNAME BKR-013 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D04XJM DRUGNAME R1295 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D04XJV DRUGNAME GRC-9332 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative TTDDRUID D04XJX DRUGNAME GP-1001 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D04XLU DRUGNAME Dendritic cell vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Preclinical TTDDRUID D04XMJ DRUGNAME LY525327 INDICATI Migraine [ICD-11: 8A80] Terminated INDICATI Neuropathic pain [ICD-11: 8E43.0] Terminated TTDDRUID D04XML DRUGNAME TRI-002 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D04XMN DRUGNAME NK-109 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D04XNQ DRUGNAME BioScavenger INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04XOX DRUGNAME Malate synthase INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D04XPD DRUGNAME DV-0100 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 TTDDRUID D04XPW DRUGNAME Cocaine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D04XQW DRUGNAME Dornase alfa INDICATI Cystic fibrosis [ICD-11: CA25] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D04XSP DRUGNAME Alpha-fetoprotein cancer vaccine INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 TTDDRUID D04XTK DRUGNAME SRM003 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Phase 2 TTDDRUID D04XUJ DRUGNAME CBT-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 2 TTDDRUID D04XVE DRUGNAME QAX-028 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D04XVJ DRUGNAME LEO-29102 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D04XVN DRUGNAME Trametinib INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D04XVU DRUGNAME GKT-137831 INDICATI Fibrosis [ICD-11: GA14-GC01] Phase 2 TTDDRUID D04XWX DRUGNAME PS-178990 INDICATI Muscle atrophy [ICD-11: FB32.Y] Phase 1 TTDDRUID D04XZE DRUGNAME NS-7 INDICATI Nerve injury [ICD-11: ND56.4] Phase 2 TTDDRUID D04YAJ DRUGNAME SELODENOSON INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Phase 2 TTDDRUID D04YAK DRUGNAME MPC-2130 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04YCE DRUGNAME Pidotimod INDICATI Urinary tract infection [ICD-11: GC08] Withdrawn from market TTDDRUID D04YCQ DRUGNAME GEN-003 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 2 TTDDRUID D04YEW DRUGNAME Tarafenacin INDICATI Overactive bladder [ICD-11: GC50.0] Phase 2 TTDDRUID D04YEY DRUGNAME PS-388023 INDICATI Ocular disease [ICD-11: 1F00.1Z] Terminated TTDDRUID D04YFA DRUGNAME VAX-161 INDICATI Influenza A virus infection [ICD-11: 1E30] Phase 1 TTDDRUID D04YGT DRUGNAME VAL-001 INDICATI Acne vulgaris [ICD-11: ED80] Investigative TTDDRUID D04YHG DRUGNAME ErepoXen INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 3 TTDDRUID D04YHJ DRUGNAME Meninge B INDICATI Meningitis [ICD-11: 1D01] Phase 1 TTDDRUID D04YHR DRUGNAME Samarium Sm-153 Lexidronam Pentasodium INDICATI Cancer related pain [ICD-11: MG30] Approved TTDDRUID D04YHW DRUGNAME R-1487 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D04YIA DRUGNAME CNVN-202 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D04YJN DRUGNAME R411 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D04YJO DRUGNAME CGS-19480A INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D04YKM DRUGNAME Microfibrillar collagen hemostat INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved TTDDRUID D04YKO DRUGNAME Piperidine derivative 2 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented TTDDRUID D04YKQ DRUGNAME NaQuinate INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D04YKY DRUGNAME NT-502 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Investigative TTDDRUID D04YLQ DRUGNAME AMG 334 INDICATI Migraine [ICD-11: 8A80] Phase 2 TTDDRUID D04YLU DRUGNAME AZ-599 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D04YMH DRUGNAME Lumiracoxib INDICATI Knee osteoarthritis [ICD-11: FA01] Approved TTDDRUID D04YNI DRUGNAME WY-48989 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D04YPN DRUGNAME Treosulfan INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D04YPZ DRUGNAME Decapeptide allergy vaccine INDICATI Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 2 TTDDRUID D04YRD DRUGNAME DTX101 INDICATI Haemophilia B [ICD-11: 3B11.0] Phase 1/2 TTDDRUID D04YSC DRUGNAME CD19 CAR T cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2/3 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 2/3 TTDDRUID D04YSK DRUGNAME Pagibaximab INDICATI Enterococcus faecium infection [ICD-11: 1D01.0Y] Phase 2/3 TTDDRUID D04YSQ DRUGNAME HepaXen INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D04YSY DRUGNAME Recombinant NOV INDICATI Corneal disease [ICD-11: 9A78.Z] Investigative TTDDRUID D04YTT DRUGNAME DAV-148 INDICATI Enterobacteriaceae infection [ICD-11: MG50.C] Investigative TTDDRUID D04YTX DRUGNAME HPy-HP 097 INDICATI Helicobacter infection [ICD-11: DA42-DA63] Investigative TTDDRUID D04YWM DRUGNAME Atacicept INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 3 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 INDICATI Lupus [ICD-11: 4A40] Phase 2 TTDDRUID D04YWS DRUGNAME RAGE-Fc fusion protein INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D04YXL DRUGNAME PEGylated IFN beta 1-a INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D04YZL DRUGNAME Sodium chloride INDICATI Skin burns [ICD-11: ME65.0] Approved TTDDRUID D04YZS DRUGNAME KIT-302 INDICATI Pain [ICD-11: MG30-MG3Z] Application submitted INDICATI Osteoarthritis [ICD-11: FA00-FA05] Application submitted INDICATI Hypertension [ICD-11: BA00-BA04] Application submitted TTDDRUID D04ZAH DRUGNAME Piperacillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04ZBA DRUGNAME NVLS/FX-18A INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D04ZBT DRUGNAME Icatibant INDICATI Hereditary angioedema [ICD-11: 4A00.14] Approved TTDDRUID D04ZBU DRUGNAME JTT-302 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 2 TTDDRUID D04ZCL DRUGNAME VZ-564 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D04ZCZ DRUGNAME GINKOLIDE B INDICATI Sepsis [ICD-11: 1G40-1G41] Terminated TTDDRUID D04ZEP DRUGNAME A-849531 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D04ZFO DRUGNAME WVE-120102 INDICATI Huntington disease [ICD-11: 8A01.10] Phase 1/2 TTDDRUID D04ZHJ DRUGNAME TNF alpha kinoid INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D04ZIJ DRUGNAME Pepstatin INDICATI Malaria [ICD-11: 1F40-1F45] Terminated TTDDRUID D04ZIO DRUGNAME NBI-640756 INDICATI Essential tremor or related tremors [ICD-11: 8A04.1] Phase 1 TTDDRUID D04ZIZ DRUGNAME DMUC-5754A INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Peritoneal cancer [ICD-11: 2C51.Z] Phase 1 INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 1 TTDDRUID D04ZJG DRUGNAME PI-88 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D04ZJP DRUGNAME HSR-113 INDICATI Nausea and vomiting [ICD-11: MD90] Discontinued in Phase 1 TTDDRUID D04ZJQ DRUGNAME VN/13-1RA INDICATI Dermatological disease [ICD-11: DA24.Y] Investigative TTDDRUID D04ZKY DRUGNAME SEP-363856 INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 1 TTDDRUID D04ZLC DRUGNAME N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D04ZLG DRUGNAME IDEC-151 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D04ZLJ DRUGNAME LOSOXANTRONE INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D04ZND DRUGNAME PGL-2001 INDICATI Endometriosis [ICD-11: GA10] Phase 2 TTDDRUID D04ZNG DRUGNAME LF-08-0133 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D04ZNL DRUGNAME RG-7234 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D04ZOZ DRUGNAME MS-322 INDICATI Spasm [ICD-11: MB47.3] Discontinued in Phase 2 TTDDRUID D04ZQB DRUGNAME KPT-9274 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04ZQO DRUGNAME TG-2349 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D04ZSL DRUGNAME SB-313-xTZ INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D04ZSZ DRUGNAME DS-AH-14 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D04ZTA DRUGNAME ANA-5 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D04ZTY DRUGNAME Voglibose INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D04ZUU DRUGNAME AKT-10081 INDICATI Clostridium infection [ICD-11: 1A04] Investigative TTDDRUID D04ZVO DRUGNAME ZS-9 INDICATI Hyperkalemia [ICD-11: 5C76] Investigative TTDDRUID D04ZWD DRUGNAME EZN-4150 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04ZWH DRUGNAME UK-279,276 INDICATI Stroke [ICD-11: 8B20] Discontinued in Phase 2 TTDDRUID D04ZWQ DRUGNAME Org-25435 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 1 TTDDRUID D04ZXP DRUGNAME Dicycloplatin INDICATI Prostate cancer [ICD-11: 2C82.0] Registered TTDDRUID D04ZYP DRUGNAME Cat-SPIRE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D04ZZD DRUGNAME AVP-6 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D04ZZM DRUGNAME Resorcinol compound 21 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D04ZZQ DRUGNAME VAS-2870 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D04ZZT DRUGNAME AGS-004 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2 TTDDRUID D04ZZX DRUGNAME Mi-TUMEX INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05AAD DRUGNAME Isatoribine INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D05AAM DRUGNAME BINOSPIRONE MESYLATE INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D05AAQ DRUGNAME BCP-1081 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D05AAW DRUGNAME VR-776 INDICATI Premature ejaculation [ICD-11: HA03.0Z] Discontinued in Phase 1 TTDDRUID D05ACQ DRUGNAME Gallium maltolate INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D05ADE DRUGNAME RAD-100 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D05ADP DRUGNAME R-roscovitine INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative TTDDRUID D05AEE DRUGNAME RG7935 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D05AFC DRUGNAME Dalfopristin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D05AFP DRUGNAME CY-301 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Investigative TTDDRUID D05AFR DRUGNAME Rolitetracycline INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D05AFX DRUGNAME Nefopam INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D05AHC DRUGNAME NOV-205 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D05AHE DRUGNAME Methylergonovine INDICATI Spontaneous abortion [ICD-11: JA00.0] Approved TTDDRUID D05AHK DRUGNAME INGN-234 INDICATI Oral cancer [ICD-11: 2B6E] Discontinued in Phase 2 TTDDRUID D05AHQ DRUGNAME Epiroprim INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D05AJT DRUGNAME XL019 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 INDICATI Polycythemia vera [ICD-11: 2A20.4] Phase 1 TTDDRUID D05AKH DRUGNAME OnabotulinumtoxinA INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D05ALG DRUGNAME RWJ-49815 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated INDICATI Obesity [ICD-11: 5B81] Investigative INDICATI Eating disorder [ICD-11: 6B82] Investigative TTDDRUID D05ALP DRUGNAME REG1 INDICATI Acute coronary syndrome [ICD-11: BA41] Phase 3 TTDDRUID D05AON DRUGNAME LSI-518P INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D05APM DRUGNAME ANG-2684 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D05APW DRUGNAME ABT-116 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D05AQB DRUGNAME FAS-89B INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D05AQP DRUGNAME ASP-0306 INDICATI Urinary dysfunction [ICD-11: GC2Z] Discontinued in Phase 1 TTDDRUID D05AQT DRUGNAME PMID28270021-Compound-WO2014078408Example1 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D05ARP DRUGNAME Ganciclovir INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D05ASV DRUGNAME VTX-1463 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 1 TTDDRUID D05ATD DRUGNAME AVX-502 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2 TTDDRUID D05ATI DRUGNAME Sodium lauryl sulfate INDICATI Constipation [ICD-11: DD91.1] Approved TTDDRUID D05ATQ DRUGNAME MVA HER-2 AutoVac INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D05AVB DRUGNAME DW-1029M INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID D05AVL DRUGNAME JNJ-61178104 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Phase 1 TTDDRUID D05AWP DRUGNAME Moxidectin INDICATI River blindness [ICD-11: 1F6A.0] Approved INDICATI Onchocerciasis [ICD-11: 1F6A] Approved TTDDRUID D05AXS DRUGNAME CRx-189 INDICATI Inflammatory bowel disease [ICD-11: DD72] Terminated TTDDRUID D05AZE DRUGNAME Biphenyl mannoside derivative 30 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D05BAJ DRUGNAME PDR001 INDICATI Melanoma [ICD-11: 2C30] Phase 3 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2 INDICATI Esophageal squamous cell carcinoma [ICD-11: 2E60.1] Phase 2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05BBB DRUGNAME Saratin INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 2 TTDDRUID D05BBQ DRUGNAME RP-66364 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D05BCA DRUGNAME MX-4509 INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1 TTDDRUID D05BCF DRUGNAME Clavulanate+Amoxicillin INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D05BCU DRUGNAME RQ-00000004 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 3 TTDDRUID D05BDY DRUGNAME PXT-3003 INDICATI Charcot marie tooth disease [ICD-11: 8C21.Z] Phase 3 TTDDRUID D05BGY DRUGNAME PM184 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D05BHF DRUGNAME Masilukast INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D05BII DRUGNAME Ancrod INDICATI Blood forming organ disorder [ICD-11: JB64.1] Phase 3 TTDDRUID D05BIJ DRUGNAME RWJ-140998 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D05BIN DRUGNAME F-14512 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D05BIT DRUGNAME Maxy-10 INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D05BJD DRUGNAME Motexafin gadolinium INDICATI Brain cancer [ICD-11: 2A00] Approved INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D05BKS DRUGNAME Nimotuzumab INDICATI Head and neck cancer [ICD-11: 2D42] Approved TTDDRUID D05BKY DRUGNAME NK-1005 INDICATI Atrial fibrillation [ICD-11: BC81.3] Investigative TTDDRUID D05BLG DRUGNAME MC-116 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D05BLN DRUGNAME MGCD516 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D05BLQ DRUGNAME Neuromed 2 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D05BMC DRUGNAME GW-42004 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 2 TTDDRUID D05BMG DRUGNAME Amphetamine INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved TTDDRUID D05BNS DRUGNAME Oral-Vimo-001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05BPC DRUGNAME Tiprelestat INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 TTDDRUID D05BPD DRUGNAME Emepepimut-S INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D05BPO DRUGNAME PF-06801591 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D05BQK DRUGNAME Butalbital INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved INDICATI Headache [ICD-11: 8A80-8A84] Approved TTDDRUID D05BRZ DRUGNAME PG-140 INDICATI Transplant rejection [ICD-11: NE84] Investigative TTDDRUID D05BSG DRUGNAME Enkastim-ev INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05BTL DRUGNAME PMID26651364-Compound-126c INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D05BTM DRUGNAME Maxacalcitol INDICATI Disorder of calcium metabolism [ICD-11: 5C64.5] Approved TTDDRUID D05BTR DRUGNAME Tallimustine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D05BUD DRUGNAME Mannoside derivative 10 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D05BWH DRUGNAME PRX-3140 INDICATI Post-traumatic stress disorder [ICD-11: 6B40] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D05BWX DRUGNAME CB-2431 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 2 TTDDRUID D05BWY DRUGNAME CLR-300 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D05BXO DRUGNAME Brasofensine INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D05BXY DRUGNAME Talimogene Laherparepvec INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D05BYA DRUGNAME NVP-AUY922 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D05BYJ DRUGNAME PF-06413367 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D05BYO DRUGNAME ISIS-SOD1 INDICATI Motor neurone disease [ICD-11: 8B60] Phase 1 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1 TTDDRUID D05BYP DRUGNAME Lupron 3-month depot INDICATI Bone marrow transplantation [ICD-11: QB63.6] Phase 2 TTDDRUID D05CBJ DRUGNAME PA-799 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05CBP DRUGNAME PMID26651364-Compound-9a INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D05CDF DRUGNAME Doramapimod INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2 TTDDRUID D05CDG DRUGNAME R-1164 INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 1 TTDDRUID D05CEK DRUGNAME CV 6209 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D05CEO DRUGNAME Brodalumab INDICATI Plaque psoriasis [ICD-11: EA90.0] Approved INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 3 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D05CEU DRUGNAME Flunarizine INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D05CFG DRUGNAME PR104 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D05CFH DRUGNAME AGN-199981 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D05CFQ DRUGNAME AMG-191 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D05CFV DRUGNAME Dapirolizumab pegol INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 TTDDRUID D05CGH DRUGNAME Evatak INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05CGO DRUGNAME XP-28 INDICATI Muscle fatigue [ICD-11: FB32.5] Phase 3 TTDDRUID D05CGX DRUGNAME SPK-FIX INDICATI Haemophilia B [ICD-11: 3B11.0] Phase 1/2 TTDDRUID D05CHI DRUGNAME Rifabutin INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Approved INDICATI Tuberculosis [ICD-11: 1B10-1B14] Approved TTDDRUID D05CHN DRUGNAME Irofulven/Taxotere INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05CHR DRUGNAME LBY-135 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D05CJN DRUGNAME HG-1336 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D05CJU DRUGNAME DLX-105 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 TTDDRUID D05CKF DRUGNAME AJD-101 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D05CKR DRUGNAME Nabumetone INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D05CMT DRUGNAME COMBO Stent INDICATI Coronary artery disease [ICD-11: BA80] Clinical trial TTDDRUID D05CMY DRUGNAME Peginterferon lambda-1a INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D05CMZ DRUGNAME ONO-2952 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 2 TTDDRUID D05COE DRUGNAME PMID30107136-Compound-Example52 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D05COG DRUGNAME DU-1777 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D05CPD DRUGNAME BIOO-2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05CPS DRUGNAME Dendritic cell vaccine INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1 TTDDRUID D05CPV DRUGNAME Dronedarone INDICATI Angina pectoris [ICD-11: BA40] Approved INDICATI Atrial fibrillation [ICD-11: BC81.3] Withdrawn from market TTDDRUID D05CQS DRUGNAME NB1011 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D05CRG DRUGNAME L-054852 INDICATI Acromegaly [ICD-11: 5A60.0] Investigative TTDDRUID D05CRY DRUGNAME ADCT-502 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05CSS DRUGNAME CAR-T cells targeting MucI INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1/2 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D05CTQ DRUGNAME CD138 CAR T cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D05CTS DRUGNAME C-202 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D05CTY DRUGNAME NV.TLM.10 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Investigative TTDDRUID D05CVC DRUGNAME 90Y-cG250 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05CVH DRUGNAME Hu neutral insulin INDICATI Type-1 diabetes [ICD-11: 5A10] Approved TTDDRUID D05CYX DRUGNAME DAV-121 INDICATI Toxicity [ICD-11: N.A.] Investigative TTDDRUID D05DAX DRUGNAME TT-120 INDICATI Coagulation defect [ICD-11: 3B10.0] Investigative TTDDRUID D05DBT DRUGNAME EG-HPV INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Investigative TTDDRUID D05DBY DRUGNAME Imagabalin INDICATI Generalized anxiety disorder [ICD-11: 6B00] Phase 3 TTDDRUID D05DBZ DRUGNAME AGS-8M4 INDICATI Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 2 TTDDRUID D05DCL DRUGNAME ZYT-1 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 1 TTDDRUID D05DCX DRUGNAME Genetically modified allogeneic sertoli cells INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D05DDN DRUGNAME HCV-796 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2 TTDDRUID D05DDZ DRUGNAME MV-6401 INDICATI Artery stenosis [ICD-11: BD52] Preclinical TTDDRUID D05DFV DRUGNAME PRO-044 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D05DKT DRUGNAME CART19 cell INDICATI B-cell prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1 TTDDRUID D05DNA DRUGNAME FR-183998 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D05DNH DRUGNAME A-79296 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Terminated TTDDRUID D05DON DRUGNAME MILACAINIDE TARTRATE INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2 TTDDRUID D05DOY DRUGNAME ING-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05DPE DRUGNAME BR-05001 INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D05DPU DRUGNAME SP-102 INDICATI Sciatica/lumbar radicular pain [ICD-11: ME84.3] Phase 3 TTDDRUID D05DQF DRUGNAME Indole N -acetamide INDICATI Hepatovirus infection [ICD-11: 1E51] Investigative TTDDRUID D05DQR DRUGNAME HDV-interferon INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D05DRG DRUGNAME PDC-31 INDICATI Dysmenorrhea [ICD-11: GA34.3] Investigative TTDDRUID D05DSK DRUGNAME E2101 INDICATI Spasm [ICD-11: MB47.3] Discontinued in Phase 1 INDICATI Cervical dystonia [ICD-11: 8A02.0Y] Discontinued in Phase 1 TTDDRUID D05DSS DRUGNAME GI-13020 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1 TTDDRUID D05DVP DRUGNAME Zafirlukast INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D05DXT DRUGNAME XEN-D0103 INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 1 TTDDRUID D05DZA DRUGNAME PUR-0110 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 2 TTDDRUID D05DZJ DRUGNAME TDI-0055 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D05DZK DRUGNAME Interferon alpha 2a INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3 TTDDRUID D05DZR DRUGNAME Elotuzumab INDICATI Multiple myeloma [ICD-11: 2A83] Approved TTDDRUID D05EAJ DRUGNAME ETV-003 INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Investigative TTDDRUID D05EAM DRUGNAME Pentamidine INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Withdrawn from market TTDDRUID D05EBY DRUGNAME PCSK9 Adnectin INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D05ECA DRUGNAME LJM716 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D05ECK DRUGNAME SKF-110679 INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Phase 2 TTDDRUID D05ECQ DRUGNAME RX-10001 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D05EEJ DRUGNAME ETRX-101 INDICATI Anemia [ICD-11: 3A00-3A9Z] Discontinued in Phase 2 TTDDRUID D05EFR DRUGNAME SprayGel INDICATI Abdominal surgical procedure [ICD-11: N.A.] Approved INDICATI Pelvic inflammatory disease [ICD-11: GA05] Approved INDICATI Gastric disease [ICD-11: DA40-DA7Z] Approved TTDDRUID D05EHJ DRUGNAME IMOVAX INDICATI Poliovirus infection [ICD-11: 1C8Y] Approved TTDDRUID D05EHS DRUGNAME MyoDys INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1 TTDDRUID D05EIT DRUGNAME CVT-E002 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D05EJG DRUGNAME L-Tryptophan INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D05EKM DRUGNAME FR-121196 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D05EKO DRUGNAME OvaSave INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D05ELM DRUGNAME AC-150 INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Phase 2 TTDDRUID D05ELO DRUGNAME Insulin, porcine INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D05ELV DRUGNAME Zinc Chloride INDICATI Common cold [ICD-11: CA00] Approved TTDDRUID D05ELY DRUGNAME Influenza A virus vaccine H9N2 INDICATI Influenza A virus H9N2 infection [ICD-11: 1E30] Phase 2 TTDDRUID D05ELZ DRUGNAME IC9/CAR.19/IL15-transduced CB-NK cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D05EMG DRUGNAME Butylscopolamine INDICATI Dysmenorrhea [ICD-11: GA34.3] Approved TTDDRUID D05EMV DRUGNAME GR148672X INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial TTDDRUID D05EMW DRUGNAME Long-acting polysialic acid-interferon alpha 2b conjugate INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D05ENG DRUGNAME AVX701 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI Rectosigmoid junction cancer [ICD-11: 2B91.Z] Phase 1/2 TTDDRUID D05ENJ DRUGNAME Fasitibant chloride INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 TTDDRUID D05EOT DRUGNAME CM-PK INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D05EPE DRUGNAME VRC-SRSDNA015-00-VP INDICATI Coronavirus infection [ICD-11: 1D92] Phase 1 TTDDRUID D05EPM DRUGNAME Ethotoin INDICATI Complex partial seizure [ICD-11: 8A68.0] Approved TTDDRUID D05EPU DRUGNAME ZD7114 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D05EPV DRUGNAME Ozoralizumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D05EPY DRUGNAME L-693612 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D05ERA DRUGNAME PXL-01 INDICATI Sarcoidosis [ICD-11: 4B20.5] Phase 2 TTDDRUID D05ERT DRUGNAME GV-196771 INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 2 TTDDRUID D05ETC DRUGNAME SN-32793 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D05EUH DRUGNAME H5N1 influenza virus vaccine INDICATI Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 1/2 TTDDRUID D05EUI DRUGNAME DeltaFLU INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D05EUR DRUGNAME LJN452 INDICATI Primary biliary cholangitis [ICD-11: DB96.1] Phase 2 TTDDRUID D05EUS DRUGNAME Human microbio modulator INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05EVF DRUGNAME Iodine-123-iodophenylpentadecanoic acid INDICATI Coronary artery disease [ICD-11: BA80] Approved TTDDRUID D05EVI DRUGNAME U-78875 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D05EXN DRUGNAME CC-223 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D05EYG DRUGNAME L-745337 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D05FBZ DRUGNAME CPHPC INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1/2 TTDDRUID D05FCR DRUGNAME GT0918 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D05FFR DRUGNAME MGBG INDICATI Head and neck cancer [ICD-11: 2D42] Terminated TTDDRUID D05FGG DRUGNAME Azilsartan INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D05FGN DRUGNAME DFV890 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D05FGP DRUGNAME DWP-418 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05FHZ DRUGNAME MGD009 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05FIJ DRUGNAME GSK2816126 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05FKU DRUGNAME ETC-1922159 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05FOB DRUGNAME GenFusAb INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D05FOF DRUGNAME CHS-0214 INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 3 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D05FPZ DRUGNAME M7824 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D05FQD DRUGNAME Metaiodobenzylguanidine I-131 INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 2 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2 INDICATI Pheochromocytoma [ICD-11: 5A75] Application submitted TTDDRUID D05FQF DRUGNAME FLUNOPROST INDICATI Nasal congestion [ICD-11: MD11.9] Investigative TTDDRUID D05FRM DRUGNAME ApoVax104-HPV INDICATI Cervical cancer [ICD-11: 2C77.0] Investigative TTDDRUID D05FRP DRUGNAME Rindopepimut INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 3 INDICATI Brain cancer [ICD-11: 2A00] Phase 3 TTDDRUID D05FSK DRUGNAME MSL-143438 INDICATI Yersinia infection [ICD-11: 1B93] Investigative TTDDRUID D05FTJ DRUGNAME Mefenamic acid INDICATI Dysmenorrhea [ICD-11: GA34.3] Approved TTDDRUID D05FTY DRUGNAME ES-1005 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D05FUP DRUGNAME CAR-T cells targeting Mesothelin INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1/2 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1/2 TTDDRUID D05FUU DRUGNAME Pratosartan INDICATI Hypertension [ICD-11: BA00-BA04] Phase 3 TTDDRUID D05FVK DRUGNAME RPI-78M INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D05FVX DRUGNAME CDP-484 INDICATI Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 1/2 TTDDRUID D05FWF DRUGNAME Fostrap INDICATI Hypophosphatasia [ICD-11: 5C64.3] Phase 1 TTDDRUID D05FWH DRUGNAME SCH-900776 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D05FYA DRUGNAME Thioperamide INDICATI Cognitive impairment [ICD-11: 6D71] Terminated TTDDRUID D05FZM DRUGNAME CD19-UCART INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Clinical trial TTDDRUID D05GBH DRUGNAME F4co vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D05GBR DRUGNAME MVA CSP INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D05GBZ DRUGNAME ABS-205 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated TTDDRUID D05GDS DRUGNAME N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D05GEF DRUGNAME KRN-5500 INDICATI Peripheral neuropathy [ICD-11: 8C0Z] Phase 2 TTDDRUID D05GGD DRUGNAME SYNVISC-ONE INDICATI Pain [ICD-11: MG30-MG3Z] Phase 4 TTDDRUID D05GGP DRUGNAME HEGF INDICATI Diabetic foot ulcer [ICD-11: BD54] Approved TTDDRUID D05GIO DRUGNAME ICT-037 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05GJJ DRUGNAME JR-051 INDICATI Fabry disease [ICD-11: 5C56.01] Investigative TTDDRUID D05GJP DRUGNAME LBVH-0101 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3 TTDDRUID D05GJW DRUGNAME Cladribine INDICATI Hairy cell leukaemia [ICD-11: 2A82.2] Approved INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 INDICATI Relapsing-remitting multiple sclerosis [ICD-11: 8A40.0] Phase 3 TTDDRUID D05GKD DRUGNAME Tramadol INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D05GKN DRUGNAME SBC-106 INDICATI Lysosomal storage disease [ICD-11: 5C56.Z] Investigative TTDDRUID D05GKZ DRUGNAME Follistatin INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D05GLT DRUGNAME Norisoboldine INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D05GMG DRUGNAME NNI-351 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D05GMT DRUGNAME Pyridinone carboxamide derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D05GNW DRUGNAME AZD-9164 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D05GOA DRUGNAME Vivia-1615 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05GOM DRUGNAME S-20928 INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Terminated TTDDRUID D05GPB DRUGNAME Eptacog alfa INDICATI Hemophilia [ICD-11: 3B10.0] Phase 1 TTDDRUID D05GPN DRUGNAME Recombinant human CFH protein INDICATI Kidney disease [ICD-11: GC2Z] Investigative TTDDRUID D05GPO DRUGNAME Olopatadine INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Approved INDICATI Ocular allergy [ICD-11: 4A81] Phase 3 TTDDRUID D05GQD DRUGNAME CSA-13 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical TTDDRUID D05GQH DRUGNAME ADX-88178 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D05GQL DRUGNAME KNI-102 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D05GQV DRUGNAME RTA-801 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D05GRY DRUGNAME Nesiritide INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D05GSI DRUGNAME LA-480 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05GUK DRUGNAME INTOPLICINE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05GVO DRUGNAME PAT-NM-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05GVQ DRUGNAME Muromonab-cd3 INDICATI Graft-versus-host disease [ICD-11: 4B24] Approved TTDDRUID D05GVV DRUGNAME Pyrimidine derivative 5 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Patented INDICATI Fibrosis [ICD-11: GA14-GC01] Patented INDICATI Blood vessel proliferative disorder [ICD-11: BE2Z] Patented TTDDRUID D05GXC DRUGNAME Peginterferon lambda alfa-1a INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D05GYL DRUGNAME UR-63325 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D05GYU DRUGNAME EP-201 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D05GZB DRUGNAME Dupixent INDICATI Atopic dermatitis [ICD-11: EA80] Phase 3 TTDDRUID D05GZD DRUGNAME Rilapladib INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 1 TTDDRUID D05HAD DRUGNAME DP-4088 INDICATI Coagulation defect [ICD-11: 3B10.0] Phase 1 TTDDRUID D05HAJ DRUGNAME Follitropin alfa/lutropin alfa INDICATI Infertility [ICD-11: GB04] Approved TTDDRUID D05HBZ DRUGNAME E 7974 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D05HCO DRUGNAME 1954U89 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D05HDX DRUGNAME GW-501516 INDICATI Type-1 diabetes [ICD-11: 5A10] Discontinued in Phase 4 TTDDRUID D05HEJ DRUGNAME Beta 1-6 glucan-conjugated trastuzumab INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D05HFN DRUGNAME 99mTc-tetrofosmin INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D05HFU DRUGNAME TGX-6B4 INDICATI Thrombosis [ICD-11: DB61-GB90] Preclinical TTDDRUID D05HFY DRUGNAME Acenocoumarol INDICATI Thrombosis [ICD-11: DB61-GB90] Approved TTDDRUID D05HGL DRUGNAME GW-695634 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D05HHP DRUGNAME Astenose INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D05HHZ DRUGNAME NX-002 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D05HID DRUGNAME rAAV1.tMCK.human-alpha-sarcoglycan INDICATI Discovery agent [ICD-11: N.A.] Phase 1 TTDDRUID D05HIJ DRUGNAME SAR260301 INDICATI Pten-deficient tumour [ICD-11: 2C50-2F93] Discontinued in Phase 1 TTDDRUID D05HIP DRUGNAME Comvac4-HB INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D05HIX DRUGNAME MK-6406 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D05HJO DRUGNAME PD-2024 INDICATI Insulin-resistant disorder [ICD-11: 5A44] Investigative TTDDRUID D05HJR DRUGNAME Oncoprex INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05HKB DRUGNAME RS 86 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D05HKC DRUGNAME PMID26651364-Compound-123 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D05HKG DRUGNAME Pegylated interferon lambda INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D05HLC DRUGNAME NVC-727 INDICATI Conjunctivitis [ICD-11: 9A60] Investigative TTDDRUID D05HPI DRUGNAME Daptomycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D05HRW DRUGNAME SKL-NP2 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D05HSC DRUGNAME Tubocurarine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved INDICATI Smoking dependence [ICD-11: 6C4A.2] Approved TTDDRUID D05HSI DRUGNAME T-0632 INDICATI Pancreatic malfunction [ICD-11: DC30-DC3Z] Discontinued in Phase 1 TTDDRUID D05HTS DRUGNAME PLX8394 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 TTDDRUID D05HUG DRUGNAME OMS-403 INDICATI Opioid dependence [ICD-11: 6C43.2Z] Phase 2 INDICATI Nicotine dependence [ICD-11: 6C4A.2] Phase 2 TTDDRUID D05HUQ DRUGNAME BIOVANCE INDICATI Wound healing [ICD-11: EL8Y] Phase 4 TTDDRUID D05HUZ DRUGNAME TTI-314 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D05HVY DRUGNAME GSK-644784 INDICATI Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 2 TTDDRUID D05HWN DRUGNAME BIIB-021 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D05HWX DRUGNAME 99mTc-depreotide INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D05HXX DRUGNAME Tranexamic Acid INDICATI Excessive bleeding [ICD-11: GA30.02] Approved TTDDRUID D05HYC DRUGNAME F-50077 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Discontinued in Phase 2 TTDDRUID D05HYL DRUGNAME YM-022 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Terminated TTDDRUID D05HYT DRUGNAME IPAZILIDE FUMARATE INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Phase 2 TTDDRUID D05HZI DRUGNAME MDL 101,731 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Discontinued in Phase 2 TTDDRUID D05HZJ DRUGNAME GPC-3298306 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 TTDDRUID D05IAN DRUGNAME G3139 + Irinotecan INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Investigative TTDDRUID D05IBA DRUGNAME Shanvac-B INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D05IBP DRUGNAME DFD-09 INDICATI Rosacea [ICD-11: ED90.0] Application submitted TTDDRUID D05IBV DRUGNAME AR-12432 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D05ICS DRUGNAME ProSavin INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1/2 TTDDRUID D05ICT DRUGNAME ABBV-744 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D05IEN DRUGNAME Epstein Barr-based gene therapy INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05IHU DRUGNAME Tetrahydrozoline INDICATI Ocular disease [ICD-11: 1F00.1Z] Approved TTDDRUID D05IHZ DRUGNAME VP-20621 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D05IIB DRUGNAME NoroVAXX INDICATI Norovirus infection [ICD-11: 1A23] Investigative TTDDRUID D05IIN DRUGNAME SSR125543 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 INDICATI Congenital adrenal hyperplasia [ICD-11: 5A71.01] Phase 2 TTDDRUID D05IIP DRUGNAME L-651582 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D05IJM DRUGNAME Recruitin INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D05ILN DRUGNAME Agalsidase alfa INDICATI Fabry disease [ICD-11: 5C56.01] Approved TTDDRUID D05ILZ DRUGNAME NN8209 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D05INV DRUGNAME PEGPH20 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Gallbladder disease [ICD-11: DC11.3] Phase 1 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 TTDDRUID D05IPF DRUGNAME Kombiglyze XR/Komboglyze FDC INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D05IPO DRUGNAME BTS-79018 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D05IQI DRUGNAME LX9211 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D05IQX DRUGNAME Belimumab INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Approved TTDDRUID D05IRT DRUGNAME P276-00 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2 TTDDRUID D05IRV DRUGNAME Elesclomol INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 TTDDRUID D05ISO DRUGNAME Bemarituzumab INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2 TTDDRUID D05ISV DRUGNAME Live attenuated human parainfluenza virus type 2 vaccine INDICATI Parainfluenza virus infection [ICD-11: 1D9Y] Phase 1 TTDDRUID D05ITS DRUGNAME ALN-VEG01 INDICATI Macular degeneration [ICD-11: 9B78.3] Terminated TTDDRUID D05IUQ DRUGNAME Anti-PECAM-1 mab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05IVZ DRUGNAME RU-33965 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D05IWE DRUGNAME Alloferon INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D05IYA DRUGNAME MEDI3902 INDICATI Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 2 INDICATI Pseudomonas infection [ICD-11: 1B92] Phase 1 TTDDRUID D05IZC DRUGNAME RGI-1001 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D05IZG DRUGNAME BAY-Z-4305 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated TTDDRUID D05JAA DRUGNAME ARRY-382 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D05JAC DRUGNAME Linagliptin INDICATI Type 2 diabetes [ICD-11: 5A11] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D05JAS DRUGNAME Biphenyl mannoside derivative 5 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D05JBC DRUGNAME N-(2-aminoethyl)-1-aziridine-ethanamine INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative TTDDRUID D05JBP DRUGNAME IPI-194 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05JCG DRUGNAME CBF-BS2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D05JDR DRUGNAME Ceftibuten INDICATI Chronic bronchitis [ICD-11: CA20.1] Approved TTDDRUID D05JEG DRUGNAME BMN-701 INDICATI Pompe disease [ICD-11: 5C51.3] Phase 3 INDICATI Type 2 glycogen storage disease [ICD-11: 5C51.3] Phase 3 TTDDRUID D05JEL DRUGNAME Onzeald INDICATI Brain metastases [ICD-11: 2D50] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D05JET DRUGNAME Remacemide INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D05JFA DRUGNAME INTERCEPT INDICATI Blood transfusion [ICD-11: QB98] Phase 3 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 2 TTDDRUID D05JFY DRUGNAME Hydralazine hydrochloride/ isosorbide dinitrate INDICATI Heart failure [ICD-11: BD10-BD13] Approved TTDDRUID D05JGR DRUGNAME TBDT INDICATI Overactive bladder [ICD-11: GC50.0] Investigative TTDDRUID D05JHB DRUGNAME ArtemiC INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D05JHJ DRUGNAME LB-10522 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D05JLG DRUGNAME ACS-6 INDICATI Respiratory distress syndrome [ICD-11: CB00] Investigative TTDDRUID D05JMP DRUGNAME IDR-803 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05JMW DRUGNAME RGA-1512 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D05JNI DRUGNAME Framycetin INDICATI Alcoholic cirrhosis of liver [ICD-11: DB94] Approved INDICATI Acute liver failure [ICD-11: DB91] Approved INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D05JPJ DRUGNAME ELND-004 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D05JQD DRUGNAME M-6040 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D05JQF DRUGNAME Tipredane INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D05JRG DRUGNAME Antithrombin alfa INDICATI Thrombin deficiency [ICD-11: 3B14.Z] Approved TTDDRUID D05JSU DRUGNAME Edivoxetine INDICATI Pediatric attention deficit hyperactivity disorder [ICD-11: 6A05] Phase 3 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 3 TTDDRUID D05JTJ DRUGNAME IC-50 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D05JXF DRUGNAME YD-501 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D05JXM DRUGNAME PF-3932295 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1 TTDDRUID D05JXR DRUGNAME SC-52012 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D05KAC DRUGNAME PG-102 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D05KBP DRUGNAME INO-8875 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1/2 TTDDRUID D05KBU DRUGNAME Gabapentin enacarbil INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 TTDDRUID D05KCJ DRUGNAME ANZ-521 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2 TTDDRUID D05KED DRUGNAME Rocilinostat INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1/2 TTDDRUID D05KEZ DRUGNAME Ethyl chloride INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D05KFA DRUGNAME BL-1832 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 3 TTDDRUID D05KFH DRUGNAME CD171 specific CAR T cells expressing EGFRt INDICATI Ganglioneuroblastoma [ICD-11: 2A00.11] Phase 1 INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 1 TTDDRUID D05KGG DRUGNAME IMA101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05KHN DRUGNAME ICI-169369 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D05KHP DRUGNAME ABC-3 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D05KIV DRUGNAME Ecopipam hydrochloride INDICATI Tourette syndrome [ICD-11: 8A05.00] Phase 2 TTDDRUID D05KKC DRUGNAME CHML INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D05KKF DRUGNAME NC-2500 INDICATI Hyperuricaemia [ICD-11: 5C55.Y] Investigative TTDDRUID D05KKP DRUGNAME PF-06252616 INDICATI Muscular dystrophy [ICD-11: 8C70] Phase 2 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D05KKV DRUGNAME Dicaffeoylquinic acids INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D05KLQ DRUGNAME HIV vaccines INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D05KME DRUGNAME ORADUR-ADHD INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1 TTDDRUID D05KNG DRUGNAME ALB-109564(a) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05KOA DRUGNAME Prophylactic DNA vaccine INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Terminated TTDDRUID D05KON DRUGNAME Felbamate INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D05KOP DRUGNAME Ii-Key hybrid peptide vaccine INDICATI Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 1 TTDDRUID D05KOY DRUGNAME Stem cell therapy, spinal cord injury INDICATI Spinal cord injury [ICD-11: ND51.2] Investigative TTDDRUID D05KQE DRUGNAME MK-287 INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2 TTDDRUID D05KRC DRUGNAME Emopamil INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D05KRH DRUGNAME CNDO-113 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05KRS DRUGNAME CT-340 INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D05KSY DRUGNAME LIM-0746 INDICATI Cholesterol metabolism disorder [ICD-11: 5C8Z] Investigative TTDDRUID D05KTK DRUGNAME CJC-1004 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D05KTV DRUGNAME NGD-93-1 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Terminated TTDDRUID D05KUP DRUGNAME ERB-257 INDICATI Sepsis [ICD-11: 1G40-1G41] Phase 1 TTDDRUID D05KVC DRUGNAME Paliroden INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D05KWY DRUGNAME ZD-9063P INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D05KXJ DRUGNAME GSK233705 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D05KZK DRUGNAME SMT-D002 INDICATI Seborrhea [ICD-11: ED91.2] Approved TTDDRUID D05KZM DRUGNAME Dimesna INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 3 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 3 TTDDRUID D05KZV DRUGNAME VR-461 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D05LBH DRUGNAME PMID28621580-Compound-WO2013112959C68 INDICATI Fibrosis [ICD-11: GA14-GC01] Patented TTDDRUID D05LBN DRUGNAME TAK-981 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D05LBU DRUGNAME Ticlopidine INDICATI Stroke [ICD-11: 8B20] Approved TTDDRUID D05LCN DRUGNAME BMP-7 bone morphogenetic protein INDICATI Kidney disease [ICD-11: GC2Z] Phase 4 TTDDRUID D05LCX DRUGNAME A-70276 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Terminated TTDDRUID D05LDK DRUGNAME IPX203 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D05LDQ DRUGNAME BAY 94-9027 INDICATI Stroke [ICD-11: 8B20] Phase 3 INDICATI Hemophilia [ICD-11: 3B10.0] Phase 3 TTDDRUID D05LEO DRUGNAME Fluorouracil INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved INDICATI Tumour [ICD-11: 2A00-2F9Z] Investigative INDICATI Colorectal cancer [ICD-11: 2B91.Z] Investigative TTDDRUID D05LGX DRUGNAME Fipamezole INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D05LIH DRUGNAME Anti-CD19 CAR-T cells INDICATI Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1/2 INDICATI B-cell prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1/2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1/2 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2 TTDDRUID D05LKP DRUGNAME Sulfadiazine INDICATI Rheumatic fever [ICD-11: 1B40-1B42] Approved TTDDRUID D05LKZ DRUGNAME HPP-607 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05LLH DRUGNAME Penciclovir INDICATI Recurrent herpes labialis [ICD-11: 1F00.01] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D05LLJ DRUGNAME MK-4815 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D05LMC DRUGNAME AMG 595 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D05LOB DRUGNAME FP-1201 INDICATI Acute lung injury [ICD-11: NB32.3] Phase 3 TTDDRUID D05LOV DRUGNAME ADV-1002401 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D05LOY DRUGNAME ACH-702 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D05LPP DRUGNAME ABH001 INDICATI Liver cancer [ICD-11: 2C12] Phase 3 TTDDRUID D05LPW DRUGNAME DA-1229 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D05LQX DRUGNAME BOL-303259-X INDICATI Open-angle glaucoma [ICD-11: 9C61] Approved INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 3 TTDDRUID D05LRD DRUGNAME BMS-933043 INDICATI Psychiatric disorder [ICD-11: 6E8Z] Phase 1 TTDDRUID D05LST DRUGNAME Myrcludex B INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D05LSY DRUGNAME AKP-020 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D05LTJ DRUGNAME ISIS 325568 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D05LTY DRUGNAME Enbrel INDICATI Arthritis [ICD-11: FA20] Approved TTDDRUID D05LUT DRUGNAME Molecule 23 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D05LVL DRUGNAME AVR-147 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D05LXC DRUGNAME QA-241 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D05LXH DRUGNAME Beta-interferon INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D05LYC DRUGNAME KR-62436 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D05LYX DRUGNAME Glibenclamide INDICATI Diabetic complication [ICD-11: 5A2Y] Approved INDICATI Stroke [ICD-11: 8B20] Phase 3 TTDDRUID D05LZG DRUGNAME R-type pyocins INDICATI Pseudomonas infection [ICD-11: 1B92] Investigative TTDDRUID D05MBE DRUGNAME NK-102 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D05MBZ DRUGNAME Tamsulosin INDICATI Benign prostatic hyperplasia [ICD-11: GA90] Approved TTDDRUID D05MCS DRUGNAME GSK2190915 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D05MDJ DRUGNAME ORG-34517 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 2 TTDDRUID D05MDQ DRUGNAME CG-701338 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05MEL DRUGNAME PV-705 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Discontinued in Phase 2 TTDDRUID D05MEP DRUGNAME AE-O INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D05MEY DRUGNAME Epitinib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05MFA DRUGNAME Valacyclovir Hydrochloride INDICATI Herpes simplex virus infection [ICD-11: 1F00] Approved TTDDRUID D05MFG DRUGNAME Spirapril INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D05MFO DRUGNAME MDL-11939 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3 TTDDRUID D05MGQ DRUGNAME MDX-1342 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2 TTDDRUID D05MHI DRUGNAME AC-607 INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 2 TTDDRUID D05MIL DRUGNAME Iopentol INDICATI Urinary tract disease [ICD-11: GC2Z] Approved TTDDRUID D05MIQ DRUGNAME O-SPC/rBRU vaccine INDICATI Shigella infection [ICD-11: 1A02] Phase 1 TTDDRUID D05MJS DRUGNAME PRO22 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D05MKA DRUGNAME Lixisenatide INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D05MKG DRUGNAME Nalmefene prodrug INDICATI Alcohol dependence [ICD-11: 6C40.2] Investigative TTDDRUID D05MLX DRUGNAME ONYX-411 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D05MNV DRUGNAME Fosclin INDICATI Malaria [ICD-11: 1F40-1F45] Phase 3 TTDDRUID D05MNW DRUGNAME Virginiamycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D05MOZ DRUGNAME G-202 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Adenocarcinoma [ICD-11: 2D40] Phase 2 TTDDRUID D05MPX DRUGNAME Bornaprine INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D05MQK DRUGNAME Tadalafil INDICATI Erectile dysfunction [ICD-11: HA01.1] Approved TTDDRUID D05MQO DRUGNAME BEA-005 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Terminated TTDDRUID D05MRY DRUGNAME Six-membered heterocyclic benzamide derivative 7 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D05MSG DRUGNAME BMS-694153 INDICATI Migraine [ICD-11: 8A80] Investigative TTDDRUID D05MSL DRUGNAME DC-756 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D05MSM DRUGNAME CK-37 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05MUA DRUGNAME NOX 2149 INDICATI Stress [ICD-11: 6B40-6B45] Investigative INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D05MVA DRUGNAME RGD-891 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 2 TTDDRUID D05MVX DRUGNAME ATA520 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D05MWY DRUGNAME RF-1051 INDICATI Genetic disease [ICD-11: 8E02] Discontinued in Phase 2 TTDDRUID D05MXK DRUGNAME GW-473178 INDICATI Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 1 TTDDRUID D05MXL DRUGNAME CHDI-003940246 INDICATI Huntington disease [ICD-11: 8A01.10] Investigative TTDDRUID D05MZI DRUGNAME nusinersen INDICATI Spinal muscular atrophy [ICD-11: 8B61] Approved TTDDRUID D05NBD DRUGNAME MONTIRELIN TETRAHYDRATE INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Preregistration TTDDRUID D05NCT DRUGNAME DPC-1528 INDICATI Acne vulgaris [ICD-11: ED80] Investigative TTDDRUID D05NDN DRUGNAME Alovudine INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D05NDR DRUGNAME Sifalimumab INDICATI Renal cell carcinoma [ICD-11: 2C90] Approved INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 TTDDRUID D05NDY DRUGNAME OAP-189 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D05NEK DRUGNAME N-acetylcysteine INDICATI Cystic fibrosis [ICD-11: CA25] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D05NFR DRUGNAME TPX-0005 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D05NHA DRUGNAME Resorcinol compound 20 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D05NHT DRUGNAME BP-C1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D05NIO DRUGNAME NP-17 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D05NIR DRUGNAME ALX-0061 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 TTDDRUID D05NJG DRUGNAME PH sensitive micelles INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05NJI DRUGNAME STX 64 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D05NJL DRUGNAME ALSE-100 INDICATI Bone disease [ICD-11: FC0Z] Investigative TTDDRUID D05NLD DRUGNAME ARRY-300 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05NLR DRUGNAME Adva-33c INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05NMJ DRUGNAME Biphasic porcine insulin INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D05NMU DRUGNAME DasKloster 0274-01 INDICATI Pseudomonas infection [ICD-11: 1B92] Investigative TTDDRUID D05NOS DRUGNAME Triflupromazine INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Approved TTDDRUID D05NQR DRUGNAME LyphoDerm INDICATI Wound healing [ICD-11: EL8Y] Terminated TTDDRUID D05NRI DRUGNAME Ceronapril INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D05NRX DRUGNAME VG-102 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05NSF DRUGNAME 4SC-207 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05NTQ DRUGNAME PRO-015 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Investigative TTDDRUID D05NTY DRUGNAME NPC-18166 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Terminated TTDDRUID D05NUH DRUGNAME Hm61713 INDICATI Lung cancer [ICD-11: 2C25.0] Approved TTDDRUID D05NUN DRUGNAME Pyrazole derivative 36 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D05NUP DRUGNAME SBS-1000 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D05NUT DRUGNAME ALS-00T2-0501 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 1 TTDDRUID D05NWJ DRUGNAME SLV-337 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D05NWM DRUGNAME Pyraclostrobin INDICATI Plant grey mould disease [ICD-11: N.A.] Investigative TTDDRUID D05NYF DRUGNAME HuMax-TF INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D05NYK DRUGNAME BEL-0222 INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 1/2 TTDDRUID D05NYO DRUGNAME Imab-027 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D05NZV DRUGNAME BRL 35135 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D05OAI DRUGNAME CART-19/22 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID D05OAJ DRUGNAME AW-814141 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D05OBK DRUGNAME DwLIP-GCGRrx INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D05ODE DRUGNAME CC-90001 INDICATI Fibrosis [ICD-11: GA14-GC01] Phase 1 INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 1 TTDDRUID D05ODU DRUGNAME Belerofon INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D05OEG DRUGNAME E-2001 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1 TTDDRUID D05OEU DRUGNAME Technetium Tc-99m Succimer Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D05OFO DRUGNAME TC-2696 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D05OFX DRUGNAME Lacosamide INDICATI Convulsion [ICD-11: 8A68.Z] Approved INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 3 TTDDRUID D05OHY DRUGNAME CAR-T cells targeting EphA2 INDICATI Malignant glioma [ICD-11: 2A00.0] Phase 1/2 TTDDRUID D05OIS DRUGNAME Benzyl alcohol INDICATI Head and body lice [ICD-11: 1G00.0] Approved TTDDRUID D05OIU DRUGNAME PMID27998201-Compound-5 INDICATI Cirrhosis [ICD-11: DB93] Patented INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Patented INDICATI Psoriasis vulgaris [ICD-11: EA90] Patented INDICATI Multiple sclerosis [ICD-11: 8A40] Patented INDICATI Gastrointestinal disease [ICD-11: DE2Z] Patented TTDDRUID D05OMO DRUGNAME PMID26651364-Compound-11b INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D05OMT DRUGNAME MK-8033 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05ONA DRUGNAME Cyt-1010 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D05OQJ DRUGNAME Methyprylon INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D05OQX DRUGNAME NCX-4016 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 2 INDICATI Claudication [ICD-11: FA11] Discontinued in Phase 2 INDICATI Nephropathy [ICD-11: GC2Z] Discontinued in Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D05ORA DRUGNAME MOR-103 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1/2 TTDDRUID D05ORI DRUGNAME AGI-350 INDICATI Pulmonary disease [ICD-11: 1B10-1F85] Investigative TTDDRUID D05ORO DRUGNAME Anti-N3pG-Abeta antibody INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D05OSR DRUGNAME Human immune globulin INDICATI Immunodeficiency [ICD-11: 4A00-4A85] Approved TTDDRUID D05OTD DRUGNAME Heterocyclic derivative 4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D05OTL DRUGNAME NW-3509 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D05OTZ DRUGNAME SMP-986 INDICATI Overactive bladder [ICD-11: GC50.0] Phase 2 TTDDRUID D05OVC DRUGNAME Atipamezole INDICATI Male sexual disorder [ICD-11: HA02.0] Discontinued in Phase 2 TTDDRUID D05OVR DRUGNAME ALP-242 INDICATI Cystic fibrosis [ICD-11: CA25] Terminated TTDDRUID D05OWB DRUGNAME mab-216 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D05OXZ DRUGNAME BIWA 4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05OZG DRUGNAME BTSCAN INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D05OZQ DRUGNAME Efpeglenatide INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D05PCM DRUGNAME PF-04965842 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 3 INDICATI Lupus [ICD-11: 4A40] Phase 2 TTDDRUID D05PDJ DRUGNAME SAGE-217b INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D05PFE DRUGNAME HC-15 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05PFS DRUGNAME LTI-291 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D05PGG DRUGNAME Prostvac INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D05PGM DRUGNAME AdV-tK INDICATI Ankylosing spondylitis [ICD-11: FA92.0] Phase 2 TTDDRUID D05PGU DRUGNAME Clostridium difficile toxoid vaccine INDICATI Clostridium infection [ICD-11: 1A04] Phase 3 TTDDRUID D05PHH DRUGNAME Gabexate INDICATI Pancreatitis [ICD-11: DC31-DC34] Approved TTDDRUID D05PIX DRUGNAME CG-400549 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D05PIZ DRUGNAME Levomethadyl Acetate INDICATI Opioid dependence [ICD-11: 6C43.2Z] Approved TTDDRUID D05PJJ DRUGNAME NOX 2137a/b INDICATI Stress [ICD-11: 6B40-6B45] Investigative INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D05PKF DRUGNAME SOM-0720 INDICATI Coagulation defect [ICD-11: 3B10.0] Investigative TTDDRUID D05PLH DRUGNAME Carisoprodol INDICATI Musculoskeletal disorder [ICD-11: FA00-FC0Z] Approved TTDDRUID D05PMU DRUGNAME Dicaffeoyltartaric acids INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D05PQF DRUGNAME ONO-4127 INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 1 TTDDRUID D05PQW DRUGNAME AZD-5180 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D05PRV DRUGNAME PerCvax INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2 TTDDRUID D05PTG DRUGNAME EPD-clofarabine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D05PTH DRUGNAME MK-8175A INDICATI Contraception [ICD-11: QA21] Phase 2 TTDDRUID D05PTL DRUGNAME NMB-T-BMX-OS01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05PTT DRUGNAME ROSMARINIC ACID INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D05PUD DRUGNAME Aldesleukin INDICATI Renal cell carcinoma [ICD-11: 2C90] Approved INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D05PVW DRUGNAME CX-2007 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Investigative TTDDRUID D05PWA DRUGNAME PNT-600 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05PWU DRUGNAME PRo antigen cancer vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D05PWX DRUGNAME Sulfatinib INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05PWZ DRUGNAME Ecromeximab INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 2 TTDDRUID D05PXA DRUGNAME BTX1503 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D05PXL DRUGNAME PL-3394 INDICATI Congestive heart failure [ICD-11: BD10] Phase 2 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D05PYB DRUGNAME Elstree-BN INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1/2 TTDDRUID D05PZB DRUGNAME AT9283 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D05PZI DRUGNAME MB-CART20.1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D05PZN DRUGNAME TRO-19622 INDICATI Peripheral neuropathy [ICD-11: 8C0Z] Phase 2 TTDDRUID D05PZZ DRUGNAME DDP-200 INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2 TTDDRUID D05QAA DRUGNAME PNU-248686A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05QBF DRUGNAME Devazepide INDICATI Gastrointestinal disease [ICD-11: DE2Z] Investigative TTDDRUID D05QBH DRUGNAME LAS-41003 INDICATI Eczema [ICD-11: EA80-EA89] Phase 2 TTDDRUID D05QCE DRUGNAME KM-01221 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D05QDC DRUGNAME Acitretin INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved TTDDRUID D05QFA DRUGNAME R-71762 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated TTDDRUID D05QFO DRUGNAME RLY-106 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D05QGH DRUGNAME DXL-625 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Investigative TTDDRUID D05QHL DRUGNAME Sivelestat sodium hydrate INDICATI Acute lung injury [ICD-11: NB32.3] Phase 4 INDICATI Community-acquired pneumonia [ICD-11: CA40.Z] Phase 2 TTDDRUID D05QHO DRUGNAME ACE-527 INDICATI Escherichia coli infection [ICD-11: 1A03] Phase 2 TTDDRUID D05QHU DRUGNAME CRS-3123 INDICATI Clostridium infection [ICD-11: 1A04] Phase 1 TTDDRUID D05QIK DRUGNAME CM4620 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D05QIM DRUGNAME TA-NIC INDICATI Nicotine dependence [ICD-11: 6C4A.2] Approved TTDDRUID D05QIS DRUGNAME VX-944 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D05QIU DRUGNAME Embeconazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 1 TTDDRUID D05QIZ DRUGNAME GTx-822 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D05QJT DRUGNAME GW274150 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D05QKI DRUGNAME LixiLan INDICATI Type-2 diabetes [ICD-11: 5A11] Application submitted TTDDRUID D05QKO DRUGNAME NBI-5788 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D05QKZ DRUGNAME Adipose-derived regenerative cell therapy INDICATI Chronic myocardial ischemia [ICD-11: BA6Z] Phase 3 TTDDRUID D05QLQ DRUGNAME HIV vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D05QMG DRUGNAME FR167653 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D05QMJ DRUGNAME RWJ-56423 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D05QML DRUGNAME PQ-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05QMQ DRUGNAME MLN-0905 INDICATI Lymphoma [ICD-11: 2A80-2A86] Investigative TTDDRUID D05QNO DRUGNAME Decamethonium INDICATI Muscle spasm [ICD-11: MB47.3] Approved TTDDRUID D05QOL DRUGNAME Polatuzumab vedotin INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Approved INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 2 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 2 TTDDRUID D05QPC DRUGNAME [L/D]-aminopterin INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D05QPW DRUGNAME Choline salicylate INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D05QTO DRUGNAME LF-801 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D05QUL DRUGNAME T89 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 3 INDICATI Angina pectoris [ICD-11: BA40] Phase 3 TTDDRUID D05QXT DRUGNAME BAY-38-1315 INDICATI Arteriosclerosis [ICD-11: BD40] Preclinical TTDDRUID D05QXW DRUGNAME TZ-111 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D05RBF DRUGNAME PMID25666693-Compound-99 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D05RBH DRUGNAME N9-GP INDICATI Factor IX deficiency [ICD-11: 3B11] Phase 1 TTDDRUID D05RBL DRUGNAME CL-184005 INDICATI Sepsis [ICD-11: 1G40-1G41] Terminated TTDDRUID D05RBO DRUGNAME OPM-3023 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 2 TTDDRUID D05RCZ DRUGNAME HSV2 DNA vaccine INDICATI Genital herpes [ICD-11: 1A94] Phase 1 TTDDRUID D05RDE DRUGNAME TJN-505 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D05REB DRUGNAME ZT-1 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D05REH DRUGNAME Flosulide INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D05REL DRUGNAME GR-82334 INDICATI Vomiting [ICD-11: MD90] Terminated TTDDRUID D05RFC DRUGNAME Tumor vascular thrombogen INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05RFI DRUGNAME QBI-206 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05RFO DRUGNAME A-928605 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05RGV DRUGNAME MK-1496 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05RHI DRUGNAME Trifluridine INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D05RIM DRUGNAME SPN-808 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1 TTDDRUID D05RIY DRUGNAME Perflubutane lipid microsphere-encapsulated INDICATI Heart disease [ICD-11: BA41-BA42] Approved TTDDRUID D05RJG DRUGNAME Schiff base compound 1 INDICATI Alzheimer disease [ICD-11: 8A20] Patented TTDDRUID D05RJP DRUGNAME Oblimersen INDICATI Multiple myeloma [ICD-11: 2A83] Phase 3 INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D05RKV DRUGNAME Sch-036 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D05RLR DRUGNAME 1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole INDICATI Conjunctival fibrosis [ICD-11: 9A61.3] Investigative TTDDRUID D05RMW DRUGNAME ZD-3638 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D05ROI DRUGNAME Dabrafenib INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D05RPN DRUGNAME BMS-488516 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D05RPT DRUGNAME MER-2101 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D05RQW DRUGNAME Guglipid INDICATI Lipoprotein disorder [ICD-11: 5C80-5C8Z] Approved TTDDRUID D05RQX DRUGNAME Cefaclidine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Preregistration TTDDRUID D05RQY DRUGNAME MM-093 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D05RRA DRUGNAME HQK-1004 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D05RRU DRUGNAME IL-2/CD40L-expressing leukemia vaccine INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 TTDDRUID D05RSC DRUGNAME Sofinicline INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2 TTDDRUID D05RSS DRUGNAME PF-03772304 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05RTB DRUGNAME Anti-Staphylococcus enterotoxin B hyperimmune globulin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D05RTF DRUGNAME AME-527 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1/2 TTDDRUID D05RTV DRUGNAME Superoxide dismutase INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 TTDDRUID D05RTX DRUGNAME RO-1752 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D05RUH DRUGNAME FMX101 INDICATI Acne vulgaris [ICD-11: ED80] Phase 3 TTDDRUID D05RUJ DRUGNAME G-1128 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Discontinued in Phase 2 TTDDRUID D05RUM DRUGNAME Melperone INDICATI Alcohol dependence [ICD-11: 6C40.2] Withdrawn from market TTDDRUID D05RVA DRUGNAME CFG920 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D05RWL DRUGNAME NSD-788 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1 TTDDRUID D05RWN DRUGNAME Lanthanum polystyrene sulfonate INDICATI Hypophosphatasia [ICD-11: 5C64.3] Investigative TTDDRUID D05RXI DRUGNAME Hydrocortamate INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D05RXW DRUGNAME LAS-41002 INDICATI Eczema [ICD-11: EA80-EA89] Phase 2 TTDDRUID D05RZE DRUGNAME LY-2623091 INDICATI Chronic kidney disease [ICD-11: GB61] Phase 2 TTDDRUID D05RZI DRUGNAME AA-193 INDICATI Hyperuricaemia [ICD-11: 5C55.Y] Discontinued in Phase 2 TTDDRUID D05RZJ DRUGNAME Recombinant human CC10 INDICATI Endometriosis [ICD-11: GA10] Investigative TTDDRUID D05RZW DRUGNAME YM-934 INDICATI Angina pectoris [ICD-11: BA40] Phase 2 TTDDRUID D05SBI DRUGNAME TBC-395 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D05SBO DRUGNAME LY2835219 INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D05SBR DRUGNAME Piclidenoson INDICATI Keratoconjunctivitis sicca [ICD-11: 9A79] Phase 3 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D05SCQ DRUGNAME TDI-0079 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D05SEW DRUGNAME OB-24 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05SFD DRUGNAME DMP-961 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D05SGI DRUGNAME BGB-3113 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID D05SHK DRUGNAME Nadolol INDICATI High blood pressure [ICD-11: BA00] Approved TTDDRUID D05SHQ DRUGNAME ASP-2002 INDICATI Ulcerative colitis [ICD-11: DD71] Investigative TTDDRUID D05SJD DRUGNAME DasKloster 0501-01 INDICATI Scleroderma [ICD-11: 4A42] Investigative TTDDRUID D05SJK DRUGNAME Bone marrow stem cell therapy INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 1 TTDDRUID D05SJW DRUGNAME Gallamine Triethiodide INDICATI Stabilize muscle contraction [ICD-11: FB3Z] Approved TTDDRUID D05SJY DRUGNAME WS-CoQ10 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D05SLM DRUGNAME LY-2590443 INDICATI Migraine [ICD-11: 8A80] Phase 2 TTDDRUID D05SMP DRUGNAME PMID25666693-Compound-116 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D05SMV DRUGNAME P2B-002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05SNX DRUGNAME APT070 INDICATI Reperfusion injury [ICD-11: ND56.Z] Phase 3 TTDDRUID D05SOF DRUGNAME SPM-3672 INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D05SOH DRUGNAME CTAP-201 INDICATI Hyperparathyroidism [ICD-11: 5A51] Phase 1 TTDDRUID D05SOW DRUGNAME SX-MTR1 INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D05SPL DRUGNAME Monofer INDICATI Iron-deficiency anemia [ICD-11: 3A00] Approved TTDDRUID D05SQU DRUGNAME BIM-64152 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D05SSC DRUGNAME Dalcetrapib INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 3 INDICATI Acute coronary syndrome [ICD-11: BA41] Phase 3 TTDDRUID D05SSJ DRUGNAME Dotarizine INDICATI Migraine [ICD-11: 8A80] Terminated TTDDRUID D05STL DRUGNAME ARRY-502 INDICATI Allergic asthma [ICD-11: CA23.0] Phase 2 TTDDRUID D05STQ DRUGNAME Pazufloxacin INDICATI Conjunctivitis [ICD-11: 9A60] Phase 3 TTDDRUID D05SUA DRUGNAME A-798 INDICATI Obesity [ICD-11: 5B81] Terminated TTDDRUID D05SVN DRUGNAME PdB-W433F INDICATI Streptococcus infection [ICD-11: 1B53] Investigative TTDDRUID D05SVQ DRUGNAME C-AFG INDICATI Virus infection [ICD-11: 1A24-1D9Z] Terminated TTDDRUID D05SWL DRUGNAME PMID25666693-Compound-28 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D05SXB DRUGNAME SMT-D004 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Investigative TTDDRUID D05SXC DRUGNAME SCR-44001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D05SXL DRUGNAME PLR-8 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D05SXT DRUGNAME INP-03 INDICATI Poison intoxication [ICD-11: NE6Z] Investigative TTDDRUID D05SYO DRUGNAME KR-33889 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Investigative TTDDRUID D05TBI DRUGNAME DG-770 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D05TBQ DRUGNAME SAR408701 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D05TCC DRUGNAME TMX-202 INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D05TDJ DRUGNAME TS01 INDICATI Stroke [ICD-11: 8B20] Phase 1 TTDDRUID D05TDS DRUGNAME Nu-2 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D05TFW DRUGNAME H1N1 HA flu vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D05TGV DRUGNAME PEG-Infergen INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 2 TTDDRUID D05TIB DRUGNAME Trospium INDICATI Spasm [ICD-11: MB47.3] Approved INDICATI Overactive bladder [ICD-11: GC50.0] Approved TTDDRUID D05TJR DRUGNAME Fluvirin INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D05TKB DRUGNAME GS-9256 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D05TKO DRUGNAME Retagliptin INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D05TKW DRUGNAME alpha-ketothiazole analogue 36 INDICATI Alzheimer disease [ICD-11: 8A20] Clinical trial TTDDRUID D05TLM DRUGNAME E-5065 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D05TLP DRUGNAME Carabersat INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Phase 2 TTDDRUID D05TLQ DRUGNAME ETR-001 INDICATI Kidney disease [ICD-11: GC2Z] Investigative TTDDRUID D05TLR DRUGNAME Tetramune INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Withdrawn from market TTDDRUID D05TMA DRUGNAME MAGE-A4 TCR INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05TMQ DRUGNAME Aprobarbital INDICATI Anaesthesia [ICD-11: 9A78.6] Approved INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D05TMW DRUGNAME Methotrexate INDICATI Choriocarcinoma [ICD-11: 2C75.0] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D05TNY DRUGNAME Generalized glucocorticoid INDICATI Adrenal adenoma [ICD-11: 2F37.Y] Investigative TTDDRUID D05TOJ DRUGNAME Peretinoin INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 TTDDRUID D05TPA DRUGNAME SP-1062C-O INDICATI Colorectal cancer [ICD-11: 2B91.Z] Investigative TTDDRUID D05TPI DRUGNAME EPICATECHIN INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1/2 INDICATI Friedreich's ataxia [ICD-11: 8A03.10] Phase 1/2 TTDDRUID D05TQG DRUGNAME Pyrazole derivative 30 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D05TRI DRUGNAME GeNOsyl INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 TTDDRUID D05TRJ DRUGNAME SB-728-HSPC INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D05TSG DRUGNAME ANB-020 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D05TSJ DRUGNAME LY2784544 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Myeloproliferative neoplasm [ICD-11: 2A20] Phase 2 TTDDRUID D05TUL DRUGNAME MB-11316 INDICATI Injury [ICD-11: NA00-ND5Z] Phase 2 TTDDRUID D05TUQ DRUGNAME MAT-302 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D05TUZ DRUGNAME Tasonermin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D05TVI DRUGNAME TD-9594 INDICATI Overactive bladder [ICD-11: GC50.0] Investigative TTDDRUID D05TVW DRUGNAME DCVax-Head/Neck INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1/2 TTDDRUID D05TWD DRUGNAME Autologous VEGF-and angiopoietin-1-expressing endothelial and smooth muscle cell therapy INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1/2 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 1/2 TTDDRUID D05TXS DRUGNAME BMN-168 INDICATI Phenylketonuria [ICD-11: 5C50.0] Investigative TTDDRUID D05TZJ DRUGNAME Ankinara INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D05UAA DRUGNAME SX-HIV1 INDICATI Retrovirus infection [ICD-11: 1D9Y] Investigative TTDDRUID D05UAO DRUGNAME J591-Ac-225 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D05UAV DRUGNAME Bis(olanzapine) pamoate monohydrate INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 3 TTDDRUID D05UBX DRUGNAME Cefmetazole INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D05UCM DRUGNAME Sulfonatoporphyrin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D05UCW DRUGNAME MEDI-2338 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1 TTDDRUID D05UDU DRUGNAME YK-3237 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05UEF DRUGNAME RR-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05UEI DRUGNAME 99mTc-besilesomab INDICATI Bone metastases [ICD-11: 2D50] Approved TTDDRUID D05UFG DRUGNAME BIBW 2992 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved TTDDRUID D05UFJ DRUGNAME Minnelide 001 INDICATI Gastrointestinal cancer [ICD-11: 2C11] Phase 1 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 TTDDRUID D05UFN DRUGNAME PN-202 INDICATI Xerophthalmia [ICD-11: 5B55.Y] Investigative TTDDRUID D05UFP DRUGNAME PEG-SN38 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D05UGH DRUGNAME LEO 124249 INDICATI Asthma [ICD-11: CA23] Phase 2 INDICATI Eczema [ICD-11: EA80-EA89] Phase 2 TTDDRUID D05UGJ DRUGNAME XL844 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D05UGL DRUGNAME 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 1 INDICATI Skin disease [ICD-11: EA00-EM0Z] Patented INDICATI Muscular wasting [ICD-11: 8C7Y] Patented TTDDRUID D05UHF DRUGNAME Galsulfase INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Approved TTDDRUID D05UHJ DRUGNAME SM-10888 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D05UIL DRUGNAME TV-4710 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Discontinued in Phase 2 TTDDRUID D05UJF DRUGNAME PBSVax INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D05UJS DRUGNAME ADVAX INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D05UJU DRUGNAME MV-2101 INDICATI Vascular disease [ICD-11: BE2Z] Preclinical TTDDRUID D05UKK DRUGNAME FK-888 INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 2 TTDDRUID D05ULR DRUGNAME Sildenafil INDICATI Erectile dysfunction [ICD-11: HA01.1] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D05UMD DRUGNAME R-87366 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D05UMO DRUGNAME BAY-793 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D05UOU DRUGNAME CD19-CAR-T2 Cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D05UPB DRUGNAME CI-972 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D05UQD DRUGNAME Omapatrilat INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D05UQF DRUGNAME NCX-226 INDICATI Pulmonary fibrosis [ICD-11: CB03.4] Investigative TTDDRUID D05URO DRUGNAME Quinvaxem INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D05URT DRUGNAME MX-7091 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D05USL DRUGNAME KU-55933 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05USQ DRUGNAME Nintedanib INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D05UTF DRUGNAME SB-41947 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05UTV DRUGNAME Albuterpenoids INDICATI Varicella zoster virus infection [ICD-11: 1E91] Phase 2 TTDDRUID D05UTW DRUGNAME ErythroMax INDICATI Hypoxia [ICD-11: MD11.1] Phase 1 TTDDRUID D05UVD DRUGNAME Timolol INDICATI High blood pressure [ICD-11: BA00] Approved TTDDRUID D05UVL DRUGNAME SND-121 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D05UXF DRUGNAME Emapunil INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D05UXU DRUGNAME INM-176 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D05UYQ DRUGNAME Camicinal INDICATI Delayed gastric emptying [ICD-11: DA41.00] Phase 2 INDICATI Diabetic gastroparesis [ICD-11: DA41.00] Phase 2 TTDDRUID D05UYW DRUGNAME Dorzolamide INDICATI Open-angle glaucoma [ICD-11: 9C61] Approved TTDDRUID D05UZO DRUGNAME MIVOBULIN ISETHIONATE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D05VAA DRUGNAME Isbufylline INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D05VAE DRUGNAME Posiphen R-phenserine INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D05VEP DRUGNAME DX-2802 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D05VEU DRUGNAME Coagulin-B INDICATI Hemophilia [ICD-11: 3B10.0] Discontinued in Phase 1/2 TTDDRUID D05VFO DRUGNAME Rh-erythropoietin-alfa INDICATI Postoperative inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D05VFQ DRUGNAME TriTAb INDICATI Poison intoxication [ICD-11: NE6Z] Discontinued in Phase 2 TTDDRUID D05VFZ DRUGNAME ABP-710 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 1 INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 1 TTDDRUID D05VGL DRUGNAME Tavaborole INDICATI Onychomycosis [ICD-11: EE12.1] Approved TTDDRUID D05VGS DRUGNAME ALB-127158(a) INDICATI Obesity [ICD-11: 5B81] Terminated TTDDRUID D05VHB DRUGNAME EMP-123 INDICATI Peanut hypersensitivity [ICD-11: 4A83] Phase 1 TTDDRUID D05VIL DRUGNAME Nalmefene INDICATI Opioid dependence [ICD-11: 6C43.2Z] Approved TTDDRUID D05VIN DRUGNAME Imidazole derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D05VIX DRUGNAME Gemfibrozil INDICATI Hyperlipidaemia [ICD-11: 5C80] Approved TTDDRUID D05VKS DRUGNAME VT-122 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D05VLB DRUGNAME PEGylated recombinant IFN-alpha2b INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05VLN DRUGNAME Isomazole INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D05VLS DRUGNAME Rofecoxib INDICATI Osteoarthritis [ICD-11: FA00-FA05] Approved TTDDRUID D05VNG DRUGNAME BB-1101 INDICATI Multiple sclerosis [ICD-11: 8A40] Terminated TTDDRUID D05VNP DRUGNAME TESTOSTERONE BUCICLATE INDICATI Contraception [ICD-11: QA21] Phase 1 TTDDRUID D05VNS DRUGNAME CD19 and CD22 CAR-T Cells INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID D05VNX DRUGNAME IPC-003 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05VOP DRUGNAME RAP-160 INDICATI Psoriasis vulgaris [ICD-11: EA90] Preclinical TTDDRUID D05VQD DRUGNAME BMS-183729 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D05VQI DRUGNAME Cyclandelate INDICATI Dementia [ICD-11: 6D80-6D86] Approved TTDDRUID D05VSH DRUGNAME REGN3767 INDICATI Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05VTE DRUGNAME CAI orotate INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Phase 2 TTDDRUID D05VTN DRUGNAME CCX-354 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D05VUX DRUGNAME BHV-0223 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1 TTDDRUID D05VVT DRUGNAME PEG-PLA-TNP-470 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05VVX DRUGNAME PTC299 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D05VWK DRUGNAME AXP-107-16 INDICATI Gynecological disease [ICD-11: GA6Z] Investigative TTDDRUID D05VWX DRUGNAME CGEN-25008 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05VXF DRUGNAME YSCMA INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID D05VXQ DRUGNAME SRSC-355 INDICATI Neuropathic pain [ICD-11: 8E43.0] Terminated TTDDRUID D05VYJ DRUGNAME SUN-09 INDICATI Hypertonia [ICD-11: KB08.1] Discontinued in Phase 3 TTDDRUID D05VYY DRUGNAME Rapamycin INDICATI Lymphangioleiomyomatosis [ICD-11: CB07] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D05VZE DRUGNAME Marimastat INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 INDICATI Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 3 TTDDRUID D05VZJ DRUGNAME J-104132 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Discontinued in Phase 2 TTDDRUID D05WCI DRUGNAME ABT-384 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D05WDD DRUGNAME Group B streptococcal vaccine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D05WDG DRUGNAME Natroba INDICATI Sarcoptes scabiei infection [ICD-11: 1G04] Phase 3 TTDDRUID D05WDM DRUGNAME Ro5203280 INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative TTDDRUID D05WEP DRUGNAME Befloxatone INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 3 TTDDRUID D05WET DRUGNAME Anti-CD38 CAR-T cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D05WFF DRUGNAME GNI-102 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 1 TTDDRUID D05WJF DRUGNAME Defibrotide INDICATI Hepatic veno-occlusive disease [ICD-11: DB98.6] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D05WJQ DRUGNAME Saredutant INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3 INDICATI Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 3 TTDDRUID D05WKQ DRUGNAME LAI287 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D05WKT DRUGNAME PK-44 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D05WLE DRUGNAME INO-1800 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1 TTDDRUID D05WOS DRUGNAME BMS-986226 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05WPQ DRUGNAME BW A4C INDICATI Arthritis [ICD-11: FA20] Terminated TTDDRUID D05WQT DRUGNAME Flanvotumab INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D05WRB DRUGNAME Galactofucan sulphate fraction INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D05WSD DRUGNAME NaAPR1M-74 INDICATI Hookworm infection [ICD-11: 1F68] Investigative TTDDRUID D05WSP DRUGNAME UK-396082 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D05WTS DRUGNAME Galavit INDICATI Autoimmune diabetes [ICD-11: 5A10] Approved TTDDRUID D05WTT DRUGNAME Remune INDICATI Hereditary angioedema [ICD-11: 4A00.14] Phase 3 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Application submitted TTDDRUID D05WTZ DRUGNAME Galarubicin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D05WUN DRUGNAME OTI-020 INDICATI Myocardial disease [ICD-11: BC43.20] Phase 3 TTDDRUID D05WUQ DRUGNAME Omtriptolide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05WUZ DRUGNAME TT-113 INDICATI Coagulation defect [ICD-11: 3B10.0] Investigative TTDDRUID D05WVO DRUGNAME EDP-17 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05WVU DRUGNAME 131i-chtnt INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D05WWJ DRUGNAME ALX-5407 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D05WWX DRUGNAME Biphenyl mannoside derivative 14 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D05WYW DRUGNAME L-373890 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D05XAH DRUGNAME Aromatic hydrazine carboxyimidoamide derivative 4 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D05XCZ DRUGNAME VPC-51299 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05XDZ DRUGNAME LMT-X INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D05XEA DRUGNAME RP5063 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1 INDICATI Bipolar disorder [ICD-11: 6A60] Phase 1 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 1 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D05XFQ DRUGNAME VLN-244 INDICATI Colon cancer [ICD-11: 2B90.Z] Investigative TTDDRUID D05XGH DRUGNAME PMID26651364-Compound-6e INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D05XGO DRUGNAME Cariprazine INDICATI Bipolar disorder [ICD-11: 6A60] Approved TTDDRUID D05XIA DRUGNAME SF-22 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Preclinical TTDDRUID D05XJW DRUGNAME Resiniferatoxin INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 1 INDICATI Cancer related pain [ICD-11: MG30] Phase 1 TTDDRUID D05XKN DRUGNAME APG-101.10 INDICATI Gout [ICD-11: FA25] Investigative TTDDRUID D05XKW DRUGNAME VM-501 INDICATI Thrombocytopenia [ICD-11: 3B64] Phase 3 TTDDRUID D05XLO DRUGNAME INCB13739 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2a INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D05XMY DRUGNAME Acteoside INDICATI Nephritis [ICD-11: GB40] Terminated TTDDRUID D05XNF DRUGNAME IM21 CART INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D05XPZ DRUGNAME JWCAR029 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D05XQE DRUGNAME Plaunotol INDICATI Ulcer [ICD-11: CA02-CB40] Approved TTDDRUID D05XRZ DRUGNAME HI-6 INDICATI Poison intoxication [ICD-11: NE6Z] Investigative TTDDRUID D05XSJ DRUGNAME Asfotase alfa INDICATI Genetic disease [ICD-11: 8E02] Approved TTDDRUID D05XTO DRUGNAME ABT-100 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D05XTQ DRUGNAME DELTIBANT INDICATI Sepsis [ICD-11: 1G40-1G41] Phase 2 TTDDRUID D05XUY DRUGNAME JM216 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D05XXF DRUGNAME ORMD-0901 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D05XXQ DRUGNAME MLR-1326 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D05XYC DRUGNAME LY-231617 INDICATI Arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D05XYH DRUGNAME MIC-31 INDICATI Gastrointestinal ulcer [ICD-11: DA60.Z] Investigative TTDDRUID D05XZQ DRUGNAME HepaStem INDICATI Liver failure [ICD-11: DB99.7] Phase 2 TTDDRUID D05YAD DRUGNAME PMID25656651-Compound-11c INDICATI Chronic myeloid leukaemia [ICD-11: 2A20] Patented TTDDRUID D05YAG DRUGNAME Recombinant human endostatin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D05YAS DRUGNAME Tolafentrine INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D05YBZ DRUGNAME Tolonium chloride INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D05YEI DRUGNAME SUN-K0706 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D05YEL DRUGNAME CH-3697 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D05YES DRUGNAME StaphVAX INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 3 TTDDRUID D05YFE DRUGNAME Diphyllin INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D05YFL DRUGNAME AFTVac INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D05YHW DRUGNAME Vapaliximab INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D05YIX DRUGNAME LymphoScan INDICATI Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 3 TTDDRUID D05YLL DRUGNAME FL-386 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D05YLN DRUGNAME SAR256212 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D05YLO DRUGNAME Her-2-Bi-armed ATC INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D05YLP DRUGNAME SP-333 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 TTDDRUID D05YMT DRUGNAME Tricomin INDICATI Alopecia [ICD-11: ED70] Approved TTDDRUID D05YOT DRUGNAME PPRT-321 INDICATI Prostate hyperplasia [ICD-11: GA90] Terminated TTDDRUID D05YQL DRUGNAME BM-ca INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D05YQT DRUGNAME LBR-101 INDICATI Migraine [ICD-11: 8A80] Phase 1 TTDDRUID D05YRG DRUGNAME TDI-0025 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D05YRP DRUGNAME C4.4a-ADC INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05YRV DRUGNAME ETX-6107 INDICATI Arteriosclerosis [ICD-11: BD40] Preclinical TTDDRUID D05YTG DRUGNAME SLx-4090 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Phase 2 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D05YTN DRUGNAME Saracatinib INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 2 INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D05YUI DRUGNAME Ex vivo adenosine deaminase-transduced hematopoietic stem cell therapy INDICATI Immunodeficiency [ICD-11: 4A00-4A85] Phase 1/2 TTDDRUID D05YUK DRUGNAME FOROPAFANT INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 3 TTDDRUID D05YWJ DRUGNAME IFX-1 INDICATI Hidradenitis suppurativa [ICD-11: ED92.0] Phase 2 TTDDRUID D05YWN DRUGNAME GS-168 INDICATI Renal cell carcinoma [ICD-11: 2C90] Investigative TTDDRUID D05YYB DRUGNAME ACE-06X INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D05YYK DRUGNAME AP-401 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D05YYP DRUGNAME RG-7599 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D05ZAI DRUGNAME Grippol TC INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D05ZBV DRUGNAME RTX-240 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D05ZCQ DRUGNAME DAP-81 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D05ZCZ DRUGNAME Beifutai INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D05ZDA DRUGNAME JZAD-IV-22 INDICATI Narcolepsy [ICD-11: 7A20] Investigative TTDDRUID D05ZDD DRUGNAME Recombinant human cartilage-derived retinoic acid-sensitive protein depot INDICATI Articular cartilage disorder [ICD-11: FA34.Y] Phase 2/3 TTDDRUID D05ZDJ DRUGNAME THR-18 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D05ZEW DRUGNAME INO-3510 INDICATI Influenza A virus H1N1/H5N1 infection [ICD-11: 1E30] Phase 1 TTDDRUID D05ZGQ DRUGNAME Dexchlorpheniramine Maleate INDICATI Rhinitis [ICD-11: FA20] Approved TTDDRUID D05ZGW DRUGNAME DPI-201-106 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D05ZHA DRUGNAME Alilusem INDICATI Diuretic vasodilator [ICD-11: BA00] Phase 3 TTDDRUID D05ZHZ DRUGNAME PMID26651364-Compound-5e INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D05ZIF DRUGNAME DFN-02 INDICATI Migraine [ICD-11: 8A80] Phase 3 TTDDRUID D05ZIK DRUGNAME Mirtazapine INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D05ZIS DRUGNAME SM-04690 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 TTDDRUID D05ZIT DRUGNAME EC-400 INDICATI Macular degeneration [ICD-11: 9B78.3] Investigative TTDDRUID D05ZJG DRUGNAME Anisodine INDICATI Central and peripheral nervous disease [ICD-11: 8A04-8E7Z] Approved TTDDRUID D05ZLH DRUGNAME IMP-731 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D05ZLY DRUGNAME AST-008 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05ZNA DRUGNAME ESBA-903 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D05ZPL DRUGNAME Polidocanol INDICATI Reticular veins [ICD-11: EF20] Approved INDICATI Spider veins [ICD-11: EF20] Approved TTDDRUID D05ZQC DRUGNAME PRISOTINOL INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D05ZQV DRUGNAME NK-611 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D05ZSB DRUGNAME Ovine corticotropin-releasing hormone INDICATI Cushing disease [ICD-11: 5A70] Approved INDICATI Diagnostic imaging [ICD-11: N.A.] Approved TTDDRUID D05ZSX DRUGNAME NN-8828 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D05ZTH DRUGNAME Iloprost INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Approved TTDDRUID D05ZTJ DRUGNAME Anileridine Hydrochloride INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D05ZVU DRUGNAME ANG-3062 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D05ZWG DRUGNAME Senktide INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 2 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 2 TTDDRUID D05ZWR DRUGNAME PMID25666693-Compound-90 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D05ZXS DRUGNAME MAXY-G34 INDICATI Neutropenia [ICD-11: 4B00.0] Phase 2 TTDDRUID D05ZXZ DRUGNAME BAY 57-1293 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 2 TTDDRUID D05ZYM DRUGNAME N-Acetyl-D-glucosamine INDICATI Autoimmune diabetes [ICD-11: 5A10] Approved TTDDRUID D06AAG DRUGNAME Anthrax Immune Globulin (AIG) INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2 TTDDRUID D06AAP DRUGNAME Ipodate INDICATI Graves disease [ICD-11: 5A02.0] Approved TTDDRUID D06ABF DRUGNAME Loratadine INDICATI Allergy [ICD-11: 4A80-4A85] Approved INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2 TTDDRUID D06ABM DRUGNAME CAB-175 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D06ACI DRUGNAME BZYX INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D06ACW DRUGNAME Adenosine monophosphate INDICATI Malnutrition [ICD-11: 5B50-5B71] Approved TTDDRUID D06AEB DRUGNAME Iodoquinol INDICATI Amoebiasis [ICD-11: 1A36] Approved TTDDRUID D06AEO DRUGNAME Cyproterone INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D06AES DRUGNAME BB-16000 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06AGD DRUGNAME MK-0963 INDICATI Prostate disease [ICD-11: GA91] Discontinued in Phase 1 TTDDRUID D06AGH DRUGNAME Trametinib + dabrafenib INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D06AHQ DRUGNAME Ro-31-8830 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D06AJL DRUGNAME Antacids INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Approved TTDDRUID D06AKC DRUGNAME IVVS-1001 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D06AKJ DRUGNAME FR-111142 INDICATI Arthritis [ICD-11: FA20] Terminated TTDDRUID D06ALB DRUGNAME BCH-2763 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D06ALD DRUGNAME Empagliflozin INDICATI Type-1 diabetes [ICD-11: 5A10] Approved TTDDRUID D06ALE DRUGNAME IFX-1 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D06ALK DRUGNAME Xmab-2513 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D06ANS DRUGNAME CVBT-141H INDICATI Coronary artery disease [ICD-11: BA80] Phase 2 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 2 INDICATI Coronary heart disease [ICD-11: BA80.Z] Phase 2 TTDDRUID D06ANT DRUGNAME Grass pollen extract sublingual vaccine INDICATI Seasonal allergic rhinitis [ICD-11: CA08.01] Approved TTDDRUID D06APK DRUGNAME Rinfabate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3 TTDDRUID D06APO DRUGNAME PDC-748 INDICATI Cough [ICD-11: MD12] Phase 2 TTDDRUID D06AQI DRUGNAME NN344 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1 TTDDRUID D06AQJ DRUGNAME TRK-530 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 2 TTDDRUID D06AQP DRUGNAME EC-0531 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06ARI DRUGNAME NM-001 INDICATI Respiratory tract infection [ICD-11: CA45] Investigative TTDDRUID D06ARV DRUGNAME Anti-IL-23 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 3 TTDDRUID D06AVN DRUGNAME CS-891B INDICATI Alopecia [ICD-11: ED70] Discontinued in Phase 2 TTDDRUID D06AWA DRUGNAME SCIB-1 INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 TTDDRUID D06AWD DRUGNAME Anti-D human immunoglobulin INDICATI Acquired haemolytic anemia [ICD-11: 3A4Z] Approved TTDDRUID D06AWE DRUGNAME Buprenorphine INDICATI Pain [ICD-11: MG30-MG3Z] Approved INDICATI Psychiatric disorder [ICD-11: 6E8Z] Phase 3 INDICATI Migraine [ICD-11: 8A80] Phase 2 TTDDRUID D06AZH DRUGNAME B-220 INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D06BBF DRUGNAME BLV-0801 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06BBO DRUGNAME Polymerized vaccine INDICATI Allergy [ICD-11: 4A80-4A85] Phase 3 TTDDRUID D06BBV DRUGNAME XZK-monascus INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D06BBZ DRUGNAME ZM-224832 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D06BCB DRUGNAME Vinpocetine INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Approved TTDDRUID D06BDE DRUGNAME Remdesivir INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D06BDP DRUGNAME OtiVax INDICATI Otitis media [ICD-11: AA80-AB0Z] Terminated TTDDRUID D06BEP DRUGNAME Chlordiazepoxide INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D06BEX DRUGNAME Gene therapy, congestive heart failure INDICATI Congestive heart failure [ICD-11: BD10] Investigative TTDDRUID D06BFH DRUGNAME 5-fluoro-1H-indole-2-carboxylic acid INDICATI Glioma [ICD-11: 2A00.0] Investigative INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D06BFP DRUGNAME CGS-17867A INDICATI Alcohol dependence [ICD-11: 6C40.2] Terminated TTDDRUID D06BGK DRUGNAME FiloVax INDICATI Ebola virus infection [ICD-11: 1D60.0] Investigative TTDDRUID D06BGO DRUGNAME Telcyta canfosfamide INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 3 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3 TTDDRUID D06BGS DRUGNAME AIDSVAX INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D06BGZ DRUGNAME LY3200882 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06BHB DRUGNAME Trastuzumab deruxtecan INDICATI HER2-positive breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D06BHG DRUGNAME Safotibant INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 TTDDRUID D06BHI DRUGNAME BMS-986089 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1/2 TTDDRUID D06BHK DRUGNAME ORG-9453 INDICATI Paralysis [ICD-11: 8B60] Investigative TTDDRUID D06BHQ DRUGNAME YM-17K INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D06BIE DRUGNAME PanBlok INDICATI Pandemic influenza infection [ICD-11: 1E30] Phase 2 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2 TTDDRUID D06BJP DRUGNAME NXB-4221 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D06BKF DRUGNAME PEGylated recombinant EPO INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D06BKH DRUGNAME GR-MD-02 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 1 TTDDRUID D06BKK DRUGNAME NN9748 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D06BLQ DRUGNAME Sofalcone INDICATI Ulcer [ICD-11: CA02-CB40] Approved TTDDRUID D06BMO DRUGNAME BI 1026706 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 1 TTDDRUID D06BPF DRUGNAME R-102557 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D06BPG DRUGNAME Nomifensine INDICATI Breast cancer [ICD-11: 2C60-2C65] Withdrawn from market TTDDRUID D06BQU DRUGNAME Salicin INDICATI Analgesia [ICD-11: MB40.8] Approved TTDDRUID D06BSE DRUGNAME EDI1200 INDICATI Ectodermal dysplasia [ICD-11: LD27.0] Phase 2 TTDDRUID D06BSG DRUGNAME Thieno[3,2-c]pyridine-7-carboxamide derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D06BSV DRUGNAME PMID30107136-Compound-Example46 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D06BTD DRUGNAME 4Ab-028 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Investigative TTDDRUID D06BTF DRUGNAME Almorexant INDICATI Insomnia [ICD-11: 7A00-7A0Z] Terminated INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Terminated TTDDRUID D06BUA DRUGNAME Nexopamil INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D06BUI DRUGNAME PN-355 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D06BUS DRUGNAME ST-7 INDICATI Neutropenia [ICD-11: 4B00.0] Investigative TTDDRUID D06BVT DRUGNAME Affitope AD-02 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2 TTDDRUID D06BYG DRUGNAME Clostridium butyricum MIYAIRI 588 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D06BYS DRUGNAME Imepitoin INDICATI Convulsion [ICD-11: 8A68.Z] Discontinued in Phase 1 TTDDRUID D06BYV DRUGNAME Phensuximide INDICATI Seizure disorder [ICD-11: 8A6Z] Approved TTDDRUID D06CAC DRUGNAME Anidulafungin INDICATI Candidiasis [ICD-11: 1F23] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D06CAS DRUGNAME Cerliponase Alfa INDICATI Tripeptidyl peptidase 1 deficiency [ICD-11: 5C50] Approved INDICATI Neuronal ceroid lipofuscinosis [ICD-11: 5C56.1] Approved TTDDRUID D06CAV DRUGNAME KiroVAX-004 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D06CCR DRUGNAME Fialuridine INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D06CDN DRUGNAME AG-TMB711 INDICATI Gastric motility disorder [ICD-11: DA21] Approved TTDDRUID D06CDO DRUGNAME Chlorphentermine Hydrochloride INDICATI Appetite suppressant [ICD-11: MG43] Approved TTDDRUID D06CDP DRUGNAME MT-176 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D06CEA DRUGNAME Purine derivative 3 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D06CFJ DRUGNAME DC-480 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D06CFT DRUGNAME PP-4001 INDICATI Cystitis [ICD-11: GC00] Phase 2 TTDDRUID D06CFZ DRUGNAME ARM-AK-105 INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D06CGB DRUGNAME Desogestrel INDICATI Contraception [ICD-11: QA21] Approved TTDDRUID D06CIE DRUGNAME Amifostine INDICATI Mucositis [ICD-11: CA00] Approved TTDDRUID D06CIJ DRUGNAME ISIS-CRP INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 1 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D06CIR DRUGNAME Thymosin beta-4 INDICATI Neurotrophic keratitis [ICD-11: 9A74] Phase 3 INDICATI Alopecia [ICD-11: ED70] Phase 2 TTDDRUID D06CJN DRUGNAME INCAGN1876 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D06CKX DRUGNAME SB-649868 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Phase 2 TTDDRUID D06CML DRUGNAME VLF-02 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D06CMW DRUGNAME MVA-BN polytope HIV vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1/2 TTDDRUID D06CNP DRUGNAME Abiraterone acetate INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D06CSK DRUGNAME BCT-194 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D06CSR DRUGNAME INP-1750 INDICATI Diarrhea [ICD-11: ME05.1] Investigative TTDDRUID D06CTD DRUGNAME IN-N01 INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D06CTE DRUGNAME Imiquimod INDICATI Skin cancer [ICD-11: 2C30-2C37] Approved TTDDRUID D06CTM DRUGNAME Ferumoxytol INDICATI Chronic kidney disease [ICD-11: GB61] Approved TTDDRUID D06CVN DRUGNAME EC0489 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06CVO DRUGNAME OrM3 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2b TTDDRUID D06CVT DRUGNAME Tianeptine INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved TTDDRUID D06CWH DRUGNAME Betamethasone Benzoate INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D06CWM DRUGNAME AZD-7507 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06CWV DRUGNAME W-205GBA2ED INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D06CWZ DRUGNAME CAR-CLD18 T cell INDICATI Adenocarcinoma [ICD-11: 2D40] Clinical trial INDICATI Pancreatic cancer [ICD-11: 2C10] Clinical trial TTDDRUID D06CXL DRUGNAME Anakinra INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D06CYI DRUGNAME Nitric Oxide INDICATI Hypertension [ICD-11: BA00-BA04] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D06CZJ DRUGNAME Idursulfase INDICATI Infertility [ICD-11: GB04] Approved INDICATI Hunter syndrome [ICD-11: 5C56.31] Approved TTDDRUID D06CZS DRUGNAME V85546 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1 TTDDRUID D06DBJ DRUGNAME REGN-846 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 1/2 TTDDRUID D06DCL DRUGNAME LY335979 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Discontinued in Phase 3 TTDDRUID D06DET DRUGNAME AE-3763 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D06DFU DRUGNAME TP-023 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Preclinical TTDDRUID D06DHB DRUGNAME E7016 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D06DKD DRUGNAME QBI-139 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06DKU DRUGNAME Amiodarone INDICATI Ventricular tachycardia [ICD-11: BC71] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D06DLI DRUGNAME MCI-186 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Approved TTDDRUID D06DLN DRUGNAME SHP621 INDICATI Eosinophilic esophagitis [ICD-11: DA24.1] Phase 2 TTDDRUID D06DLO DRUGNAME Ro-24-7341 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D06DLQ DRUGNAME CGP-37849 INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1 TTDDRUID D06DMQ DRUGNAME VX-970 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06DMV DRUGNAME ER-21018 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Investigative TTDDRUID D06DOJ DRUGNAME Seribantumab INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D06DPJ DRUGNAME HITOPK-032 INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative TTDDRUID D06DPQ DRUGNAME AIM-101 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D06DPS DRUGNAME PD-170292 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D06DQF DRUGNAME RO-5095932 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D06DRU DRUGNAME ELP-10 INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D06DSQ DRUGNAME DPIV/CD26 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D06DUO DRUGNAME SSR-182289 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2 TTDDRUID D06DUS DRUGNAME PVX-410 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06DWQ DRUGNAME TOPIXANTRONE HYDROCHLORIDE INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Discontinued in Phase 2 TTDDRUID D06DZI DRUGNAME GR-127935 INDICATI Major depressive disorder [ICD-11: 6A70.3] Terminated TTDDRUID D06DZZ DRUGNAME NVX-188 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06EBJ DRUGNAME CX-02 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06EBU DRUGNAME ALTU-242 INDICATI Gout [ICD-11: FA25] Investigative TTDDRUID D06ECI DRUGNAME TD-101 INDICATI Flavivirus infection [ICD-11: 1C80] Phase 2 INDICATI Pachyonychia [ICD-11: EE10.3] Phase 1 TTDDRUID D06ECJ DRUGNAME Verapamil INDICATI Hypertension [ICD-11: BA00-BA04] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D06ECM DRUGNAME HBN-2 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D06EDP DRUGNAME DSP-0565 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 1 TTDDRUID D06EDT DRUGNAME ZOPOLRESTAT INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D06EEL DRUGNAME Miokamycin INDICATI Bronchitis [ICD-11: CA20] Approved TTDDRUID D06EEM DRUGNAME JD-3000 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D06EFW DRUGNAME RG7304 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06EGV DRUGNAME LY2801653 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Biliary tract cancer [ICD-11: 2C17] Phase 2 TTDDRUID D06EHW DRUGNAME IAI-100 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06EHX DRUGNAME TAK-935 INDICATI Dravet syndrome [ICD-11: 8A61.11] Phase 2 INDICATI LennoxGastaut syndrome [ICD-11: 8A62.1] Phase 2 INDICATI Tuberous sclerosis [ICD-11: LD2D.2] Phase 2 INDICATI Glutamate excitotoxity [ICD-11: 5C73] Phase 1 TTDDRUID D06EIC DRUGNAME ASP-015K INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D06EIJ DRUGNAME RFT-5.dgA INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D06EIM DRUGNAME IPN-200 INDICATI Flavivirus infection [ICD-11: 1C80] Investigative TTDDRUID D06EIO DRUGNAME Trimelamol INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D06EIY DRUGNAME Lm-Malaria INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D06EMM DRUGNAME CERC-301 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D06EMQ DRUGNAME AM-112 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D06EMT DRUGNAME Chlormerodrin INDICATI Diagnostic imaging [ICD-11: N.A.] Approved TTDDRUID D06EMW DRUGNAME AZD8566 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D06ENH DRUGNAME Prostacyclin analog INDICATI Pulmonary hypertension [ICD-11: BB01] Investigative TTDDRUID D06ENM DRUGNAME Oliceridine INDICATI Acute pain [ICD-11: MG31] Approved INDICATI Thyroid disease [ICD-11: 5A00-5A06] Clinical trial TTDDRUID D06ENR DRUGNAME HG-1096 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D06EPF DRUGNAME Plicamycin INDICATI Testicular cancer [ICD-11: 2C80] Approved INDICATI Hypercalcaemia [ICD-11: 5B91.0] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Withdrawn from market INDICATI Lung cancer [ICD-11: 2C25.0] Investigative INDICATI Ovarian cancer [ICD-11: 2C73] Investigative TTDDRUID D06EPO DRUGNAME PF-4136309 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D06EPP DRUGNAME CNB-001 INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D06EQN DRUGNAME XR-510 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D06EQP DRUGNAME Aceprometazine INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Approved TTDDRUID D06ERY DRUGNAME BMS-394136 INDICATI Arrhythmia [ICD-11: BC9Z] Phase 1 TTDDRUID D06ESU DRUGNAME AM-461 INDICATI Respiratory disease [ICD-11: CB40] Phase 1 TTDDRUID D06ETI DRUGNAME ABT-263 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 3 INDICATI Relapsed or refractory chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D06EUC DRUGNAME PMX-10098 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D06EVZ DRUGNAME Anti-GD2 CART INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 2 TTDDRUID D06EWO DRUGNAME Gemtuzumab ozogamicin INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved TTDDRUID D06EWT DRUGNAME CLR1404-I-124 INDICATI Glioma [ICD-11: 2A00.0] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 INDICATI Brain cancer [ICD-11: 2A00] Phase 1/2 TTDDRUID D06EWW DRUGNAME Sacrovir INDICATI Herpes simplex virus infection [ICD-11: 1F00] Investigative TTDDRUID D06EXA DRUGNAME SALVINORIN A INDICATI Cerebral vasospasm [ICD-11: BA85.Z] Phase 1 TTDDRUID D06EXI DRUGNAME FGLL INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D06EYQ DRUGNAME TDI-0094 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D06EZI DRUGNAME Capreomycin Sulfate INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Approved TTDDRUID D06FAA DRUGNAME Metelimumab INDICATI Scleroderma [ICD-11: 4A42] Phase 1/2 TTDDRUID D06FBB DRUGNAME Azithromycin/chloroquine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3 TTDDRUID D06FCR DRUGNAME CL-277082 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D06FDR DRUGNAME Didanosine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D06FEA DRUGNAME Dinoprostone INDICATI Medical abortion [ICD-11: JA00.1Z] Approved TTDDRUID D06FEQ DRUGNAME WIT-301 INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Investigative TTDDRUID D06FER DRUGNAME BMX-010 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 TTDDRUID D06FES DRUGNAME Doxepin INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D06FGJ DRUGNAME Protexia INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D06FGM DRUGNAME Snake venom antisera INDICATI Poison intoxication [ICD-11: NE6Z] Investigative TTDDRUID D06FHQ DRUGNAME BMS-936561 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D06FIT DRUGNAME SB-728-T INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D06FJO DRUGNAME Benzydamine INDICATI Chemotherapy or radiotherapy-induced mucositis [ICD-11: DA42-DA60] Discontinued in Phase 2 TTDDRUID D06FKC DRUGNAME Eltoprazine INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Dyskinesia [ICD-11: MB47.4] Phase 2 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D06FLP DRUGNAME AMG 811 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 INDICATI Discoid lupus erythematosus [ICD-11: EB51.0] Phase 1 TTDDRUID D06FMO DRUGNAME ABP 501 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 INDICATI Plaque psoriasis [ICD-11: EA90.0] Application submitted TTDDRUID D06FMY DRUGNAME CGP-70726 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated TTDDRUID D06FOA DRUGNAME Bone morphogenetic protein-2 INDICATI Bone injury [ICD-11: ND56.Y] Investigative TTDDRUID D06FOF DRUGNAME Imidazole derivative 5 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D06FOL DRUGNAME CALDARET HYDRATE INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D06FOU DRUGNAME Trifarotene INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D06FPF DRUGNAME Valortim INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D06FPQ DRUGNAME Frovatriptan INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D06FQS DRUGNAME TGOF02N INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D06FQU DRUGNAME INCB53914 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D06FRB DRUGNAME ACH-0137171 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D06FSC DRUGNAME NP-118809 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D06FSD DRUGNAME NN-9161 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1/2 TTDDRUID D06FSV DRUGNAME Onco-D INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06FTM DRUGNAME RG7221 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 2 TTDDRUID D06FTW DRUGNAME RP135 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D06FTY DRUGNAME CT-400 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06FUE DRUGNAME CDX-3379 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06FUM DRUGNAME PMID26815044-Compound-114 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D06FUQ DRUGNAME MIQ-003 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D06FVX DRUGNAME Nedocromil sodium INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Approved TTDDRUID D06FWC DRUGNAME Fludiazepam INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D06FWG DRUGNAME Oncomer INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D06FYE DRUGNAME Atorvastatin + aspirin + ramipril INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D06FZH DRUGNAME MazF gene therapy INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID D06FZX DRUGNAME Antazoline INDICATI Nasal congestion [ICD-11: MD11.9] Approved TTDDRUID D06GAM DRUGNAME Fleroxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D06GAP DRUGNAME SAR252067 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 1 INDICATI Crohn disease [ICD-11: DD70] Phase 1 TTDDRUID D06GAQ DRUGNAME Atu-111 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D06GBQ DRUGNAME Enfuvirtide INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D06GCK DRUGNAME Eupatilin INDICATI Pancreatitis [ICD-11: DC31-DC34] Approved INDICATI Chronic diarrhoea [ICD-11: 1A36.0Z] Approved TTDDRUID D06GCO DRUGNAME Gonadoreline-6-d-trp acetate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D06GCP DRUGNAME PSD-506 INDICATI Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 2 TTDDRUID D06GDH DRUGNAME DA-5018 INDICATI Postherpetic neuralgia [ICD-11: 1E91.5] Discontinued in Phase 2 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Discontinued in Phase 2 TTDDRUID D06GDR DRUGNAME VAP-1 monoclonal antibody INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 2a TTDDRUID D06GDY DRUGNAME Paroxetine INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D06GFG DRUGNAME KD-3020 INDICATI Non-alcoholic fatty liver disease [ICD-11: DB92] Preclinical TTDDRUID D06GGL DRUGNAME MSB11022 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 TTDDRUID D06GGT DRUGNAME MCL-1-specific antisense oligonucleotide + nilotinib (AMN107) INDICATI Systemic mastocytosis [ICD-11: 2A21.0] Investigative TTDDRUID D06GIP DRUGNAME Thymol INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D06GJT DRUGNAME Alizapride INDICATI Vomiting [ICD-11: MD90] Approved TTDDRUID D06GKE DRUGNAME GZ402665 INDICATI Niemann-pick disease [ICD-11: 5C56.0Y] Phase 2/3 TTDDRUID D06GKN DRUGNAME Alosetron INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved TTDDRUID D06GKR DRUGNAME Deferoxamine INDICATI Acute iron or aluminum toxicity [ICD-11: FB83.20] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D06GMG DRUGNAME Etoposide INDICATI Testicular cancer [ICD-11: 2C80] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D06GMJ DRUGNAME GSK945237 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D06GMM DRUGNAME FT-026 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D06GNF DRUGNAME TS-022 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D06GOF DRUGNAME IDP-123 INDICATI Acne vulgaris [ICD-11: ED80] Phase 3 TTDDRUID D06GOT DRUGNAME Pyrrolo[2,3-b]pyridine derivative 2 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D06GRK DRUGNAME ARC029 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D06GSA DRUGNAME CMV DNA vaccine INDICATI Cytomegalovirus infection [ICD-11: 1D82] Preclinical TTDDRUID D06GSE DRUGNAME GPI-1337 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated TTDDRUID D06GUA DRUGNAME GSK2269557 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D06GUG DRUGNAME BTT-1023 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D06GWF DRUGNAME Valganciclovir INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D06GYJ DRUGNAME PD-01 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 4 TTDDRUID D06GYY DRUGNAME Ifenprodil INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D06GZW DRUGNAME PEGylated leptin INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D06HBJ DRUGNAME BAY2306001 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 2 TTDDRUID D06HBQ DRUGNAME Gliquidone INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D06HBT DRUGNAME LT-1951 INDICATI Coronary artery disease [ICD-11: BA80] Phase 1/2 TTDDRUID D06HCC DRUGNAME LANEPITANT INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D06HCD DRUGNAME SM-6586 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D06HCF DRUGNAME SPD-557 INDICATI Diabetic gastroparesis [ICD-11: DA41.00] Phase 2 TTDDRUID D06HCP DRUGNAME MELARSOPROL INDICATI Trypanosomiasis [ICD-11: 1D51-1F53] Approved TTDDRUID D06HFI DRUGNAME L-ornithine phenylacetate INDICATI Acute liver failure [ICD-11: DB91] Phase 2 TTDDRUID D06HGM DRUGNAME LPO-1010CA INDICATI Cataract [ICD-11: 9B10] Investigative TTDDRUID D06HGO DRUGNAME MDY-1001 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Investigative TTDDRUID D06HGY DRUGNAME RTA-403 analog INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D06HIO DRUGNAME Istaroxime INDICATI Cardiac disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2 TTDDRUID D06HKB DRUGNAME Lodenosine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D06HLY DRUGNAME Pilocarpine INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved TTDDRUID D06HMN DRUGNAME BAY1251152 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D06HMO DRUGNAME CVBT-141B topical INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 2 TTDDRUID D06HNO DRUGNAME MEDI4920 INDICATI Sjogren syndrome [ICD-11: 4A43.20] Phase 1 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D06HPA DRUGNAME Argidene INDICATI Dermatological disease [ICD-11: DA24.Y] Discontinued in Preregistration TTDDRUID D06HPP DRUGNAME AGT-182 INDICATI Hunter syndrome [ICD-11: 5C56.31] Phase 1 TTDDRUID D06HQG DRUGNAME SPM-5185 INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D06HQM DRUGNAME Apo805K1 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D06HRD DRUGNAME EUR-1100 INDICATI Eosinophilic esophagitis [ICD-11: DA24.1] Phase 1/2 TTDDRUID D06HRY DRUGNAME SNAP-5089 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D06HUF DRUGNAME AM-365 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 2 TTDDRUID D06HUH DRUGNAME Recombinant human butyrylcholinesterase INDICATI Poison intoxication [ICD-11: NE6Z] Investigative TTDDRUID D06HUS DRUGNAME PF-06755347 INDICATI Chronic inflammatory demyelinating polyneuropathy [ICD-11: 8C01.3] Phase 1 TTDDRUID D06HWG DRUGNAME Inflexal V INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D06HWU DRUGNAME CHR-4487 INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D06HXC DRUGNAME NPY-1 antagonist INDICATI Eating disorder [ICD-11: 6B82] Investigative TTDDRUID D06HYC DRUGNAME VLI-01B INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06HYF DRUGNAME M2698 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06HYG DRUGNAME Barucainide INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D06HZA DRUGNAME GSK2586184 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 INDICATI Arthritis [ICD-11: FA20] Phase 1 TTDDRUID D06HZY DRUGNAME Fructose INDICATI Vomiting [ICD-11: MD90] Approved TTDDRUID D06IAA DRUGNAME LK-410 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D06IAQ DRUGNAME Ambenonium INDICATI Myasthenia gravis [ICD-11: 8C6Y] Approved TTDDRUID D06IAR DRUGNAME Adenosine INDICATI Paroxysmal supraventricular tachycardia [ICD-11: BC81.Z] Approved TTDDRUID D06IBG DRUGNAME MK-3415A INDICATI Malaria [ICD-11: 1F40-1F45] Phase 3 INDICATI Clostridium infection [ICD-11: 1A04] Phase 3 TTDDRUID D06ICE DRUGNAME Radiolabeled anti-PSMA huJ591 minibodies INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D06ICW DRUGNAME MDI-P INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D06IDT DRUGNAME Demecarium bromide INDICATI Open-angle glaucoma [ICD-11: 9C61] Approved TTDDRUID D06IEX DRUGNAME Cardiotrophin-1 INDICATI Acute liver failure [ICD-11: DB91] Phase 1 TTDDRUID D06IFR DRUGNAME PF-3654764 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D06IGC DRUGNAME ACT-0932 INDICATI Glioma [ICD-11: 2A00.0] Investigative TTDDRUID D06IGE DRUGNAME Factor IX-XTEN INDICATI Hemophilia [ICD-11: 3B10.0] Investigative TTDDRUID D06IGU DRUGNAME Troleandomycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D06IGW DRUGNAME Coronary artery disease gene therapy INDICATI Coronary artery disease [ICD-11: BA80] Phase 1 TTDDRUID D06IHW DRUGNAME SCF-I2 INDICATI Discovery agent [ICD-11: N.A.] Preclinical TTDDRUID D06IIB DRUGNAME Halcinonide INDICATI Skin disease [ICD-11: EA00-EM0Z] Approved TTDDRUID D06IJG DRUGNAME Silyman DD INDICATI Liver disease [ICD-11: DB90-BD99] Approved TTDDRUID D06ILL DRUGNAME BMS-986158 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D06IME DRUGNAME CCX-140 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID D06IPN DRUGNAME Sunscreens INDICATI Skin cancer [ICD-11: 2C30-2C37] Approved TTDDRUID D06IPV DRUGNAME Pyrazolo[1,5-a]pyrimidine derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D06IPZ DRUGNAME MK-3281 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D06IQE DRUGNAME H1N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Discontinued in Phase 3 TTDDRUID D06IVH DRUGNAME Org-20781 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D06IVN DRUGNAME PolongaTab INDICATI Poison intoxication [ICD-11: NE6Z] Discontinued in Preregistration TTDDRUID D06IXT DRUGNAME Propyphenazone INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D06IYV DRUGNAME TAK-810 INDICATI Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 1 TTDDRUID D06IZM DRUGNAME Erythrityl Tetranitrate INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D06IZQ DRUGNAME JKB-121 INDICATI Fatty liver disease [ICD-11: DB92.Z] Phase 1/2 TTDDRUID D06IZS DRUGNAME XEL-004FP INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D06JAL DRUGNAME 8H9 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Brain cancer [ICD-11: 2A00] Phase 1 TTDDRUID D06JBA DRUGNAME HGS-TR2J INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D06JBV DRUGNAME SGN LIV1A INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D06JCO DRUGNAME Palomid-529 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D06JDK DRUGNAME Perflexane-lipid microsphere INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D06JDV DRUGNAME K-312 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D06JED DRUGNAME Subcuvia INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved TTDDRUID D06JGH DRUGNAME Pyridoxal Phosphate INDICATI Malnutrition [ICD-11: 5B50-5B71] Approved TTDDRUID D06JHN DRUGNAME VG-WNV INDICATI West nile virus infection [ICD-11: 1D46] Investigative TTDDRUID D06JHV DRUGNAME Flumatinib INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 2 TTDDRUID D06JHW DRUGNAME PMID25666693-Compound-37 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D06JKO DRUGNAME Dust mite allergen extract INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D06JKV DRUGNAME [111In]SRVII23 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D06JLG DRUGNAME AVX-601 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Phase 1 TTDDRUID D06JLQ DRUGNAME KIN-100 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D06JLX DRUGNAME Measles vaccine INDICATI Measles [ICD-11: 1F03] Approved TTDDRUID D06JNC DRUGNAME CRD-007 INDICATI Aortic aneurysm [ICD-11: BD50] Phase 2 TTDDRUID D06JPB DRUGNAME Ergocalciferol INDICATI Hypoparathyroidism [ICD-11: 5A50] Approved TTDDRUID D06JPY DRUGNAME AZD2995 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D06JQM DRUGNAME SPP-800 INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D06JQS DRUGNAME HuM195/rGel INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D06JRD DRUGNAME Metamizole INDICATI Pain [ICD-11: MG30-MG3Z] Withdrawn from market INDICATI Fever [ICD-11: MG26] Withdrawn from market TTDDRUID D06JTW DRUGNAME FM-VP4 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D06JTZ DRUGNAME Contepo INDICATI Acute bacterial skin infection [ICD-11: 1C41] Phase 2 TTDDRUID D06JUE DRUGNAME NN8555 INDICATI Crohn disease [ICD-11: DD70] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D06JUR DRUGNAME Rogletimide INDICATI Breast cancer [ICD-11: 2C60-2C65] Terminated TTDDRUID D06JVU DRUGNAME A-68552 INDICATI Obesity [ICD-11: 5B81] Terminated TTDDRUID D06JVV DRUGNAME ALD-151 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Discontinued in Phase 1 TTDDRUID D06JWO DRUGNAME KT-362 INDICATI Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 1 TTDDRUID D06KCF DRUGNAME Mavrilimumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D06KCM DRUGNAME CUV-3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06KCU DRUGNAME MLN1202 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 2 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Terminated TTDDRUID D06KDP DRUGNAME Ganglioside gm1 INDICATI Thrombin deficiency [ICD-11: 3B14.Z] Approved INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Withdrawn from market TTDDRUID D06KEJ DRUGNAME PV903 INDICATI Infertility [ICD-11: GB04] Discontinued in Phase 1 TTDDRUID D06KFR DRUGNAME RP-73163 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D06KGC DRUGNAME AEZS-120 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D06KGI DRUGNAME TG-0054 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 2 TTDDRUID D06KGV DRUGNAME HUMAN CORTICOTROPIN-RELEASING HORMONE INDICATI leukaemia [ICD-11: 2A60-2B33] Approved TTDDRUID D06KIJ DRUGNAME AG-858 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2 TTDDRUID D06KJG DRUGNAME CLX-0301 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D06KJQ DRUGNAME BI 201335 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3 TTDDRUID D06KKL DRUGNAME PulmoXen INDICATI Cystic fibrosis [ICD-11: CA25] Investigative TTDDRUID D06KKO DRUGNAME PMID26815044-Compound-50 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D06KKS DRUGNAME Cefradine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D06KLJ DRUGNAME STAMP INDICATI Dental caries [ICD-11: DA08.0] Phase 3 TTDDRUID D06KNE DRUGNAME INCB15050 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D06KNJ DRUGNAME PB-127 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3 TTDDRUID D06KNK DRUGNAME TDZD-8 INDICATI Malignant glioma [ICD-11: 2A00.0] Patented TTDDRUID D06KOL DRUGNAME Napitane mesilate INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D06KOM DRUGNAME DN24-02 INDICATI Urogenital cancer [ICD-11: 2C95-2C9Z] Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D06KOR DRUGNAME SWT-05104 INDICATI Vitiligo [ICD-11: ED63.0] Investigative TTDDRUID D06KPR DRUGNAME CER-002 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Phase 1 TTDDRUID D06KPV DRUGNAME CreaVax-RCC INDICATI Renal cell carcinoma [ICD-11: 2C90] Approved TTDDRUID D06KPW DRUGNAME U-103017 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D06KQG DRUGNAME HER-2-targeting CAR T Cells INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D06KQN DRUGNAME TPI-926 INDICATI Neurological disorder [ICD-11: 6B60] Phase 2 TTDDRUID D06KRZ DRUGNAME MC-4232 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D06KSA DRUGNAME TK-115339 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D06KSV DRUGNAME Omigapil INDICATI Lateral sclerosis [ICD-11: 8B61] Phase 2 INDICATI Muscular dystrophy [ICD-11: 8C70] Phase 1 TTDDRUID D06KTF DRUGNAME HL-029 INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D06KTJ DRUGNAME TAK-659 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID D06KUY DRUGNAME ACH-2684 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D06KVU DRUGNAME ABP 215 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Application submitted TTDDRUID D06KWU DRUGNAME DWP-09031 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D06KXS DRUGNAME PT-112 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06KYN DRUGNAME Arbutamine INDICATI Coronary artery disease [ICD-11: BA80] Approved TTDDRUID D06KYU DRUGNAME Rycals INDICATI Heart failure [ICD-11: BD10-BD13] Preclinical TTDDRUID D06KZL DRUGNAME AG140699 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D06LAN DRUGNAME BlockAide/CR INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D06LAX DRUGNAME PGI-02749 INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D06LBO DRUGNAME Croconazole INDICATI Dermatological disease [ICD-11: DA24.Y] Approved TTDDRUID D06LBV DRUGNAME E-4767 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D06LBZ DRUGNAME MVA-BN JEV INDICATI Japanese encephalitis virus infection [ICD-11: 1C85] Preclinical TTDDRUID D06LCB DRUGNAME Thiazole carboxamide derivative 9 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D06LCS DRUGNAME Legionella pneumophila vaccine INDICATI Legionella infection [ICD-11: 1C19] Terminated TTDDRUID D06LCW DRUGNAME KIN-4044 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative TTDDRUID D06LDC DRUGNAME Palonidipine hydrochloride INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Preregistration TTDDRUID D06LDT DRUGNAME Segesterone acetate; ethinyl estradiol INDICATI Contraception [ICD-11: QA21] Approved TTDDRUID D06LEA DRUGNAME MER-102 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D06LEC DRUGNAME LPD-608 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Investigative TTDDRUID D06LEG DRUGNAME Influenza A virus H5N1 vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D06LEJ DRUGNAME Lu-AA44608 INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 1 TTDDRUID D06LFE DRUGNAME Indomethacin INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D06LFV DRUGNAME NM-702 INDICATI Angina pectoris [ICD-11: BA40] Phase 3 TTDDRUID D06LGC DRUGNAME ZD-2486 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 2 TTDDRUID D06LGZ DRUGNAME ET-007 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Investigative TTDDRUID D06LHE DRUGNAME Inactivated H7N7 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2 TTDDRUID D06LHG DRUGNAME FENBUFEN INDICATI Arthritis [ICD-11: FA20] Approved TTDDRUID D06LHI DRUGNAME GCH-01 INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D06LHK DRUGNAME 2X-111 INDICATI Brain metastases [ICD-11: 2D50] Phase 1 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D06LHU DRUGNAME Iodamide INDICATI Contrast medium for intravenous urography [ICD-11: GC2Z] Approved INDICATI Brain disease [ICD-11: 8C70-8E61] Withdrawn from market TTDDRUID D06LIQ DRUGNAME Cyclohexyl carbamate derivative 8 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D06LJG DRUGNAME BURKE-104 INDICATI Verruca vulgaris [ICD-11: 1E80] Investigative TTDDRUID D06LKA DRUGNAME L2-05 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D06LKM DRUGNAME PNU-282987 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D06LKP DRUGNAME OTI-050 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Investigative TTDDRUID D06LLS DRUGNAME PMID25684022-Compound-WO2009153313 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D06LMS DRUGNAME P-coumaric acid derivative 4 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D06LNW DRUGNAME Fidaxomicin INDICATI Clostridium difficile associated diarrhea [ICD-11: 1A04] Approved TTDDRUID D06LOQ DRUGNAME ARZOXIFENE INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D06LPT DRUGNAME STI-003 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Phase 2 TTDDRUID D06LQF DRUGNAME 131-I-MIP-1095 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D06LQY DRUGNAME BI-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D06LRG DRUGNAME TRV027 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D06LRQ DRUGNAME TKP-1001 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D06LSZ DRUGNAME PMID25684022-Compound-US20120277229 40(1.2) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D06LUH DRUGNAME ABX-201 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D06LUI DRUGNAME Ad-IL-12 DNA therapeutic INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D06LUZ DRUGNAME GS-5885 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D06LVJ DRUGNAME Mam-06.301 INDICATI Allergy [ICD-11: 4A80-4A85] Phase 2 TTDDRUID D06LXP DRUGNAME POL-7080 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D06LYG DRUGNAME Prilocaine INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D06LYI DRUGNAME BPX-501 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 1/2 INDICATI Immunodeficiency [ICD-11: 4A00-4A85] Phase 1/2 INDICATI Hematopoietic stem cell transplantation [ICD-11: QB63] Phase 1/2 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D06LYS DRUGNAME Prednimustine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D06LYZ DRUGNAME A-841720 INDICATI Pain [ICD-11: MG30-MG3Z] Preclinical TTDDRUID D06MAJ DRUGNAME Mizolastine INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D06MBR DRUGNAME ACI-636 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D06MCH DRUGNAME TG-6002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06MDT DRUGNAME INV-155 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D06MEC DRUGNAME THA-901 INDICATI Cancer related pain [ICD-11: MG30] Investigative TTDDRUID D06MGW DRUGNAME OrniFlu INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D06MHZ DRUGNAME NLG919 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06MIQ DRUGNAME MRE-0094 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 2 TTDDRUID D06MIU DRUGNAME Mycoprex INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D06MIW DRUGNAME Pyrazole derivative 37 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D06MJP DRUGNAME TNFQb therapeutic vaccines INDICATI Crohn disease [ICD-11: DD70] Terminated TTDDRUID D06MKG DRUGNAME MBP(75-95) INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D06MLA DRUGNAME GET 73 INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 TTDDRUID D06MLZ DRUGNAME WAY-123223 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D06MMU DRUGNAME LM-CD45 INDICATI Transplant rejection [ICD-11: NE84] Phase 1 TTDDRUID D06MMW DRUGNAME ADCON-T/N INDICATI Wound healing [ICD-11: EL8Y] Approved TTDDRUID D06MNC DRUGNAME PRS-050 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06MNF DRUGNAME Pardoprunox INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D06MOB DRUGNAME WSB-102 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D06MOY DRUGNAME DM-99 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D06MPF DRUGNAME Sch-40120 INDICATI Pruritus [ICD-11: EC90] Terminated TTDDRUID D06MPH DRUGNAME Pyrazole derivative 28 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D06MPJ DRUGNAME BD-NP INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D06MQM DRUGNAME Lumefantrine INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D06MQW DRUGNAME GP-1002 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D06MRR DRUGNAME WilGraf INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D06MRS DRUGNAME NSD-761 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D06MRT DRUGNAME Acitazanolast INDICATI Allergy [ICD-11: 4A80-4A85] Approved TTDDRUID D06MRY DRUGNAME Enteric-coated mycophenolate sodium INDICATI Transplant rejection [ICD-11: NE84] Approved TTDDRUID D06MTH DRUGNAME KIN-4050 INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D06MTM DRUGNAME S-16276-1 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D06MUB DRUGNAME SMOi2-17 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06MUI DRUGNAME A-81988 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D06MUZ DRUGNAME SDZ-87-469 INDICATI Coronary artery disease [ICD-11: BA80] Terminated TTDDRUID D06MWK DRUGNAME Aimpila INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D06MWU DRUGNAME LUF-5833 INDICATI Ischemia [ICD-11: 8B10-8B11] Investigative TTDDRUID D06MXB DRUGNAME IB-09C190 INDICATI Angiogenesis disorder [ICD-11: BE2Z] Investigative TTDDRUID D06MXY DRUGNAME BL-1827 INDICATI Cancer related pain [ICD-11: MG30] Discontinued in Phase 1 TTDDRUID D06MYP DRUGNAME SK-MS10 INDICATI Gastritis [ICD-11: DA42] Phase 2 TTDDRUID D06NAG DRUGNAME Anti-CD137 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D06NBK DRUGNAME Sodium Iodide I-131 Capsules INDICATI Thyroid disease [ICD-11: 5A00-5A06] Approved TTDDRUID D06NDP DRUGNAME CIGB-128 INDICATI Basal cell carcinoma [ICD-11: 2C32] Phase 1 TTDDRUID D06NEU DRUGNAME CJ-23423 INDICATI Arthralgia [ICD-11: ME82] Discontinued in Phase 2 TTDDRUID D06NHK DRUGNAME Sitagliptin + atorvastatin INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3 TTDDRUID D06NIT DRUGNAME PF-4181366 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D06NJB DRUGNAME AM-802 INDICATI Lung inflammation [ICD-11: CA40.Z] Investigative TTDDRUID D06NKA DRUGNAME IRC-083927 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06NLP DRUGNAME WTC-01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06NMP DRUGNAME CGP-29030A INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D06NMY DRUGNAME MDC-1231 INDICATI Colon cancer [ICD-11: 2B90.Z] Investigative TTDDRUID D06NMZ DRUGNAME NVP-ADW742 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D06NND DRUGNAME FPA144 INDICATI Bladder cancer [ICD-11: 2C94] Phase 1 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 TTDDRUID D06NNQ DRUGNAME VRC-HIVADV014-00-VP INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D06NNU DRUGNAME NSC-631570 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D06NOF DRUGNAME ATI-9242 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D06NOR DRUGNAME IVL745 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D06NOU DRUGNAME D-9120 INDICATI Inflammatory bowel disease [ICD-11: DD72] Terminated TTDDRUID D06NPB DRUGNAME GLPG-0259 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D06NQA DRUGNAME Plasmid IL-12 immunotherapy INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1 TTDDRUID D06NQH DRUGNAME RG7155 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D06NQJ DRUGNAME Triproamylin acetate INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D06NSA DRUGNAME Thiamylal INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D06NSL DRUGNAME PIC-060 INDICATI Dermatitis [ICD-11: EA80-EA89] Terminated TTDDRUID D06NSS DRUGNAME Cromoglicate INDICATI Asthma [ICD-11: CA23] Approved INDICATI Allergic rhinitis [ICD-11: CA08.0] Terminated TTDDRUID D06NVJ DRUGNAME Nicotinamide INDICATI Inflammatory skin condition [ICD-11: EF20.Y] Approved TTDDRUID D06NVN DRUGNAME BMS-599793 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D06NXG DRUGNAME PF-04236921 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D06NXY DRUGNAME Ethinyl Estradiol INDICATI Female hypogonadism [ICD-11: GA30.6] Approved TTDDRUID D06NYA DRUGNAME 2-Methoxyestradiol INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 TTDDRUID D06OAV DRUGNAME Aminohippurate sodium INDICATI Kidney disease [ICD-11: GC2Z] Approved TTDDRUID D06ODM DRUGNAME Talsaclidine fumarate INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2 TTDDRUID D06OES DRUGNAME CART-38 cells INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D06OFD DRUGNAME BAY-85-8102 INDICATI Brain disease [ICD-11: 8C70-8E61] Phase 1 TTDDRUID D06OFJ DRUGNAME NPI-3304 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D06OFS DRUGNAME Rilmenidine INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D06OFZ DRUGNAME LEISH-F1 INDICATI Leishmania infection [ICD-11: 1F54.0] Phase 2 TTDDRUID D06OIG DRUGNAME Hib-MenCY-TT vaccine INDICATI Meningitis [ICD-11: 1D01] Phase 3 TTDDRUID D06OIV DRUGNAME Tolbutamide INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Approved TTDDRUID D06OMH DRUGNAME Safflower seed-derived apolipoprotein A1 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D06OMK DRUGNAME Tacrolimus INDICATI Organ transplant rejection [ICD-11: NE84] Approved INDICATI Ocular allergy [ICD-11: 4A81] Phase 3 TTDDRUID D06OMW DRUGNAME Rasagiline INDICATI Parkinson disease [ICD-11: 8A00.0] Approved INDICATI Skin cancer [ICD-11: 2C30-2C37] Patented INDICATI Skin imperfections [ICD-11: EK71] Patented TTDDRUID D06ONB DRUGNAME AZ505 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D06OQI DRUGNAME Tilarginine acetate INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 3 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 2 TTDDRUID D06ORI DRUGNAME Ketamine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D06ORU DRUGNAME Butacaine INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D06OSM DRUGNAME Tandospirone INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D06OUL DRUGNAME Ceforanide INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D06OUT DRUGNAME ANG-4011 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D06OUW DRUGNAME PBI-220 INDICATI Bacillus anthracis infection [ICD-11: 1G40] Investigative TTDDRUID D06OVF DRUGNAME Santalum INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 2 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D06OVM DRUGNAME KM-3413 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06OVY DRUGNAME Cefixime INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D06OWF DRUGNAME TBI-301 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D06OZJ DRUGNAME RWJ-67657 INDICATI Arthritis [ICD-11: FA20] Phase 1 TTDDRUID D06OZW DRUGNAME Artemisone INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2/3 TTDDRUID D06PAW DRUGNAME Z-4105 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D06PAZ DRUGNAME Encainide INDICATI Heart arrhythmia [ICD-11: BC65] Withdrawn from market TTDDRUID D06PBH DRUGNAME NN8640 INDICATI Growth failure [ICD-11: LD2F.1Y] Phase 3 TTDDRUID D06PDQ DRUGNAME AOP-200704 INDICATI Heart arrhythmia [ICD-11: BC65] Phase 2 TTDDRUID D06PDT DRUGNAME TARP peptide-pulsed autologous dendritic cell vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D06PEB DRUGNAME Cinalukast INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D06PEW DRUGNAME IT-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D06PFK DRUGNAME TDT-044 INDICATI Dermatological disease [ICD-11: DA24.Y] Investigative TTDDRUID D06PFT DRUGNAME Rhumab Beta7 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 3 TTDDRUID D06PGZ DRUGNAME Setrobuvir INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D06PHH DRUGNAME Rimacalib INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D06PHO DRUGNAME E-3030 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1 TTDDRUID D06PHS DRUGNAME EVT302 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D06PJK DRUGNAME Euro-Celtique 3 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D06PKL DRUGNAME BPL-003 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D06PKS DRUGNAME ONO-4007 INDICATI Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2 TTDDRUID D06PLP DRUGNAME Resten-MP INDICATI Coronary artery disease [ICD-11: BA80] Phase 2 TTDDRUID D06PNN DRUGNAME Biaryl mannoside derivative 26 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D06PPL DRUGNAME BIX-01294 INDICATI Breast cancer [ICD-11: 2C60-2C65] Preclinical TTDDRUID D06PQR DRUGNAME OPC-8490 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2 TTDDRUID D06PQT DRUGNAME Vitamin B1 INDICATI Vitamin B1 deficiency [ICD-11: 5B5A] Approved TTDDRUID D06PSS DRUGNAME Nateglinide INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D06PSU DRUGNAME BAY1143572 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06PTA DRUGNAME Levosalbutamol/ipratropium INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 4 TTDDRUID D06PTG DRUGNAME ARX788 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D06PTT DRUGNAME MS-424 INDICATI Ischemia [ICD-11: 8B10-8B11] Discontinued in Phase 2 TTDDRUID D06PTW DRUGNAME Thiazole carboxamide derivative 12 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D06PVA DRUGNAME Volociximab INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D06PVN DRUGNAME R-65 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D06PXT DRUGNAME CF602 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Preclinical TTDDRUID D06PYP DRUGNAME JTS-653 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 INDICATI Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 2 TTDDRUID D06PZC DRUGNAME SAM-6 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D06PZO DRUGNAME ASC-101 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID D06QAJ DRUGNAME PS948115 INDICATI Respiratory failure [ICD-11: CB41] Discontinued in Phase 1 TTDDRUID D06QAK DRUGNAME BMN-111 INDICATI Achondroplasia [ICD-11: LD24.00] Phase 3 TTDDRUID D06QBV DRUGNAME BI 894999 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06QBX DRUGNAME VDA-1102 INDICATI Actinic keratosis [ICD-11: EK90.0] Phase 2 TTDDRUID D06QBY DRUGNAME INT131 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D06QCC DRUGNAME Cefmenoxime INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D06QCE DRUGNAME MTKi-328 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06QDR DRUGNAME Choline alfoscerate INDICATI Amnesia [ICD-11: MB21.1] Approved TTDDRUID D06QEL DRUGNAME FARANOXI INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D06QEW DRUGNAME CLT-003 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Investigative TTDDRUID D06QGH DRUGNAME Dukoral INDICATI Escherichia coli infection [ICD-11: 1A03] Approved TTDDRUID D06QHT DRUGNAME Risotilide INDICATI Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 2 TTDDRUID D06QIP DRUGNAME AP-022 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D06QIW DRUGNAME EPO peptide mimetics INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D06QJE DRUGNAME F-992 INDICATI Urinary incontinence [ICD-11: MF50.2] Terminated TTDDRUID D06QJG DRUGNAME PG-1014491 INDICATI Bone disease [ICD-11: FC0Z] Investigative TTDDRUID D06QKV DRUGNAME Brodimoprim INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D06QMA DRUGNAME MK-5286 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D06QMV DRUGNAME DWP-450 INDICATI Glabellar frown line [ICD-11: NA0Z] Application submitted TTDDRUID D06QOA DRUGNAME PSI-938 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D06QOC DRUGNAME GX-301 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D06QOD DRUGNAME CT-120 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D06QOF DRUGNAME R7128 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2 TTDDRUID D06QOJ DRUGNAME RS-8359 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D06QOK DRUGNAME DW-2282 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D06QOM DRUGNAME TP-101 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D06QPI DRUGNAME NY-ESO-1 tumour vaccine INDICATI Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 1 TTDDRUID D06QQH DRUGNAME T-1210 INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Phase 2 TTDDRUID D06QRW DRUGNAME Lazabemide INDICATI Skin imperfections [ICD-11: EK71] Patented INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 3 TTDDRUID D06QRY DRUGNAME IDN-5390 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06QSN DRUGNAME Itolizumab INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D06QUY DRUGNAME CO-18 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D06QWM DRUGNAME OI338GT INDICATI Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 2 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D06QXI DRUGNAME NRX-4204 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D06QYJ DRUGNAME Anticancer glycosaminoglycans INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D06QYR DRUGNAME PF-4800567 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Preclinical TTDDRUID D06QZL DRUGNAME Lerisetron INDICATI Vomiting [ICD-11: MD90] Phase 3 INDICATI Testicular germ cell tumour [ICD-11: 2C80.2] Phase 3 INDICATI Nausea [ICD-11: MD90] Phase 3 TTDDRUID D06RBJ DRUGNAME DIPROTEVERINE HYDROCHLORIDE INDICATI Angina pectoris [ICD-11: BA40] Phase 3 TTDDRUID D06RCB DRUGNAME Diethylcarbamazine INDICATI Lymphatic filariasis [ICD-11: 1F66.3] Approved TTDDRUID D06RCE DRUGNAME HER2-specific T cells INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D06RCS DRUGNAME Besonprodil INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1 TTDDRUID D06REJ DRUGNAME MX-7065 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D06REO DRUGNAME Befunolol hci INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved TTDDRUID D06RFG DRUGNAME Estradiol valerate/dienogest INDICATI Discovery agent [ICD-11: N.A.] Approved TTDDRUID D06RGG DRUGNAME Levothyroxine INDICATI Hypothyroidism [ICD-11: 5A00] Approved TTDDRUID D06RGW DRUGNAME PMID25684022-Compound-WO2004087707 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D06RHC DRUGNAME DS-1040 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 1 TTDDRUID D06RIM DRUGNAME LIM-0705 INDICATI Insulin-resistant disorder [ICD-11: 5A44] Phase 2 TTDDRUID D06RNK DRUGNAME Hi8 HBV vaccine INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2 TTDDRUID D06RQD DRUGNAME Anti-GD2 mab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06RQU DRUGNAME HC-Toxin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D06RRD DRUGNAME Fibrates INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Investigative TTDDRUID D06RSE DRUGNAME V935 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06RUD DRUGNAME FT-011 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D06RUK DRUGNAME Combotox INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D06RUL DRUGNAME Bitolterol INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved INDICATI Asthma [ICD-11: CA23] Withdrawn from market TTDDRUID D06RVQ DRUGNAME Xenon INDICATI Brain injury [ICD-11: NA07.Z] Phase 3 TTDDRUID D06RVY DRUGNAME SIR-1076 INDICATI Retinopathy [ICD-11: 9B71] Preclinical TTDDRUID D06RWM DRUGNAME Carmeseal INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D06RYG DRUGNAME PRAME-SLP INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D06RYU DRUGNAME RLP-035 INDICATI Escherichia coli infection [ICD-11: 1A03] Investigative TTDDRUID D06RYY DRUGNAME ZD-9379 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1 TTDDRUID D06RZQ DRUGNAME HG-1091 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D06SAT DRUGNAME HZ-166 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D06SBB DRUGNAME Basiliximab INDICATI Organ transplant rejection [ICD-11: NE84] Approved TTDDRUID D06SBD DRUGNAME DS-2248 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06SBK DRUGNAME Atocalcitol INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D06SBL DRUGNAME MM-121 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D06SBS DRUGNAME SSR-504734 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D06SCK DRUGNAME MB-311 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06SCP DRUGNAME VISION 5 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2 TTDDRUID D06SCQ DRUGNAME QBM076 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D06SCY DRUGNAME BM-32 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D06SDP DRUGNAME Melanotetan II INDICATI Type-2 diabetes [ICD-11: 5A11] Preclinical INDICATI Obesity [ICD-11: 5B81] Preclinical INDICATI Sexual dysfunction [ICD-11: HA00-HA01] Preclinical TTDDRUID D06SDQ DRUGNAME UCB0599 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D06SEA DRUGNAME CX-7000 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06SEL DRUGNAME NNRTIs INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D06SEY DRUGNAME Etilevodopa INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 3 TTDDRUID D06SFX DRUGNAME Soybean Oil INDICATI Bupicavaine toxicity [ICD-11: NE6Z] Approved TTDDRUID D06SHZ DRUGNAME SHP616 INDICATI Neuromyelitis optica [ICD-11: 8A43] Phase 1 TTDDRUID D06SIG DRUGNAME AR177 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D06SJO DRUGNAME GSK-2282512A INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D06SJZ DRUGNAME XB-947 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06SMP DRUGNAME SMT-15000 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D06SMU DRUGNAME SMT-D003 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D06SNS DRUGNAME Mirostipen INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D06SNV DRUGNAME MORAb-28 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06SRB DRUGNAME Brain-derived neurotrophic factor peptidomimetics INDICATI Rett syndrome [ICD-11: LD90.4] Investigative TTDDRUID D06SRX DRUGNAME MDA-19 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D06SSR DRUGNAME AVP-26452 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1 TTDDRUID D06STK DRUGNAME Purine derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D06STX DRUGNAME Thiadiazolyl carboxamide derivative 1 INDICATI Alzheimer disease [ICD-11: 8A20] Patented TTDDRUID D06SUS DRUGNAME AZD-3043 INDICATI Anaesthesia [ICD-11: 9A78.6] Phase 1 TTDDRUID D06SVC DRUGNAME M-0011 INDICATI Alpha-mannosidosis [ICD-11: 5C56.21] Phase 3 TTDDRUID D06SVW DRUGNAME Insulin recombinant INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D06SWS DRUGNAME NN-1952 INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D06SWT DRUGNAME Aryl mannoside derivative 5 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D06SYA DRUGNAME MT-061 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D06SYN DRUGNAME Ioflubenzamide (131I) INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D06SZU DRUGNAME WVE-210201 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2/3 TTDDRUID D06TAL DRUGNAME Tazofelone INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2 TTDDRUID D06TAR DRUGNAME DM-512 INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D06TEO DRUGNAME UCL-1390 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated INDICATI Eating disorder [ICD-11: 6B82] Terminated TTDDRUID D06TFE DRUGNAME Technetium Tc-99m Depreotide INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D06TFI DRUGNAME LY2157299 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 2/3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2/3 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 INDICATI Glioma [ICD-11: 2A00.0] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D06TGE DRUGNAME Taranabant INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 3 TTDDRUID D06TGS DRUGNAME Cx-603 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Preclinical TTDDRUID D06THG DRUGNAME DS-1205 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D06THT DRUGNAME INGN-402 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D06TJJ DRUGNAME FLUORESCEIN INDICATI Ocular disease [ICD-11: 1F00.1Z] Approved TTDDRUID D06TJQ DRUGNAME CRLX301 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D06TKE DRUGNAME ZD-7288 INDICATI Angina pectoris [ICD-11: BA40] Phase 2 TTDDRUID D06TKI DRUGNAME CHR-3996 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06TKR DRUGNAME CART 19 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Preclinical TTDDRUID D06TLK DRUGNAME EPB-600 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D06TME DRUGNAME MEDI-546 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D06TMH DRUGNAME HG-1164 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06TNG DRUGNAME Polythiazide INDICATI Edema [ICD-11: MG29] Approved INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D06TNL DRUGNAME Ethacrynic acid INDICATI High blood pressure [ICD-11: BA00] Approved TTDDRUID D06TNO DRUGNAME CD19 CAR T-cells INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D06TOE DRUGNAME Micafungin INDICATI Candidiasis [ICD-11: 1F23] Approved TTDDRUID D06TQD DRUGNAME CMPD-167 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D06TQR DRUGNAME PF-06372865 INDICATI Chronic pain [ICD-11: MG30] Phase 2 TTDDRUID D06TQZ DRUGNAME Meticillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D06TTS DRUGNAME LZ-8 INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D06TTT DRUGNAME Recombinant Tat protein vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D06TVC DRUGNAME Tienoxolol INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D06TVG DRUGNAME Inaperisone INDICATI Pollakiuria [ICD-11: MF50.1] Discontinued in Preregistration TTDDRUID D06TVU DRUGNAME Q-101 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D06TWA DRUGNAME TB-403 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 2 TTDDRUID D06TWE DRUGNAME CLX-0921 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D06TWS DRUGNAME CAR-T cells targeting CD2 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1/2 TTDDRUID D06TZT DRUGNAME RIPISARTAN INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D06TZZ DRUGNAME CAT 1004 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D06UAD DRUGNAME HR2P peptide INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D06UBF DRUGNAME V180 INDICATI Dengue fever [ICD-11: 1D2Z] Phase 1 TTDDRUID D06UCV DRUGNAME Z-335 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D06UDG DRUGNAME Valsartan INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D06UDO DRUGNAME Phenindamine INDICATI Common cold [ICD-11: CA00] Approved TTDDRUID D06UDV DRUGNAME AZD2516 INDICATI Chronic neuropathic pain [ICD-11: MG30.5] Discontinued in Phase 2 TTDDRUID D06UEC DRUGNAME ADXS-HER2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D06UEP DRUGNAME GKT-136901 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D06UFH DRUGNAME CZ-112 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D06UIS DRUGNAME LY-2828360 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D06UJD DRUGNAME H-102 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative TTDDRUID D06UJO DRUGNAME Rhenex INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D06UKG DRUGNAME LY-377604 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D06ULU DRUGNAME Sucralfate INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D06UND DRUGNAME FP-85A INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1 TTDDRUID D06UNI DRUGNAME RBx-10017609 INDICATI Respiratory disease [ICD-11: CB40] Phase 2 TTDDRUID D06UNR DRUGNAME Unithiol INDICATI Metal intoxication [ICD-11: NE60] Approved TTDDRUID D06UNW DRUGNAME IVN-mite INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D06UNY DRUGNAME SB204 INDICATI Acne vulgaris [ICD-11: ED80] Phase 3 TTDDRUID D06UOL DRUGNAME PIROTIODECANE INDICATI Ophthalmic graves disease [ICD-11: 5A02.0] Investigative TTDDRUID D06UOU DRUGNAME MGA271 INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 1 TTDDRUID D06UPS DRUGNAME Rozrolimupab INDICATI Anemia [ICD-11: 3A00-3A9Z] Discontinued in Phase 2 TTDDRUID D06UPW DRUGNAME WSS-45 INDICATI Dengue fever [ICD-11: 1D2Z] Investigative TTDDRUID D06URI DRUGNAME ATL101 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D06URK DRUGNAME CKD-533 INDICATI Erectile dysfunction [ICD-11: HA01.1] Investigative TTDDRUID D06URS DRUGNAME Arcitumomab INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D06URX DRUGNAME CAR-T Cells targeting MUCI INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D06USG DRUGNAME CS-560 INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 3 TTDDRUID D06UTH DRUGNAME RDEA-684 INDICATI Gout [ICD-11: FA25] Phase 2 TTDDRUID D06UTM DRUGNAME Anti-CD19-CAR T cells INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D06UUE DRUGNAME AZ-AAV9 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D06UUU DRUGNAME BLX-1017 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D06UVD DRUGNAME Bleomycin INDICATI Hodgkin lymphoma [ICD-11: 2B30] Approved TTDDRUID D06UVO DRUGNAME DuP-654 INDICATI Pruritus [ICD-11: EC90] Discontinued in Phase 2 TTDDRUID D06UVZ DRUGNAME DPD-207 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D06UWD DRUGNAME Clobutinol INDICATI Cough [ICD-11: MD12] Withdrawn from market TTDDRUID D06UWF DRUGNAME SOR-C13 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D06UXL DRUGNAME GI-248573 INDICATI Bladder disease [ICD-11: DC11-DC1Z] Terminated TTDDRUID D06UYI DRUGNAME AM103 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2 TTDDRUID D06UZS DRUGNAME VDA-1124 INDICATI Aortic aneurysm [ICD-11: BD50] Investigative TTDDRUID D06VAQ DRUGNAME EUK-189 INDICATI Skin burns [ICD-11: ME65.0] Phase 1 TTDDRUID D06VCC DRUGNAME REGN-421 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06VCJ DRUGNAME Fusion toxin protein INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06VCN DRUGNAME Denagliptin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2/3 TTDDRUID D06VFF DRUGNAME EGFR antisense DNA INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1/2 TTDDRUID D06VFI DRUGNAME PRTT-200 INDICATI Fibromyalgia [ICD-11: MG30.01] Investigative TTDDRUID D06VFO DRUGNAME Anisodamine INDICATI Central and peripheral nervous disease [ICD-11: 8A04-8E7Z] Approved TTDDRUID D06VFP DRUGNAME SOTB07 INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D06VHG DRUGNAME NSI-189 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D06VIZ DRUGNAME NVX-144 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06VJK DRUGNAME Verpasep caltespen INDICATI Cervical Intraepithelial neoplasia [ICD-11: 2E66.1] Discontinued in Phase 3 TTDDRUID D06VLI DRUGNAME HPPH photodynamic therapy INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D06VMJ DRUGNAME Melogliptin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D06VMV DRUGNAME BHF-177 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D06VNK DRUGNAME Succinic acid INDICATI Malnutrition [ICD-11: 5B50-5B71] Approved TTDDRUID D06VOM DRUGNAME NEBO-174 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1 TTDDRUID D06VPE DRUGNAME Lu-AA38466 INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1 TTDDRUID D06VPT DRUGNAME TDI-0028 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D06VRI DRUGNAME Leflunomide INDICATI Multiple sclerosis [ICD-11: 8A40] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D06VRS DRUGNAME CRB-15 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D06VSD DRUGNAME Captopril INDICATI Hypertension [ICD-11: BA00-BA04] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D06VTI DRUGNAME Macrocycle derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D06VTL DRUGNAME ZO-Y49 INDICATI Gynecological disease [ICD-11: GA6Z] Investigative TTDDRUID D06VVH DRUGNAME GSK-2115160A INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D06VWA DRUGNAME FR-901469 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D06VWL DRUGNAME VA-106483 INDICATI Nocturia [ICD-11: MF55] Phase 2 TTDDRUID D06VXE DRUGNAME ALS-2160 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D06VXY DRUGNAME SB-237376 INDICATI Arrhythmia [ICD-11: BC9Z] Terminated TTDDRUID D06VYE DRUGNAME Belotecan hydrocholoride INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Approved TTDDRUID D06VYF DRUGNAME PMID25666693-Compound-3 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D06VYK DRUGNAME Azithromycin INDICATI Bronchitis [ICD-11: CA20] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D06VZN DRUGNAME SPK-843 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 3 TTDDRUID D06WAA DRUGNAME CKBP-004 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06WAM DRUGNAME Oradoxel INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06WAN DRUGNAME Benzimidazole and imidazopyridine derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D06WBA DRUGNAME SQ-28603 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D06WBE DRUGNAME ERTIPROTAFIB INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D06WCR DRUGNAME JAIVAC-1 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1 TTDDRUID D06WCW DRUGNAME UCB-1350883 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06WDT DRUGNAME PF-04094667 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D06WEB DRUGNAME LAF-389 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D06WEK DRUGNAME Ammonium chloride INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D06WGK DRUGNAME Q-LAIV INDICATI Seasonal influenza infection [ICD-11: 1E30] Approved TTDDRUID D06WGO DRUGNAME Resorcinol compound 8 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D06WGQ DRUGNAME Anthrax DNA vaccine INDICATI Anthrax [ICD-11: 1B97] Discontinued in Phase 1 TTDDRUID D06WHL DRUGNAME NS-257 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D06WHN DRUGNAME KDT-500 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D06WHY DRUGNAME AZD-5438 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06WJC DRUGNAME GC-24 INDICATI Hyperthyroidism [ICD-11: 5A02] Investigative TTDDRUID D06WJI DRUGNAME OPC-28326 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 2 TTDDRUID D06WKA DRUGNAME MD-1100 INDICATI Constipation [ICD-11: DD91.1] Approved INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 2 TTDDRUID D06WLG DRUGNAME P53 fusion protein INDICATI Liver cancer [ICD-11: 2C12] Investigative TTDDRUID D06WLY DRUGNAME PN-951 INDICATI Hematologic disease [ICD-11: 3C0Z] Investigative TTDDRUID D06WNQ DRUGNAME TKM-PLK1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D06WOF DRUGNAME Rova-T INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1 TTDDRUID D06WOJ DRUGNAME JTH-601 INDICATI Prostate disease [ICD-11: GA91] Discontinued in Phase 2 TTDDRUID D06WPM DRUGNAME Coprexa INDICATI Neurological disorder [ICD-11: 6B60] Phase 3 TTDDRUID D06WQT DRUGNAME Nolatrexed INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D06WRF DRUGNAME KD019 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Polycystic kidney disease [ICD-11: GB8Y] Phase 2 INDICATI Brain metastases [ICD-11: 2D50] Phase 2 INDICATI Meningioma metastases [ICD-11: 2D51] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D06WRJ DRUGNAME Icotinib hydrochloride INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Registered TTDDRUID D06WRY DRUGNAME NFTC-103 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D06WSG DRUGNAME AP-005 INDICATI Ulcerative colitis [ICD-11: DD71] Investigative TTDDRUID D06WSQ DRUGNAME AWD-140-190 INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 1 TTDDRUID D06WTI DRUGNAME NRP290 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D06WTQ DRUGNAME TD-0714 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 1 TTDDRUID D06WTZ DRUGNAME Lovastatin INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Approved INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3 TTDDRUID D06WUK DRUGNAME Carlumab INDICATI Pulmonary fibrosis [ICD-11: CB03.4] Phase 2 TTDDRUID D06WXJ DRUGNAME Thiazole carboxamide derivative 14 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D06WXS DRUGNAME APX-002 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D06WYG DRUGNAME 99mTc-MIP-1407 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Investigative TTDDRUID D06WZQ DRUGNAME LPO-1010UV INDICATI Uveitis [ICD-11: 9A96.Z] Investigative TTDDRUID D06XAA DRUGNAME RG7667 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Phase 2 TTDDRUID D06XAE DRUGNAME Drotaverine INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved TTDDRUID D06XAK DRUGNAME H-216/44 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Terminated TTDDRUID D06XAT DRUGNAME BCT-100 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D06XBG DRUGNAME MIP-1267 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06XBN DRUGNAME ACT-GRO-777 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D06XCD DRUGNAME PMID27998201-Compound-12 INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Bone cancer [ICD-11: 2B5Z] Patented TTDDRUID D06XCF DRUGNAME EQ-917 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D06XCP DRUGNAME AZD5991 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D06XDI DRUGNAME QAW-039 INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D06XDJ DRUGNAME Clemizole INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D06XDS DRUGNAME GSK-1070806 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D06XEL DRUGNAME DG051 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2 TTDDRUID D06XES DRUGNAME Melphalan INDICATI Ovarian cancer [ICD-11: 2C73] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D06XFV DRUGNAME Neo-Kidney Augment INDICATI Chronic kidney disease [ICD-11: GB61] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D06XGB DRUGNAME Tissue Repair Cells (TRCs) INDICATI Spinal cord injury [ICD-11: ND51.2] Phase 2 TTDDRUID D06XGC DRUGNAME BMS-986202 INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Preclinical TTDDRUID D06XGW DRUGNAME Acetylcysteine INDICATI Liver disease [ICD-11: DB90-BD99] Approved TTDDRUID D06XHC DRUGNAME Amcinonide INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D06XIT DRUGNAME ABT-414 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 INDICATI Brain cancer [ICD-11: 2A00] Phase 1 TTDDRUID D06XIX DRUGNAME RHuA1AT INDICATI Alpha-1 antitrypsin deficiency [ICD-11: 5C5A] Investigative TTDDRUID D06XIZ DRUGNAME HM-2002 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D06XJP DRUGNAME APT-222 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D06XJQ DRUGNAME SIRS-T INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D06XKM DRUGNAME Privigen INDICATI Spinal cord injury [ICD-11: ND51.2] Phase 1 TTDDRUID D06XLC DRUGNAME BMS-739562 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06XME DRUGNAME TT-105 INDICATI Deep vein thrombosis [ICD-11: BD71] Investigative TTDDRUID D06XMF DRUGNAME KT&G-101 INDICATI Atrophy [ICD-11: 9A2Y-9C40] Phase 3 TTDDRUID D06XMU DRUGNAME Testosterone INDICATI Osteoporosis [ICD-11: FB83.0] Approved INDICATI Hormone deficiency [ICD-11: 5A61.1] Phase 2 INDICATI Male hormonal deficiency [ICD-11: 5A81] Investigative TTDDRUID D06XMW DRUGNAME DPK-060 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D06XNW DRUGNAME NKP-3752 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06XOI DRUGNAME BMY-41802 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D06XOT DRUGNAME F18-flutemetamol INDICATI Alzheimer disease [ICD-11: 8A20] Approved TTDDRUID D06XPL DRUGNAME TOCA-511 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2/3 TTDDRUID D06XPX DRUGNAME CERE-135 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D06XRA DRUGNAME LU AA24493 INDICATI Stroke [ICD-11: 8B20] Discontinued in Phase 2 TTDDRUID D06XRQ DRUGNAME AA-861 INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D06XSB DRUGNAME GW-870086-X INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D06XSG DRUGNAME AZD8075 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D06XTA DRUGNAME PMID27998201-Compound-17 INDICATI Hair loss [ICD-11: ED70] Patented TTDDRUID D06XVF DRUGNAME CBT-1 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Application submitted TTDDRUID D06XVN DRUGNAME Farletuzumab INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID D06XVR DRUGNAME BAN2401 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D06XVX DRUGNAME RP-5000 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D06XWB DRUGNAME Huperzine A INDICATI Alzheimer disease [ICD-11: 8A20] Approved TTDDRUID D06XWD DRUGNAME CAR-T Cells targeting HER2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D06XWQ DRUGNAME Benzothiazine-carboxamide compound 2 INDICATI Skin inflammation [ICD-11: EF20.Y] Patented TTDDRUID D06XXA DRUGNAME AMA-1-Dico INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D06XXD DRUGNAME IG-AI-025 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D06XXH DRUGNAME Dacomitinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved TTDDRUID D06XYL DRUGNAME DP-6001 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D06XZM DRUGNAME GBL-100 INDICATI Dermatological disease [ICD-11: DA24.Y] Discontinued in Phase 1 TTDDRUID D06XZR DRUGNAME Pizotyline INDICATI Headache [ICD-11: 8A80-8A84] Approved TTDDRUID D06XZW DRUGNAME Troglitazone INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D06YAG DRUGNAME ABX-102 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06YAI DRUGNAME SOM-0004 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D06YAK DRUGNAME MG-3 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D06YCR DRUGNAME Marburg virus DNA vaccine INDICATI Marburg virus infection [ICD-11: 1D60.1] Phase 1 TTDDRUID D06YEE DRUGNAME Prodigiosin INDICATI Pancreatic cancer [ICD-11: 2C10] Investigative TTDDRUID D06YEG DRUGNAME Indirab INDICATI Rabies [ICD-11: 1C82] Approved TTDDRUID D06YEK DRUGNAME 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 4 INDICATI Skin disease [ICD-11: EA00-EM0Z] Patented INDICATI Muscular wasting [ICD-11: 8C7Y] Patented TTDDRUID D06YFA DRUGNAME Bromocriptine INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D06YFO DRUGNAME AD-121 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1/2 TTDDRUID D06YFT DRUGNAME 1-methyl-L-tryptophan INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D06YGP DRUGNAME BN-OD-026 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D06YHL DRUGNAME Cefamandole INDICATI Microorganisms infection [ICD-11: 1A00-1A09] Approved TTDDRUID D06YKN DRUGNAME Resorcinol compound 22 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D06YMT DRUGNAME PLX-ORI3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06YNK DRUGNAME TRM-88 INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D06YOD DRUGNAME ZD-7717 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D06YPQ DRUGNAME SPI-452 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D06YPU DRUGNAME Dexibuprofen INDICATI Ankylosing spondylitis [ICD-11: FA92.0] Approved TTDDRUID D06YRR DRUGNAME GSK2254233A INDICATI Pneumococcal infection [ICD-11: CA00-CA40] Phase 2 INDICATI Haemophilus influenza [ICD-11: 1G40] Phase 2 TTDDRUID D06YSK DRUGNAME HuMax-Her2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06YSP DRUGNAME AT13387 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D06YTE DRUGNAME NOX-D14 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D06YUM DRUGNAME AZD6423 INDICATI Suicidal ideation [ICD-11: MB26.A] Phase 1 TTDDRUID D06YUR DRUGNAME Oxindole derivative INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D06YWA DRUGNAME BVA-101 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D06YWH DRUGNAME YM155 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D06YXD DRUGNAME Taprostene INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 3 TTDDRUID D06YYD DRUGNAME Dexlansoprazole INDICATI Non-erosive gastro-esophageal reflux disease [ICD-11: DA22.0] Approved INDICATI Erosive esophagitis [ICD-11: DA25.0] Approved INDICATI Peptic ulcer [ICD-11: DA61] Approved INDICATI NSAID-associated gastric ulcer [ICD-11: DA60] Phase 3 TTDDRUID D06YYY DRUGNAME KAR-1880 INDICATI Dermatitis [ICD-11: EA80-EA89] Investigative TTDDRUID D06ZAK DRUGNAME CA-50040 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Investigative TTDDRUID D06ZAM DRUGNAME MF268 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D06ZAS DRUGNAME Technetium Tc-99m Ferpentetate Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D06ZAY DRUGNAME Haloprogin INDICATI Dermatophytosis [ICD-11: 1F28.2] Approved INDICATI Candidiasis [ICD-11: 1F23] Approved TTDDRUID D06ZCH DRUGNAME SA-ANP INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D06ZCP DRUGNAME Ischemic tolerant allogeneic mesenchymal stem cell therapy INDICATI Acute myocardial infarction [ICD-11: BA41] Phase 2 TTDDRUID D06ZEC DRUGNAME Glucagon INDICATI Hypoglycemia [ICD-11: 5A41] Phase 1 TTDDRUID D06ZEE DRUGNAME Atovaquone INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D06ZEO DRUGNAME Vericiguat INDICATI Heart failure [ICD-11: BD10-BD13] Approved TTDDRUID D06ZFV DRUGNAME QPI-1007 INDICATI Ischemic optic neuropathy [ICD-11: 9C40.4] Phase 3 INDICATI Non-arteritic anterior ischemic optic neuropathy [ICD-11: 9C40.40] Phase 3 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2/3 TTDDRUID D06ZHN DRUGNAME Lactermin INDICATI Oral mucositis [ICD-11: DA01.11] Phase 1 TTDDRUID D06ZHZ DRUGNAME FX-125L INDICATI Sarcoidosis [ICD-11: 4B20.5] Phase 2 TTDDRUID D06ZII DRUGNAME Eszopiclone INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D06ZIL DRUGNAME CTA-001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06ZIS DRUGNAME SIG-990 INDICATI Rosacea [ICD-11: ED90.0] Investigative TTDDRUID D06ZIT DRUGNAME Pegloticase INDICATI Gout [ICD-11: FA25] Approved TTDDRUID D06ZJD DRUGNAME Melapuldencel-T INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D06ZKG DRUGNAME SC-56525 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D06ZME DRUGNAME RTL-551 INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D06ZNU DRUGNAME Pyrrolo[2,3-d]pyrimidine derivative 16 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Patented TTDDRUID D06ZPS DRUGNAME Oxyphenbutazone INDICATI Arthritis [ICD-11: FA20] Approved TTDDRUID D06ZPX DRUGNAME BTL-TML-001 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 INDICATI Herpes simplex labialis [ICD-11: 1F00.01] Phase 2 TTDDRUID D06ZQK DRUGNAME Nucleozin analog 3061 (FA-2) INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D06ZQL DRUGNAME NP-2 gene therapy INDICATI Cancer related pain [ICD-11: MG30] Phase 2 TTDDRUID D06ZUK DRUGNAME Imipramine INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D06ZUP DRUGNAME Dirithromycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D06ZVC DRUGNAME WAY-181187 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D06ZVG DRUGNAME AST-120 INDICATI Poison intoxication [ICD-11: NE6Z] Approved INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved INDICATI Thrombocytopenia [ICD-11: 3B64] Investigative TTDDRUID D06ZVO DRUGNAME PX-478 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06ZVZ DRUGNAME Duvelisib INDICATI Follicular lymphoma [ICD-11: 2A80] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D06ZWG DRUGNAME AVE-5997EF INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D06ZWL DRUGNAME Amdoxovir INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D06ZXF DRUGNAME U3-1565 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06ZXH DRUGNAME PHN-131 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2/3 TTDDRUID D06ZXT DRUGNAME N-6547 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D06ZYC DRUGNAME MLN0415 INDICATI Arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D06ZYM DRUGNAME Cholestyramine INDICATI Diarrhea [ICD-11: ME05.1] Approved TTDDRUID D06ZZL DRUGNAME MEDI-500 INDICATI Bone marrow transplantation [ICD-11: QB63.6] Terminated TTDDRUID D07AAN DRUGNAME Sodium Iodide I-123 INDICATI Thyroid disease [ICD-11: 5A00-5A06] Approved TTDDRUID D07ABV DRUGNAME Posaconazole INDICATI Aspergillosis [ICD-11: 1F20] Approved TTDDRUID D07ACL DRUGNAME PNT-2258 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 TTDDRUID D07ACP DRUGNAME CWF-0902 INDICATI Migraine [ICD-11: 8A80] Investigative TTDDRUID D07ACT DRUGNAME Ceftriaxone INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07ACZ DRUGNAME CLR457 INDICATI Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D07ADU DRUGNAME AEM-28 INDICATI Familial hypercholesterolemia [ICD-11: 5C80.00] Phase 2 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 1/2 TTDDRUID D07AEO DRUGNAME Isotretinoin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D07AGR DRUGNAME SB-206284A INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D07AHC DRUGNAME LITOXETINE INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 3 TTDDRUID D07AHW DRUGNAME Vitamin C INDICATI Vitamin C deficiency [ICD-11: 5B56] Approved INDICATI Urinary tract infection [ICD-11: GC08] Phase 2 TTDDRUID D07AIE DRUGNAME BAL-2299 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D07AJC DRUGNAME HIV MAG pDNA vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D07AJO DRUGNAME Bicyclic heteroaryl benzamide derivative 9 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D07AKD DRUGNAME TOL-101 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1/2 TTDDRUID D07ALX DRUGNAME Sirolimus INDICATI Lymphangioleiomyomatosis [ICD-11: CB07] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D07ANO DRUGNAME Synthetic neutrophil inhibitor peptide INDICATI Rhinitis [ICD-11: FA20] Phase 1 TTDDRUID D07AOL DRUGNAME PEITC INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D07AOO DRUGNAME Rilotumumab INDICATI Grade IV malignant glioma [ICD-11: 2A00.0] Discontinued in Phase 2 TTDDRUID D07AOY DRUGNAME Avarofloxacin INDICATI Bacterial pneumonia [ICD-11: CA40.0] Discontinued in Phase 2 TTDDRUID D07APS DRUGNAME TRC093 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07APX DRUGNAME Neuromed 5 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D07ARN DRUGNAME SAR-125844 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D07ATG DRUGNAME GSK2190914 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D07AUI DRUGNAME Influenza A virus vaccine H5N1 INDICATI Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 2 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D07AUS DRUGNAME KRL-901 INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 1 TTDDRUID D07AVU DRUGNAME PMID28621580-Compound-WO2015089220C70 INDICATI Retinopathy [ICD-11: 9B71] Patented INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Patented TTDDRUID D07AVV DRUGNAME Ac-YVAD-cmk INDICATI Photocontact dermatitis [ICD-11: EK20] Patented INDICATI Irritant contact dermatitis [ICD-11: EK02] Patented INDICATI Allergic contact dermatitis [ICD-11: EK00] Patented TTDDRUID D07AWM DRUGNAME Segard INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 3 TTDDRUID D07AYI DRUGNAME CWP232291 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D07AYN DRUGNAME Chikungunya virus vaccine INDICATI Chikungunya virus infection [ICD-11: 1D40] Phase 2 TTDDRUID D07BAE DRUGNAME SUN-0597 INDICATI Allergic rhinitis [ICD-11: CA08.0] Investigative TTDDRUID D07BAJ DRUGNAME Clade D HIV vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D07BBD DRUGNAME Zona pellucida contraceptive vaccine INDICATI Contraception [ICD-11: QA21] Terminated TTDDRUID D07BCO DRUGNAME WAY-100635 INDICATI Eating disorder [ICD-11: 6B82] Terminated TTDDRUID D07BCT DRUGNAME Tobramycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07BCU DRUGNAME Eflornithine + sulindac INDICATI Familial adenomatous polyposis [ICD-11: 2B90.Y] Phase 3 INDICATI Colon cancer [ICD-11: 2B90.Z] Phase 3 TTDDRUID D07BDW DRUGNAME OC-108 INDICATI Hemorrhoids [ICD-11: DB60] Approved TTDDRUID D07BDY DRUGNAME Tisocalcitate INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D07BEE DRUGNAME AnergiX.RA INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D07BFP DRUGNAME PMID27215781-Compound-37 INDICATI Prostate cancer [ICD-11: 2C82.0] Patented TTDDRUID D07BGC DRUGNAME GDC-0084 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 2 TTDDRUID D07BIK DRUGNAME VEL-0230 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D07BKL DRUGNAME KW-2170 INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D07BKR DRUGNAME ARQ 621 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D07BLC DRUGNAME AMT-090 INDICATI Huntington disease [ICD-11: 8A01.10] Investigative TTDDRUID D07BNG DRUGNAME RHIgM12B7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07BNL DRUGNAME NV.AT.08 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D07BPO DRUGNAME Ingavirin INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D07BPS DRUGNAME Suprofen INDICATI Miosis [ICD-11: LA11.62] Approved TTDDRUID D07BQE DRUGNAME Alteplase INDICATI Pulmonary embolism [ICD-11: BB00] Approved TTDDRUID D07BRZ DRUGNAME LY-517717 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 2 TTDDRUID D07BSE DRUGNAME Hyaluronate sodium INDICATI Joint lubricant [ICD-11: FA30-FA38] Approved INDICATI Enthesopathy [ICD-11: FB53-FB55] Phase 3 INDICATI Pancytopenia [ICD-11: 3A70.Z] Investigative TTDDRUID D07BSQ DRUGNAME Progesterone INDICATI Premature labour [ICD-11: JB00] Approved INDICATI Contraception [ICD-11: QA21] Phase 3 TTDDRUID D07BUH DRUGNAME F-627 INDICATI Neutropenia [ICD-11: 4B00.0] Phase 2 TTDDRUID D07BUO DRUGNAME AZD-3783 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D07BVI DRUGNAME Ipilimumab INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D07BWU DRUGNAME PMX-10072 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D07BXC DRUGNAME IZONSTERIDE INDICATI Hirsutism [ICD-11: ED72] Phase 1/2 TTDDRUID D07BXE DRUGNAME Daniquidone INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D07BXQ DRUGNAME VR632 INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D07BYK DRUGNAME Penciclovir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D07BZW DRUGNAME PMID25666693-Compound-85 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D07CAQ DRUGNAME SAFINGOL INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D07CBH DRUGNAME SKL13865 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1 TTDDRUID D07CBY DRUGNAME Cyclin A2 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Investigative TTDDRUID D07CCV DRUGNAME MK-0431C INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 3 TTDDRUID D07CEI DRUGNAME Zinc Sulfate INDICATI Zinc deficiency [ICD-11: 5B5K.2] Approved TTDDRUID D07CGH DRUGNAME 1D09C3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D07CGI DRUGNAME M-M-R II INDICATI Measles [ICD-11: 1F03] Approved TTDDRUID D07CIB DRUGNAME CI-1013 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1 TTDDRUID D07CIN DRUGNAME (-)-Phenserine INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D07CIX DRUGNAME FM-101 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D07CJN DRUGNAME ST-101 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D07CLV DRUGNAME GDC-0152 INDICATI Obesity [ICD-11: 5B81] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D07CMM DRUGNAME Interferon alfa-n3 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D07CMN DRUGNAME PD-200390 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Phase 2 TTDDRUID D07CNF DRUGNAME G-CSF INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D07CNL DRUGNAME Anisotropine Methylbromide INDICATI Peptic ulcer [ICD-11: DA61] Approved TTDDRUID D07CNY DRUGNAME Instiladrin INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 TTDDRUID D07CPL DRUGNAME Bicyclic heteroaryl benzamide derivative 6 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D07CPM DRUGNAME GP2013 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D07CPU DRUGNAME Rosoxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07CQJ DRUGNAME F-50040 INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 1 TTDDRUID D07CQW DRUGNAME Lomab B INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D07CTM DRUGNAME Carbol-fuchsin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07CUR DRUGNAME Bb2121 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D07CUU DRUGNAME SC-02 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D07CWD DRUGNAME Hydroxyurea INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Approved TTDDRUID D07CWH DRUGNAME INCB40093 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D07CXM DRUGNAME AVI-7288 INDICATI Marburg virus infection [ICD-11: 1D60.1] Phase 1 TTDDRUID D07DAU DRUGNAME Tafluposide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07DBE DRUGNAME Amolimogene INDICATI Dysplasia [ICD-11: LB30-LD2F] Phase 2/3 TTDDRUID D07DBS DRUGNAME RP-64477 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D07DCG DRUGNAME Ivosidenib INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved INDICATI Cholangiocarcinoma [ICD-11: 2C12.10] Phase 3 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D07DCX DRUGNAME CDP-855 INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D07DDK DRUGNAME HG-1177 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07DFC DRUGNAME Aromatic hydrazine carboxyimidoamide derivative 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D07DGA DRUGNAME Imatinib and nilotinib derivative 2 INDICATI Cas mediated disorder [ICD-11: N.A.] Patented TTDDRUID D07DGM DRUGNAME BQ-518 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D07DGR DRUGNAME SEL-113 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D07DIM DRUGNAME Herbimycin A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D07DIS DRUGNAME MG-1110 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07DIX DRUGNAME ALO-1567 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1 TTDDRUID D07DJP DRUGNAME Avigen Parkinson INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1/2 TTDDRUID D07DJQ DRUGNAME Emetine INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Approved TTDDRUID D07DLA DRUGNAME ISF-402 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D07DMY DRUGNAME MK-3475 INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D07DNV DRUGNAME ARN-2966 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D07DPC DRUGNAME IMGN-853 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07DPI DRUGNAME Aspirin/ esomeprazole fixed-dose combination INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D07DPM DRUGNAME HP-011-101 INDICATI Ulcer [ICD-11: CA02-CB40] Phase 2 TTDDRUID D07DQZ DRUGNAME CN-16 INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D07DRO DRUGNAME SF-106 INDICATI Retinopathy [ICD-11: 9B71] Investigative TTDDRUID D07DSK DRUGNAME BSI-302 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07DSN DRUGNAME BIIB 033 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D07DSQ DRUGNAME Vapreotide acetate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D07DTC DRUGNAME L-97-1 intravenous INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D07DTM DRUGNAME Cetraxal Otic INDICATI Otitis externa [ICD-11: AA00-AA13] Phase 3 TTDDRUID D07DTV DRUGNAME AT7519 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07DTZ DRUGNAME VK0612 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D07DUU DRUGNAME Alglucosidase alfa INDICATI Pompe disease [ICD-11: 5C51.3] Approved TTDDRUID D07DVK DRUGNAME Beclomethasone INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D07DWB DRUGNAME Revascor INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 TTDDRUID D07DWC DRUGNAME SDX-7320 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07DWF DRUGNAME ARQ 092 INDICATI Proteus syndrome [ICD-11: LD2C] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07DZS DRUGNAME 1,3-bis(1,3-benzothiazol-2-ylthio)acetone INDICATI Glioma [ICD-11: 2A00.0] Investigative INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D07DZT DRUGNAME H2TFPC-SGlc INDICATI Colon cancer [ICD-11: 2B90.Z] Investigative TTDDRUID D07EAV DRUGNAME PMID25666693-Compound-41 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D07EBF DRUGNAME CK-2017357 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 3 INDICATI Muscle fatigue [ICD-11: FB32.5] Phase 2 TTDDRUID D07EBU DRUGNAME AMG-221 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Discontinued in Phase 1 TTDDRUID D07EDB DRUGNAME Ozanimod INDICATI Multiple sclerosis [ICD-11: 8A40] Approved INDICATI Ulcerative colitis [ICD-11: DD71] Phase 3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D07EEN DRUGNAME Lixivaptan INDICATI Hyponatraemia [ICD-11: 5C72] Phase 3 INDICATI Skin infection [ICD-11: 1F28-1G0Z] Phase 2 INDICATI Congestive heart failure [ICD-11: BD10] Phase 2 TTDDRUID D07EFA DRUGNAME AST-915 INDICATI Movement disorder [ICD-11: 8A07-8A0Z] Discontinued in Phase 1/2 TTDDRUID D07EFB DRUGNAME LFn-p24-B-C INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D07EFM DRUGNAME Arecoline INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D07EGF DRUGNAME PMID25666693-Compound-56 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D07EGS DRUGNAME CGS-23425 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D07EGW DRUGNAME AE-0047 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Preregistration TTDDRUID D07EHB DRUGNAME Latrunculin B INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1 TTDDRUID D07EHV DRUGNAME LGH-447 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D07EIJ DRUGNAME EPI-12323 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D07EIQ DRUGNAME Fluvoxamine INDICATI Obsessive compulsive disorder [ICD-11: 6B20] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D07EJY DRUGNAME AR-12286 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2 TTDDRUID D07EKK DRUGNAME PTC596 INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1 TTDDRUID D07ELC DRUGNAME ABI-2088 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07ELT DRUGNAME NOX-700 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D07ENB DRUGNAME NPI-32101 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D07ENH DRUGNAME IVV-001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07EPV DRUGNAME Teneligliptin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D07EQJ DRUGNAME RG-7594 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D07ESC DRUGNAME Apremilast INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved TTDDRUID D07ESH DRUGNAME PF-1913539 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 3 TTDDRUID D07EUO DRUGNAME Naltrexone INDICATI Chronic alcoholism [ICD-11: 6C40.2Z] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D07EUY DRUGNAME H5N1 influenza vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D07EXH DRUGNAME Phloroglucinol INDICATI Urinary tract disease [ICD-11: GC2Z] Approved TTDDRUID D07EXV DRUGNAME XEMILOFIBAN INDICATI Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 3 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3 TTDDRUID D07FBM DRUGNAME ASP1941 INDICATI Liver disease [ICD-11: DB90-BD99] Phase 3 TTDDRUID D07FCA DRUGNAME BAMLET INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D07FDM DRUGNAME FR-901379 INDICATI Pneumocystis pneumonia [ICD-11: CA40.20] Terminated TTDDRUID D07FDV DRUGNAME Melaxin INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 2 TTDDRUID D07FEC DRUGNAME Plecanatide INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved INDICATI Chronic idiopathic constipation [ICD-11: DC32] Approved INDICATI Crohn disease [ICD-11: DD70] Phase 3 TTDDRUID D07FGA DRUGNAME ZYC101a INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 2/3 TTDDRUID D07FGK DRUGNAME SAR-3419 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D07FGU DRUGNAME SAR440067 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D07FGV DRUGNAME LLL-2011 INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 3 TTDDRUID D07FHI DRUGNAME Chlamydia vaccine INDICATI Chlamydia infection [ICD-11: 1A81] Terminated TTDDRUID D07FHW DRUGNAME PF-915275 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D07FHZ DRUGNAME Ro 20-1724 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D07FIC DRUGNAME CYT-6091 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07FIF DRUGNAME APH-0701 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D07FIY DRUGNAME PMID25666693-Compound-50 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D07FJM DRUGNAME BRECANAVIR INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D07FKQ DRUGNAME Siponimod INDICATI Multiple sclerosis [ICD-11: 8A40] Approved INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D07FKX DRUGNAME HMPL-011 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D07FMW DRUGNAME PMID25684022-Compound-US20130053382 38(5-7) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D07FND DRUGNAME Nabi-HB INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D07FNG DRUGNAME AM336 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D07FPJ DRUGNAME MK-4214 INDICATI Neutropenia [ICD-11: 4B00.0] Phase 3 TTDDRUID D07FPR DRUGNAME R4996 INDICATI Neurological disorder [ICD-11: 6B60] Phase 1 TTDDRUID D07FPY DRUGNAME SB-639 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07FQL DRUGNAME Diannexin INDICATI Myocardial reperfusion injury [ICD-11: NB31] Phase 2 TTDDRUID D07FQS DRUGNAME ZP-011 INDICATI Sinusitis [ICD-11: CA0A.Z] Investigative TTDDRUID D07FRV DRUGNAME Ramipril INDICATI Acute heart failure [ICD-11: BD10-BD13] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D07FTD DRUGNAME Sodium Monofluorophosphate INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved TTDDRUID D07FUH DRUGNAME LPCN-1087 INDICATI Cough [ICD-11: MD12] Investigative TTDDRUID D07FUJ DRUGNAME Fluorescein Sodium INDICATI Diagnostic fluorescein angiography or angioscopy of vasculature [ICD-11: BA00-BE2Z] Approved TTDDRUID D07FUO DRUGNAME TA-264 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D07FUP DRUGNAME Dupilumab INDICATI Atopic dermatitis [ICD-11: EA80] Approved INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D07FWF DRUGNAME PMID25666693-Compound-117 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D07FWH DRUGNAME RU-59863 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D07FXF DRUGNAME CP-613 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D07FYK DRUGNAME HuMax-VEGF INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07FZC DRUGNAME Recombinant vaccine INDICATI Allergy [ICD-11: 4A80-4A85] Phase 2 TTDDRUID D07FZF DRUGNAME XMT-1522 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D07GAA DRUGNAME ACP-001 INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Phase 2 TTDDRUID D07GAN DRUGNAME Biaryl mannoside derivative 12 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D07GCK DRUGNAME ARC-100 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D07GDN DRUGNAME Torcetrapib INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 2 TTDDRUID D07GDR DRUGNAME AMG 282 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D07GET DRUGNAME ALTU-236 INDICATI Genetic disease [ICD-11: 8E02] Investigative TTDDRUID D07GFF DRUGNAME PKI166 INDICATI Esophageal cancer [ICD-11: 2B70] Discontinued in Phase 2 TTDDRUID D07GFZ DRUGNAME VVZ-138 INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D07GGQ DRUGNAME ND-801 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D07GGT DRUGNAME ANT-429 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07GHA DRUGNAME PLX2853 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D07GHV DRUGNAME PF-05180999 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D07GIB DRUGNAME AZD5672 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D07GJH DRUGNAME PMID26161824-Compound-68 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D07GJZ DRUGNAME CQA 206-291 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D07GKS DRUGNAME MAGE-101 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D07GLB DRUGNAME PEV-7 INDICATI Candidiasis [ICD-11: 1F23] Phase 1 TTDDRUID D07GLF DRUGNAME Nemifitide INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D07GLX DRUGNAME CNS-1531 INDICATI Nervous system disease [ICD-11: 8A00-8E7Z] Terminated TTDDRUID D07GMF DRUGNAME MVA-85A INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2 TTDDRUID D07GNL DRUGNAME GSK-523338 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D07GNO DRUGNAME KRN-330 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 TTDDRUID D07GNP DRUGNAME Iopromide INDICATI X-rays imaging [ICD-11: N.A.] Approved TTDDRUID D07GNR DRUGNAME Vivaglobin INDICATI Nervous system disease [ICD-11: 8A00-8E7Z] Approved TTDDRUID D07GOY DRUGNAME CD59 gene therapy INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Investigative TTDDRUID D07GQA DRUGNAME ZD-7155 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D07GRH DRUGNAME Ciclopirox INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D07GTF DRUGNAME Aipusheng INDICATI Japanese encephalitis virus infection [ICD-11: 1C85] Approved TTDDRUID D07GTW DRUGNAME Fosdenopterin INDICATI Molybdenum cofactor deficiency [ICD-11: 5B5K.A] Approved INDICATI Encephalopathy [ICD-11: 8E47] Phase 2 TTDDRUID D07GVE DRUGNAME EDP-14 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D07GVM DRUGNAME JNJ-42491293 INDICATI Psychiatric disorder [ICD-11: 6E8Z] Phase 1 TTDDRUID D07GWZ DRUGNAME NT-501 CNTF INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 TTDDRUID D07GXR DRUGNAME Ubrogepant INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D07GYP DRUGNAME TYT-1 INDICATI West nile virus infection [ICD-11: 1D46] Investigative TTDDRUID D07GZG DRUGNAME Endomorphins INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D07GZL DRUGNAME R-701 INDICATI Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 1 TTDDRUID D07GZZ DRUGNAME Grass allergy vaccine INDICATI Allergic rhinitis [ICD-11: CA08.0] Terminated TTDDRUID D07HAD DRUGNAME Telbermin INDICATI Diabetic foot ulcer [ICD-11: BD54] Discontinued in Phase 2 TTDDRUID D07HAR DRUGNAME OMS-302 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D07HBI DRUGNAME ZD-2138 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D07HBX DRUGNAME Salicyclic acid INDICATI Seborrhoeic dermatitis [ICD-11: EA81] Approved TTDDRUID D07HCH DRUGNAME LY2812176 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D07HGR DRUGNAME Lisinopril INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D07HJS DRUGNAME Anti-BCMA CAR-T cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D07HJT DRUGNAME Amidine compound 3 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Patented TTDDRUID D07HKV DRUGNAME IMGN-388 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07HLS DRUGNAME Anacetrapib INDICATI Arteriosclerosis [ICD-11: BD40] Phase 3 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D07HLZ DRUGNAME GZ404477 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D07HOA DRUGNAME Heterocyclic derivative 9 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D07HOB DRUGNAME Irinotecan INDICATI Colorectal cancer [ICD-11: 2B91.Z] Approved TTDDRUID D07HOF DRUGNAME Picibanil INDICATI Carcinoma [ICD-11: 2A00-2F9Z] Phase 4 TTDDRUID D07HOH DRUGNAME MM-398 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 TTDDRUID D07HOP DRUGNAME Alkyl mannoside derivative 9 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D07HOT DRUGNAME ALXN1007 INDICATI Phospholipid syndrome [ICD-11: 4A45] Phase 2 TTDDRUID D07HPH DRUGNAME MEDI5083 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07HPJ DRUGNAME AEW-541 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D07HQC DRUGNAME Modafinil INDICATI Narcolepsy [ICD-11: 7A20] Approved INDICATI Bipolar disorder [ICD-11: 6A60] Phase 4 INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D07HRU DRUGNAME KRN633 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Glioma [ICD-11: 2A00.0] Phase 1 TTDDRUID D07HSR DRUGNAME GSK2798745 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D07HTX DRUGNAME GL-331 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2 TTDDRUID D07HUW DRUGNAME Oregovomab INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 INDICATI Epithelial ovarian cancer [ICD-11: 2B5D] Phase 2 TTDDRUID D07HVY DRUGNAME Efavirenz INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D07HYR DRUGNAME GCC-1290K INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D07HZG DRUGNAME PF-00734200 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D07HZP DRUGNAME CNTO888 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07HZY DRUGNAME Xylose INDICATI Gastrointestinal disease [ICD-11: DE2Z] Approved TTDDRUID D07IBY DRUGNAME STA-9584 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07IEC DRUGNAME GSK2340273A INDICATI Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 2 TTDDRUID D07IEF DRUGNAME Bisacodyl INDICATI Constipation [ICD-11: DD91.1] Approved TTDDRUID D07IEM DRUGNAME AMG-8562 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D07IEU DRUGNAME MLN2480 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D07IGC DRUGNAME DSP-8658 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D07IGE DRUGNAME Glyfoline INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D07IGQ DRUGNAME C-Immune INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D07IHT DRUGNAME N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 1 INDICATI Osteoporosis [ICD-11: FB83.0] Patented TTDDRUID D07IIX DRUGNAME AMELTOLIDE INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 1 TTDDRUID D07ILQ DRUGNAME Guanfacine extended release INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved TTDDRUID D07IMX DRUGNAME BMS-844421 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 1 TTDDRUID D07IND DRUGNAME SRD-285 INDICATI Wound healing [ICD-11: EL8Y] Preclinical TTDDRUID D07INL DRUGNAME SCY-078 INDICATI Invasive candidiasis [ICD-11: 1F23] Phase 3 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 2 TTDDRUID D07INU DRUGNAME LDN-22684 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D07INV DRUGNAME Ethoxzolamide INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved INDICATI Duodenal ulcer [ICD-11: DA63] Withdrawn from market TTDDRUID D07IOT DRUGNAME TPI 287 INDICATI Glioma [ICD-11: 2A00.0] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 INDICATI Brain metastases [ICD-11: 2D50] Phase 1 INDICATI Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 1 TTDDRUID D07IPB DRUGNAME Valrubicin INDICATI Bladder cancer [ICD-11: 2C94] Approved INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D07IQE DRUGNAME Heterocyclic derivative 10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D07IQS DRUGNAME Atazanavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D07IRF DRUGNAME Prasugrel INDICATI Acute coronary syndrome [ICD-11: BA41] Approved TTDDRUID D07IRG DRUGNAME Calcium polycarbophil INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved TTDDRUID D07ISD DRUGNAME AFPep INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D07ISE DRUGNAME Interferon alpha INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2 TTDDRUID D07ISO DRUGNAME VariZIG INDICATI Postherpetic neuralgia [ICD-11: 1E91.5] Approved TTDDRUID D07ISX DRUGNAME Thalidomide INDICATI Multiple myeloma [ICD-11: 2A83] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D07ITH DRUGNAME 4SCAR19 cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D07IVS DRUGNAME Gerilimzumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D07IXD DRUGNAME P-0654 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D07IYC DRUGNAME TDI-0067 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D07IYO DRUGNAME Triazavirin INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D07IZF DRUGNAME Sch-57790 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D07IZG DRUGNAME GSK4112 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Preclinical TTDDRUID D07IZP DRUGNAME ND-401 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D07IZS DRUGNAME ITE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07JAG DRUGNAME Upadacitinib INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 3 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 INDICATI Crohn disease [ICD-11: DD70] Phase 2 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 TTDDRUID D07JAI DRUGNAME NSC-639829 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07JBE DRUGNAME CG-200745 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07JCU DRUGNAME PRS-040 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D07JDR DRUGNAME LRN-672 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D07JEW DRUGNAME Human coagulation factor X INDICATI Renal cell carcinoma [ICD-11: 2C90] BLA submitted TTDDRUID D07JFE DRUGNAME CVT-427 INDICATI Migraine [ICD-11: 8A80] Phase 1 TTDDRUID D07JFU DRUGNAME CGEN-712 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative TTDDRUID D07JGH DRUGNAME UR-13756 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D07JGT DRUGNAME Nalidixic Acid INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D07JHH DRUGNAME Meclocycline INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07JHJ DRUGNAME IGANIDIPINE HYDROCHLORIDE INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 1 TTDDRUID D07JHK DRUGNAME AMG 151 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D07JHV DRUGNAME Carimune NF INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved TTDDRUID D07JIN DRUGNAME FMX103 INDICATI Rosacea [ICD-11: ED90.0] Phase 3 TTDDRUID D07JJC DRUGNAME DPC-684 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D07JJS DRUGNAME Sulfamethizole INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D07JKA DRUGNAME SEN-1500 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D07JKY DRUGNAME KP-496 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D07JLM DRUGNAME Alagebrium chloride INDICATI Hypotension [ICD-11: BA20-BA21] Phase 2/3 TTDDRUID D07JMX DRUGNAME XEN-600 INDICATI Iron overload disease [ICD-11: 5C64.10] Investigative TTDDRUID D07JNJ DRUGNAME PMID25666693-Compound-17 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D07JOS DRUGNAME NS-004 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D07JOW DRUGNAME XTL-Pseudomonas-mab INDICATI Pseudomonas infection [ICD-11: 1B92] Investigative TTDDRUID D07JPC DRUGNAME Arbekacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07JPK DRUGNAME ETX-1153b INDICATI MRSA infection [ICD-11: 1D01.0Y] Preclinical TTDDRUID D07JPL DRUGNAME RT-401 INDICATI Rhinitis [ICD-11: FA20] Investigative TTDDRUID D07JQO DRUGNAME SB 249417 INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1 TTDDRUID D07JRF DRUGNAME Influenza A virus H1N1 vaccine INDICATI Familial chylomicronemia syndrome [ICD-11: 5C80] Phase 3 TTDDRUID D07JRL DRUGNAME Epithalon INDICATI Ocular inflammation [ICD-11: 9C61.24] Phase 1/2 TTDDRUID D07JSI DRUGNAME Salicylihalamide A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D07JSK DRUGNAME Sulotroban INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D07JSX DRUGNAME IL-2 pDNA INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D07JTD DRUGNAME NSC-645809 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D07JTH DRUGNAME MM-Q01 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Approved TTDDRUID D07JUL DRUGNAME JR-032 INDICATI Hunter syndrome [ICD-11: 5C56.31] Investigative TTDDRUID D07JVL DRUGNAME Diazepam INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D07JVO DRUGNAME Fosbretabulin INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D07JVS DRUGNAME Cephalosporin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07JVT DRUGNAME GWN323 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07JVU DRUGNAME Ciclosporin INDICATI Graft-versus-host disease [ICD-11: 4B24] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D07JWO DRUGNAME IL-21 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D07JWT DRUGNAME Perazine INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Approved TTDDRUID D07JXN DRUGNAME SPP-600 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D07JXR DRUGNAME IMD-4852 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D07JZF DRUGNAME Netilmicin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07JZT DRUGNAME LA-EP2006 INDICATI Neutropenia [ICD-11: 4B00.0] Phase 3 TTDDRUID D07KAB DRUGNAME AST-VAC1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D07KAK DRUGNAME OSH-101 INDICATI Alopecia [ICD-11: ED70] Phase 2 TTDDRUID D07KAQ DRUGNAME L19-IL-2 fusion protein INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 TTDDRUID D07KBM DRUGNAME AZD4573 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D07KCA DRUGNAME Aryl mannoside derivative 22 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D07KDE DRUGNAME Fusafungine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Withdrawn from market TTDDRUID D07KDI DRUGNAME AR-42 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 TTDDRUID D07KEH DRUGNAME AKB-6548 INDICATI Anaemia [ICD-11: 3A90] Phase 3 TTDDRUID D07KFB DRUGNAME Varespladib methyl INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D07KFG DRUGNAME Human prothrombin complex concentrate INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved TTDDRUID D07KGR DRUGNAME VI-1121 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D07KGV DRUGNAME Anti-HCV agent INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D07KGW DRUGNAME PF-3392455 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D07KHH DRUGNAME LAS-34273 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D07KHR DRUGNAME PSMA-VRP INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D07KIB DRUGNAME 4-fluoroselegiline INDICATI Dementia [ICD-11: 6D80-6D86] Investigative TTDDRUID D07KIE DRUGNAME LYC-30937 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 TTDDRUID D07KIJ DRUGNAME INCB3344 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D07KJH DRUGNAME LYMErix INDICATI Lyme disease [ICD-11: 1C1G] Approved TTDDRUID D07KKQ DRUGNAME Hepatitis A vaccine INDICATI Hepatitis A virus infection [ICD-11: 1E50.0] Approved TTDDRUID D07KKZ DRUGNAME Ga 68 dotatate INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Approved TTDDRUID D07KMA DRUGNAME T-oligos INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07KMI DRUGNAME ACI-518 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D07KOR DRUGNAME INOC-002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D07KSG DRUGNAME Tamoxifen INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D07KTA DRUGNAME Ab-01 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 2 TTDDRUID D07KTP DRUGNAME SCH79687 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D07KUN DRUGNAME RAD-1901 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D07KVD DRUGNAME ARGX-109 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D07KVL DRUGNAME PMID28270021-Compound-WO2010077680 811 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D07KVV DRUGNAME Selinexor INDICATI Multiple myeloma [ICD-11: 2A83] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D07KWN DRUGNAME Isosteviol INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D07KYK DRUGNAME NK-111 INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative TTDDRUID D07KYT DRUGNAME AC220 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 3 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 TTDDRUID D07KYU DRUGNAME Benactyzine INDICATI Depression [ICD-11: 6A70-6A7Z] Withdrawn from market TTDDRUID D07KYZ DRUGNAME GABA-B receptor PAM INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D07LAP DRUGNAME BMS-184476 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D07LBP DRUGNAME RabiCide INDICATI Rabies [ICD-11: 1C82] Investigative TTDDRUID D07LBQ DRUGNAME GSK2398852 INDICATI Amyloidosis [ICD-11: 5D00] Phase 1 TTDDRUID D07LCA DRUGNAME AMG0714 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D07LCF DRUGNAME Naloxegol INDICATI Opioid-induced constipation [ICD-11: DB32.1] Approved TTDDRUID D07LCP DRUGNAME Ad5Ag85A INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1 TTDDRUID D07LCY DRUGNAME RVSVIN HIV-1 gag vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D07LEW DRUGNAME BIBS-39 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D07LFJ DRUGNAME BU-32 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07LGU DRUGNAME MMPT INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07LJR DRUGNAME CDR-267F018 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D07LLI DRUGNAME Mucin type glycoproteins INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D07LMO DRUGNAME Drug 2862277 INDICATI Acute lung injury [ICD-11: NB32.3] Phase 2 TTDDRUID D07LPT DRUGNAME EP-7041 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D07LRB DRUGNAME Factor VIII-XTEN INDICATI Hemophilia [ICD-11: 3B10.0] Investigative TTDDRUID D07LRT DRUGNAME A-425619 INDICATI Pain [ICD-11: MG30-MG3Z] Preclinical TTDDRUID D07LSU DRUGNAME CDRI-S002-333 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D07LSV DRUGNAME Recombinant galectin-3 INDICATI Corneal abrasion [ICD-11: NA06.4] Investigative TTDDRUID D07LUA DRUGNAME PfSPZ-GA1 INDICATI Plasmodium falciparum malaria [ICD-11: 1F40] Phase 2 TTDDRUID D07LUJ DRUGNAME URSOLIC ACID INDICATI Metabolic syndrome x [ICD-11: 5C50-5D2Z] Phase 2 TTDDRUID D07LWK DRUGNAME AVE0118 INDICATI Obstructive sleep apnea [ICD-11: 7A41] Phase 1 TTDDRUID D07LWL DRUGNAME WIN-34B INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 TTDDRUID D07LWT DRUGNAME FE-202767 INDICATI Erectile dysfunction [ICD-11: HA01.1] Phase 2 TTDDRUID D07LYC DRUGNAME SCYX-7158 INDICATI Trypanosomiasis [ICD-11: 1D51-1F53] Phase 1 TTDDRUID D07LZH DRUGNAME ERB-041 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2 TTDDRUID D07MBQ DRUGNAME CNTO-736 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D07MCK DRUGNAME Salicylamide INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D07MDY DRUGNAME Elsulfavirine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D07MED DRUGNAME RG7716 INDICATI Neovascular age-related macular degeneration [ICD-11: 9B78.3Z] Phase 3 INDICATI Choroidal neovascularization [ICD-11: 9B76] Phase 2 TTDDRUID D07MEH DRUGNAME Meglitinides INDICATI Type-2 diabetes [ICD-11: 5A11] Approved INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 4 TTDDRUID D07MEL DRUGNAME Amiprilose INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Preregistration TTDDRUID D07MEX DRUGNAME CLR-1401 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D07MFY DRUGNAME STX-200 INDICATI Acute lung injury [ICD-11: NB32.3] Investigative TTDDRUID D07MGA DRUGNAME Hesperetin INDICATI High blood cholesterol level [ICD-11: 5C80.00] Approved TTDDRUID D07MGC DRUGNAME Talacotuzumab INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D07MHM DRUGNAME PP-405 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07MKL DRUGNAME ABT-229 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D07MLA DRUGNAME CIGB-200 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D07MLP DRUGNAME APN-601 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D07MMC DRUGNAME STP-702 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D07MME DRUGNAME Dexamethasone palmitate INDICATI Choroidal neovascularization [ICD-11: 9B76] Phase 1/2 TTDDRUID D07MNI DRUGNAME PMID25666693-Compound-127 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D07MNT DRUGNAME P52-/p36- GAP vaccine INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1/2 TTDDRUID D07MOK DRUGNAME KANAb-071 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D07MON DRUGNAME ONAPRISTONE INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D07MOX DRUGNAME Norepinephrine INDICATI Sepsis [ICD-11: 1G40-1G41] Approved TTDDRUID D07MPI DRUGNAME MEDI-0639 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07MPJ DRUGNAME A-75925 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2 TTDDRUID D07MPL DRUGNAME SNX-5422 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1 TTDDRUID D07MQC DRUGNAME PS-1145 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D07MQY DRUGNAME HIV-LAMP-vax INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D07MSB DRUGNAME Thiazole carboxamide derivative 11 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D07MSL DRUGNAME TL-1836 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07MTL DRUGNAME SRSC-371 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D07MTT DRUGNAME HP-831-064 INDICATI Wound healing [ICD-11: EL8Y] Phase 1 TTDDRUID D07MUN DRUGNAME Vitamin B6 INDICATI Vitamin B6 deficiency [ICD-11: 5B5D] Approved TTDDRUID D07MUS DRUGNAME CPA-7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07MUT DRUGNAME TDI-0032 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D07MVE DRUGNAME PD-151832 INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1/2 TTDDRUID D07MVK DRUGNAME Halofantrine INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D07MWY DRUGNAME XR-1853 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D07MXA DRUGNAME C75 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D07MXF DRUGNAME Zabofloxacin INDICATI Pneumonia [ICD-11: CA40] Phase 3 TTDDRUID D07MZC DRUGNAME Vasoflux INDICATI Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2 TTDDRUID D07NAA DRUGNAME Sulfonylated piperazine derivative 4 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D07NAJ DRUGNAME Chloroprocaine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D07NBA DRUGNAME Veltuzumab INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Thrombocytopenia [ICD-11: 3B64] Phase 1/2 TTDDRUID D07NCC DRUGNAME VTT-201 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D07NCN DRUGNAME Doxofylline INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D07NCV DRUGNAME BXT-51072 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D07NDK DRUGNAME WAY-644 INDICATI Aortic aneurysm [ICD-11: BD50] Investigative TTDDRUID D07NEE DRUGNAME AEZS-131 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07NEI DRUGNAME PMID30280939-Compound-US20179642901 INDICATI Malaria [ICD-11: 1F40-1F45] Patented TTDDRUID D07NFT DRUGNAME P-2281 INDICATI Ulcerative colitis [ICD-11: DD71] Investigative TTDDRUID D07NFW DRUGNAME BMS-196085 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D07NGJ DRUGNAME S-23906-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D07NGZ DRUGNAME Insulin-glargine INDICATI Diabetic complication [ICD-11: 5A2Y] Approved INDICATI Malaria [ICD-11: 1F40-1F45] Phase 3 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 INDICATI Type-2 diabetes [ICD-11: 5A11] Application submitted TTDDRUID D07NHZ DRUGNAME CD19 CAR T cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D07NJI DRUGNAME Treximet INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D07NJN DRUGNAME Siltuximab INDICATI Anemia [ICD-11: 3A00-3A9Z] Approved INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D07NKJ DRUGNAME AT-001 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D07NKZ DRUGNAME VVP-808 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D07NLI DRUGNAME Vismed INDICATI Eye disorder [ICD-11: 9A01-9A0Z] Phase 4 TTDDRUID D07NOI DRUGNAME BAY-57-9352 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2 TTDDRUID D07NPH DRUGNAME Colostrinin INDICATI Alzheimer disease [ICD-11: 8A20] Approved TTDDRUID D07NPS DRUGNAME Zarnestra INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 2 INDICATI Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D07NPX DRUGNAME Triiodothyronine INDICATI Euthyroid goiter [ICD-11: 5A01.1] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D07NSU DRUGNAME Glucosamine INDICATI Osteoarthritis [ICD-11: FA00-FA05] Approved TTDDRUID D07NTC DRUGNAME WCK-771 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D07NTN DRUGNAME CERM-11956 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 1 TTDDRUID D07NUH DRUGNAME IDX-15971 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D07NUL DRUGNAME PF-06650833 INDICATI Lupus [ICD-11: 4A40] Phase 1 TTDDRUID D07NUO DRUGNAME JNJ-39588146 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D07NUZ DRUGNAME Phospho-aspirins INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07NVF DRUGNAME WAS gene therapy INDICATI Wiskott-Aldrich syndrome [ICD-11: 3B62.0] Phase 1/2 TTDDRUID D07NVI DRUGNAME CPI-613 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 2 INDICATI Recurrent adult burkitt lymphoma [ICD-11: 2A85.6] Phase 2 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 1 INDICATI T-cell lymphoma [ICD-11: 2A90] Phase 1 TTDDRUID D07NVU DRUGNAME Midostaurin INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved INDICATI Systemic mastocytosis [ICD-11: 2A21.0] Approved INDICATI Chronic myelomonocytic leukaemia [ICD-11: 2A40] Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D07NWC DRUGNAME SC-241 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D07NWZ DRUGNAME CL-301 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D07NYF DRUGNAME MLN-2201 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1 TTDDRUID D07NZC DRUGNAME AMG 581 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 1 TTDDRUID D07OAD DRUGNAME GO-203-2c INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D07OAO DRUGNAME IONIS-HTTRX INDICATI Huntington disease [ICD-11: 8A01.10] Phase 3 TTDDRUID D07OBJ DRUGNAME PHX-1766 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D07OBK DRUGNAME SL-201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07OCC DRUGNAME JSM-10292 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D07OCM DRUGNAME Dendritic cell-based immunotherapy INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D07OCV DRUGNAME HT-0712 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 TTDDRUID D07ODC DRUGNAME VBY- 036 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D07OED DRUGNAME BL-5040 INDICATI Cachexia [ICD-11: MG20] Investigative TTDDRUID D07OEY DRUGNAME ZK-118182 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D07OFM DRUGNAME GSK525762 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D07OGR DRUGNAME YM-26734 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D07OGZ DRUGNAME Darexaban maleate INDICATI Acute coronary syndrome [ICD-11: BA41] Discontinued in Phase 3 TTDDRUID D07OHO DRUGNAME Ampiroxicam INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D07OHT DRUGNAME ABT-450 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D07OIO DRUGNAME AZD-2461 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07OIX DRUGNAME Iodipamide INDICATI Gallbladder disease [ICD-11: DC11.3] Approved TTDDRUID D07OIZ DRUGNAME R-84 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07OJZ DRUGNAME Capmatinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D07OLO DRUGNAME Milacemide INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D07OMK DRUGNAME RO-48-6791 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D07ONP DRUGNAME Phenacemide INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D07OQJ DRUGNAME GM-CAIX INDICATI Renal cell carcinoma [ICD-11: 2C90] Investigative TTDDRUID D07ORE DRUGNAME TVGV-1 vaccine INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 2 TTDDRUID D07ORO DRUGNAME Solamargine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D07OSS DRUGNAME 9cUAB-30 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07OTU DRUGNAME NRX-1050 INDICATI Bipolar disorder [ICD-11: 6A60] Investigative TTDDRUID D07OTW DRUGNAME WT2725 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D07OUE DRUGNAME AUX-202 INDICATI Bone metastases [ICD-11: 2D50] Terminated TTDDRUID D07OVM DRUGNAME Benzothiazine-carboxamide compound 4 INDICATI Skin inflammation [ICD-11: EF20.Y] Patented TTDDRUID D07OXW DRUGNAME FVh1 DNA-based influenza vaccine INDICATI Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 1 TTDDRUID D07OYT DRUGNAME NPB-2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07OZO DRUGNAME BMP-4 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Investigative TTDDRUID D07OZR DRUGNAME TKI258 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 3 INDICATI Endometrial cancer [ICD-11: 2C76] Phase 2 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D07PAG DRUGNAME U-97456 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D07PAO DRUGNAME Sulphadoxine INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D07PAY DRUGNAME B-956 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D07PBZ DRUGNAME Epoetin alfa INDICATI Anemia [ICD-11: 3A00-3A9Z] Approved TTDDRUID D07PCI DRUGNAME Carboprost Tromethamine INDICATI Abortion [ICD-11: JA00] Approved TTDDRUID D07PCZ DRUGNAME AR20.5 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D07PFG DRUGNAME HL-009 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D07PFU DRUGNAME JNJ-63733657 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D07PHS DRUGNAME CXCL8 INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D07PIA DRUGNAME AG-1350 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D07PIH DRUGNAME Pyrazole derivative 60 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D07PJR DRUGNAME Cyclic compound 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D07PJS DRUGNAME JNJ-68284528 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D07PLK DRUGNAME WIN-64821 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D07PMG DRUGNAME Afeletecan INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D07PMH DRUGNAME VH-0445 based conjugated therapeutics INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D07PML DRUGNAME Ublituximab + umbralisib INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2/3 TTDDRUID D07PMP DRUGNAME PKI-402 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07PMU DRUGNAME 111In-OC-125 F(ab1/2)-DTPA INDICATI Ovarian cancer [ICD-11: 2C73] Terminated TTDDRUID D07PNC DRUGNAME Organon INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D07PND DRUGNAME Diphenyl purine derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D07PNQ DRUGNAME CD200Fc INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D07PNT DRUGNAME XL999 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07PNX DRUGNAME PMID26815044-Compound-115 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D07POC DRUGNAME Erlotinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 INDICATI Colon cancer [ICD-11: 2B90.Z] Phase 2 TTDDRUID D07POS DRUGNAME Alkyl mannoside derivative 12 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D07POY DRUGNAME Peptagon INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D07PQJ DRUGNAME ARQ-087 INDICATI Intrahepatic cholangiocarcinoma [ICD-11: 2C12.10] Phase 3 INDICATI Cholangiocarcinoma [ICD-11: 2C12.10] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07PRA DRUGNAME UX-005 INDICATI Lysosomal storage disease [ICD-11: 5C56.Z] Investigative TTDDRUID D07PRC DRUGNAME BAL-30072 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D07PRH DRUGNAME DE-098 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D07PSJ DRUGNAME Resorcinol compound 24 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D07PSL DRUGNAME PLX7486 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07PSP DRUGNAME U-75875 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D07PSX DRUGNAME ABBV-084 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 TTDDRUID D07PTH DRUGNAME 13-cis-retinoic acid INDICATI Glioma [ICD-11: 2A00.0] Phase 3 INDICATI Infertility [ICD-11: GB04] Phase 2 INDICATI Azoospermia [ICD-11: GB04.0] Phase 2 TTDDRUID D07PUS DRUGNAME DSM1 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D07PVB DRUGNAME Squalamine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 TTDDRUID D07PVT DRUGNAME NVC-638 INDICATI Conjunctivitis [ICD-11: 9A60] Investigative TTDDRUID D07PVX DRUGNAME Aryl mannoside derivative 21 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D07PWY DRUGNAME Anti-RON receptor mabs INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07PXQ DRUGNAME ASP-2151 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 3 TTDDRUID D07QAA DRUGNAME BRL-46470 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D07QAF DRUGNAME BI 207127 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D07QAH DRUGNAME Biaryl mannoside derivative 17 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D07QAK DRUGNAME Xanomeline tartrate INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D07QAR DRUGNAME Dalbavancin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07QBJ DRUGNAME HJP-272 INDICATI Premature labour [ICD-11: JB00] Investigative TTDDRUID D07QCA DRUGNAME GDNF-producing adult stem cell therapy INDICATI Lateral sclerosis [ICD-11: 8B61] Phase 2 TTDDRUID D07QCE DRUGNAME Azathioprine INDICATI Organ transplant rejection [ICD-11: NE84] Approved TTDDRUID D07QDT DRUGNAME MA-0211 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1 TTDDRUID D07QFM DRUGNAME TP10 INDICATI Myocardial ischemia [ICD-11: BA6Z] Phase 2 TTDDRUID D07QFP DRUGNAME Teriflunomide INDICATI Hyperlipidaemia [ICD-11: 5C80] Approved INDICATI Multiple sclerosis [ICD-11: 8A40] Approved INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1 TTDDRUID D07QFU DRUGNAME T-607 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D07QHF DRUGNAME SAR-260093 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D07QIQ DRUGNAME Anti-BCMA-CAR-transduced T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D07QIT DRUGNAME GPX-150D INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Soft tissue sarcoma [ICD-11: 2B57] Phase 2 TTDDRUID D07QJK DRUGNAME Plitidepsin INDICATI Multiple myeloma [ICD-11: 2A83] Phase 3 INDICATI Angioimmunoblastic T-cell Lymphoma [ICD-11: 2A90.9] Phase 2 TTDDRUID D07QKK DRUGNAME CHLORIDE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D07QKM DRUGNAME HL-1225 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D07QKN DRUGNAME Terpin hydrate INDICATI Cough [ICD-11: MD12] Approved TTDDRUID D07QLD DRUGNAME Pyrazole derivative 7 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D07QLG DRUGNAME Oxilofrine INDICATI Orthostatic hypotension [ICD-11: BA21] Approved TTDDRUID D07QNH DRUGNAME SAIT301 INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative TTDDRUID D07QPM DRUGNAME Potassium Citrate INDICATI Kidney stone [ICD-11: GB70.0Z] Approved TTDDRUID D07QQD DRUGNAME Aescin INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D07QQP DRUGNAME INS-37217 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 TTDDRUID D07QSA DRUGNAME CP-83101 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D07QTB DRUGNAME AF-243 INDICATI Deafness [ICD-11: AB52] Investigative TTDDRUID D07QTG DRUGNAME JNJ-479655 INDICATI Alzheimer disease [ICD-11: 8A20] Clinical trial TTDDRUID D07QVY DRUGNAME DBT-066 INDICATI Dementia [ICD-11: 6D80-6D86] Investigative TTDDRUID D07QWW DRUGNAME NBI-34041 INDICATI Eating disorder [ICD-11: 6B82] Phase 1 TTDDRUID D07QWZ DRUGNAME AZT-P-DDI INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D07QXG DRUGNAME EF-27 INDICATI Radiation syndrome [ICD-11: NF00] Terminated TTDDRUID D07QXM DRUGNAME AVI-4020 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 1 TTDDRUID D07QXU DRUGNAME NS 2359 INDICATI Cocaine addiction [ICD-11: 6C45.2] Phase 2 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Discontinued in Phase 2 INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2 TTDDRUID D07QYQ DRUGNAME Chloroquine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 INDICATI Malaria [ICD-11: 1F40-1F45] Withdrawn from market INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D07QZO DRUGNAME MPS-AAV8 INDICATI Maroteaux-lamy syndrome [ICD-11: 5C56.33] Investigative TTDDRUID D07RAA DRUGNAME PMID26651364-Compound-119 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D07RDQ DRUGNAME LMB-100 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 1 TTDDRUID D07RDU DRUGNAME IDP-107 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D07RGW DRUGNAME Mephenytoin INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D07RHF DRUGNAME GDC 695 INDICATI Actinic keratosis [ICD-11: EK90.0] Phase 3 TTDDRUID D07RHP DRUGNAME INCB50465 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 2 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2 INDICATI Marginal zone lymphoma [ICD-11: 2A85.0] Phase 2 TTDDRUID D07RIE DRUGNAME BC-PN-02 INDICATI Nervous system disease [ICD-11: 8A00-8E7Z] Investigative TTDDRUID D07RIJ DRUGNAME Autologous melanoma cell vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07RJD DRUGNAME Resorcinol compound 2 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D07RKN DRUGNAME GGTI-2418 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07RKO DRUGNAME MRX-6 INDICATI Contact dermatitis [ICD-11: EK0Z] Phase 2 TTDDRUID D07RME DRUGNAME GX-401 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D07RMX DRUGNAME ZK-thiazolidinone INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D07RPB DRUGNAME HT-90B INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D07RPC DRUGNAME RAP-103 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D07RPK DRUGNAME NIP-151 INDICATI Atrial fibrillation [ICD-11: BC81.3] Investigative TTDDRUID D07RPR DRUGNAME Bropirimine INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 3 TTDDRUID D07RPT DRUGNAME Lentiviral RNAi therapy INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID D07RQA DRUGNAME Alkyl mannoside derivative 8 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D07RQR DRUGNAME SYN-120 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D07RRC DRUGNAME BioHib INDICATI Haemophilus influenza [ICD-11: 1G40] Approved TTDDRUID D07RSI DRUGNAME Lipobean INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Approved TTDDRUID D07RST DRUGNAME Ibuprofenamine INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 TTDDRUID D07RUC DRUGNAME E-6087 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1 TTDDRUID D07RUD DRUGNAME Progesterone INDICATI Amenorrhea [ICD-11: GA20.0] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D07RUH DRUGNAME Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 14 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D07RUR DRUGNAME HB-1345 INDICATI Acne vulgaris [ICD-11: ED80] Investigative TTDDRUID D07RUV DRUGNAME Terflavoxate INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2 TTDDRUID D07RVP DRUGNAME GR-63799X INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D07RWY DRUGNAME LMI1195 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D07RXM DRUGNAME HM-90822 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07RXX DRUGNAME HG-1051 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D07RYI DRUGNAME Etelcalcetide INDICATI Secondary hyperparathyroidism [ICD-11: 5A51.1] Approved INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 3 TTDDRUID D07RYM DRUGNAME PMID25666693-Compound-131 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D07RYX DRUGNAME Antide INDICATI Prostate hyperplasia [ICD-11: GA90] Discontinued in Phase 2 TTDDRUID D07RZW DRUGNAME AZD9150 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID D07SBP DRUGNAME AZD4831 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 1 TTDDRUID D07SBX DRUGNAME Anti-HCV peptides INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D07SCN DRUGNAME KC-11458 INDICATI Gastric motility disorder [ICD-11: DA21] Discontinued in Phase 2 TTDDRUID D07SDE DRUGNAME Pranidipine INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D07SDQ DRUGNAME Curcumin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D07SDT DRUGNAME HPP-376 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D07SEB DRUGNAME BM-17.0505 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D07SEZ DRUGNAME HG-1072 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07SGB DRUGNAME ABT-299 INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1 TTDDRUID D07SHZ DRUGNAME COTI-58 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Investigative TTDDRUID D07SJT DRUGNAME Pantothenic acid INDICATI Vitamin deficiency [ICD-11: 5B55-5B71] Approved TTDDRUID D07SKJ DRUGNAME LY3015014 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D07SKN DRUGNAME PF-885706 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 2 TTDDRUID D07SLJ DRUGNAME JCAR024 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D07SMH DRUGNAME MK-5172 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D07SNG DRUGNAME DF-098 INDICATI Haemophilus influenza [ICD-11: 1G40] Approved TTDDRUID D07SNN DRUGNAME STxB-E7 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Investigative TTDDRUID D07SNO DRUGNAME Dabrafenib + trametinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D07SOJ DRUGNAME Adenovirus/Semliki Forest virus hybrid vector delivered IL-12 immunotherapy INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D07SOO DRUGNAME Methoxyflurane INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D07SPG DRUGNAME ARGX-110 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D07SQT DRUGNAME Ferroportin mab INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 1 TTDDRUID D07SRN DRUGNAME Debio-1036 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D07STB DRUGNAME EG-1962 INDICATI Subarachnoid hemorrhage [ICD-11: 8B01] Phase 3 INDICATI Aneurysmal subarachnoid hemorrhage [ICD-11: 8B01.0] Phase 3 TTDDRUID D07SUG DRUGNAME Busulfan INDICATI Myeloproliferative syndrome [ICD-11: 2A22] Approved TTDDRUID D07SWU DRUGNAME TM30338 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 2 TTDDRUID D07SXG DRUGNAME PRT-061103 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D07SXO DRUGNAME AG-041R INDICATI Ulcerative colitis [ICD-11: DD71] Terminated TTDDRUID D07SYJ DRUGNAME Sulfameter INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07SYN DRUGNAME FX-007 INDICATI Pain [ICD-11: MG30-MG3Z] Preclinical TTDDRUID D07SYO DRUGNAME Stromal stem cell therapy INDICATI Liver failure [ICD-11: DB99.7] Phase 1 TTDDRUID D07SYY DRUGNAME Pyrazolo[1,5-a]pyrimidine derivative 3 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D07SYZ DRUGNAME RX-0201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D07SZJ DRUGNAME A-75169 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Terminated TTDDRUID D07TAS DRUGNAME CI-959 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D07TBD DRUGNAME DT-2228 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D07TBJ DRUGNAME NuThrax INDICATI Anthrax [ICD-11: 1B97] Phase 2 TTDDRUID D07TCS DRUGNAME CDP-6038 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D07TCV DRUGNAME Anti-CD19 anti-CD20 Bispecific CAR-T INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D07TDT DRUGNAME L-733560 INDICATI Aspergillosis [ICD-11: 1F20] Terminated TTDDRUID D07TDV DRUGNAME Bendavia INDICATI Mitochondrial myopathy [ICD-11: 8C73] Phase 3 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 INDICATI Acute myocardial infarction [ICD-11: BA41] Phase 2 TTDDRUID D07TEE DRUGNAME Gene therapy, mucopolysaccharidosis type I INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Investigative TTDDRUID D07TEP DRUGNAME SCH 420814 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D07TFL DRUGNAME Blosozumab INDICATI Osteoporosis [ICD-11: FB83.0] Phase 2 TTDDRUID D07TGN DRUGNAME Deslanoside INDICATI Heart failure [ICD-11: BD10-BD13] Approved INDICATI Arrhythmia [ICD-11: BC9Z] Approved INDICATI Congestive cardiac insufficiency [ICD-11: BD1Z] Approved TTDDRUID D07TGY DRUGNAME Indeloxazine INDICATI Dementia [ICD-11: 6D80-6D86] Approved TTDDRUID D07THJ DRUGNAME IPH-3102 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D07TIX DRUGNAME TDI-0018 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D07TJM DRUGNAME PMID30784880-compound-6-5 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical TTDDRUID D07TJT DRUGNAME Imilecleucel-T INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D07TKZ DRUGNAME BIOD-123 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D07TMJ DRUGNAME EGFRt/19-28z/4-1BBL CAR T cells INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 TTDDRUID D07TMR DRUGNAME ISIS 23722 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D07TNU DRUGNAME DACTIMICIN INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D07TOK DRUGNAME Larotrectinib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D07TPL DRUGNAME Ro-40-0655 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Investigative TTDDRUID D07TQN DRUGNAME Asimadoline INDICATI Diarrhea-predominant irritable bowel syndrome [ICD-11: DD91.01] Phase 3 INDICATI Pruritus [ICD-11: EC90] Phase 2 TTDDRUID D07TQU DRUGNAME FibroStem INDICATI Sarcoidosis [ICD-11: 4B20.5] Investigative TTDDRUID D07TQV DRUGNAME Lamivudine INDICATI Chronic HBV infection [ICD-11: 1E51.0Z] Approved INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Approved TTDDRUID D07TRF DRUGNAME F18-florbetaben INDICATI Alzheimer disease [ICD-11: 8A20] Approved TTDDRUID D07TRP DRUGNAME APTO-253 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07TRV DRUGNAME Anthrax vaccine INDICATI Bacillus anthracis infection [ICD-11: 1G40] Discontinued in Phase 1 TTDDRUID D07TSS DRUGNAME MSC-100-IV INDICATI Crohn disease [ICD-11: DD70] Phase 3 TTDDRUID D07TSV DRUGNAME Atorvastatin INDICATI Hyperlipidemia [ICD-11: 5C80.Z] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D07TTI DRUGNAME AZD-8309 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D07TUD DRUGNAME PF-2391677 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 1 TTDDRUID D07TUT DRUGNAME ND-07 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D07TWK DRUGNAME TCN-P INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D07TWN DRUGNAME Tafenoquine INDICATI Plasmodium vivax malaria [ICD-11: 1F41] Approved INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D07TWZ DRUGNAME TDI-0053 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D07TXJ DRUGNAME Dextofisopam INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 2 TTDDRUID D07TYE DRUGNAME GS-9857 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D07TYJ DRUGNAME PRO-98498 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D07TYM DRUGNAME Autologous T-lymphocyte cell therapy INDICATI Peripheral vascular disease [ICD-11: BD4Z] Phase 2 TTDDRUID D07TYV DRUGNAME BAY1862864 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D07TZT DRUGNAME A-007 INDICATI Skin cancer [ICD-11: 2C30-2C37] Phase 2 TTDDRUID D07UAJ DRUGNAME CMB-401 INDICATI Breast cancer [ICD-11: 2C60-2C65] Terminated TTDDRUID D07UAS DRUGNAME PEG arginine deiminase INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D07UBB DRUGNAME ITI-003 INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative TTDDRUID D07UBG DRUGNAME Olmesartan medoxomil INDICATI High blood pressure [ICD-11: BA00] Approved TTDDRUID D07UBK DRUGNAME AS-1892802 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D07UBZ DRUGNAME Thiazoline derivative 2 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D07UDI DRUGNAME HO/04/08 INDICATI Dermatological disease [ICD-11: DA24.Y] Investigative TTDDRUID D07UDO DRUGNAME DNX-3000 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07UDW DRUGNAME COG-112 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07UEJ DRUGNAME Empagli ozin INDICATI Type-2 diabetes [ICD-11: 5A11] Investigative TTDDRUID D07UFS DRUGNAME SPI-5557 INDICATI Deafness [ICD-11: AB52] Investigative TTDDRUID D07UGA DRUGNAME Sphingosine-1-phosphate INDICATI Acne vulgaris [ICD-11: ED80] Phase 1 TTDDRUID D07UGI DRUGNAME PPS14 PCMV INDICATI Streptococcus infection [ICD-11: 1B53] Investigative TTDDRUID D07UHS DRUGNAME Fingolimod INDICATI Primary progressive multiple sclerosis [ICD-11: 8A40.1] Approved TTDDRUID D07UHX DRUGNAME 9-AMINOCAMPTOTHECIN INDICATI Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 2 TTDDRUID D07UHY DRUGNAME NIK-616 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated TTDDRUID D07UIS DRUGNAME CORT125281 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D07UJA DRUGNAME DRL-17822 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 2 TTDDRUID D07UKF DRUGNAME VBY-129 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 INDICATI Crohn disease [ICD-11: DD70] Phase 1 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D07UKJ DRUGNAME Enavatuzumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07UKT DRUGNAME ALRN-6924 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07ULK DRUGNAME OX-23 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D07ULS DRUGNAME DDG-39 INDICATI Acquired immune deficiency syndrome [ICD-11: 1C62.3] Terminated TTDDRUID D07UNH DRUGNAME Pyridine and pyrimidine derivative 1 INDICATI Fibrosis [ICD-11: GA14-GC01] Patented INDICATI Pain [ICD-11: MG30-MG3Z] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented TTDDRUID D07UOS DRUGNAME MK-434 INDICATI Prostate disease [ICD-11: GA91] Discontinued in Phase 1 TTDDRUID D07UQQ DRUGNAME ACE-536 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 3 INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 2 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 2 TTDDRUID D07UQR DRUGNAME Keyhole limpet hemocyanin INDICATI Bladder cancer [ICD-11: 2C94] Discontinued in Phase 3 TTDDRUID D07URD DRUGNAME PRX-102 INDICATI Fabry disease [ICD-11: 5C56.01] Phase 1/2 TTDDRUID D07URH DRUGNAME AP-004 INDICATI Proctitis [ICD-11: DB33.Z] Investigative TTDDRUID D07USR DRUGNAME SAVX-1 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D07USV DRUGNAME MM-302 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D07UTC DRUGNAME QNL-111 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D07UUB DRUGNAME 4SC-203 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07UWJ DRUGNAME Bromhexine INDICATI Sjogren syndrome [ICD-11: 4A43.20] Approved TTDDRUID D07UWV DRUGNAME Argatroban INDICATI Thrombosis [ICD-11: DB61-GB90] Approved TTDDRUID D07UXF DRUGNAME AR19 INDICATI Mental disease [ICD-11: 6E8Z] Phase 3 TTDDRUID D07UXJ DRUGNAME Aom-0785 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D07UXP DRUGNAME Cinoxacin INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D07UYO DRUGNAME Linezolid INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07UZX DRUGNAME Nerve growth factor conjugated RAP peptide INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D07UZY DRUGNAME Lpathomab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07VAI DRUGNAME ALZ-801 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D07VAQ DRUGNAME MG-1109 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D07VBA DRUGNAME Estradiol Valerate INDICATI Hormone replacement therapy [ICD-11: 8E01] Approved TTDDRUID D07VDF DRUGNAME CXCR4 gene disrupted T cells INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D07VDZ DRUGNAME Topiramate INDICATI Alcohol dependence [ICD-11: 6C40.2] Approved INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved INDICATI Seizure disorder [ICD-11: 8A6Z] Investigative TTDDRUID D07VFD DRUGNAME Mirogabalin INDICATI Peripheral neuropathy [ICD-11: 8C0Z] Registered INDICATI Fibromyalgia [ICD-11: MG30.01] Phase 3 INDICATI Cancer related pain [ICD-11: MG30] Phase 3 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3 TTDDRUID D07VFQ DRUGNAME Six-membered heterocyclic benzamide derivative 3 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D07VHR DRUGNAME Phenylbutazone INDICATI Chronic pain [ICD-11: MG30] Approved TTDDRUID D07VHS DRUGNAME Isavuconazole INDICATI Invasive aspergillosis [ICD-11: 1F20.0] Phase 3 INDICATI Invasive candidiasis [ICD-11: 1F23] Phase 3 INDICATI Candidemia [ICD-11: 1F23.3Y] Phase 3 TTDDRUID D07VHU DRUGNAME NIS793 INDICATI Pancreatic ductal carcinoma [ICD-11: 2C10.0] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D07VHX DRUGNAME Augmab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07VIB DRUGNAME Tecarfarin INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 3 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 3 TTDDRUID D07VIK DRUGNAME Arsenic trioxide INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved TTDDRUID D07VJI DRUGNAME Hookworm vaccine INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D07VJK DRUGNAME IDN-6384 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07VKT DRUGNAME Ch14.18 mab INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 3 INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 3 TTDDRUID D07VLY DRUGNAME Doxorubicin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Tumour [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07VMC DRUGNAME LY-243062 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D07VNH DRUGNAME Acebilustat INDICATI Chronic blistering skin disorder [ICD-11: ME63.3] Phase 1 TTDDRUID D07VOF DRUGNAME THA-904 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D07VPG DRUGNAME BW-773U82 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D07VQW DRUGNAME Sant7 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D07VRO DRUGNAME Benzalkonium chloride INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07VRP DRUGNAME EG-Mirotin INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Investigative TTDDRUID D07VSA DRUGNAME KRX-0403 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D07VTD DRUGNAME HBV-MF59 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 2 TTDDRUID D07VUD DRUGNAME ZD-3980 INDICATI Prostate hyperplasia [ICD-11: GA90] Terminated TTDDRUID D07VWP DRUGNAME S-9947 INDICATI Atrial fibrillation [ICD-11: BC81.3] Investigative TTDDRUID D07VXT DRUGNAME INCB8696 INDICATI Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1 TTDDRUID D07VYO DRUGNAME Recombinant human alkaline phosphatase INDICATI Ulcerative colitis [ICD-11: DD71] Investigative TTDDRUID D07VYP DRUGNAME FT-2102 INDICATI Glioma [ICD-11: 2A00.0] Phase 1/2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID D07VZV DRUGNAME N-0861 INDICATI Cardiac disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3 TTDDRUID D07WAF DRUGNAME Anti-Fas mabs INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07WCB DRUGNAME Colchicine INDICATI Acute gout flare [ICD-11: FA25.0] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D07WCT DRUGNAME SAR-100842 INDICATI Fibrosis [ICD-11: GA14-GC01] Phase 2 INDICATI Systemic sclerosis [ICD-11: 4A42] Phase 2 TTDDRUID D07WDS DRUGNAME NNC-14-0189 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D07WDW DRUGNAME VR496 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 TTDDRUID D07WEN DRUGNAME Venglustat INDICATI Fabry disease [ICD-11: 5C56.01] Phase 2 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 INDICATI Gaucher disease [ICD-11: 5C56.0Y] Phase 1 TTDDRUID D07WEP DRUGNAME Diazoxide INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D07WEV DRUGNAME PMID26868298-compound-5705213 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D07WFK DRUGNAME Acetohexamide INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D07WFQ DRUGNAME VBP 926 INDICATI Paronychia [ICD-11: 1F23.13] Phase 2 TTDDRUID D07WGE DRUGNAME C-KAD INDICATI Cataract [ICD-11: 9B10] Phase 2 TTDDRUID D07WGN DRUGNAME DP9 INDICATI Myocardial ischemia [ICD-11: BA6Z] Phase 2 TTDDRUID D07WGW DRUGNAME WJ-9708011 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D07WHN DRUGNAME FASORACETAM INDICATI Cognitive impairment [ICD-11: 6D71] Phase 3 TTDDRUID D07WHS DRUGNAME CL-316,243 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D07WJE DRUGNAME NVC-422 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 2/3 TTDDRUID D07WJU DRUGNAME SUVN-911 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 1 TTDDRUID D07WLI DRUGNAME 99mTc-fanolesomab INDICATI Appendicitis [ICD-11: DB10] Approved TTDDRUID D07WMD DRUGNAME MK-5478 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 TTDDRUID D07WMH DRUGNAME GT102-279 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Discontinued in Phase 2 TTDDRUID D07WNG DRUGNAME Atrimer INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D07WON DRUGNAME Bronchostat INDICATI Bronchitis [ICD-11: CA20] Approved TTDDRUID D07WPE DRUGNAME Epothilon INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 TTDDRUID D07WPQ DRUGNAME Oxycodone hydrochloride INDICATI Chronic pain [ICD-11: MG30] Application submitted TTDDRUID D07WQT DRUGNAME Ivermectin INDICATI Onchocerciasis [ICD-11: 1F6A] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D07WRW DRUGNAME LADIRUBICIN INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D07WSR DRUGNAME TS-032 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1 TTDDRUID D07WTG DRUGNAME Recombinant acidic fibroblast growth factor INDICATI Skin burns [ICD-11: ME65.0] Phase 3 TTDDRUID D07WTH DRUGNAME UltraCD40L INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 TTDDRUID D07WUJ DRUGNAME H5N1 influenza vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D07WXE DRUGNAME L-alanyl-l-glutamine INDICATI Mucositis [ICD-11: CA00] Approved TTDDRUID D07WXH DRUGNAME Pandemrix INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D07WXI DRUGNAME Maribavir INDICATI Cytomegalovirus infection [ICD-11: 1D82] Phase 3 TTDDRUID D07WXQ DRUGNAME CKD-404 INDICATI Growth failure [ICD-11: LD2F.1Y] Investigative TTDDRUID D07WYI DRUGNAME SPI-1620 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D07WYO DRUGNAME JI-3292 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D07WZH DRUGNAME Cephaloglycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07XAX DRUGNAME AEP-924 INDICATI Major depressive disorder [ICD-11: 6A70.3] Terminated TTDDRUID D07XBA DRUGNAME PMID25684022-Compound-US20130053382 36(3-5) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D07XBE DRUGNAME Lentinan INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D07XBI DRUGNAME AVR118 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2 TTDDRUID D07XBZ DRUGNAME ARC-200 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07XCF DRUGNAME Benfluorex INDICATI Hyperlipidaemia [ICD-11: 5C80] Withdrawn from market TTDDRUID D07XCG DRUGNAME Apligraf INDICATI Diabetic foot ulcer [ICD-11: BD54] Approved TTDDRUID D07XCQ DRUGNAME MDX-1414 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07XDQ DRUGNAME Figopitant INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D07XDS DRUGNAME Tomopenem INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D07XEV DRUGNAME WPP-201 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 1 TTDDRUID D07XGH DRUGNAME Pristinamycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07XGR DRUGNAME Fenofibrate INDICATI High cholesterol level [ICD-11: 5C80.0] Approved TTDDRUID D07XGT DRUGNAME AM-577 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D07XHJ DRUGNAME TAN-950A INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D07XHO DRUGNAME Nafamostat INDICATI Pancreatitis [ICD-11: DC31-DC34] Approved INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2 TTDDRUID D07XJJ DRUGNAME M118 INDICATI Acute coronary syndrome [ICD-11: BA41] Phase 2 TTDDRUID D07XJM DRUGNAME Dicyclomine INDICATI Functional bowel syndrome [ICD-11: DD91.0] Approved TTDDRUID D07XLA DRUGNAME GM04-001 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D07XMG DRUGNAME IFN-alpha 2B-XL INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 2 TTDDRUID D07XOV DRUGNAME EFT508 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D07XPE DRUGNAME Phenformin INDICATI Diabetic complication [ICD-11: 5A2Y] Withdrawn from market TTDDRUID D07XPT DRUGNAME Ronacaleret INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2 TTDDRUID D07XQS DRUGNAME ONC201 INDICATI Glioma [ICD-11: 2A00.0] Phase 2 INDICATI Endometrial cancer [ICD-11: 2C76] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2 INDICATI Recurring respiratory infection [ICD-11: CA07-CA45] Phase 2 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07XRU DRUGNAME Telmisartan INDICATI Hypertension [ICD-11: BA00-BA04] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D07XSD DRUGNAME SUN-13333 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D07XSN DRUGNAME Cytarabine INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved TTDDRUID D07XVL DRUGNAME PMID25666693-Compound-119 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D07XVN DRUGNAME Dexrazoxane INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Chemoprotection [ICD-11: N.A.] Approved INDICATI Respiratory tract disease [ICD-11: CB7Z] Investigative TTDDRUID D07XVR DRUGNAME Sodium nitroprusside INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D07XXT DRUGNAME DEDN-6526A INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D07XYT DRUGNAME Medusa IL-2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D07XYV DRUGNAME Bambuterol INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D07XZR DRUGNAME PMID25666693-Compound-134 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D07YAC DRUGNAME Anticalin INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D07YAR DRUGNAME NX-1207 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D07YCR DRUGNAME S-16020-2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D07YDE DRUGNAME Nitroglycerin INDICATI Diabetic foot ulcer [ICD-11: BD54] Approved INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D07YDO DRUGNAME GTx-186 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07YEK DRUGNAME NV-52 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 1 TTDDRUID D07YGH DRUGNAME GSK239512 INDICATI Dementia [ICD-11: 6D80-6D86] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D07YGK DRUGNAME Vilaprisan INDICATI Endometriosis [ICD-11: GA10] Phase 2 TTDDRUID D07YGQ DRUGNAME Anti-MUC1 AR20.5 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D07YHM DRUGNAME LY-2456302 INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D07YHT DRUGNAME ENRASENTAN INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Discontinued in Phase 2 TTDDRUID D07YHY DRUGNAME CR-2093 INDICATI Intestine cancer [ICD-11: 2C0Z] Discontinued in Phase 1 TTDDRUID D07YIX DRUGNAME NmVac4 INDICATI Meningococcal infection [ICD-11: 1C1C] Phase 1 TTDDRUID D07YJK DRUGNAME ShRNA apolipoprotein B100 gene siliencer INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D07YKJ DRUGNAME EVT-103 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1 TTDDRUID D07YKQ DRUGNAME EPX-100 INDICATI Dravet syndrome [ICD-11: 8A61.11] Phase 1 TTDDRUID D07YLK DRUGNAME LE-300 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D07YLO DRUGNAME SDF-1 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 2 TTDDRUID D07YLV DRUGNAME Ciclesonide INDICATI Asthma [ICD-11: CA23] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D07YMP DRUGNAME TAB001 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07YNC DRUGNAME NCI-4650 INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 TTDDRUID D07YNH DRUGNAME SAN-61 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D07YNM DRUGNAME NN8765 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D07YOP DRUGNAME JBD-401 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07YPA DRUGNAME CGEN-920 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D07YPB DRUGNAME Hu-CART meso cells INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 1 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Peritoneal mesothelioma [ICD-11: 2C51.2] Phase 1 INDICATI Pleural mesothelioma [ICD-11: 2C26.0] Phase 1 TTDDRUID D07YPP DRUGNAME BreMel/TNF alpha INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D07YPV DRUGNAME AbelaDrug200 INDICATI Head injury [ICD-11: NA00-NA0Z] Phase 1/2 TTDDRUID D07YPW DRUGNAME Shigamabs INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3 INDICATI Haemolytic uraemic syndrome [ICD-11: 3A21.2] Phase 2 TTDDRUID D07YRJ DRUGNAME AERAS-405 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D07YRV DRUGNAME AER-002 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D07YRW DRUGNAME ASP7991 INDICATI Hyperparathyroidism [ICD-11: 5A51] Phase 2 TTDDRUID D07YUH DRUGNAME HybriCell INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D07YUY DRUGNAME MDL-29311 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D07YVK DRUGNAME Sumanirole INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D07YVM DRUGNAME CLX-090700 INDICATI Diabetic complication [ICD-11: 5A2Y] Preclinical TTDDRUID D07YWY DRUGNAME Nafronyl INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved TTDDRUID D07YXD DRUGNAME HL-024 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07YZK DRUGNAME CAMI-103 INDICATI Heart failure [ICD-11: BD10-BD13] Investigative TTDDRUID D07YZQ DRUGNAME Melanoma DNA vaccine INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D07ZAH DRUGNAME ACH-1625 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D07ZAK DRUGNAME RGX 501 INDICATI Familial hypercholesterolemia [ICD-11: 5C80.00] Phase 1/2 TTDDRUID D07ZAO DRUGNAME OVI-123 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 TTDDRUID D07ZBE DRUGNAME Iobitridol INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D07ZBO DRUGNAME ADepVac INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D07ZCK DRUGNAME ZK-93423 INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Phase 3 TTDDRUID D07ZCU DRUGNAME BKT-120 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07ZDG DRUGNAME EDN-OL1 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D07ZES DRUGNAME T2CA INDICATI Allergic rhinitis [ICD-11: CA08.0] Investigative TTDDRUID D07ZGF DRUGNAME Biothrax INDICATI Bacillus anthracis infection [ICD-11: 1G40] Approved TTDDRUID D07ZHM DRUGNAME ATX-S10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07ZHV DRUGNAME CB1954 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D07ZJC DRUGNAME INOC-005 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D07ZKE DRUGNAME PMID25684022-Compound-US20120277229 45(1.5) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D07ZKK DRUGNAME 131I-81C6 INDICATI Brain cancer [ICD-11: 2A00] Terminated TTDDRUID D07ZMG DRUGNAME Thiazole carboxamide derivative 29 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D07ZMQ DRUGNAME HD-003 INDICATI Kidney disease [ICD-11: GC2Z] Phase 2 TTDDRUID D07ZNF DRUGNAME IMC-EB10 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D07ZNI DRUGNAME STX-140 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 2 TTDDRUID D07ZQS DRUGNAME Macrocycle derivative 9 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D07ZRI DRUGNAME Technetium Tc-99m Oxidronate Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D07ZSU DRUGNAME Freeze-dried bee venom INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 TTDDRUID D07ZTB DRUGNAME HG-1068 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07ZTD DRUGNAME MB-07811 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D07ZTO DRUGNAME Bethanechol INDICATI Urinary retention [ICD-11: MF50.3] Approved TTDDRUID D07ZUW DRUGNAME Nanoemulsion INDICATI Molluscum contagiosum infection [ICD-11: 1E76] Phase 2/3 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 TTDDRUID D07ZUX DRUGNAME CR-3465 INDICATI Allergy [ICD-11: 4A80-4A85] Phase 1 TTDDRUID D07ZUZ DRUGNAME CK-2127107 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 INDICATI Spinal muscular atrophy [ICD-11: 8B61] Phase 2 INDICATI Muscle atrophy [ICD-11: FB32.Y] Phase 1 TTDDRUID D07ZVO DRUGNAME PT1.2 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 1 TTDDRUID D07ZXE DRUGNAME Wetimicin INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Discontinued in Phase 1 TTDDRUID D07ZZI DRUGNAME SLV-341 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D07ZZS DRUGNAME AGS-22ME INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07ZZX DRUGNAME MDX-1110 INDICATI Lung cancer [ICD-11: 2C25.0] Investigative TTDDRUID D08AAB DRUGNAME VLX600 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08AAV DRUGNAME AZD-3514 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D08ABQ DRUGNAME Acalabrutinib INDICATI leukaemia [ICD-11: 2A60-2B33] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D08ABX DRUGNAME CAR-T cells targeting CD34 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Preclinical TTDDRUID D08ADK DRUGNAME Glycoferon INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D08ADX DRUGNAME Clevudine INDICATI Hepatitis B [ICD-11: 1E51] phase 4 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D08AFD DRUGNAME NP-252 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D08AHH DRUGNAME LHW090 INDICATI Kidney failure [ICD-11: GB6Z] Phase 2 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D08AJF DRUGNAME PI-0824 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D08ALK DRUGNAME Cisatracurium INDICATI Muscle spasm [ICD-11: MB47.3] Approved TTDDRUID D08ALQ DRUGNAME RPR-101821 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D08AMJ DRUGNAME TK-DLI INDICATI Graft-versus-host disease [ICD-11: 4B24] Preregistration TTDDRUID D08AMQ DRUGNAME SB-234551 INDICATI Nerve injury [ICD-11: ND56.4] Discontinued in Phase 1 TTDDRUID D08ANE DRUGNAME Opdivo nivolumab +Yervoy ipilimumab INDICATI Brain and central nervous system tumour [ICD-11: 2A00.11] Phase 2 TTDDRUID D08ANF DRUGNAME Cerebral EDV INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D08ANJ DRUGNAME AP-30663 INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 1/2 TTDDRUID D08ANZ DRUGNAME Pembrolizumab INDICATI Melanoma [ICD-11: 2C30] Approved INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 3 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 INDICATI Esophageal cancer [ICD-11: 2B70] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 INDICATI Cutaneous squamous cell carcinoma [ICD-11: 2C30] Phase 2 INDICATI Primary mediastinal B-cell lymphoma [ICD-11: 2A81] Application submitted TTDDRUID D08AOV DRUGNAME INO-1002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08AOZ DRUGNAME BMS-986142 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D08APZ DRUGNAME NT-100 INDICATI Implantation failure [ICD-11: QB50] Phase 2 TTDDRUID D08AWI DRUGNAME PRX-00023 INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2 TTDDRUID D08AXM DRUGNAME VALERGENT-BT INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D08BBL DRUGNAME Iomab-B INDICATI Bone marrow transplantation [ICD-11: QB63.6] Phase 3 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 TTDDRUID D08BBU DRUGNAME GW-42003 INDICATI Opioid dependence [ICD-11: 6C43.2Z] Phase 2 TTDDRUID D08BCU DRUGNAME U-90042 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D08BDT DRUGNAME Halopredone acetate INDICATI Arthritis [ICD-11: FA20] Approved TTDDRUID D08BEA DRUGNAME Ipamorelin INDICATI Postoperative ileus [ICD-11: DA91-DB30] Phase 1/2 TTDDRUID D08BED DRUGNAME CERE-140 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D08BEO DRUGNAME Talampanel INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D08BIH DRUGNAME N-acylpyrrolidine ether derivative 2 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D08BIJ DRUGNAME IL-1 Monoclonal Antibody INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D08BIN DRUGNAME Munumbicins INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D08BKH DRUGNAME 18-Methoxycoronaridine INDICATI Drug abuse [ICD-11: 6C4G.1Z] Investigative TTDDRUID D08BKM DRUGNAME Porcine isophane insulin INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D08BLZ DRUGNAME Aryl mannoside derivative 23 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D08BMC DRUGNAME Olea europaea-containing vaccine INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Phase 3 TTDDRUID D08BMO DRUGNAME Resveratrol INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D08BMV DRUGNAME PEG-hGH INDICATI Dwarfism [ICD-11: 5B11] Phase 2 TTDDRUID D08BNB DRUGNAME Biaryl mannoside derivative 5 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D08BNJ DRUGNAME DTP-HepB-Polio-Hib INDICATI Pertussis [ICD-11: 1C12.Z] Phase 3 INDICATI Tetanus [ICD-11: 1C13] Phase 3 INDICATI Diphtheria [ICD-11: 1C17] Phase 3 TTDDRUID D08BPD DRUGNAME EC-70124 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08BPS DRUGNAME JCAR017 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1 INDICATI Primary mediastinal B-cell lymphoma [ICD-11: 2A81] Phase 1 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Multiple myeloma [ICD-11: 2A83] Clinical trial TTDDRUID D08BQJ DRUGNAME Brain dendritic cell-based vaccine INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1/2 TTDDRUID D08BTB DRUGNAME protirelin INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Approved TTDDRUID D08BTX DRUGNAME X-387 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08BVM DRUGNAME TTP-355 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D08BXT DRUGNAME Spermidine INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D08BYJ DRUGNAME WIN-902A INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D08BZZ DRUGNAME Omburtamab I-131 INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 2/3 INDICATI Small round cell desmoplastic tumour [ICD-11: 2A20.5] Phase 1/2 TTDDRUID D08CCC DRUGNAME AFP-Scan INDICATI Liver cancer [ICD-11: 2C12] Discontinued in Phase 2 TTDDRUID D08CCE DRUGNAME Guaimesal INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D08CCF DRUGNAME IPX-159 INDICATI Restless legs syndrome [ICD-11: 7A80] Discontinued in Phase 2 TTDDRUID D08CDE DRUGNAME Celgosivir INDICATI Dengue fever [ICD-11: 1D2Z] Phase 1/2 TTDDRUID D08CDI DRUGNAME Lapatinib INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D08CEA DRUGNAME 122-0551 foam INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 TTDDRUID D08CEU DRUGNAME Recombinant Factor X INDICATI Hemophilia [ICD-11: 3B10.0] Investigative TTDDRUID D08CGE DRUGNAME Integrin alpha 5/beta 1 INDICATI Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Investigative TTDDRUID D08CGG DRUGNAME VRC-EBOADV018-00-VP INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 1 TTDDRUID D08CGU DRUGNAME Bevacizumab + Rituximab INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 3 TTDDRUID D08CJM DRUGNAME Peptide YY 3-36 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D08CKJ DRUGNAME Fonsartan INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D08CLA DRUGNAME PMID25666693-Compound-123 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D08CLN DRUGNAME Suritozole INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D08CMF DRUGNAME Angeloxin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08CNP DRUGNAME AC430 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D08COR DRUGNAME ARC-520 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D08COU DRUGNAME FSH patch INDICATI Infertility [ICD-11: GB04] Phase 1 TTDDRUID D08CPL DRUGNAME MIST-B03 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D08CPT DRUGNAME AC 137-164594 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 2 TTDDRUID D08CQE DRUGNAME AVE-9940 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D08CQY DRUGNAME Brilacidin INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 2 INDICATI Acute bacterial skin infection [ICD-11: 1C41] Phase 2 TTDDRUID D08CRO DRUGNAME PNH-192 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08CSE DRUGNAME IP-880 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Approved TTDDRUID D08CSZ DRUGNAME HMR-3004 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D08CTT DRUGNAME Dimethindene INDICATI Respiratory allergy [ICD-11: 4A80] Approved TTDDRUID D08CUE DRUGNAME BI-661051 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08CVC DRUGNAME Tocofersolan INDICATI Vitamin E deficiency [ICD-11: 5B58] Phase 3 TTDDRUID D08CVQ DRUGNAME Mipomersen INDICATI Familial hypercholesterolemia [ICD-11: 5C80.00] Approved TTDDRUID D08CWX DRUGNAME BVX-20-CD20 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative TTDDRUID D08CZE DRUGNAME Dihydropyrone INDICATI Hepatovirus infection [ICD-11: 1E51] Investigative TTDDRUID D08CZY DRUGNAME PMID28270021-Compound-WO2016054807Example71 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D08DBE DRUGNAME R-343 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D08DCP DRUGNAME BI-847325 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08DFF DRUGNAME AM-001 INDICATI Dermatological disease [ICD-11: DA24.Y] Phase 2 INDICATI Actinic keratosis [ICD-11: EK90.0] Phase 2 TTDDRUID D08DFU DRUGNAME CMX-157 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D08DFX DRUGNAME Canagliflozin INDICATI Type-2 diabetes [ICD-11: 5A11] Approved INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 3 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D08DGC DRUGNAME CPL-7075 INDICATI Diffuse systemic sclerosis [ICD-11: 4A42.1] Phase 3 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 INDICATI Systemic sclerosis [ICD-11: 4A42] Phase 2 TTDDRUID D08DGG DRUGNAME SnPP Protoporphyrin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D08DGW DRUGNAME CXL INDICATI Methicillin-resistant staphylococci infection [ICD-11: 1A00-1A09] Phase 2 TTDDRUID D08DHN DRUGNAME VX-787 INDICATI Influenza A virus infection [ICD-11: 1E30] Phase 3 TTDDRUID D08DHR DRUGNAME EDP-22 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D08DIU DRUGNAME LN-144 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D08DJE DRUGNAME K-133W INDICATI Dysmenorrhea [ICD-11: GA34.3] Investigative TTDDRUID D08DJH DRUGNAME Juvenile chondrocyte grafts INDICATI Contraception [ICD-11: QA21] Phase 2 TTDDRUID D08DJP DRUGNAME AE-298p INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08DJV DRUGNAME TAK-195 INDICATI Poliovirus infection [ICD-11: 1C8Y] Phase 1 TTDDRUID D08DKA DRUGNAME Levcromakalim INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Preregistration TTDDRUID D08DMH DRUGNAME BAY2402234 INDICATI Myeloid leukaemia [ICD-11: 2B33.1] Phase 1 TTDDRUID D08DMY DRUGNAME Bria-IMT INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D08DNA DRUGNAME PA-517 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D08DOE DRUGNAME ML-04 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 TTDDRUID D08DOQ DRUGNAME IGN301 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D08DPN DRUGNAME GSK-625433 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D08DPV DRUGNAME PRO-052 INDICATI Duchenne dystrophy [ICD-11: 8C70] Investigative TTDDRUID D08DRU DRUGNAME Influenza A virus H5N1 cell culture-based vaccine INDICATI Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 1 TTDDRUID D08DSC DRUGNAME BST-1005 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D08DSF DRUGNAME MEDI-557 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1 TTDDRUID D08DTD DRUGNAME Biostrophin INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1 TTDDRUID D08DTR DRUGNAME RHPIV1 84/del/170/942A INDICATI Parainfluenza virus infection [ICD-11: 1D9Y] Phase 1 TTDDRUID D08DUF DRUGNAME GL-0817 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Oral cavity squamous cell carcinoma [ICD-11: 2B6E.0] Phase 2 TTDDRUID D08DUY DRUGNAME T-1249 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D08DVE DRUGNAME BI-660848 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D08DWC DRUGNAME MSC2015103B INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08DWH DRUGNAME Idrapril INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D08DWM DRUGNAME Gp100:209-217(210M) peptide vaccine INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D08DZO DRUGNAME Malaria DNA vaccine INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1/2 TTDDRUID D08DZZ DRUGNAME HE2100 INDICATI Thrombocytopenia [ICD-11: 3B64] Discontinued in Phase 1 TTDDRUID D08EAI DRUGNAME AS-101 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D08EAR DRUGNAME HE2200 INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D08EBN DRUGNAME Nitazoxanide INDICATI Diarrhea [ICD-11: ME05.1] Approved TTDDRUID D08ECB DRUGNAME LAS-101057 INDICATI Asthma [ICD-11: CA23] Preclinical TTDDRUID D08ECW DRUGNAME Racotumomab INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D08EDE DRUGNAME MIRNA-Rx07 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08EEM DRUGNAME PV-701 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08EEO DRUGNAME Demobesin INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D08EES DRUGNAME XR-5000 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D08EEU DRUGNAME Englitazone sodium INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D08EGT DRUGNAME PMID25684022-Compound-WO2008005457 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D08EHL DRUGNAME Macrocycle derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D08EIK DRUGNAME LY3016859 INDICATI Chronic kidney disease [ICD-11: GB61] Phase 1/2 TTDDRUID D08EIX DRUGNAME T-686 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D08ELL DRUGNAME TBE-80E INDICATI Encephalitis virus infection [ICD-11: 1C83-1C84] Investigative TTDDRUID D08ELM DRUGNAME RWJ-58259 INDICATI Artery stenosis [ICD-11: BD52] Terminated TTDDRUID D08ENB DRUGNAME GSK1995057 INDICATI Adult respiratory distress syndrome [ICD-11: CB00] Phase 1 TTDDRUID D08ENJ DRUGNAME Anti-CGEN-153 mab INDICATI Ovarian cancer [ICD-11: 2C73] Investigative TTDDRUID D08ENK DRUGNAME Insulin Susp Isophane Recombinant Human INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D08EOD DRUGNAME Methsuximide INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Approved TTDDRUID D08EOW DRUGNAME RG7112 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D08EPK DRUGNAME UBP-551 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D08EQD DRUGNAME FGF401 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D08EQQ DRUGNAME LPD-1050 INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D08ESA DRUGNAME CI-966 INDICATI Convulsion [ICD-11: 8A68.Z] Phase 1 TTDDRUID D08EUS DRUGNAME CGC-11047 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D08EVF DRUGNAME Anti-Notch-1 mabs INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08EVM DRUGNAME FR-128998 INDICATI Thrombocytopenia [ICD-11: 3B64] Terminated TTDDRUID D08EVN DRUGNAME Tyropanoate sodium INDICATI Gallbladder disease [ICD-11: DC11.3] Approved TTDDRUID D08EWE DRUGNAME Plitidepsin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D08EWM DRUGNAME UCB-0942 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 2 INDICATI Seizure disorder [ICD-11: 8A6Z] Phase 2 TTDDRUID D08EYQ DRUGNAME ORE-1001 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1/2 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D08FAC DRUGNAME CaCP-29 INDICATI Sepsis [ICD-11: 1G40-1G41] Phase 2 TTDDRUID D08FAT DRUGNAME RP-170 INDICATI Carcinoma [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D08FDD DRUGNAME HL-4130 INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D08FDX DRUGNAME MGCD265 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08FGX DRUGNAME PALOSURAN INDICATI Renal failure [ICD-11: GB60-GB6Z] Discontinued in Phase 2 TTDDRUID D08FHP DRUGNAME BFKB8488A INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D08FHV DRUGNAME NY-008 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D08FHZ DRUGNAME ATL-313 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 1/2 TTDDRUID D08FIB DRUGNAME LY3316531 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D08FIX DRUGNAME OTSSP167 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Myeloproliferative neoplasm [ICD-11: 2A20] Phase 1 TTDDRUID D08FJG DRUGNAME EHT/AGN-0002 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D08FJL DRUGNAME Carbetocin INDICATI Postpartum haemorrhage [ICD-11: JA43] Approved TTDDRUID D08FKD DRUGNAME Autologous renal cell carcinoma vaccine INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 TTDDRUID D08FKH DRUGNAME KLH-2109 INDICATI Endometriosis [ICD-11: GA10] Phase 2 TTDDRUID D08FKL DRUGNAME ACHN-975 INDICATI Pseudomonas infection [ICD-11: 1B92] Phase 1 TTDDRUID D08FKX DRUGNAME SDZ-MAR-327 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 2 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D08FMK DRUGNAME LY2944876 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D08FMR DRUGNAME ARC-1905 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 1 TTDDRUID D08FNJ DRUGNAME RO-14 INDICATI Phlebothrombosis [ICD-11: GB90.3] Phase 1 TTDDRUID D08FOX DRUGNAME Piroximone INDICATI Cardiac failure [ICD-11: BD10-BD13] Discontinued in Phase 3 TTDDRUID D08FPM DRUGNAME Dhaq diacetate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D08FSD DRUGNAME SER-100 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D08FSR DRUGNAME QLT-091382 INDICATI Sebaceous gland disease [ICD-11: EM0Z] Investigative TTDDRUID D08FTG DRUGNAME Phenindione INDICATI Coagulation defect [ICD-11: 3B10.0] Approved INDICATI Pulmonary embolism [ICD-11: BB00] Approved TTDDRUID D08FTP DRUGNAME 99mTc-MIP-1404 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D08FUR DRUGNAME IMU-838 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D08FVH DRUGNAME 4SCAR19/22 T cells INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID D08FWJ DRUGNAME GSK3377794 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Synovial sarcoma [ICD-11: 2B5A] Phase 2 TTDDRUID D08FWK DRUGNAME Oxypurinol INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2/3 TTDDRUID D08FWO DRUGNAME Lixte-1.2 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D08FWW DRUGNAME Gammaplex INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved TTDDRUID D08FXE DRUGNAME MD-920 INDICATI Wound healing [ICD-11: EL8Y] Phase 1 TTDDRUID D08FXZ DRUGNAME RP-525 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08FYH DRUGNAME PF-04776548 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D08FZT DRUGNAME Corus 1030 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D08GAH DRUGNAME EV-075 INDICATI Ebola virus infection [ICD-11: 1D60.0] Investigative TTDDRUID D08GBB DRUGNAME Valopicitabine dihydrochloride INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 2 TTDDRUID D08GBT DRUGNAME SAR-131675 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08GEX DRUGNAME TriGem INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 2 TTDDRUID D08GFN DRUGNAME MVA-BN Breast INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D08GHB DRUGNAME Fluvastatin INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Approved TTDDRUID D08GHI DRUGNAME 18F-AV-45 dimer INDICATI Cerebral amyloid angiopathy [ICD-11: 5D00.0] Investigative TTDDRUID D08GHX DRUGNAME TA-104 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D08GIH DRUGNAME NGR-hTNF INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 INDICATI Malignant pleural mesothelioma [ICD-11: 2C26.0] Phase 3 TTDDRUID D08GIM DRUGNAME Elisidepsin INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D08GJH DRUGNAME Blonanserin INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 TTDDRUID D08GJO DRUGNAME Benorilate INDICATI Arthritis [ICD-11: FA20] Approved TTDDRUID D08GKD DRUGNAME AZD-2315 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D08GKU DRUGNAME BriaVax INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D08GLH DRUGNAME DBP-118 INDICATI Vomiting [ICD-11: MD90] Investigative TTDDRUID D08GLX DRUGNAME MDT-2004 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D08GNA DRUGNAME SKF-106610 INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D08GNX DRUGNAME FPL-14294 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D08GNY DRUGNAME Lactococcus lactis anti-IL-27 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D08GOD DRUGNAME Tradipitant INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D08GOI DRUGNAME FT596 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D08GQK DRUGNAME WS-75624B INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D08GRF DRUGNAME LG-1550 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D08GRY DRUGNAME DUP 697 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1 TTDDRUID D08GSC DRUGNAME KPE-02001003 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D08GSF DRUGNAME Proflavine INDICATI Sepsis [ICD-11: 1G40-1G41] Approved TTDDRUID D08GSM DRUGNAME AG-014 INDICATI Coeliac disease [ICD-11: DA95] Investigative TTDDRUID D08GSX DRUGNAME MOR-104 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D08GUX DRUGNAME TD-4001 INDICATI Bladder disease [ICD-11: DC11-DC1Z] Investigative TTDDRUID D08GUZ DRUGNAME Somatrem INDICATI Hormone deficiency [ICD-11: 5A61.1] Approved TTDDRUID D08GVB DRUGNAME AMR-001 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D08GYO DRUGNAME Procarbazine INDICATI Hodgkin lymphoma [ICD-11: 2B30] Approved TTDDRUID D08GZE DRUGNAME AbGn-107 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 TTDDRUID D08GZJ DRUGNAME MK-2918 INDICATI Migraine [ICD-11: 8A80] Investigative TTDDRUID D08GZX DRUGNAME PF-613322 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D08HDD DRUGNAME RP-58802B INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D08HDY DRUGNAME Pivmecillinam INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D08HES DRUGNAME MC-02331 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Terminated TTDDRUID D08HFA DRUGNAME Y-27152 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 2 TTDDRUID D08HFW DRUGNAME TAK-901 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D08HGR DRUGNAME LLL-3348 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D08HGY DRUGNAME Naronapride INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2 TTDDRUID D08HHT DRUGNAME Procervix INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 2 TTDDRUID D08HIH DRUGNAME ERB-196 INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1 TTDDRUID D08HJI DRUGNAME WT2527 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08HJT DRUGNAME Peplomycin INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D08HKK DRUGNAME CD10-CART INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D08HKT DRUGNAME BEMORADAN INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D08HMK DRUGNAME ETC-276 INDICATI Ischemia [ICD-11: 8B10-8B11] Discontinued in Phase 1 TTDDRUID D08HNA DRUGNAME SMT-D001 INDICATI Hypersalivation [ICD-11: DA04.6] Investigative TTDDRUID D08HOM DRUGNAME ABT-348 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 2 TTDDRUID D08HPZ DRUGNAME Tocilizumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved INDICATI Juvenile idiopathic arthritis [ICD-11: FA24] Phase 3 TTDDRUID D08HQI DRUGNAME ISIS-EIF4E INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D08HQK DRUGNAME Tetracaine INDICATI Spinal anesthesia [ICD-11: MB40.3] Approved INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D08HQT DRUGNAME ZK-005 INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D08HRD DRUGNAME Plasmodium vivax vaccine INDICATI Plasmodium vivax malaria [ICD-11: 1F41] Phase 1/2 TTDDRUID D08HRJ DRUGNAME Cyclizine INDICATI Nausea [ICD-11: MD90] Approved TTDDRUID D08HSS DRUGNAME LY3300054 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08HTF DRUGNAME JNJ-1930942 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D08HUB DRUGNAME ANG-2004 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D08HUC DRUGNAME Isoetharine INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D08HVD DRUGNAME NRLU-10 INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1 TTDDRUID D08HVE DRUGNAME Dimethyl Sulfoxide INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D08HVG DRUGNAME BAL-8557 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 3 TTDDRUID D08HVR DRUGNAME Levodopa INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D08HWV DRUGNAME BGB-A317 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08HXB DRUGNAME Lopinavir + ritonavir + interferon beta INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D08HXG DRUGNAME PMX-60056 INDICATI Coagulation defect [ICD-11: 3B10.0] Phase 2 TTDDRUID D08HZC DRUGNAME Penicillamine INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D08HZL DRUGNAME Trimeprazine INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D08HZN DRUGNAME ABC-4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08IAQ DRUGNAME ARC-AAT INDICATI Alpha-1 antitrypsin deficiency [ICD-11: 5C5A] Phase 1 TTDDRUID D08IBS DRUGNAME Adenine INDICATI Malnutrition [ICD-11: 5B50-5B71] Approved TTDDRUID D08ICT DRUGNAME PMID25666693-Compound-13 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D08ICX DRUGNAME Tofacitinib INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D08IDB DRUGNAME HuA33 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D08IDQ DRUGNAME BILA-2157BS INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D08IFG DRUGNAME Interferon-alpha dimers INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08IFL DRUGNAME Meclofenamic acid INDICATI Ankylosing spondylitis [ICD-11: FA92.0] Approved INDICATI Joint pain [ICD-11: ME82] Approved TTDDRUID D08IHF DRUGNAME A-74932 INDICATI Lung cancer [ICD-11: 2C25.0] Terminated TTDDRUID D08IID DRUGNAME TNO155 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08IKV DRUGNAME 58-1066 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08IMD DRUGNAME AZD-6495 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D08IMP DRUGNAME AAV-hAADC gene therapy INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D08INO DRUGNAME WX-UK1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1/2 TTDDRUID D08IRG DRUGNAME BIIB 015 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08IRR DRUGNAME Org-10490 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Terminated TTDDRUID D08IST DRUGNAME SB-509 INDICATI Nervous system disease [ICD-11: 8A00-8E7Z] Phase 2 TTDDRUID D08IUW DRUGNAME VLI-03B INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative TTDDRUID D08IVF DRUGNAME BP1001 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D08IWD DRUGNAME Finasteride INDICATI Benign prostatic hyperplasia [ICD-11: GA90] Approved TTDDRUID D08IXA DRUGNAME BQ788 INDICATI Acute kidney injury [ICD-11: GB60] Phase 3 INDICATI Encephalopathy [ICD-11: 8E47] Phase 3 INDICATI Myasthenia gravis [ICD-11: 8C6Y] Phase 3 INDICATI Neuromyelitis optica [ICD-11: 8A43] Phase 3 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 TTDDRUID D08IYF DRUGNAME GSK-692342 INDICATI Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 2 TTDDRUID D08JAC DRUGNAME Fenretinide INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 3 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 INDICATI Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Tumour [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08JAH DRUGNAME TPM-001 INDICATI Peritoneal cavity cancer [ICD-11: 2C51.Z] Investigative TTDDRUID D08JAN DRUGNAME Cipatinib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08JAP DRUGNAME Robalzotan INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D08JBL DRUGNAME PF-03446962 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D08JCA DRUGNAME Silver sulfadiazine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D08JCL DRUGNAME ONO-3805 INDICATI Prostate disease [ICD-11: GA91] Discontinued in Phase 3 TTDDRUID D08JEA DRUGNAME AKB-4924 INDICATI MRSA infection [ICD-11: 1D01.0Y] Investigative TTDDRUID D08JGB DRUGNAME Otlertuzumab INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 INDICATI Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2 TTDDRUID D08JGE DRUGNAME SonoLysis Prolyse INDICATI Cerebral ischemia [ICD-11: 8B11] Phase 2 TTDDRUID D08JHG DRUGNAME ChimeriVax-Dengue INDICATI Dengue fever [ICD-11: 1D2Z] Phase 2 TTDDRUID D08JHY DRUGNAME AVM0703 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D08JHZ DRUGNAME BLD-2660 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D08JIP DRUGNAME Rintatolimod INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D08JIV DRUGNAME Amlodipine INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D08JKK DRUGNAME RWJ-63556 INDICATI Arthritis [ICD-11: FA20] Terminated TTDDRUID D08JLC DRUGNAME J-607Y INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D08JLH DRUGNAME Spartalizumab INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D08JLV DRUGNAME TH-337 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08JMI DRUGNAME ALN-VSP INDICATI Liver cancer [ICD-11: 2C12] Phase 1 TTDDRUID D08JML DRUGNAME Microxine INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D08JMO DRUGNAME Iron proteinsuccinylate INDICATI Anemia [ICD-11: 3A00-3A9Z] Approved TTDDRUID D08JNE DRUGNAME RG1578 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D08JNG DRUGNAME Malonic acid INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D08JNI DRUGNAME MEDI5872 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 TTDDRUID D08JOE DRUGNAME ANA971 INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 1 TTDDRUID D08JOY DRUGNAME Avrina INDICATI Skin infection [ICD-11: 1F28-1G0Z] Phase 1/2 TTDDRUID D08JPU DRUGNAME G6976 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08JRT DRUGNAME RhApo2L/TRAIL INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1/2 TTDDRUID D08JSA DRUGNAME SB208 INDICATI Onychomycosis [ICD-11: EE12.1] Phase 2 INDICATI Tinea pedis [ICD-11: 1F28.2] Phase 2 TTDDRUID D08JSE DRUGNAME JNJ-42041935 INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D08JSQ DRUGNAME DS-3032 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D08JTI DRUGNAME Anti-CD19/22-CAR vector-transduced T cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1/2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1/2 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2 INDICATI Prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1/2 TTDDRUID D08JTN DRUGNAME AFM-20 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08JTU DRUGNAME R-944 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D08JUO DRUGNAME CR-4056 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D08JVS DRUGNAME NU-206 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Phase 1 TTDDRUID D08JWC DRUGNAME GS-9620 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D08JWJ DRUGNAME PF-1228305 INDICATI Pulmonary hypertension [ICD-11: BB01] Phase 3 TTDDRUID D08JWM DRUGNAME In-111-DAC imaging agent INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08JWY DRUGNAME PMID30107136-Compound-Example43 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D08JXR DRUGNAME HG-1202 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08JXW DRUGNAME INS-117548 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1 TTDDRUID D08JYV DRUGNAME PSMA subunit vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D08JYW DRUGNAME CZ-ON002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08JZS DRUGNAME Mepyramine INDICATI Allergy [ICD-11: 4A80-4A85] Approved TTDDRUID D08KAD DRUGNAME CYT-004-MelQbG10 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D08KBB DRUGNAME DT-310 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08KBK DRUGNAME Tedizolid INDICATI Skin infection [ICD-11: 1F28-1G0Z] Approved TTDDRUID D08KCA DRUGNAME Leupeptin INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D08KCJ DRUGNAME ABY-025 INDICATI Bladder cancer [ICD-11: 2C94] Phase 1/2 TTDDRUID D08KCK DRUGNAME ART621 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1/2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1/2 TTDDRUID D08KDK DRUGNAME T-2007 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 2 TTDDRUID D08KDL DRUGNAME TES-23-NCS INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D08KDP DRUGNAME AS-8112 INDICATI Vomiting [ICD-11: MD90] Terminated TTDDRUID D08KDU DRUGNAME PT-201 INDICATI Urinary dysfunction [ICD-11: GC2Z] Phase 1 TTDDRUID D08KEC DRUGNAME AG-NPN803 INDICATI Nephritis [ICD-11: GB40] Investigative TTDDRUID D08KGY DRUGNAME PRX-302 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D08KHD DRUGNAME Leonurine INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative TTDDRUID D08KIB DRUGNAME SAR-114137 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D08KMU DRUGNAME Gca-186 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Clinical trial TTDDRUID D08KNG DRUGNAME VAN-10-4-eluting stent INDICATI Artery stenosis [ICD-11: BD52] Phase 1 TTDDRUID D08KNK DRUGNAME MPL-containing Pollinex allergy desensitization vaccine INDICATI Allergy [ICD-11: 4A80-4A85] Preregistration TTDDRUID D08KOD DRUGNAME ISIS 15770 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08KPA DRUGNAME BZL-101 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D08KQK DRUGNAME PMID31244113-compound-2c INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D08KSU DRUGNAME AP12009 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 TTDDRUID D08KSV DRUGNAME RG6146 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08KTO DRUGNAME AD04 INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 INDICATI Opioid dependence [ICD-11: 6C43.2Z] Phase 1 TTDDRUID D08KTQ DRUGNAME CJC-1295 INDICATI Cachexia [ICD-11: MG20] Phase 2 TTDDRUID D08KVK DRUGNAME CYT-009-GhrQb INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1/2 TTDDRUID D08KVZ DRUGNAME Sibutramine INDICATI Obesity [ICD-11: 5B81] Approved TTDDRUID D08KWQ DRUGNAME Sn-117m-DTPA INDICATI Bone metastases [ICD-11: 2D50] Discontinued in Phase 2 TTDDRUID D08KWV DRUGNAME NXT-1021 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D08KXC DRUGNAME SGX201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D08KXE DRUGNAME RP-67580 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D08KXO DRUGNAME CCP-020 INDICATI Epidermolysis bullosa [ICD-11: EC3Z] Phase 3 TTDDRUID D08KXX DRUGNAME JBD-411 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D08KYN DRUGNAME INNO-105 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08KYQ DRUGNAME Sulopenem INDICATI Urinary tract infection [ICD-11: GC08] Phase 3 TTDDRUID D08KZJ DRUGNAME CAY 10471 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D08KZM DRUGNAME CC49 humanized radioimmunoconjugates INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08KZR DRUGNAME BXL-746 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1 TTDDRUID D08LAE DRUGNAME LGD-4033 INDICATI Musculoskeletal disorder [ICD-11: FA00-FC0Z] Phase 1 TTDDRUID D08LDB DRUGNAME GSK1265744 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D08LDG DRUGNAME Org-31433 INDICATI Dementia [ICD-11: 6D80-6D86] Terminated TTDDRUID D08LDS DRUGNAME LUBELUZOLE INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Preregistration TTDDRUID D08LDV DRUGNAME PA-1050040 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D08LEY DRUGNAME Lanadelumab INDICATI Hereditary angioedema [ICD-11: 4A00.14] Approved TTDDRUID D08LFX DRUGNAME MB-300 INDICATI Breast cancer [ICD-11: 2C60-2C65] Terminated TTDDRUID D08LFZ DRUGNAME Diflunisal INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D08LHE DRUGNAME Prinoxodan INDICATI Cardiac failure [ICD-11: BD10-BD13] Terminated TTDDRUID D08LIF DRUGNAME Propiram fumarate INDICATI Cancer related pain [ICD-11: MG30] Discontinued in Phase 3 TTDDRUID D08LIU DRUGNAME Amooranin INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D08LJP DRUGNAME Rasburicase INDICATI Hyperuricaemia [ICD-11: 5C55.Y] Approved TTDDRUID D08LJY DRUGNAME MB-312 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08LLB DRUGNAME Human CD19 targeted T Cells INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 TTDDRUID D08LLM DRUGNAME NS-8 INDICATI Urinary incontinence [ICD-11: MF50.2] Phase 1 TTDDRUID D08LLR DRUGNAME UK-51656 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D08LMS DRUGNAME CG201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D08LQD DRUGNAME RESEQUINIL INDICATI Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 2 TTDDRUID D08LQS DRUGNAME ETBX-021 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D08LRU DRUGNAME Disorazol Z-LHRH conjugates INDICATI Ovarian cancer [ICD-11: 2C73] Investigative TTDDRUID D08LRV DRUGNAME BGP-15 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D08LSA DRUGNAME SCY-524 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D08LTU DRUGNAME Minocycline INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved INDICATI Rosacea [ICD-11: ED90.0] Phase 2 TTDDRUID D08LUT DRUGNAME ABT-702 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D08LVF DRUGNAME Nitecapone INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D08LXJ DRUGNAME Heterologous liver cell therapy INDICATI Urea cycle disorder [ICD-11: 5C50.A] Phase 2 TTDDRUID D08LYB DRUGNAME SB 239063 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D08LYZ DRUGNAME VesiGel INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 TTDDRUID D08LZI DRUGNAME NS-220 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D08LZZ DRUGNAME DPO-1 INDICATI Atrial fibrillation [ICD-11: BC81.3] Investigative TTDDRUID D08MAR DRUGNAME CP-230821 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D08MCC DRUGNAME NRX-101 INDICATI Suicidal ideation [ICD-11: MB26.A] Phase 2 TTDDRUID D08MCI DRUGNAME L1Q-001 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D08MCL DRUGNAME Recombinant human biglycan INDICATI Duchenne dystrophy [ICD-11: 8C70] Investigative TTDDRUID D08MCO DRUGNAME SPD-703 INDICATI Otitis media [ICD-11: AA80-AB0Z] Terminated TTDDRUID D08MCS DRUGNAME ADS-5102 INDICATI Dyskinesia [ICD-11: MB47.4] Phase 3 TTDDRUID D08MCT DRUGNAME BMS-192548 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D08MDV DRUGNAME CT-3501 INDICATI Coronary artery disease [ICD-11: BA80] Terminated TTDDRUID D08MDX DRUGNAME ED-001 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Terminated TTDDRUID D08MEF DRUGNAME BAY-86-4884 INDICATI Liver disease [ICD-11: DB90-BD99] Approved TTDDRUID D08MGU DRUGNAME SLIT TR-03 INDICATI Lung cancer [ICD-11: 2C25.0] Preclinical TTDDRUID D08MHD DRUGNAME E-2609 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D08MHM DRUGNAME PF-3758309 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08MID DRUGNAME T-115 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08MIG DRUGNAME RPA-102 INDICATI Anthrax [ICD-11: 1B97] Phase 2 TTDDRUID D08MJO DRUGNAME CDP323 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D08MJX DRUGNAME R-56865 INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D08MKR DRUGNAME DT388IL-3 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D08MLG DRUGNAME CNI-H0294 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated TTDDRUID D08MLH DRUGNAME TUG-469 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D08MMP DRUGNAME ENDG-8010 INDICATI Epilepsy [ICD-11: 8A60-8A68] Investigative TTDDRUID D08MOL DRUGNAME Anti-CMV mabs INDICATI Cytomegalovirus infection [ICD-11: 1D82] Investigative TTDDRUID D08MPA DRUGNAME AMA-76 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2 TTDDRUID D08MRN DRUGNAME Hexylcaine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D08MTA DRUGNAME Tetanolic acid INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D08MTG DRUGNAME Abafungin INDICATI Fungal infection [ICD-11: 1F29-1F2F] Discontinued in Phase 3 TTDDRUID D08MTN DRUGNAME Glucose analogue INDICATI Infection of P. falciparum [ICD-11: 1F40] Investigative TTDDRUID D08MUX DRUGNAME S33005 INDICATI Depression [ICD-11: 6A70-6A7Z] Investigative TTDDRUID D08MVK DRUGNAME GCC-AP0341 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D08MVV DRUGNAME PRX-111 INDICATI Female infertility [ICD-11: GA31.Z] Investigative TTDDRUID D08MVY DRUGNAME R-116712 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D08MXB DRUGNAME NCX-125 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D08MXP DRUGNAME LEE011 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D08MYF DRUGNAME Bio-Hep-B INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D08MYL DRUGNAME NIM-811 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D08MYO DRUGNAME LAG-078 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Terminated TTDDRUID D08MYW DRUGNAME Human M-SAA3 peptide INDICATI Gastrointestinal infection [ICD-11: 1A40.Z] Investigative TTDDRUID D08NAB DRUGNAME Chymotrypsin INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D08NAD DRUGNAME Batabulin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3 TTDDRUID D08NAI DRUGNAME SAR438584 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 3 TTDDRUID D08NCO DRUGNAME Vanadate INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 INDICATI Plaque psoriasis [ICD-11: EA90.0] Application submitted TTDDRUID D08NDA DRUGNAME ISIS-HBV INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D08NDE DRUGNAME BLZ-945 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08NEM DRUGNAME BVRS-GamVac vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 1/2 TTDDRUID D08NES DRUGNAME S-3536 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 1 TTDDRUID D08NGV DRUGNAME PMID25553724-Compound-US2012820715110 INDICATI Immune System disease [ICD-11: 4A01-4B41] Patented TTDDRUID D08NHF DRUGNAME SR-11335 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated TTDDRUID D08NIN DRUGNAME NN-9926 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D08NJE DRUGNAME CR-845 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2/3 INDICATI Chronic pain [ICD-11: MG30] Phase 2 TTDDRUID D08NJQ DRUGNAME TJ-8117 INDICATI Nephritis [ICD-11: GB40] Discontinued in Phase 2 TTDDRUID D08NLC DRUGNAME Cu64-CNND1-B INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D08NLN DRUGNAME Biolimus a9 INDICATI Artery stenosis [ICD-11: BD52] Approved INDICATI Coronary artery disease [ICD-11: BA80] Phase 3 TTDDRUID D08NLQ DRUGNAME Licarbazepine INDICATI Bipolar disorder [ICD-11: 6A60] Discontinued in Phase 3 TTDDRUID D08NMV DRUGNAME Ixekizumab INDICATI Plaque psoriasis [ICD-11: EA90.0] Approved INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 3 TTDDRUID D08NNR DRUGNAME Testosterone glucoside INDICATI Hypogonadism [ICD-11: 5A61.0] Discontinued in Phase 2 TTDDRUID D08NNW DRUGNAME Boric acid INDICATI Otitis media [ICD-11: AA80-AB0Z] Approved TTDDRUID D08NPB DRUGNAME TO-195 INDICATI Nephritis [ICD-11: GB40] Terminated TTDDRUID D08NPG DRUGNAME MBX-2044 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D08NQG DRUGNAME VB2-011 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D08NQZ DRUGNAME Tetracycline INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D08NRG DRUGNAME HYP-10 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D08NTD DRUGNAME Trappsol Cyclo INDICATI Niemann-pick disease [ICD-11: 5C56.0Y] Investigative TTDDRUID D08NTW DRUGNAME Antineoplaston A10 + antineoplaston AS2-2 INDICATI Glioma [ICD-11: 2A00.0] Phase 2 TTDDRUID D08NUS DRUGNAME XEL-005OP INDICATI Urinary tract disease [ICD-11: GC2Z] Investigative TTDDRUID D08NWC DRUGNAME Peginterferon alfa-2b INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Approved TTDDRUID D08NWF DRUGNAME crisaborole INDICATI Atopic dermatitis [ICD-11: EA80] Approved TTDDRUID D08NWY DRUGNAME ALS-2158 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D08NXP DRUGNAME ABBV-951 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D08NXW DRUGNAME GLP-1 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 3 TTDDRUID D08NYL DRUGNAME AGN211745 INDICATI Choroidal neovascularization [ICD-11: 9B76] Discontinued in Phase 2 TTDDRUID D08NYO DRUGNAME PDGF gene therapy INDICATI Diabetic foot ulcer [ICD-11: BD54] Investigative TTDDRUID D08NYZ DRUGNAME ASM-024 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D08NZG DRUGNAME Ifabotuzumab INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D08OAS DRUGNAME Flavimun INDICATI Yellow fever virus infection [ICD-11: 1D47] Discontinued in Preregistration TTDDRUID D08ODH DRUGNAME Atiratecan INDICATI Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2 TTDDRUID D08ODP DRUGNAME CSC-700008 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D08OES DRUGNAME NiCord INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 3 INDICATI Sickle-cell anaemia [ICD-11: 3A51] Phase 1/2 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 1/2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2 TTDDRUID D08OGB DRUGNAME YourDex INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D08OHK DRUGNAME AKP-501 INDICATI Female infertility [ICD-11: GA31.Z] Phase 1 TTDDRUID D08OIT DRUGNAME Viroprev INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D08OJB DRUGNAME Benzoic acid linked peptide analog 4 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D08OJE DRUGNAME Femoxetine INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 3 TTDDRUID D08OJF DRUGNAME ICA-105665 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 2 TTDDRUID D08OJU DRUGNAME SOU-001 INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2 TTDDRUID D08OKJ DRUGNAME Iron Dextran INDICATI Iron-deficiency anemia [ICD-11: 3A00] Approved TTDDRUID D08OKW DRUGNAME Metalfullerene INDICATI Alopecia [ICD-11: ED70] Investigative TTDDRUID D08OLB DRUGNAME CH-5015765 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08OLR DRUGNAME ART-144 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Investigative TTDDRUID D08OLU DRUGNAME AVP-5 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative TTDDRUID D08OMM DRUGNAME BL-1040 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 1/2 TTDDRUID D08ONJ DRUGNAME MPC-3100 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08OOJ DRUGNAME CB-5083 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08OPS DRUGNAME ATYR 1940 INDICATI Muscular dystrophy [ICD-11: 8C70] Phase 1/2 TTDDRUID D08OPW DRUGNAME ARRY-575 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08OPX DRUGNAME 4SC-205 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D08OQQ DRUGNAME Lavoltidine INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2 TTDDRUID D08ORO DRUGNAME OPC-21268 INDICATI Cardiac disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2 TTDDRUID D08ORV DRUGNAME AZD-4992 INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1 TTDDRUID D08OTE DRUGNAME RO-4995819 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D08OUL DRUGNAME EGT-0001474 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D08OUU DRUGNAME Genevx INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D08OUV DRUGNAME CHF-4227 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 1 TTDDRUID D08OVG DRUGNAME CKD-516 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08OVR DRUGNAME AMG 357 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D08OWA DRUGNAME NVC-704 INDICATI Conjunctivitis [ICD-11: 9A60] Investigative TTDDRUID D08OWW DRUGNAME SLP-0906 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D08OXC DRUGNAME INDUS-82030 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D08OXD DRUGNAME Mannoside derivative 8 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D08OXU DRUGNAME IMO-3100 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D08OYF DRUGNAME Ad/PSA INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D08PAV DRUGNAME CDP-860 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D08PBB DRUGNAME L-694,458 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 TTDDRUID D08PBQ DRUGNAME Pancreas algenpantucel-L INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 TTDDRUID D08PCE DRUGNAME Oxantel pamoate INDICATI Trichuris trichiura infection [ICD-11: 1F6G] Approved TTDDRUID D08PCH DRUGNAME Javelin INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D08PCR DRUGNAME CM3.1-AC100 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D08PFA DRUGNAME Rivoglitazone INDICATI Ocular inflammation [ICD-11: 9C61.24] Phase 3 TTDDRUID D08PGC DRUGNAME Andolast INDICATI Rhinitis [ICD-11: FA20] Phase 3 TTDDRUID D08PHD DRUGNAME DR-5001 INDICATI Adenovirus infection [ICD-11: 1A20] Phase 3 TTDDRUID D08PIE DRUGNAME Brigatinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved INDICATI Anaplastic large cell lymphoma [ICD-11: 2A90.A] Approved TTDDRUID D08PIJ DRUGNAME JTV-506 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 2 TTDDRUID D08PIK DRUGNAME 11C-GSK-215083 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 1 TTDDRUID D08PIQ DRUGNAME Methylprednisolone INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved INDICATI Spinal cord injury [ICD-11: ND51.2] Investigative TTDDRUID D08PKF DRUGNAME AMI-HS INDICATI Liver disease [ICD-11: DB90-BD99] Discontinued in Phase 1 TTDDRUID D08PKG DRUGNAME LY2541546 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 2 TTDDRUID D08PKI DRUGNAME EV-077 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D08PLK DRUGNAME Fremanezumab INDICATI Hyperprolactinaemia [ICD-11: 5A60.1] Approved TTDDRUID D08PMB DRUGNAME Imeglimin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D08PMW DRUGNAME BMS-223131 INDICATI Erectile dysfunction [ICD-11: HA01.1] Phase 2 TTDDRUID D08PNQ DRUGNAME Trombodipine INDICATI Platelet aggregation disorder [ICD-11: 3B62] Discontinued in Phase 2 TTDDRUID D08PNW DRUGNAME JPH-101 INDICATI Hypophosphatasia [ICD-11: 5C64.3] Investigative TTDDRUID D08POF DRUGNAME ALX-0081 INDICATI Thrombotic thrombocytopenic purpura [ICD-11: 3B64.14] Phase 3 INDICATI Thrombocytopenia [ICD-11: 3B64] Phase 2 TTDDRUID D08POH DRUGNAME Invaplex 50 INDICATI Shigella infection [ICD-11: 1A02] Phase 1/2 TTDDRUID D08PRP DRUGNAME IMGX003 INDICATI Coeliac disease [ICD-11: DA95] Phase 2 TTDDRUID D08PSC DRUGNAME BI 860585 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08PSI DRUGNAME H5N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D08PSU DRUGNAME Lmw heparin INDICATI Hematologic disease [ICD-11: 3C0Z] Approved INDICATI Coagulation defect [ICD-11: 3B10.0] Approved TTDDRUID D08PSV DRUGNAME CIGB-428 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Investigative TTDDRUID D08PUW DRUGNAME BAICALIN INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D08PVL DRUGNAME Ibulocydine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08PXL DRUGNAME MK-8457 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D08PXM DRUGNAME MDX-214 INDICATI Autoimmune diabetes [ICD-11: 5A10] Discontinued in Phase 1/2 TTDDRUID D08PXR DRUGNAME ABT-761 INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D08PYC DRUGNAME AL-38583 INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Phase 2 TTDDRUID D08PYO DRUGNAME KW-2478 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D08PYQ DRUGNAME EDL-2000 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D08PZF DRUGNAME Liposomal disintergrin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08QAC DRUGNAME Ferumoxides INDICATI Liver cancer [ICD-11: 2C12] Approved INDICATI Liver disease [ICD-11: DB90-BD99] Approved TTDDRUID D08QAN DRUGNAME BVRS-GamVac-Combi vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 1/2 TTDDRUID D08QCJ DRUGNAME Thiabendazole INDICATI Helminth infection [ICD-11: 1F90.0] Approved INDICATI Dutch elm disease [ICD-11: 8D64] Approved TTDDRUID D08QDB DRUGNAME KSI-4088 INDICATI Nematode infection [ICD-11: 1F60-1F69] Investigative TTDDRUID D08QDF DRUGNAME Systebryl INDICATI Amyloidosis [ICD-11: 5D00] Phase 1 TTDDRUID D08QED DRUGNAME TAK-850 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 TTDDRUID D08QEF DRUGNAME CEP-37250 INDICATI Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08QGD DRUGNAME Ammonium lactate INDICATI Dermatological disease [ICD-11: DA24.Y] Approved TTDDRUID D08QGE DRUGNAME SI-614 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2/3 TTDDRUID D08QGT DRUGNAME GDC0941 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D08QHJ DRUGNAME UPAR-lock INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08QHS DRUGNAME DG041 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 2 TTDDRUID D08QHX DRUGNAME PRX00933 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D08QIP DRUGNAME Pranlukast INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D08QJD DRUGNAME IGN-311 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D08QJS DRUGNAME Carbazochrome salicylate INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved TTDDRUID D08QKJ DRUGNAME Stanozolol INDICATI Hereditary angioedema [ICD-11: 4A00.14] Approved TTDDRUID D08QKY DRUGNAME IXS-312 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D08QLL DRUGNAME AG-NDT802 INDICATI Cough [ICD-11: MD12] Investigative TTDDRUID D08QLM DRUGNAME Merimepodib INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2b INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D08QME DRUGNAME Ethambutol INDICATI Pulmonary tuberculosis [ICD-11: 1B10.Z] Approved TTDDRUID D08QMX DRUGNAME Estradiol INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D08QPJ DRUGNAME MBI-2401 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D08QRE DRUGNAME MB-11319 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D08QRO DRUGNAME BL-6020 INDICATI Cachexia [ICD-11: MG20] Investigative TTDDRUID D08QRT DRUGNAME 99mTc-siboroxime INDICATI Diagnostic imaging [ICD-11: N.A.] Investigative TTDDRUID D08QTK DRUGNAME Anti-EGFL7 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D08QTP DRUGNAME BMS-433771 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Terminated TTDDRUID D08QUC DRUGNAME OT-121 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D08QUV DRUGNAME Amineptine INDICATI Major depressive disorder [ICD-11: 6A70.3] Withdrawn from market TTDDRUID D08QVM DRUGNAME NU-400 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D08QWQ DRUGNAME bimatoprost (free acid form) INDICATI Alzheimer disease [ICD-11: 8A20] Clinical trial TTDDRUID D08QXE DRUGNAME HP-161 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08QYJ DRUGNAME SORETOLIDE INDICATI Convulsion [ICD-11: 8A68.Z] Terminated TTDDRUID D08QYL DRUGNAME ISV-102 INDICATI Ocular infection [ICD-11: 1F00.1] Investigative TTDDRUID D08QYS DRUGNAME Heat shock protein vaccine INDICATI Meningococcal infection [ICD-11: 1C1C] Phase 2 TTDDRUID D08QYW DRUGNAME CAR-T Cells targeting EpCAM INDICATI Colon cancer [ICD-11: 2B90.Z] Phase 1/2 INDICATI Esophageal cancer [ICD-11: 2B70] Phase 1/2 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D08QZH DRUGNAME Anti-HER2 CAR-T INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2 INDICATI Glioma [ICD-11: 2A00.0] Phase 1/2 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1/2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D08RAK DRUGNAME Japanese cedar pollen allergy sublingual immunotherapy INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D08RBC DRUGNAME Escitalopram INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved TTDDRUID D08RBS DRUGNAME WX-037 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08RBV DRUGNAME Autologous dendritic cell vaccine, St Anna Children's Hospital INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D08RBW DRUGNAME LY900014 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D08RCI DRUGNAME CRTX-072 INDICATI Cough [ICD-11: MD12] Investigative TTDDRUID D08RCV DRUGNAME Pyrido[2,3-d]pyrimidine derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D08RDB DRUGNAME Polyamine INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D08RDC DRUGNAME R-765 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Terminated TTDDRUID D08RDD DRUGNAME PF-06823859 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Dermatomycosis [ICD-11: EA60] Phase 2 INDICATI Lupus [ICD-11: 4A40] Phase 1 TTDDRUID D08RDG DRUGNAME PBI-4419 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D08RET DRUGNAME PMID30107136-Compound-Example47 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D08RFA DRUGNAME TAK-816 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Application submitted TTDDRUID D08RFZ DRUGNAME RSV mAb INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2/3 TTDDRUID D08RGA DRUGNAME AZD6370 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D08RGH DRUGNAME ChAdOx1 MERS001 vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 1 TTDDRUID D08RHR DRUGNAME Optaflu INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D08RHU DRUGNAME Cissampeline INDICATI Skeletal muscle relaxant [ICD-11: NE60] Approved TTDDRUID D08RIB DRUGNAME Edetate disodium INDICATI Heart arrhythmia [ICD-11: BC65] Approved TTDDRUID D08RID DRUGNAME MK-8616 INDICATI Poison intoxication [ICD-11: NE6Z] Approved TTDDRUID D08RIL DRUGNAME GKT-03 INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D08RJM DRUGNAME SD-101 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3 INDICATI Skin disease [ICD-11: EA00-EM0Z] Phase 2 INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1/2 INDICATI Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 1/2 TTDDRUID D08RJY DRUGNAME Anti-EGFRvIII CAR transduced PBL INDICATI Brain cancer [ICD-11: 2A00] Phase 1/2 INDICATI Malignant glioma [ICD-11: 2A00.0] Phase 1/2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2 TTDDRUID D08RKZ DRUGNAME IN0-3106 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1 TTDDRUID D08RMH DRUGNAME APC-2059 INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2 TTDDRUID D08RMJ DRUGNAME GSK461364 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08ROP DRUGNAME Leflunomide INDICATI Arthritis [ICD-11: FA20] Approved INDICATI Multiple sclerosis [ICD-11: 8A40] Approved TTDDRUID D08ROQ DRUGNAME S-25585 INDICATI Eating disorder [ICD-11: 6B82] Investigative TTDDRUID D08RPV DRUGNAME IDM-4 INDICATI leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 1/2 TTDDRUID D08RQE DRUGNAME DepoVax INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Investigative TTDDRUID D08RSL DRUGNAME Genz-644470 INDICATI Hypophosphatasia [ICD-11: 5C64.3] Phase 2 TTDDRUID D08RUN DRUGNAME 2-Bromopalmitate INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D08RUW DRUGNAME PD-176931 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical TTDDRUID D08RUX DRUGNAME Z-321 INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1 TTDDRUID D08RWO DRUGNAME CAB-ROR2-ADC INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D08RXW DRUGNAME MT-062 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D08RYN DRUGNAME RQ-00202730 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D08RZV DRUGNAME HSR-609 INDICATI Rhinitis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D08SAO DRUGNAME ZN-1014 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D08SAX DRUGNAME DB-772d INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D08SCL DRUGNAME MK-3697 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Phase 2 TTDDRUID D08SCQ DRUGNAME Poractant alfa INDICATI Respiratory distress syndrome [ICD-11: CB00] Approved TTDDRUID D08SDI DRUGNAME House dust mite allergy vaccine INDICATI Allergy [ICD-11: 4A80-4A85] Phase 1 TTDDRUID D08SEI DRUGNAME Levocabastine INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Approved TTDDRUID D08SGE DRUGNAME M7583 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D08SHE DRUGNAME SEP-228432 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 1 TTDDRUID D08SHI DRUGNAME SG-1311 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Investigative TTDDRUID D08SHM DRUGNAME NB-007 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D08SIC DRUGNAME BDB001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D08SIF DRUGNAME Milatuzumab INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 TTDDRUID D08SIR DRUGNAME CL-314698 INDICATI Type-2 diabetes [ICD-11: 5A11] Preclinical INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D08SIT DRUGNAME NKP-1339 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08SJT DRUGNAME Sarilumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D08SJY DRUGNAME MRX34 INDICATI Liver cancer [ICD-11: 2C12] Phase 1 TTDDRUID D08SJZ DRUGNAME Ibandronate INDICATI Osteoporosis [ICD-11: FB83.0] Approved TTDDRUID D08SKH DRUGNAME Methoxsalen INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Approved INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved TTDDRUID D08SMN DRUGNAME POP-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08SNL DRUGNAME JTC-801 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D08SNT DRUGNAME Heteroaryl-carboxamide derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D08SNX DRUGNAME V-11294A INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D08SOF DRUGNAME Terfenadine INDICATI Allergy [ICD-11: 4A80-4A85] Withdrawn from market TTDDRUID D08SPH DRUGNAME Eculizumab INDICATI Neuromyelitis optica [ICD-11: 8A43] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D08SPP DRUGNAME TG-44 INDICATI Helicobacter infection [ICD-11: DA42-DA63] Investigative TTDDRUID D08SSO DRUGNAME CNSB-006 INDICATI Arthralgia [ICD-11: ME82] Investigative TTDDRUID D08SSP DRUGNAME Lersivirine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D08STA DRUGNAME CAL-203 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Investigative TTDDRUID D08SUQ DRUGNAME ES-285 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D08SVH DRUGNAME Tacalcitol INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved TTDDRUID D08SXS DRUGNAME Polyflu INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D08SXV DRUGNAME DWP-422 INDICATI Arthritis [ICD-11: FA20] Phase 1 TTDDRUID D08SZO DRUGNAME F-12458 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08SZP DRUGNAME TA-103 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08TAB DRUGNAME XL-499 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D08TBK DRUGNAME Opdivo + Yervoynivolumab + ipilimumab INDICATI Malignant pleural mesothelioma [ICD-11: 2C26.0] Phase 3 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 TTDDRUID D08TCU DRUGNAME GT-4001 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D08TDK DRUGNAME ANA-011 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08TEJ DRUGNAME Clascoterone INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D08TGG DRUGNAME Insulin transdermal INDICATI Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 1 TTDDRUID D08TIA DRUGNAME IC-200214 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D08TJM DRUGNAME Binodenoson INDICATI Hypertension [ICD-11: BA00-BA04] Phase 3 TTDDRUID D08TKV DRUGNAME SKF-97426 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D08TLI DRUGNAME E-4716 INDICATI Respiratory disease [ICD-11: CB40] Phase 2 TTDDRUID D08TNG DRUGNAME RG7775 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D08TPH DRUGNAME TC-5653 INDICATI Nicotine dependence [ICD-11: 6C4A.2] Investigative TTDDRUID D08TPS DRUGNAME Epidermal growth factor INDICATI Vulnerary [ICD-11: ND56.Z] Approved INDICATI Wound healing [ICD-11: EL8Y] Phase 2 TTDDRUID D08TQK DRUGNAME NM-9405 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D08TQP DRUGNAME INX-189 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D08TRG DRUGNAME AZD-3241 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D08TRM DRUGNAME ChAdOx1 MERS002 vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 1 TTDDRUID D08TRX DRUGNAME CST-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08TVI DRUGNAME HPP-854 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D08TXL DRUGNAME A-796260 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D08TYK DRUGNAME GLS-5300 vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 1/2 TTDDRUID D08TZZ DRUGNAME Oleuropein INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D08UAT DRUGNAME DPS-151 INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D08UDB DRUGNAME GSK-2263167 INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D08UDE DRUGNAME Peptide-conjugated phosphorodiamidate morpholino oligomers INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D08UDF DRUGNAME PIBAXIZINE INDICATI Spasm [ICD-11: MB47.3] Discontinued in Phase 2 TTDDRUID D08UDG DRUGNAME MEDI4276 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08UDZ DRUGNAME MK-6105 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D08UEC DRUGNAME PMID25666693-Compound-135 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D08UEJ DRUGNAME Ajinomoto 2 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D08UGB DRUGNAME VRX806 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D08UGJ DRUGNAME Vincamine INDICATI Cerebrovascular disease [ICD-11: 8B2Z] Approved TTDDRUID D08UGS DRUGNAME JNJ 63723283 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D08UGX DRUGNAME LIAROZOLE INDICATI Dermatological disease [ICD-11: DA24.Y] Phase 2/3 TTDDRUID D08UHC DRUGNAME PMA-104R INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08UHN DRUGNAME Irtemazole INDICATI Hyperuricaemia [ICD-11: 5C55.Y] Discontinued in Phase 2 TTDDRUID D08UHV DRUGNAME AMG 780 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08UJH DRUGNAME Toca 511 + Toca FC combination INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1/2 TTDDRUID D08ULI DRUGNAME Org-4094 INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D08UMH DRUGNAME Methylphenobarbital INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D08UMZ DRUGNAME STD-07 INDICATI Constipation [ICD-11: DD91.1] Phase 1/2 TTDDRUID D08UNC DRUGNAME GPC3 targeting CAR-T cells INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1 INDICATI Lung squamous cell carcinoma [ICD-11: 2C25.2] Phase 1 TTDDRUID D08UNQ DRUGNAME NSD-644 INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1 TTDDRUID D08UOY DRUGNAME Vadimezan INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D08UQC DRUGNAME Oshadi R INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D08UQS DRUGNAME MEM-1003 INDICATI Bipolar disorder [ICD-11: 6A60] Phase 2a INDICATI Dementia [ICD-11: 6D80-6D86] Phase 2 TTDDRUID D08USJ DRUGNAME Neostigmine INDICATI Myasthenia gravis [ICD-11: 8C6Y] Approved TTDDRUID D08USU DRUGNAME Ticarcillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D08UUD DRUGNAME R-1663 INDICATI Coagulation defect [ICD-11: 3B10.0] Phase 1 TTDDRUID D08UUK DRUGNAME Rostafuroxin INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D08UUL DRUGNAME LY2606368 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1 INDICATI Squamous cell anal carcinoma [ICD-11: 2C00.3] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08UVN DRUGNAME Anti-CEA CAR-T cells INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D08UVZ DRUGNAME E004 INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D08UXQ DRUGNAME FHT-1106 INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative TTDDRUID D08UYM DRUGNAME ONO-2333Ms INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D08UZA DRUGNAME Chitosan/IL-12 INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D08UZD DRUGNAME Viraplex INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D08UZL DRUGNAME TMPyP4 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D08UZP DRUGNAME MPL-containing Pollinex allergy desensitization vaccine INDICATI Angina pectoris [ICD-11: BA40] Phase 3 INDICATI Allergy [ICD-11: 4A80-4A85] Phase 2 TTDDRUID D08VAR DRUGNAME APH-0812 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D08VBV DRUGNAME TAP311 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Phase 1 TTDDRUID D08VDJ DRUGNAME IDN-13389 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08VDM DRUGNAME AZD4694 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D08VDV DRUGNAME PMID30107136-Compound-Example15 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D08VFX DRUGNAME Full-length Factor VIII molecule INDICATI Hemophilia [ICD-11: 3B10.0] Investigative TTDDRUID D08VGS DRUGNAME Recombinant protein subunit vaccine (seasonal influenza) INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Terminated TTDDRUID D08VGT DRUGNAME BMY-30129 INDICATI Pruritus [ICD-11: EC90] Discontinued in Phase 2 TTDDRUID D08VHG DRUGNAME RPL-554 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D08VIS DRUGNAME AKB-9778 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 2 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 TTDDRUID D08VJC DRUGNAME PSMA ADC INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D08VJI DRUGNAME F-14413 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D08VKQ DRUGNAME INGN-007 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D08VKZ DRUGNAME Edaglitazone INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D08VLN DRUGNAME CAT-2000 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative TTDDRUID D08VMO DRUGNAME JTT-811 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D08VMW DRUGNAME MP-529 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08VRM DRUGNAME RO-0534 INDICATI Dengue fever [ICD-11: 1D2Z] Investigative TTDDRUID D08VRO DRUGNAME Ketanserin INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D08VRQ DRUGNAME EVIRNA INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08VRX DRUGNAME GHRP-2 INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Approved TTDDRUID D08VSI DRUGNAME Revolade/Promacta INDICATI Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Approved INDICATI Chronic liver disease [ICD-11: DB99.0] Phase 3 INDICATI Thrombocytopenia [ICD-11: 3B64] Phase 2 TTDDRUID D08VSQ DRUGNAME BMS-816336 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 1 TTDDRUID D08VTA DRUGNAME EXP-6803 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D08VTV DRUGNAME PMID28350212-Compound-7 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Patented TTDDRUID D08VUJ DRUGNAME ABT-202 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1 TTDDRUID D08VVI DRUGNAME AR-54 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08VVR DRUGNAME TY-51924 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 TTDDRUID D08VWF DRUGNAME GSK-932121A INDICATI Malaria [ICD-11: 1F40-1F45] Preclinical TTDDRUID D08VWJ DRUGNAME TD-1770 INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D08VWK DRUGNAME Vaxchora INDICATI Vibrio cholerae infection [ICD-11: 1A00] Phase 3 TTDDRUID D08VWL DRUGNAME BRL-42715 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D08VWM DRUGNAME QUAN-0806 INDICATI Epilepsy [ICD-11: 8A60-8A68] Investigative TTDDRUID D08VWO DRUGNAME LFF571 INDICATI Clostridium infection [ICD-11: 1A04] Phase 2 TTDDRUID D08VXD DRUGNAME CGF166 INDICATI Deafness [ICD-11: AB52] Phase 1/2 TTDDRUID D08VXL DRUGNAME Molsidomine INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D08VXO DRUGNAME Brompheniramine INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D08VYC DRUGNAME Phosphate INDICATI Constipation [ICD-11: DD91.1] Approved TTDDRUID D08VYV DRUGNAME Metoclopramide INDICATI Nausea [ICD-11: MD90] Approved TTDDRUID D08VZH DRUGNAME ESS INDICATI Burn and burn infection [ICD-11: ND90-NE2Z] Phase 2 TTDDRUID D08WAN DRUGNAME Lu-AF11167 INDICATI Neurological disorder [ICD-11: 6B60] Phase 1 TTDDRUID D08WBF DRUGNAME BB-3644 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D08WBJ DRUGNAME KOS-2187 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 1 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Phase 1 TTDDRUID D08WCU DRUGNAME BMS-180448 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 2 TTDDRUID D08WCY DRUGNAME Seysara INDICATI Acne vulgaris [ICD-11: ED80] Application submitted TTDDRUID D08WDH DRUGNAME HXTC-901 INDICATI Bleeding disorder [ICD-11: GA20-GA21] Investigative TTDDRUID D08WDP DRUGNAME AM-3840 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D08WDT DRUGNAME VDA, HIV-1 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D08WFH DRUGNAME DNA-HIV-C/NYVAC-HIV-C INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D08WGI DRUGNAME AK-2 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D08WGZ DRUGNAME TS-033 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D08WHX DRUGNAME AGS-348 INDICATI Hereditary angioedema [ICD-11: 4A00.14] Phase 1 TTDDRUID D08WII DRUGNAME Anti-MUC1 CAR T Cells INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D08WLY DRUGNAME ME-401 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D08WNO DRUGNAME GGF INDICATI Congestive heart failure [ICD-11: BD10] Phase 1b TTDDRUID D08WOE DRUGNAME MC-3002 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Preclinical TTDDRUID D08WOJ DRUGNAME OBE-101 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D08WOW DRUGNAME LY3039478 INDICATI T-cell acute lymphoblastic leukaemia [ICD-11: 2A90.5] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D08WQH DRUGNAME BI 1361849 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D08WQU DRUGNAME AEB1102 INDICATI Arginase 1 deficiency [ICD-11: 5C50.A2] Phase 2 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID D08WSG DRUGNAME AZD-8683 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D08WSW DRUGNAME BRL-32872A INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2 TTDDRUID D08WSY DRUGNAME Denosumab INDICATI Postmenopausal osteoporosis [ICD-11: FB83.11] Approved INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D08WTE DRUGNAME Vorsetuzumab mafodotin INDICATI Renal cell carcinoma [ICD-11: 2C90] Discontinued in Phase 1 TTDDRUID D08WTW DRUGNAME Pyrazole derivative 12 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D08WUF DRUGNAME Influenza DNA vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D08WUK DRUGNAME MVA-MERS-S_DF-1 vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 1b TTDDRUID D08WVA DRUGNAME UK-224671 INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1 TTDDRUID D08WWN DRUGNAME RG7853 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved TTDDRUID D08WYH DRUGNAME LY-2228820 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D08WYK DRUGNAME OJP-2028 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D08WYM DRUGNAME Nafarelin INDICATI Endometriosis [ICD-11: GA10] Approved TTDDRUID D08WYO DRUGNAME 6F4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08WZC DRUGNAME PMID26651364-Compound-48 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D08WZQ DRUGNAME MRG-201 INDICATI Keloid [ICD-11: EE60] Phase 2 INDICATI Scleroderma [ICD-11: 4A42] Phase 1 TTDDRUID D08XAC DRUGNAME Nystatin INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D08XBF DRUGNAME AMEP INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D08XDL DRUGNAME KHK2455 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08XDO DRUGNAME Glial progenitor cell therapy INDICATI Brain injury [ICD-11: NA07.Z] Phase 1/2 TTDDRUID D08XFA DRUGNAME IL-2 XL INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1/2 TTDDRUID D08XFJ DRUGNAME NN-1218 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 INDICATI Type-1 diabetes [ICD-11: 5A10] Application submitted INDICATI Type-2 diabetes [ICD-11: 5A11] Application submitted TTDDRUID D08XFR DRUGNAME AEZS-115 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08XFV DRUGNAME Flurazepam INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D08XHN DRUGNAME AL-59412C INDICATI Ocular hypertension [ICD-11: 9C61.01] Phase 2 TTDDRUID D08XIF DRUGNAME GSK-0862 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D08XKL DRUGNAME SPI-014 INDICATI Hypophosphatasia [ICD-11: 5C64.3] Phase 1 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D08XLV DRUGNAME Sharon-5000 INDICATI MRSA infection [ICD-11: 1D01.0Y] Investigative TTDDRUID D08XMM DRUGNAME NicVAX INDICATI Nicotine dependence [ICD-11: 6C4A.2] Phase 3 TTDDRUID D08XOF DRUGNAME P-13 INDICATI Otitis media [ICD-11: AA80-AB0Z] Investigative TTDDRUID D08XOT DRUGNAME LY467711 INDICATI Migraine [ICD-11: 8A80] Terminated INDICATI Neuropathic pain [ICD-11: 8E43.0] Terminated TTDDRUID D08XOY DRUGNAME ABT-126 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D08XPI DRUGNAME CMV-specific STAR fusions INDICATI Cytomegalovirus infection [ICD-11: 1D82] Investigative TTDDRUID D08XPN DRUGNAME mab 1-7F9 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D08XPW DRUGNAME CYTISINE INDICATI Tobacco dependence [ICD-11: 6C4A.2] Phase 3 TTDDRUID D08XQA DRUGNAME RSD-921 INDICATI Anaesthesia [ICD-11: 9A78.6] Discontinued in Phase 2 TTDDRUID D08XQV DRUGNAME USL311 INDICATI Recurring respiratory infection [ICD-11: CA07-CA45] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D08XRD DRUGNAME SF-108 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D08XRX DRUGNAME ANGX-3227 INDICATI Sickle-cell anaemia [ICD-11: 3A51] Discontinued in Phase 2 TTDDRUID D08XUP DRUGNAME GE-37468A INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D08XVR DRUGNAME Baminercept INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D08XVU DRUGNAME MVA-BN anthrax INDICATI Bacillus anthracis infection [ICD-11: 1G40] Investigative TTDDRUID D08XWZ DRUGNAME ALX-0646 INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 1 TTDDRUID D08XYX DRUGNAME Aprotinin INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved TTDDRUID D08XZQ DRUGNAME PF-4287881 INDICATI Respiratory tract infection [ICD-11: CA45] Phase 1 TTDDRUID D08YAD DRUGNAME Disarmin INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D08YAL DRUGNAME PMID25666693-Compound-111 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D08YCS DRUGNAME TQ-1017 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D08YFD DRUGNAME PF-05212372 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D08YGD DRUGNAME Haempatch INDICATI Bleeding disorder [ICD-11: GA20-GA21] Investigative TTDDRUID D08YGY DRUGNAME MK-6302 INDICATI Neutropenia [ICD-11: 4B00.0] Phase 1 TTDDRUID D08YHB DRUGNAME BIIB 023 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D08YHE DRUGNAME NKR-2 CAR-T Cells INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D08YHS DRUGNAME Linopirdine INDICATI Cognitive impairment [ICD-11: 6D71] Phase 3 TTDDRUID D08YIN DRUGNAME Dalfampridine INDICATI Multiple sclerosis [ICD-11: 8A40] Approved TTDDRUID D08YJN DRUGNAME BRT-FC-83C INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D08YKD DRUGNAME CLT-011 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D08YLC DRUGNAME ONO-01210 INDICATI Acute radiation syndrome [ICD-11: NF00] Phase 1 TTDDRUID D08YNC DRUGNAME MU-1140-S INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D08YNI DRUGNAME Somatoprim INDICATI Acromegaly [ICD-11: 5A60.0] Phase 2 TTDDRUID D08YOM DRUGNAME Sulopenem etzadroxil INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D08YPQ DRUGNAME Thiazole carboxamide derivative 7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D08YPZ DRUGNAME Ammoniated mercury INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved TTDDRUID D08YQG DRUGNAME Entelon INDICATI Lymphatic disease [ICD-11: BD9Z] Investigative TTDDRUID D08YRD DRUGNAME A-717 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D08YRM DRUGNAME Long-acting interferon beta conjugate INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D08YRO DRUGNAME Ad VEGF-C INDICATI Lymphatic disease [ICD-11: BD9Z] Investigative TTDDRUID D08YSY DRUGNAME VGX-200 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08YTF DRUGNAME RG6013 INDICATI Haemophilia A [ICD-11: 3B10.0] Phase 3 TTDDRUID D08YTQ DRUGNAME M2e influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D08YVP DRUGNAME Vericigiuat INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D08YVT DRUGNAME SCH-211803 INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1 TTDDRUID D08YWK DRUGNAME FX-006 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D08YWN DRUGNAME HIV vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D08YWY DRUGNAME SCH-900117 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D08YXS DRUGNAME CAP-3.2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08YYY DRUGNAME Ocinaplon INDICATI Generalized anxiety disorder [ICD-11: 6B00] Discontinued in Phase 3 TTDDRUID D08ZAC DRUGNAME ICAR30 T cells INDICATI Anaplastic large cell lymphoma [ICD-11: 2A90.A] Phase 1 INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 1 TTDDRUID D08ZAX DRUGNAME RS-93522 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D08ZBB DRUGNAME PMID25666693-Compound-84 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D08ZBT DRUGNAME SDZ-WAG-994 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D08ZBU DRUGNAME Cyanocobalamin Co-60 INDICATI Vitamin B12 deficiency [ICD-11: 5B5F] Approved TTDDRUID D08ZCC DRUGNAME MTC-896 INDICATI Seborrhea [ICD-11: ED91.2] Phase 2 TTDDRUID D08ZCI DRUGNAME ALN-AT3SC INDICATI Haemophilia A [ICD-11: 3B10.0] Phase 1 INDICATI Haemophilia B [ICD-11: 3B11.0] Phase 1 TTDDRUID D08ZCW DRUGNAME ZD-8321 INDICATI Acute lung injury [ICD-11: NB32.3] Discontinued in Phase 2 TTDDRUID D08ZDI DRUGNAME Anti-Factor D INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Phase 1/2 TTDDRUID D08ZDM DRUGNAME Nh-125 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08ZEB DRUGNAME Chlorzoxazone INDICATI Acute pain [ICD-11: MG31] Approved TTDDRUID D08ZEM DRUGNAME Quinazoline derivative 11 INDICATI Cirrhosis [ICD-11: DB93] Patented INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Patented INDICATI Psoriasis vulgaris [ICD-11: EA90] Patented INDICATI Multiple sclerosis [ICD-11: 8A40] Patented INDICATI Gastrointestinal disease [ICD-11: DE2Z] Patented TTDDRUID D08ZFC DRUGNAME IGN-312 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D08ZFJ DRUGNAME Colestilan INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D08ZGG DRUGNAME P-218 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D08ZHL DRUGNAME FGF-1 INDICATI Coronary heart disease [ICD-11: BA80.Z] Phase 2 TTDDRUID D08ZHQ DRUGNAME C4X-301 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D08ZIH DRUGNAME CGX-1160 INDICATI Acute or chronic pain [ICD-11: MG30-MG31] Terminated TTDDRUID D08ZJJ DRUGNAME H1N1 pandemic influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D08ZJX DRUGNAME LY3076226 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08ZKJ DRUGNAME Ontazolast INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D08ZKN DRUGNAME PG-530742 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 2 TTDDRUID D08ZLL DRUGNAME Quick-acting insulin INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D08ZOY DRUGNAME Tecogalan sodium INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08ZPO DRUGNAME H-1152 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 TTDDRUID D08ZQI DRUGNAME FPA-008 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1/2 INDICATI Pigmented villonodular synovitis [ICD-11: FA27.1] Phase 1 INDICATI Tenosynovial giant cell tumour [ICD-11: 2F7B] Phase 1 TTDDRUID D08ZRR DRUGNAME KW-5092 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D08ZRW DRUGNAME Cantide + Cisplatin INDICATI Tumour [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08ZSQ DRUGNAME Parke-Davis 1 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D08ZTH DRUGNAME SLP-1002 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D08ZUC DRUGNAME TRK-950 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08ZUG DRUGNAME RBT-05 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D08ZVY DRUGNAME Technetium Tc-99m Lidofenin Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D08ZXG DRUGNAME INT-2500 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D08ZXH DRUGNAME AX-208 INDICATI Parkinson disease [ICD-11: 8A00.0] Terminated TTDDRUID D08ZXM DRUGNAME REG2 INDICATI Venous thrombosis [ICD-11: BA43] Phase 1 TTDDRUID D08ZXQ DRUGNAME Neublastin INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D08ZYZ DRUGNAME Chikungunya vaccine INDICATI Chikungunya virus infection [ICD-11: 1D40] Phase 2 TTDDRUID D08ZZO DRUGNAME NS-696 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D08ZZP DRUGNAME EchoGen INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1/2 TTDDRUID D09AAK DRUGNAME Ripretinib INDICATI Gastrointestinal stromal tumour [ICD-11: 2B5B] Approved INDICATI Glioma [ICD-11: 2A00.0] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Systemic mastocytosis [ICD-11: 2A21.0] Phase 1 TTDDRUID D09AAM DRUGNAME ICI-164384 INDICATI Breast cancer [ICD-11: 2C60-2C65] Terminated TTDDRUID D09ACC DRUGNAME CNTO-0007 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1 TTDDRUID D09ADN DRUGNAME VOXERGOLIDE HYDROCHLORIDE INDICATI Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1 TTDDRUID D09ADS DRUGNAME Immuncell-LC INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Approved TTDDRUID D09ADT DRUGNAME ABT-418 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2 TTDDRUID D09AFE DRUGNAME AG-NDP803 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D09AFI DRUGNAME INCB039110 INDICATI Malignant neoplasm [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D09AFJ DRUGNAME SR-121787 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D09AFV DRUGNAME GLG-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09AGG DRUGNAME GSK2890457 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D09AGZ DRUGNAME CEE-04-421 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D09AHK DRUGNAME ZYN002-CBD INDICATI Seizure disorder [ICD-11: 8A6Z] Phase 2 TTDDRUID D09AHZ DRUGNAME Celivarone INDICATI Ventricular arrhythmias [ICD-11: BC71] Phase 2/3 TTDDRUID D09AIH DRUGNAME PCUR-101 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D09AIT DRUGNAME BHT-3201 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D09AJU DRUGNAME TS-111 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 1 TTDDRUID D09ALE DRUGNAME Enadoline INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D09ALM DRUGNAME BIIB061 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D09ALR DRUGNAME MM36 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D09AMZ DRUGNAME Enprofylline INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D09ANC DRUGNAME MC-02,479 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D09ANG DRUGNAME Misoprostol INDICATI Medical abortion [ICD-11: JA00.1Z] Approved TTDDRUID D09AOO DRUGNAME ANAVEX 2-73 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 INDICATI Infantile spasm [ICD-11: 8A62.0] Phase 1 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 INDICATI Rett syndrome [ICD-11: LD90.4] Phase 1 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 1 TTDDRUID D09APA DRUGNAME Plasma derived factor VIII PEGylated liposomal INDICATI Factor VIII deficiency [ICD-11: 3B10] Phase 3 TTDDRUID D09APB DRUGNAME IDX-189 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D09ATR DRUGNAME PF-06804103 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09AUP DRUGNAME GW-215864 INDICATI Rhinitis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D09AVX DRUGNAME WIB-901H INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D09AVZ DRUGNAME E1/E4-deleted adenoviral vector INDICATI Ornithine transcarbamylase deficiency [ICD-11: 5C50.AY] Investigative TTDDRUID D09AWJ DRUGNAME H5N1 influenza vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D09AWM DRUGNAME ODSH INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D09AXQ DRUGNAME CD22-CART INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D09AYA DRUGNAME IB-08C175 INDICATI Graft-versus-host disease [ICD-11: 4B24] Investigative TTDDRUID D09AYM DRUGNAME MABp1 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 INDICATI Hidradenitis suppurativa [ICD-11: ED92.0] Phase 2 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 INDICATI Pyoderma gangrenosum [ICD-11: EB21] Phase 2 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Phase 2 TTDDRUID D09AYQ DRUGNAME PIRITREXIM INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 TTDDRUID D09AYS DRUGNAME Antineoplaston-A5 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D09BAP DRUGNAME KUR-212 INDICATI Wound healing [ICD-11: EL8Y] Phase 2 TTDDRUID D09BBA DRUGNAME TAK-071 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D09BBW DRUGNAME Sodium stibogluconate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D09BCC DRUGNAME ImmuDyn INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D09BCJ DRUGNAME PMID30124346-Compound-34TABLE4 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Patented TTDDRUID D09BCL DRUGNAME DCB-AD1 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D09BDE DRUGNAME PAC-14028 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D09BDH DRUGNAME Rabeximod INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D09BDK DRUGNAME SNG-163 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09BEG DRUGNAME CNS-5161 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D09BEJ DRUGNAME AQST-305 INDICATI Malignant carcinoid syndrome [ICD-11: 5B10] Phase 1 TTDDRUID D09BEO DRUGNAME DBP-192 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D09BGB DRUGNAME Aryl mannoside derivative 1 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D09BHA DRUGNAME LY-353433 INDICATI Inflammatory bowel disease [ICD-11: DD72] Terminated TTDDRUID D09BHB DRUGNAME Tolmetin INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D09BHF DRUGNAME WF-2421 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D09BID DRUGNAME PRO-206 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Terminated TTDDRUID D09BIW DRUGNAME 99mTc-sestamibi INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D09BIX DRUGNAME Nexagon INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 2 TTDDRUID D09BJH DRUGNAME Retroviral MGMT-transduced hematopoietic cells INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 1 TTDDRUID D09BKE DRUGNAME NS398 INDICATI Endometriosis [ICD-11: GA10] Terminated TTDDRUID D09BKY DRUGNAME Bevacizumab + Erlotinib INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 INDICATI Hypopharyngeal squamous cell carcinoma [ICD-11: 2B6D.0] Phase 1/2 TTDDRUID D09BLW DRUGNAME TgAAV-CFTR INDICATI Cystic fibrosis [ICD-11: CA25] Discontinued in Phase 2 TTDDRUID D09BNP DRUGNAME Heterocyclic derivative 11 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D09BNR DRUGNAME Gazyva INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D09BNZ DRUGNAME LDE225 INDICATI Skin cancer [ICD-11: 2C30-2C37] Phase 2 INDICATI Medulloblastoma [ICD-11: 2A00.10] Phase 2 TTDDRUID D09BOH DRUGNAME Verubulin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Brain metastases [ICD-11: 2D50] Phase 2 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D09BPN DRUGNAME Anatibant INDICATI Traumatic brain injury [ICD-11: NA07.Z] Phase 2 TTDDRUID D09BPT DRUGNAME Anti-CD9 mab INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Investigative TTDDRUID D09BQO DRUGNAME ATD transdermal gel INDICATI Contraception [ICD-11: QA21] Phase 1 TTDDRUID D09BRE DRUGNAME U-78517F INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D09BSI DRUGNAME TDI-0039 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D09BTK DRUGNAME NCX-1000 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D09BVL DRUGNAME NS-1619 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D09BWC DRUGNAME E-4080 INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D09BWG DRUGNAME CAR-T cells targeting CD19 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D09BXF DRUGNAME CLS003 INDICATI Plantar wart [ICD-11: 1E80.1] Phase 2 TTDDRUID D09BXJ DRUGNAME PF-5177624 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09BZJ DRUGNAME MEHD-7945A INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D09BZS DRUGNAME CK-101 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D09BZY DRUGNAME Nibentan INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Phase 1 TTDDRUID D09CAC DRUGNAME U-96988 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D09CBI DRUGNAME Anti-Her-2 mab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09CCZ DRUGNAME Triciribine prodrug INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D09CEJ DRUGNAME CYT003 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D09CEY DRUGNAME SKL-PSY INDICATI Bipolar disorder [ICD-11: 6A60] Phase 1 TTDDRUID D09CFM DRUGNAME DANOFLOXACIN INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D09CGE DRUGNAME Florbetapir F-18 INDICATI Diagnostic imaging [ICD-11: N.A.] Approved TTDDRUID D09CHX DRUGNAME AMR-SIX-1 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D09CIB DRUGNAME BC-22 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D09CIF DRUGNAME TH-9402 INDICATI Graft-versus-host disease [ICD-11: 4B24] Phase 2 TTDDRUID D09CIQ DRUGNAME Cadralazine INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D09CJO DRUGNAME CXB-029 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D09CKF DRUGNAME Licostinel INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1 TTDDRUID D09CKG DRUGNAME MVA-MERS-S vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Discontinued in Phase 1 TTDDRUID D09CKT DRUGNAME LY433222 INDICATI Depression [ICD-11: 6A70-6A7Z] Investigative TTDDRUID D09CLC DRUGNAME C188-9 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09CLG DRUGNAME VRC-SRSDNA015-00-VP vaccine INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Discontinued in Phase 1 TTDDRUID D09CLH DRUGNAME Samarium SM-153 lexidronam INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D09CLX DRUGNAME MDT-006 INDICATI Constipation [ICD-11: DD91.1] Investigative TTDDRUID D09CMK DRUGNAME R-salbutamol sulphate INDICATI Skin infection [ICD-11: 1F28-1G0Z] Phase 2 TTDDRUID D09CNO DRUGNAME Grass pollen allergy vaccine INDICATI Seasonal allergic rhinitis [ICD-11: CA08.01] Phase 2/3 TTDDRUID D09CNR DRUGNAME KLS-Npk INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D09CNV DRUGNAME EDG-005 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D09COD DRUGNAME Romurtide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D09CPR DRUGNAME Penicillin V INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D09CQB DRUGNAME GPs-0193 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D09CRQ DRUGNAME RPK-739 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D09CTF DRUGNAME Human recombinant factor VIII INDICATI Factor VIII deficiency [ICD-11: 3B10] Investigative TTDDRUID D09CTH DRUGNAME RP-701 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09CTY DRUGNAME OPHD-002 INDICATI Inflammatory bowel disease [ICD-11: DD72] Terminated TTDDRUID D09CUR DRUGNAME Trans-sodium crocetinate INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 3 INDICATI Brain metastases [ICD-11: 2D50] Phase 1 TTDDRUID D09CXE DRUGNAME Norovirus bivalent vaccine INDICATI Norovirus infection [ICD-11: 1A23] Phase 1/2 TTDDRUID D09CYK DRUGNAME ENDG-3010 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D09CZA DRUGNAME Travoprost INDICATI Open-angle glaucoma [ICD-11: 9C61] Approved TTDDRUID D09CZS DRUGNAME DRF-1042 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09DAJ DRUGNAME FG-6874 INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D09DAQ DRUGNAME ISIS 353512 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D09DBR DRUGNAME Micronomicin sulfate INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D09DBY DRUGNAME Rilonacept INDICATI Arthritis [ICD-11: FA20] Approved INDICATI Acute gout flare [ICD-11: FA25.0] Phase 3 TTDDRUID D09DDQ DRUGNAME FUB-130 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D09DER DRUGNAME QR-336 INDICATI Radiation syndrome [ICD-11: NF00] Preclinical TTDDRUID D09DEU DRUGNAME HMPL-342 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D09DFB DRUGNAME EFEGATRAN SULFATE HYDRATE INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 TTDDRUID D09DGE DRUGNAME LD-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09DHL DRUGNAME TDI-0090 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D09DHT DRUGNAME phorbol 12-myristate 13-acetate INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 2 TTDDRUID D09DHY DRUGNAME Colchicine INDICATI Acute gouty arthritis [ICD-11: FA25.0] Approved TTDDRUID D09DIB DRUGNAME RG-4929 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 2 TTDDRUID D09DIG DRUGNAME Ablukast INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 3 TTDDRUID D09DIQ DRUGNAME CART22 cells expressing anti-CD22 scFv TCRz:41BB INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D09DJC DRUGNAME IRX4204 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D09DJO DRUGNAME Pafuramidine INDICATI Malaria [ICD-11: 1F40-1F45] Phase 3 TTDDRUID D09DJS DRUGNAME INV-400 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D09DJU DRUGNAME SU-14813 INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D09DKY DRUGNAME AEZS-123 INDICATI Alcohol dependence [ICD-11: 6C40.2] Preclinical TTDDRUID D09DLN DRUGNAME L-739749 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D09DLP DRUGNAME Tramiprosate INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D09DND DRUGNAME Anti-GD2-CAR engineered T cells INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 1 INDICATI Osteosarcoma [ICD-11: 2B51] Phase 1 INDICATI Sarcoma [ICD-11: 2A60-2C35] Phase 1 TTDDRUID D09DRG DRUGNAME NE-100 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D09DRM DRUGNAME NT-1635 INDICATI Sarcopenia [ICD-11: FB32.Y] Investigative TTDDRUID D09DSK DRUGNAME JWH-051 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D09DTY DRUGNAME DABO-1047 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D09DUQ DRUGNAME AN-2718 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 1 TTDDRUID D09DWL DRUGNAME Zaleplon INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D09DXX DRUGNAME PF-06282999 INDICATI Acute coronary syndrome [ICD-11: BA41] Phase 1 TTDDRUID D09DYB DRUGNAME CHDI-00316226 INDICATI Huntington disease [ICD-11: 8A01.10] Investigative TTDDRUID D09DYT DRUGNAME EP-5001 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D09EBJ DRUGNAME MC-02306 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D09EBL DRUGNAME Antegren INDICATI Multiple sclerosis [ICD-11: 8A40] Approved TTDDRUID D09EBS DRUGNAME Oxymetazoline INDICATI Eye inflammation [ICD-11: 9A02] Approved INDICATI Nasal congestion [ICD-11: MD11.9] Approved TTDDRUID D09EDA DRUGNAME PRM-151 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 2 INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 2 INDICATI Polycythemia vera [ICD-11: 2A20.4] Phase 2 INDICATI Thrombocythemia [ICD-11: 3B63] Phase 2 TTDDRUID D09EDW DRUGNAME Deligoparin sodium INDICATI Ulcerative colitis [ICD-11: DD71] Discontinued in Phase 3 TTDDRUID D09EED DRUGNAME SYM-009 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D09EEV DRUGNAME Declopramide INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2 TTDDRUID D09EFC DRUGNAME CAP-232 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2a INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D09EFW DRUGNAME Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 13 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D09EGZ DRUGNAME Chloroquine INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D09EHO DRUGNAME ABT-751 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D09EIQ DRUGNAME Biaryl mannoside derivative 18 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D09EIX DRUGNAME PMID26936077-Compound-13 INDICATI Type-2 diabetes [ICD-11: 5A11] Patented INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Patented INDICATI Gastric ulcer [ICD-11: DA60] Patented TTDDRUID D09EJC DRUGNAME IRX-03 INDICATI Neutropenia [ICD-11: 4B00.0] Investigative TTDDRUID D09ELC DRUGNAME AVI-7537 INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 1 TTDDRUID D09ELP DRUGNAME Clevidipine butyrate INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D09ELW DRUGNAME Enalkiren INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 2 TTDDRUID D09EMS DRUGNAME CO-8 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D09ENA DRUGNAME Org-30035 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Terminated TTDDRUID D09ENF DRUGNAME PNT-300 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09ENR DRUGNAME Itarnafloxin INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2 TTDDRUID D09ENZ DRUGNAME EPZ-004777 INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D09EOZ DRUGNAME CX-99 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09EPU DRUGNAME 18F-BAY-85-8050 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09EPX DRUGNAME MitoLinoleic INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Investigative TTDDRUID D09EQA DRUGNAME SpirH INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D09EQZ DRUGNAME XN-0502 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09ESW DRUGNAME Anipamil INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 3 TTDDRUID D09ETH DRUGNAME E-7050 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1 TTDDRUID D09EVP DRUGNAME NNZ-4921 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D09EVZ DRUGNAME BMS-488043 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D09EWK DRUGNAME PRO-053 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1/2 TTDDRUID D09EXD DRUGNAME Rituximab INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D09EXQ DRUGNAME PMID26651364-Compound-8a INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D09EYJ DRUGNAME IPS cell program INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D09EYN DRUGNAME RSV F protein vaccine INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 3 TTDDRUID D09EZU DRUGNAME Myrrhanol A INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D09FAZ DRUGNAME Azacitidine INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Approved TTDDRUID D09FDN DRUGNAME IMA201 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D09FEN DRUGNAME PRO-515 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D09FFI DRUGNAME SARS-CoV vaccine INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Discontinued in Phase 1 TTDDRUID D09FFS DRUGNAME FT-071 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D09FGM DRUGNAME ZP-10719 INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Investigative TTDDRUID D09FGV DRUGNAME Recombinant S protein SARS vaccine INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Discontinued in Phase 1 TTDDRUID D09FGX DRUGNAME ELACRIDAR INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D09FHM DRUGNAME Fluzone QIV INDICATI Ovarian cancer [ICD-11: 2C73] Approved INDICATI Influenza [ICD-11: 1E30-1E32] Approved INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D09FHY DRUGNAME HIV multiantigen vaccine INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID D09FJB DRUGNAME Tolazamide INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D09FJH DRUGNAME CFC-240 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D09FKY DRUGNAME GED-0301 INDICATI Crohn disease [ICD-11: DD70] Phase 3 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 TTDDRUID D09FNI DRUGNAME Nonocog beta pegol INDICATI Haemophilia B [ICD-11: 3B11.0] Phase 3 TTDDRUID D09FOP DRUGNAME MCP-202 INDICATI Overactive bladder [ICD-11: GC50.0] Phase 1 TTDDRUID D09FQB DRUGNAME UR-12460 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D09FQP DRUGNAME PMID25684022-Compound-US20120277229 39(1.1) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D09FQS DRUGNAME FG-3622 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Preclinical TTDDRUID D09FQW DRUGNAME THVD-201 INDICATI Overactive bladder [ICD-11: GC50.0] Phase 3 TTDDRUID D09FSG DRUGNAME Golimumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2/3 TTDDRUID D09FTC DRUGNAME BacTRL-Spike vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D09FTJ DRUGNAME TTP-054 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D09FWK DRUGNAME E-003 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09FYW DRUGNAME PF-06743649 INDICATI Gout [ICD-11: FA25] Phase 1 TTDDRUID D09FZI DRUGNAME TALTOBULIN INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D09FZM DRUGNAME BreMel/rGel INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D09GAG DRUGNAME DC-159a INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D09GBM DRUGNAME GD-AAV8 INDICATI Gaucher disease [ICD-11: 5C56.0Y] Investigative TTDDRUID D09GDD DRUGNAME Regorafenib INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Approved TTDDRUID D09GDY DRUGNAME GNI-103 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1/2 TTDDRUID D09GEK DRUGNAME ASP3026 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 TTDDRUID D09GFL DRUGNAME Trihexyphenidyl INDICATI Dystonia [ICD-11: 8A02] Approved INDICATI Parkinson disease [ICD-11: 8A00.0] Approved INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D09GGJ DRUGNAME CVT-124 INDICATI Autoimmune diabetes [ICD-11: 5A10] Discontinued in Phase 3 TTDDRUID D09GGO DRUGNAME A-252444.0 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D09GHB DRUGNAME RO-4987655 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D09GHO DRUGNAME LY-334370 INDICATI Migraine [ICD-11: 8A80] Phase 2 TTDDRUID D09GIA DRUGNAME SAR391786 INDICATI Muscle atrophy [ICD-11: FB32.Y] Phase 2 TTDDRUID D09GIP DRUGNAME QRS-5-005 INDICATI Sepsis [ICD-11: 1G40-1G41] Terminated TTDDRUID D09GJQ DRUGNAME Tricyclic phytocannabinoid derivative 1 INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented TTDDRUID D09GLS DRUGNAME GSK1614235 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D09GMC DRUGNAME GX-101 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Investigative TTDDRUID D09GME DRUGNAME Covid-19 aAPC vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D09GMH DRUGNAME Hepatitis B virus vaccine INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D09GOS DRUGNAME Clotrimazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D09GPB DRUGNAME AZD2066 INDICATI Chronic neuropathic pain [ICD-11: MG30.5] Discontinued in Phase 2 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D09GPI DRUGNAME FRM-6308 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1b TTDDRUID D09GQS DRUGNAME JD-0100 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D09GRB DRUGNAME NNC-90-0270 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D09GRH DRUGNAME O-Vax INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 TTDDRUID D09GRX DRUGNAME Tucatinib INDICATI HER2-positive breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2/3 TTDDRUID D09GSV DRUGNAME FBT-A05 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 TTDDRUID D09GUI DRUGNAME PTL-68001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D09GUJ DRUGNAME Omadacycline INDICATI Acute bacterial skin infection [ICD-11: 1C41] Approved INDICATI Bacterial pneumonia [ICD-11: CA40.0] Approved INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3 TTDDRUID D09GVB DRUGNAME OL-135 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D09GVI DRUGNAME VSF-173 INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 2 TTDDRUID D09GWA DRUGNAME SARS-CoV-2 rS vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D09GXF DRUGNAME RB-105 INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D09GYJ DRUGNAME BNT162a1 vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D09GYT DRUGNAME Methoxamine INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D09HAL DRUGNAME JTT-651 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D09HCE DRUGNAME Long-acting FSH conjugate INDICATI Female infertility [ICD-11: GA31.Z] Investigative TTDDRUID D09HCR DRUGNAME FM-401 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D09HDR DRUGNAME Deserpidine INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D09HDV DRUGNAME AD-529 INDICATI Neuropathic pain [ICD-11: 8E43.0] Preclinical TTDDRUID D09HEV DRUGNAME GS-9005 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1/2 TTDDRUID D09HFJ DRUGNAME NM-3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09HFL DRUGNAME GSK2398852 + GSK2315698 INDICATI Amyloidosis [ICD-11: 5D00] Phase 2 TTDDRUID D09HFS DRUGNAME AFP464 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D09HIC DRUGNAME BF-388 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D09HJS DRUGNAME BIZELESIN INDICATI Skin disease [ICD-11: EA00-EM0Z] Phase 1 TTDDRUID D09HKX DRUGNAME Cefoselis INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D09HNR DRUGNAME Telithromycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D09HNV DRUGNAME Intedanib INDICATI Colorectal cancer [ICD-11: 2B91.Z] Approved INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Approved INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D09HOJ DRUGNAME NPB-01 INDICATI Pemphigoid [ICD-11: EB41] Phase 3 TTDDRUID D09HOW DRUGNAME S-364735 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D09HRH DRUGNAME Anti-CD133-CAR vector-transduced T cells INDICATI Brain cancer [ICD-11: 2A00] Phase 1 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 INDICATI Liver cancer [ICD-11: 2C12] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D09HRS DRUGNAME GHB-16L2 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2 TTDDRUID D09HTB DRUGNAME SAR153191 INDICATI Ankylosing spondylitis [ICD-11: FA92.0] Phase 3 TTDDRUID D09HTE DRUGNAME HA20 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D09HTS DRUGNAME Lanatoside a INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D09HUF DRUGNAME UR-60427 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D09HUU DRUGNAME EC1456 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09HVD DRUGNAME Ramucirumab INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Approved TTDDRUID D09HVH DRUGNAME NMS-E973 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09HVL DRUGNAME Bivalirudin INDICATI Thrombocytopenia [ICD-11: 3B64] Approved TTDDRUID D09HVY DRUGNAME Cystatin C INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D09HYG DRUGNAME NP16 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Investigative TTDDRUID D09HYI DRUGNAME M-2001 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D09IAN DRUGNAME Anti-CD19 Chimeric Antigen Receptor T Cells INDICATI leukaemia [ICD-11: 2A60-2B33] Clinical trial TTDDRUID D09ICC DRUGNAME SB220025 INDICATI Arthritis [ICD-11: FA20] Terminated TTDDRUID D09ICH DRUGNAME CD7.CAR/28zeta CAR T cells INDICATI B-cell acute lymphoblastic leukaemia [ICD-11: 2B33.3] Phase 1 INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D09IEE DRUGNAME Prednicarbate INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D09IFW DRUGNAME Cruentaren INDICATI Fungal infection [ICD-11: 1F29-1F2F] Preclinical TTDDRUID D09IGF DRUGNAME MG-28 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09IGR DRUGNAME AZX-100 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D09IIX DRUGNAME HMAG-1 targeting GRSA INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D09IJP DRUGNAME A-71378 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D09IKZ DRUGNAME AS-1949490 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D09IMN DRUGNAME SAR153192 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09IMS DRUGNAME Mequitazine INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved INDICATI Respiratory disease [ICD-11: CB40] Phase 2 TTDDRUID D09IMY DRUGNAME SLP-0905 INDICATI Enterococcus faecium infection [ICD-11: 1D01.0Y] Investigative TTDDRUID D09INA DRUGNAME HD-148 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09INF DRUGNAME Laquinamod INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 TTDDRUID D09INX DRUGNAME DSP-3905 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D09IOA DRUGNAME EM-3106B INDICATI Insulinoma [ICD-11: 2C10.1] Investigative TTDDRUID D09IOF DRUGNAME Troplasminogen alfa INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 TTDDRUID D09IOI DRUGNAME Amoxapine INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved TTDDRUID D09IPV DRUGNAME Danazol INDICATI Menorrhagia [ICD-11: GA20.50] Approved INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D09IRN DRUGNAME LU AE58054 INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 TTDDRUID D09IRQ DRUGNAME Ataluren INDICATI Cystic fibrosis [ICD-11: CA25] Phase 3 INDICATI Dravet syndrome [ICD-11: 8A61.11] Phase 2 INDICATI Muscular dystrophy [ICD-11: 8C70] Phase 2 INDICATI Aniridia [ICD-11: LA11.3] Phase 1 INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1 INDICATI Duchenne dystrophy [ICD-11: 8C70] Application submitted TTDDRUID D09ISJ DRUGNAME SOM-0856 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D09ISS DRUGNAME CZEN-001 INDICATI Pruritus [ICD-11: EC90] Phase 1 TTDDRUID D09ITH DRUGNAME Botulism immune globulin INDICATI Clostridium infection [ICD-11: 1A04] Approved TTDDRUID D09IUG DRUGNAME F-3796 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D09IUR DRUGNAME Midismase INDICATI Cerebral infarction [ICD-11: 8B11.5Z] Phase 2 TTDDRUID D09IVP DRUGNAME Anti-folate receptor 1 humanized mab INDICATI Ovarian cancer [ICD-11: 2C73] Investigative TTDDRUID D09IYH DRUGNAME Pyrazole derivative 58 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D09IYM DRUGNAME AT13148 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09IZX DRUGNAME GW-275919 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D09JBP DRUGNAME Paramethadione INDICATI Seizure disorder [ICD-11: 8A6Z] Approved INDICATI Fetal trimethadione syndrome [ICD-11: LD2F.0Y] Approved TTDDRUID D09JCH DRUGNAME CDNA vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D09JDV DRUGNAME PMID26651364-Compound-5a INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D09JDX DRUGNAME RCD-2 INDICATI Fecal incontinence [ICD-11: ME07] Preclinical TTDDRUID D09JEJ DRUGNAME CX-4945 INDICATI Coronavirus infection [ICD-11: 1D92] Phase 2 INDICATI Cholangiocarcinoma [ICD-11: 2C12.10] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09JES DRUGNAME Sampatrilat INDICATI Hypotension [ICD-11: BA20-BA21] Phase 2 TTDDRUID D09JET DRUGNAME NGD 96-3 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Investigative TTDDRUID D09JFY DRUGNAME Dutasteride + tamsulosin INDICATI Benign prostatic hyperplasia [ICD-11: GA90] Phase 3 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D09JGH DRUGNAME EC-145 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D09JGK DRUGNAME TAK-960 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09JJG DRUGNAME MCT-465 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09JJU DRUGNAME EchiTAb INDICATI Poison intoxication [ICD-11: NE6Z] Approved TTDDRUID D09JKN DRUGNAME P-BCMA-101 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D09JKS DRUGNAME GRASPA INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 3 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D09JLI DRUGNAME Vicriviroc INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D09JLP DRUGNAME Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 10 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D09JMW DRUGNAME IHV001 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D09JNP DRUGNAME MVax INDICATI Ovarian cancer [ICD-11: 2C73] Approved TTDDRUID D09JPT DRUGNAME CB-183872 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D09JSM DRUGNAME IMC-3C5 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09JTE DRUGNAME BIOO-6 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09JUG DRUGNAME Zileuton INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D09JUL DRUGNAME Naltrexone prodrug INDICATI Alcohol dependence [ICD-11: 6C40.2] Investigative TTDDRUID D09JVK DRUGNAME LY3090106 INDICATI Sjogren syndrome [ICD-11: 4A43.20] Phase 2/3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D09JVV DRUGNAME Physostigmine INDICATI Xerostomia [ICD-11: DA02.1] Discontinued in Phase 2 TTDDRUID D09JXH DRUGNAME LUM001 INDICATI Primary biliary cirrhosis [ICD-11: DB96.1] Phase 2 INDICATI Primary biliary cholangitis [ICD-11: DB96.1] Phase 2 INDICATI Primary sclerosing cholangitis [ICD-11: DB96.2] Phase 2 INDICATI Progressive familial intrahepatic cholestasis [ICD-11: 5C58.03] Phase 2 INDICATI Structural developmental anomalies of liver [ICD-11: LB20.0] Phase 2 TTDDRUID D09JXL DRUGNAME SEGLITIDE INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D09JXM DRUGNAME Phenylpropanolamine INDICATI Obesity [ICD-11: 5B81] Withdrawn from market TTDDRUID D09JYF DRUGNAME Epocarbazolin-A INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D09JYL DRUGNAME Hu5F9-G4 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D09JYY DRUGNAME F-1013 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09KAK DRUGNAME NOX-F37 INDICATI Acute and chronic heart failure [ICD-11: BD1Z] Preclinical TTDDRUID D09KDN DRUGNAME Cefazolin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D09KDV DRUGNAME Dihydroxyacetone INDICATI Sunburn [ICD-11: EJ40] Approved TTDDRUID D09KEB DRUGNAME PRT-060318 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D09KEW DRUGNAME KPL-716 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 1 INDICATI Nodular prurigo [ICD-11: EC91.0] Phase 1 TTDDRUID D09KGQ DRUGNAME Menadiol sodium diphosphate INDICATI Coagulation defect [ICD-11: 3B10.0] Approved TTDDRUID D09KGZ DRUGNAME QG-AGC1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D09KHE DRUGNAME EN3488 INDICATI Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 3 TTDDRUID D09KIG DRUGNAME ETX201 INDICATI Crohn disease [ICD-11: DD70] Phase 1 TTDDRUID D09KIP DRUGNAME Chondrogel INDICATI Pediatric cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3 TTDDRUID D09KKD DRUGNAME AZD-3118 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D09KKH DRUGNAME Mepartricin INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D09KLO DRUGNAME AZD-5106 INDICATI Urinary incontinence [ICD-11: MF50.2] Terminated TTDDRUID D09KLR DRUGNAME Alendronate INDICATI Paget's disease [ICD-11: FB85] Approved INDICATI Osteoporosis [ICD-11: FB83.0] Approved TTDDRUID D09KLX DRUGNAME Cartistem-adipo INDICATI Arthropathy [ICD-11: FA11-FA38] Investigative TTDDRUID D09KMA DRUGNAME Zofroxia INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D09KNG DRUGNAME RSV-604 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 2 TTDDRUID D09KRE DRUGNAME Bezlotoxumab INDICATI C. difficile infection [ICD-11: 1A04] Approved TTDDRUID D09KRU DRUGNAME BI-831266 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09KRV DRUGNAME Adhexil INDICATI Injury [ICD-11: NA00-ND5Z] Phase 3 TTDDRUID D09KRX DRUGNAME AVR-168 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D09KSW DRUGNAME 3-CLA INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09KTE DRUGNAME BCL-004 INDICATI Renal cell carcinoma [ICD-11: 2C90] Investigative TTDDRUID D09KTI DRUGNAME GS-5816 INDICATI Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D09KTS DRUGNAME Ibrutinib INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Approved INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 3 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D09KUE DRUGNAME NSC-88915 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09KWN DRUGNAME Anti-MUC1 CAR-T cells INDICATI Esophageal cancer [ICD-11: 2B70] Phase 1/2 TTDDRUID D09KWX DRUGNAME Hl-con1 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 1 TTDDRUID D09KXA DRUGNAME PD-131112 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D09KYB DRUGNAME Pyrimidine derivative 7 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Patented INDICATI Fibrosis [ICD-11: GA14-GC01] Patented INDICATI Blood vessel proliferative disorder [ICD-11: BE2Z] Patented TTDDRUID D09KYR DRUGNAME RP-49356 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D09KYZ DRUGNAME V-24343 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D09LBS DRUGNAME Sennoside b INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D09LDR DRUGNAME Oxazepam INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D09LEB DRUGNAME RG7641 INDICATI Kidney disease [ICD-11: GC2Z] Discontinued in Phase 1 TTDDRUID D09LEN DRUGNAME Pneumococcal 13-valent conjugate vaccine INDICATI Streptococcus infection [ICD-11: 1B53] Approved TTDDRUID D09LEP DRUGNAME Pyrethroids INDICATI Pest attack [ICD-11: N.A.] Phase 2 TTDDRUID D09LGV DRUGNAME MT-204 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D09LHG DRUGNAME YY-162 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3 TTDDRUID D09LIE DRUGNAME ASIbcl vaccine INDICATI B-cell lymphoma [ICD-11: 2A86] Terminated TTDDRUID D09LIZ DRUGNAME KI-0502 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D09LKR DRUGNAME TS-011 INDICATI Stroke [ICD-11: 8B20] Phase 1 TTDDRUID D09LKU DRUGNAME NOX-E36 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D09LLS DRUGNAME Havrix INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Approved TTDDRUID D09LMQ DRUGNAME Vaginal ring INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Investigative TTDDRUID D09LMX DRUGNAME Revatropate INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D09LNI DRUGNAME Fluconazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D09LOZ DRUGNAME TTAC-0001 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D09LPI DRUGNAME BCG65-E7 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Discontinued in Phase 3 INDICATI Anal intraepithelial neoplasia [ICD-11: 2E92.5] Discontinued in Phase 3 TTDDRUID D09LPK DRUGNAME 4E2Rcat INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D09LPN DRUGNAME Lepirudin INDICATI Thrombocytopenia [ICD-11: 3B64] Approved TTDDRUID D09LPV DRUGNAME N6022 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D09LQK DRUGNAME BQ-123 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 TTDDRUID D09LQP DRUGNAME RG-14893 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D09LSX DRUGNAME KU-0058948 INDICATI Ovarian cancer [ICD-11: 2C73] Approved TTDDRUID D09LSY DRUGNAME EDP-322 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D09LTC DRUGNAME Non GC-C INDICATI Gastrointestinal disease [ICD-11: DE2Z] Investigative TTDDRUID D09LTO DRUGNAME A-76341 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D09LVD DRUGNAME ISIS-APOARx INDICATI Coronary artery disease [ICD-11: BA80] Phase 1 TTDDRUID D09LVK DRUGNAME TDI-0026 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D09LWP DRUGNAME PMID26651364-Compound-105 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D09LWS DRUGNAME Ezetimibe INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Approved TTDDRUID D09LWZ DRUGNAME Mannoside derivative 7 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D09LZA DRUGNAME CS-4771 INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1 TTDDRUID D09LZN DRUGNAME ACER-001 INDICATI Maple-syrup-urine disease [ICD-11: 5C50.D0] Investigative TTDDRUID D09LZT DRUGNAME Levomepromazine INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Approved INDICATI Bipolar disorder [ICD-11: 6A60] Approved TTDDRUID D09MAB DRUGNAME Anti-CD5 humanized mab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09MAS DRUGNAME FR-901483 INDICATI Graft-versus-host disease [ICD-11: 4B24] Discontinued in Phase 1 TTDDRUID D09MCG DRUGNAME Amantidine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative TTDDRUID D09MED DRUGNAME Toca 511/Toca FC INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 3 INDICATI Glioma [ICD-11: 2A00.0] Phase 3 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09MEV DRUGNAME JES-9501 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D09MFV DRUGNAME KC-7F2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09MGR DRUGNAME Etoricoxib INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D09MHC DRUGNAME CJC-1134-PC INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D09MHN DRUGNAME Ixmyelocel-T INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 INDICATI Dilated cardiomyopathy [ICD-11: BC43.0] Phase 3 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D09MHU DRUGNAME Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 6 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D09MIN DRUGNAME LCL161 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D09MJH DRUGNAME SEA-CD40 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09MJJ DRUGNAME RP4010 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D09MJO DRUGNAME HL-004 INDICATI Arteriosclerosis [ICD-11: BD40] Preclinical TTDDRUID D09MKH DRUGNAME TRI-102 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3 TTDDRUID D09MKL DRUGNAME TD-1607 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Phase 1 TTDDRUID D09MKQ DRUGNAME AMG 317 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D09MOD DRUGNAME NNC-252504 INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D09MON DRUGNAME A-75998 INDICATI Hormone deficiency [ICD-11: 5A61.1] Discontinued in Phase 1 TTDDRUID D09MPD DRUGNAME ALX-0651 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D09MPN DRUGNAME TDI-0087 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D09MPO DRUGNAME HLD100 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2 TTDDRUID D09MPU DRUGNAME Astromycin sulfate INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D09MPX DRUGNAME SPF66 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1 TTDDRUID D09MQQ DRUGNAME CDD-0199-J INDICATI Alzheimer disease [ICD-11: 8A20] Preclinical TTDDRUID D09MQU DRUGNAME OGX-225 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D09MQY DRUGNAME CKD-403 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09MRD DRUGNAME MGN-4220 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D09MRL DRUGNAME Pidilizumab INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 TTDDRUID D09MRY DRUGNAME ACU-0101979 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D09MSE DRUGNAME JNJ-38224342 INDICATI Seasonal allergic rhinitis [ICD-11: CA08.01] Phase 1 TTDDRUID D09MTC DRUGNAME ADL-5945 INDICATI Constipation [ICD-11: DD91.1] Discontinued in Phase 2 TTDDRUID D09MUS DRUGNAME JBD-201 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D09MVZ DRUGNAME mab17-1a INDICATI Colorectal cancer [ICD-11: 2B91.Z] Approved TTDDRUID D09MWJ DRUGNAME Alfuzosin INDICATI Benign prostatic hyperplasia [ICD-11: GA90] Approved TTDDRUID D09MXE DRUGNAME TCK-1 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D09MXS DRUGNAME Sorbitol INDICATI Constipation [ICD-11: DD91.1] Approved TTDDRUID D09NAF DRUGNAME AV 133 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D09NAW DRUGNAME PF-05105679 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D09NBH DRUGNAME ICT-121 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D09NBM DRUGNAME SB-435495 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D09NCH DRUGNAME AM-230 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Investigative TTDDRUID D09NCU DRUGNAME GS-6624 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D09NDM DRUGNAME IN-001 INDICATI Erectile dysfunction [ICD-11: HA01.1] Phase 3 TTDDRUID D09NEE DRUGNAME BVT-115959 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D09NEL DRUGNAME CWF-0804 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D09NFN DRUGNAME Pentetate calcium trisodium INDICATI Acute radiation syndrome [ICD-11: NF00] Approved TTDDRUID D09NFW DRUGNAME Dendritic cell vaccine INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D09NHD DRUGNAME Peptide P21S10 INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D09NHS DRUGNAME PfCS-102 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1/2 TTDDRUID D09NIA DRUGNAME Chlorthalidone INDICATI Edema [ICD-11: MG29] Approved INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D09NIB DRUGNAME Epipodophyllotoxin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D09NIY DRUGNAME Trolamine Polypeptide Oleate Condensate INDICATI Impacted cerumen [ICD-11: AA42] Approved TTDDRUID D09NKX DRUGNAME ANA-246 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Terminated TTDDRUID D09NLC DRUGNAME Guar gum INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Approved TTDDRUID D09NLK DRUGNAME Minokine INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D09NMD DRUGNAME Lasofoxifene INDICATI Osteoporosis [ICD-11: FB83.0] Approved INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1 TTDDRUID D09NNA DRUGNAME Dromostanolone INDICATI Mammary tumour [ICD-11: 2C60-2C6Z] Approved TTDDRUID D09NNH DRUGNAME Dihydroergocristine INDICATI Alcohol dependence [ICD-11: 6C40.2] Approved TTDDRUID D09NQD DRUGNAME CIGB-55 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D09NQX DRUGNAME HBV-002 INDICATI West nile virus infection [ICD-11: 1D46] Phase 1 TTDDRUID D09NST DRUGNAME Afimoxifene INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Ductal carcinoma [ICD-11: 2E65.2] Phase 2 TTDDRUID D09NTC DRUGNAME CC-486 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 3 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 TTDDRUID D09NTG DRUGNAME Taurocholic Acid INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1/2 TTDDRUID D09NTM DRUGNAME VR506 INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D09NUH DRUGNAME 4SCAR-FRa INDICATI Bladder cancer [ICD-11: 2C94] Phase 1/2 TTDDRUID D09NVR DRUGNAME PRN2246 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D09NVU DRUGNAME ZP-1848 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 1 TTDDRUID D09NWW DRUGNAME AMG-247 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D09NXZ DRUGNAME HL-038 INDICATI Angina pectoris [ICD-11: BA40] Investigative TTDDRUID D09NYB DRUGNAME CASTANOSPERMINE INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D09NYS DRUGNAME Methylene blue INDICATI Acquired methemoglobinemia [ICD-11: 3A93] Approved TTDDRUID D09NYU DRUGNAME Polaprezinc INDICATI Ulcer [ICD-11: CA02-CB40] Approved INDICATI Helicobacter infection [ICD-11: DA42-DA63] Approved TTDDRUID D09OAQ DRUGNAME TNP-470 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D09OBB DRUGNAME Dextromethorphan INDICATI Cough [ICD-11: MD12] Approved TTDDRUID D09OBF DRUGNAME CMUS-100 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09OCK DRUGNAME UK-371800 INDICATI Erectile dysfunction [ICD-11: HA01.1] Phase 1 TTDDRUID D09ODU DRUGNAME XL475 INDICATI Type-2 diabetes [ICD-11: 5A11] Preclinical TTDDRUID D09OHH DRUGNAME OS-440 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 INDICATI Muscle spasm [ICD-11: MB47.3] Application submitted TTDDRUID D09OHP DRUGNAME Indeglitazar INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D09OHR DRUGNAME SY-1365 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09OHW DRUGNAME Dendritic cell therapy INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D09OJI DRUGNAME D-0502 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D09OJQ DRUGNAME Methadone INDICATI Dry cough [ICD-11: MD12] Approved TTDDRUID D09OKV DRUGNAME Amprenavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D09OKZ DRUGNAME CA4P INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D09OLR DRUGNAME Debio-1141 INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D09OLZ DRUGNAME Cetrorelix INDICATI Ovarian stimulation [ICD-11: LB45.1] Approved TTDDRUID D09OMK DRUGNAME Tarvacin Anti-Viral INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 1 TTDDRUID D09ONL DRUGNAME SAR439794 INDICATI Allergy [ICD-11: 4A80-4A85] Phase 1 TTDDRUID D09OOC DRUGNAME Gp100 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D09OOQ DRUGNAME TGFK08AA INDICATI Generalized anxiety disorder [ICD-11: 6B00] Phase 2 TTDDRUID D09OOV DRUGNAME Polymyxin B Sulfate INDICATI Pseudomonas infection [ICD-11: 1B92] Approved TTDDRUID D09OPH DRUGNAME NPB-3 INDICATI Allergic rhinitis [ICD-11: CA08.0] Investigative TTDDRUID D09OPS DRUGNAME SN-28049 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09OQV DRUGNAME N-0923 INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D09ORU DRUGNAME ZELANDOPAM HYDROCHLORIDE INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D09OSC DRUGNAME Anti-EGFRvIII CAR T cells INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D09OSM DRUGNAME TGFTX-1 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D09OTF DRUGNAME ACEA-1031 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D09OTG DRUGNAME MS-377 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D09OTU DRUGNAME SSR-180575 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D09OTX DRUGNAME RG7800 INDICATI Spinal muscular atrophy [ICD-11: 8B61] Phase 1/2 TTDDRUID D09OUT DRUGNAME NN-818 INDICATI Brain injury [ICD-11: NA07.Z] Preclinical TTDDRUID D09OWC DRUGNAME SKLB-010 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D09OWI DRUGNAME HDV-insulin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2/3 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D09OWK DRUGNAME AGN-2979 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 2 TTDDRUID D09OXR DRUGNAME Diffistat-G INDICATI Clostridium infection [ICD-11: 1A04] Discontinued in Phase 2 TTDDRUID D09OZC DRUGNAME Lucanthone INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D09PAU DRUGNAME M87o INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D09PCL DRUGNAME JNJ-64565111 INDICATI Obesity [ICD-11: 5B81] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D09PDK DRUGNAME F-9TG INDICATI Factor IX deficiency [ICD-11: 3B11] Investigative TTDDRUID D09PEQ DRUGNAME Gentamicine sulfate INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D09PEV DRUGNAME Itazigrel INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D09PFR DRUGNAME LAMB3-transduced autologous epidermal stem cells INDICATI Epidermolysis bullosa [ICD-11: EC3Z] Phase 1 TTDDRUID D09PGG DRUGNAME MVI-816 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D09PGH DRUGNAME PA-508 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D09PGL DRUGNAME Capromab INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D09PGM DRUGNAME BY-1949 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D09PGT DRUGNAME T2c-002 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 2 TTDDRUID D09PHB DRUGNAME Mefenamic INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D09PIH DRUGNAME NK-1007 INDICATI Atrial fibrillation [ICD-11: BC81.3] Investigative TTDDRUID D09PJB DRUGNAME ARG301 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D09PJX DRUGNAME Tetrabenazine INDICATI Hyperkinetic movement disorder [ICD-11: 6B60.8] Approved INDICATI Huntington disease [ICD-11: 8A01.10] Approved TTDDRUID D09PKU DRUGNAME ERBULOZOLE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D09PKZ DRUGNAME NM-9308 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Investigative TTDDRUID D09PLF DRUGNAME Org-30029 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D09PLI DRUGNAME Efalith INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D09PLZ DRUGNAME NI-1201 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D09PMV DRUGNAME Interferon Alfa-2a, Recombinant INDICATI Chronic HCV-1 infection [ICD-11: 1E51.1] Approved TTDDRUID D09PNS DRUGNAME UGP-281 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D09PNV DRUGNAME KSG-504 INDICATI Pancreatic malfunction [ICD-11: DC30-DC3Z] Investigative TTDDRUID D09PNY DRUGNAME Tropicamide INDICATI Mydriasis [ICD-11: LA11.62] Approved TTDDRUID D09POH DRUGNAME AEG-33773 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 TTDDRUID D09PON DRUGNAME MRLP-098 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D09POQ DRUGNAME OM-174 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09PPF DRUGNAME CNS-1067 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D09PPG DRUGNAME Metformin arginine-hemisuccinimide INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D09PPU DRUGNAME CA-170 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09PQP DRUGNAME SGN-70 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D09PQZ DRUGNAME Acalabrutinib INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Approved INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3 TTDDRUID D09PRN DRUGNAME TROVIRDINE HYDROCHLORIDE INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D09PRY DRUGNAME CB-28 INDICATI Aging skin [ICD-11: EE40] Terminated TTDDRUID D09PSB DRUGNAME DPC-082 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D09PSY DRUGNAME ANS-6637 INDICATI Substance use disorder [ICD-11: 6C4Z] Phase 1 TTDDRUID D09PSZ DRUGNAME Deferitrin INDICATI Iron overload disease [ICD-11: 5C64.10] Phase 1/2 TTDDRUID D09PTA DRUGNAME HP-290 INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2 TTDDRUID D09PTD DRUGNAME BMS-986168 INDICATI Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 1 TTDDRUID D09PTL DRUGNAME SRI-3072 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Terminated TTDDRUID D09PTP DRUGNAME CEP-28122 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09PTY DRUGNAME V-212 INDICATI Varicella zoster virus infection [ICD-11: 1E91] Phase 3 INDICATI Zoster [ICD-11: 1E91] Phase 3 TTDDRUID D09PUL DRUGNAME L-Alanine INDICATI Glioma [ICD-11: 2A00.0] Approved INDICATI Dietary shortage [ICD-11: 5B5K] Approved TTDDRUID D09PVO DRUGNAME Aramchol INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 2/3 TTDDRUID D09PWS DRUGNAME KI-0902 INDICATI Gastrointestinal ulcer [ICD-11: DA60.Z] Investigative TTDDRUID D09PYD DRUGNAME CGS-25462 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D09PYV DRUGNAME AZ-40140 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D09PYZ DRUGNAME MK-3328 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D09PZO DRUGNAME Idoxuridine INDICATI Herpes simplex virus infection [ICD-11: 1F00] Approved TTDDRUID D09PZV DRUGNAME ITV-4 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D09PZZ DRUGNAME Lypressin INDICATI Amnesia [ICD-11: MB21.1] Approved TTDDRUID D09QAD DRUGNAME CGS-15873A INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 2 TTDDRUID D09QBG DRUGNAME Cangrelor INDICATI Thrombosis [ICD-11: DB61-GB90] Approved TTDDRUID D09QDP DRUGNAME Clorgyline INDICATI Parkinson disease [ICD-11: 8A00.0] Approved INDICATI Skin imperfections [ICD-11: EK71] Patented TTDDRUID D09QEI DRUGNAME Pentoxifylline INDICATI Intermittent claudication [ICD-11: BD40.00] Approved TTDDRUID D09QHP DRUGNAME PS-873266 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D09QHU DRUGNAME SD-560 INDICATI Pulmonary fibrosis [ICD-11: CB03.4] Investigative TTDDRUID D09QIJ DRUGNAME PF-3491165 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D09QKI DRUGNAME PPL-100 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D09QLR DRUGNAME Dibenzothiazepines INDICATI Drug abuse [ICD-11: 6C4G.1Z] Investigative TTDDRUID D09QMX DRUGNAME Q-301 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D09QOF DRUGNAME EM-2487 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D09QOR DRUGNAME Eniluracil INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D09QPD DRUGNAME HPP-515 INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative TTDDRUID D09QPE DRUGNAME AP-1189 INDICATI Atopic dermatitis [ICD-11: EA80] Investigative TTDDRUID D09QQE DRUGNAME Crodox INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D09QQS DRUGNAME Diazepinone derivative 1 INDICATI Reflux disease [ICD-11: DA22] Patented INDICATI Parkinson disease [ICD-11: 8A00.0] Patented TTDDRUID D09QRG DRUGNAME BXT-25 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D09QRI DRUGNAME NX-001 INDICATI Kidney transplant rejection [ICD-11: NE84] Phase 1 TTDDRUID D09QRO DRUGNAME CGS-13080 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D09QRS DRUGNAME Chondrocelect INDICATI Articular cartilage disorder [ICD-11: FA34.Y] Approved TTDDRUID D09QSC DRUGNAME PSMA protein vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D09QTS DRUGNAME LC-01 INDICATI Ocular inflammation [ICD-11: 9C61.24] Investigative TTDDRUID D09QUE DRUGNAME MVA-BN HIV Polytope INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1/2 TTDDRUID D09QUQ DRUGNAME Levobupivacaine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D09QVI DRUGNAME LQB-118 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09QVR DRUGNAME BMS-986218 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D09QVT DRUGNAME Streptococcus vaccines INDICATI Streptococcus infection [ICD-11: 1B53] Terminated TTDDRUID D09QVU DRUGNAME APH-0703 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1/2 TTDDRUID D09QVV DRUGNAME Vincristine INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved TTDDRUID D09QWD DRUGNAME CEP-37251 INDICATI Bone metastases [ICD-11: 2D50] Phase 1 TTDDRUID D09QWK DRUGNAME AMG-327 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D09QWN DRUGNAME CB4211 INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 1 TTDDRUID D09QXC DRUGNAME PMID25666693-Compound-79 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D09QYD DRUGNAME ILS920 INDICATI Stroke [ICD-11: 8B20] Phase 1 TTDDRUID D09QZB DRUGNAME Resorcinol compound 32 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D09QZI DRUGNAME Norgestimate INDICATI Contraception [ICD-11: QA21] Approved TTDDRUID D09QZK DRUGNAME RIG-I adjuvant INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09QZS DRUGNAME Olaratumab INDICATI Soft tissue sarcoma [ICD-11: 2B57] Approved INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D09RAB DRUGNAME PRO-300 INDICATI Mucositis [ICD-11: CA00] Investigative TTDDRUID D09RBQ DRUGNAME Zutectra INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D09RDT DRUGNAME GT-3021 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Discontinued in Phase 1 TTDDRUID D09RED DRUGNAME Prostat INDICATI Prostate hyperplasia [ICD-11: GA90] Approved TTDDRUID D09RGS DRUGNAME Anti-CD97 mab INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D09RGW DRUGNAME AZD-3778 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D09RHQ DRUGNAME Ropivacaine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D09RHS DRUGNAME Arilvax INDICATI Yellow fever virus infection [ICD-11: 1D47] Approved TTDDRUID D09RII DRUGNAME Voxelotor INDICATI Sickle-cell disorder [ICD-11: 3A51] Approved TTDDRUID D09RJA DRUGNAME RELVARTM or BREOTM ELLIPTATM INDICATI Asthma [ICD-11: CA23] NDA filed TTDDRUID D09RJN DRUGNAME S-17092-1 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 1 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Clinical trial TTDDRUID D09RKU DRUGNAME SCH-1518291 INDICATI Schizophrenia [ICD-11: 6A20] Investigative TTDDRUID D09RLQ DRUGNAME CDX-1127 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D09RMS DRUGNAME AMT-070 INDICATI Liver cirrhosis [ICD-11: DB93.1] Terminated TTDDRUID D09RMU DRUGNAME GPI-0100 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D09RMZ DRUGNAME HibTITER INDICATI Pneumococcal infection [ICD-11: CA00-CA40] Phase 2 TTDDRUID D09RND DRUGNAME EZN-4176 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D09RNI DRUGNAME ESN-YY INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D09RNP DRUGNAME GSK 679769 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 INDICATI Chemotherapy-induced nausea [ICD-11: MD90] Discontinued in Phase 2 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 INDICATI Incontinence [ICD-11: MF50.2] Discontinued in Phase 2 TTDDRUID D09RON DRUGNAME LY-2300559 INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 2 TTDDRUID D09RPB DRUGNAME DFD-06 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 TTDDRUID D09RPP DRUGNAME CAR-GPC3 T cell INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Clinical trial TTDDRUID D09RPU DRUGNAME 4'-GALACTOSYLLACTOSE INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D09RRG DRUGNAME BK-4SP INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D09RSN DRUGNAME MediPhage MRPA INDICATI Pseudomonas infection [ICD-11: 1B92] Investigative TTDDRUID D09RSY DRUGNAME Onyvax-P INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D09RTF DRUGNAME VT-1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Terminated TTDDRUID D09RTK DRUGNAME Tapet INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09RUJ DRUGNAME SX-GLP1 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D09RUO DRUGNAME SGN-CD352A INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D09RUW DRUGNAME Iomeprol INDICATI Brain disease [ICD-11: 8C70-8E61] Approved TTDDRUID D09RVI DRUGNAME Tegobuvir INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D09RXG DRUGNAME EA-230 INDICATI Bacillus anthracis infection [ICD-11: 1G40] Phase 2 TTDDRUID D09RYU DRUGNAME Tractinostat INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09RZB DRUGNAME BBI-11008 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D09RZH DRUGNAME AdRTVP-1 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D09RZM DRUGNAME E-1101 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D09SAH DRUGNAME PZ01 CAR-T cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID D09SAU DRUGNAME IMM-160 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative TTDDRUID D09SAV DRUGNAME Dendritic cell PEG fusion cancer vaccine INDICATI Kidney cancer [ICD-11: 2C90.0] Discontinued in Phase 1/2 TTDDRUID D09SBE DRUGNAME Anti-CD7 CAR-T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D09SBY DRUGNAME Hebervis INDICATI Oral mucositis [ICD-11: DA01.11] Investigative TTDDRUID D09SCI DRUGNAME SKF-104351 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D09SCP DRUGNAME ADXS-PSA INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D09SFH DRUGNAME R-82150 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D09SFV DRUGNAME LY294002 INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 1 TTDDRUID D09SFX DRUGNAME AGEN1884 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09SGL DRUGNAME BTP-114 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09SGV DRUGNAME Daclatasvir INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Approved TTDDRUID D09SHC DRUGNAME ALT-804 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09SHH DRUGNAME BAX-817 INDICATI Hemophilia [ICD-11: 3B10.0] Phase 3 TTDDRUID D09SHL DRUGNAME S. epidermidis vaccine INDICATI Skin infection [ICD-11: 1F28-1G0Z] Phase 1 TTDDRUID D09SHX DRUGNAME GM-CSF cancer vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D09SIK DRUGNAME Azaribine INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved TTDDRUID D09SIR DRUGNAME Lonidamine INDICATI Benign prostatic hyperplasia [ICD-11: GA90] Discontinued in Phase 3 TTDDRUID D09SJE DRUGNAME KB002/003 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D09SLI DRUGNAME Aryl mannoside derivative 13 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D09SLU DRUGNAME LG-101280 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D09SMA DRUGNAME PMID25666693-Compound-128 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D09SMG DRUGNAME Hepatyrix INDICATI Hepatitis A virus infection [ICD-11: 1E50.0] Approved TTDDRUID D09SOA DRUGNAME Clonixin INDICATI Dysmenorrhea [ICD-11: GA34.3] Approved TTDDRUID D09SOD DRUGNAME RAP-102 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D09SQM DRUGNAME VAY736 INDICATI Sjogren syndrome [ICD-11: 4A43.20] Phase 2 INDICATI Pemphigus vulgaris [ICD-11: EB40] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D09SRR DRUGNAME Unoprostone INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved TTDDRUID D09SRZ DRUGNAME Recombinant factor IX-Fc INDICATI Haemophilia B [ICD-11: 3B11.0] Approved TTDDRUID D09SSC DRUGNAME Nipradilol INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D09SSY DRUGNAME Foscarnet + Cidofovir INDICATI Cytomegalovirus infection [ICD-11: 1D82] Investigative TTDDRUID D09SVB DRUGNAME SEB-Humab INDICATI Staphylococcus infection [ICD-11: 1B5Y] Investigative TTDDRUID D09SWM DRUGNAME Epostane INDICATI Abortion [ICD-11: JA00] Investigative TTDDRUID D09SXJ DRUGNAME NC-0604 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09SXR DRUGNAME KRH-102053 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09SYB DRUGNAME J5dLPS/OMP INDICATI Sepsis [ICD-11: 1G40-1G41] Phase 1 TTDDRUID D09SZY DRUGNAME IQ-DAA INDICATI Bacillus anthracis infection [ICD-11: 1G40] Phase 1 TTDDRUID D09TAB DRUGNAME Pexidartinib INDICATI Tenosynovial giant cell tumour [ICD-11: 2F7B] Approved INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 INDICATI Pigmented villonodular synovitis [ICD-11: FA27.1] Phase 3 INDICATI Neurofibromatosis type 1 [ICD-11: LD2D.10] Phase 1/2 TTDDRUID D09TBD DRUGNAME Sulfisoxazole INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D09TBM DRUGNAME PRX-12261 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D09TCY DRUGNAME CDX-1401 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D09TDG DRUGNAME NFTB-104 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D09TDK DRUGNAME DPN-205-734 INDICATI Cardiac disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D09TEI DRUGNAME ReN-1869 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D09TFB DRUGNAME TOFIMILAST INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D09TFL DRUGNAME PCI-27483 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D09TGC DRUGNAME MK-1903 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 2 TTDDRUID D09TGD DRUGNAME KUR-112 INDICATI Bone disease [ICD-11: FC0Z] Phase 1 TTDDRUID D09TGO DRUGNAME Autologous ET1402L1-CART cells INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1 INDICATI Liver cancer [ICD-11: 2C12] Phase 1 INDICATI Metastatic liver cancer [ICD-11: 2C12] Phase 1 TTDDRUID D09TGT DRUGNAME Atu-027 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09TGX DRUGNAME Valspodar INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Discontinued in Phase 3 TTDDRUID D09TGZ DRUGNAME Examorelin INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Discontinued in Phase 2 TTDDRUID D09THN DRUGNAME IMGN901 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D09TIW DRUGNAME SLP-0904 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D09TJJ DRUGNAME Pamrevlumab INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D09TJV DRUGNAME PGC-lysostaphin INDICATI Staphylococcus infection [ICD-11: 1B5Y] Investigative TTDDRUID D09TKY DRUGNAME Biaryl mannoside derivative 7 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D09TLE DRUGNAME Tefinostat INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09TLJ DRUGNAME ATOFLUDING INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D09TLT DRUGNAME BZF961 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2 TTDDRUID D09TMV DRUGNAME AZD-4619 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Discontinued in Phase 1 TTDDRUID D09TNR DRUGNAME Ki-23057 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09TOK DRUGNAME PF-4531083 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D09TOL DRUGNAME RG-7816 INDICATI Autism spectrum disorder [ICD-11: 6A02] Phase 1 TTDDRUID D09TOS DRUGNAME ST-669 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D09TPF DRUGNAME Molindone INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D09TPW DRUGNAME PF-04475270 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D09TQI DRUGNAME VT-401 INDICATI Muscular dystrophy [ICD-11: 8C70] Investigative TTDDRUID D09TQY DRUGNAME Dusigitumab INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D09TRM DRUGNAME D-5410 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D09TSD DRUGNAME I-vation INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Phase 2 TTDDRUID D09TSX DRUGNAME CEL-011 INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D09TUW DRUGNAME Hepatitis C vaccine INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D09TVH DRUGNAME TCH-013 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D09TXA DRUGNAME HelicoVax INDICATI Helicobacter infection [ICD-11: DA42-DA63] Investigative TTDDRUID D09TXG DRUGNAME CEMADOTIN HYDROCHLORIDE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D09TXO DRUGNAME humanin INDICATI Alzheimer disease [ICD-11: 8A20] Preclinical TTDDRUID D09TXU DRUGNAME DT-831j INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D09TYS DRUGNAME Loviride INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D09TYX DRUGNAME GC-501 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D09UAI DRUGNAME TB-402 INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 2 INDICATI Venous thromboembolism [ICD-11: BD72] Phase 2 TTDDRUID D09UCO DRUGNAME BMS-986046 INDICATI Heart failure [ICD-11: BD10-BD13] Preclinical TTDDRUID D09UCU DRUGNAME APT3111 INDICATI Blood forming organ disorder [ICD-11: JB64.1] Investigative TTDDRUID D09UCV DRUGNAME SRW-LAMP-vax INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D09UDL DRUGNAME LTX-315 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09UFV DRUGNAME AZD-5423 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D09UFZ DRUGNAME CD38 CAR T cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D09UGG DRUGNAME Zemab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09UGP DRUGNAME RPR-106541 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D09UHY DRUGNAME SMK-01/03 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D09UIM DRUGNAME LXR-0151 INDICATI Diarrhea [ICD-11: ME05.1] Discontinued in Phase 1 TTDDRUID D09UJB DRUGNAME PMID28350212-Compound-19 INDICATI Alzheimer disease [ICD-11: 8A20] Patented TTDDRUID D09UKH DRUGNAME XL550 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D09UMN DRUGNAME LEQ-506 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09UMP DRUGNAME MN-305 INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 2 TTDDRUID D09UMR DRUGNAME UV1 + GM-CSF vaccine INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D09UQS DRUGNAME LPG-1030I INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D09URP DRUGNAME DABIS MALEATE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09URT DRUGNAME OCO-1112 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D09USN DRUGNAME IC-485 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D09UTQ DRUGNAME GC-7101 INDICATI Stomach ulcer [ICD-11: DA60.Z] Investigative TTDDRUID D09UVK DRUGNAME MK-8835A INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D09UVX DRUGNAME PRX-12247 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D09UXE DRUGNAME Fosmidomycin INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D09UXI DRUGNAME MGN-5804 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D09UXP DRUGNAME AZD-1744 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D09UXU DRUGNAME T1-1081 INDICATI Macular degeneration [ICD-11: 9B78.3] Investigative TTDDRUID D09UZB DRUGNAME Glucopyranoside derivatives INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D09UZL DRUGNAME TAK-063 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D09UZO DRUGNAME Mercaptopurine INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved INDICATI Crohn disease [ICD-11: DD70] Phase 4 TTDDRUID D09VAB DRUGNAME BPR1K-0224 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09VAD DRUGNAME Angiopoietin 2 mAb INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09VAS DRUGNAME M281 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Phase 1 TTDDRUID D09VAZ DRUGNAME TRIENTINE INDICATI Inborn error of metabolism [ICD-11: 5C50-5C59] Approved TTDDRUID D09VBC DRUGNAME Carbetapentane INDICATI Cough [ICD-11: MD12] Approved TTDDRUID D09VBE DRUGNAME Elinogrel INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 1 TTDDRUID D09VBN DRUGNAME CTX110 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D09VCC DRUGNAME PL-6983 INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative TTDDRUID D09VFA DRUGNAME Live attenuated cholera vaccine INDICATI Vibrio cholerae infection [ICD-11: 1A00] Phase 2 TTDDRUID D09VFU DRUGNAME MST-400 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09VFX DRUGNAME SAR342434 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 3 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D09VGC DRUGNAME Milnacipran INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D09VHA DRUGNAME BDF-9148 INDICATI Cardiac failure [ICD-11: BD10-BD13] Terminated TTDDRUID D09VHS DRUGNAME EM-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09VIX DRUGNAME VRC01LS INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D09VKP DRUGNAME C-Cure INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 2/3 INDICATI Chronic heart failure [ICD-11: BD1Z] Phase 2/3 TTDDRUID D09VLQ DRUGNAME VP-50406 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2 TTDDRUID D09VMI DRUGNAME Cediranib INDICATI Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 3 TTDDRUID D09VOK DRUGNAME Trientine Hydrochloride INDICATI Wilson disease [ICD-11: 5C64.00] Approved TTDDRUID D09VOS DRUGNAME ETI-204 INDICATI Anthrax [ICD-11: 1B97] Approved TTDDRUID D09VQO DRUGNAME CLR-901 INDICATI Neurological disorder [ICD-11: 6B60] Terminated TTDDRUID D09VQW DRUGNAME MCTP-39 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D09VRO DRUGNAME Cyclohexyl carbamate derivative 6 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D09VRZ DRUGNAME AZM-131 INDICATI Obesity [ICD-11: 5B81] Terminated TTDDRUID D09VSV DRUGNAME PH80-PMD INDICATI Migraine [ICD-11: 8A80] Phase 3 TTDDRUID D09VTB DRUGNAME IDX-320 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1/2 TTDDRUID D09VWI DRUGNAME BRX-005 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 1 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Discontinued in Phase 2 TTDDRUID D09VXM DRUGNAME Crofelemer INDICATI HIV-associated diarrhoea [ICD-11: 1A2Z] Approved TTDDRUID D09VYF DRUGNAME RDEN1delta30 INDICATI Dengue fever [ICD-11: 1D2Z] Phase 2 TTDDRUID D09VYS DRUGNAME BXL-1H5 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D09VYT DRUGNAME CD19-targeted CAR-T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Clinical trial INDICATI Lymphoma [ICD-11: 2A80-2A86] Clinical trial TTDDRUID D09VZR DRUGNAME SGI-1252 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09WAY DRUGNAME OPN-501 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D09WBQ DRUGNAME DSM2 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D09WCC DRUGNAME MP-0270 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D09WCE DRUGNAME IS-159 INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 2 TTDDRUID D09WCM DRUGNAME Spinosad INDICATI Head and body lice [ICD-11: 1G00.0] Approved TTDDRUID D09WCN DRUGNAME Intetumumab INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D09WDK DRUGNAME Tbo-Filgrastim INDICATI Neutropenia [ICD-11: 4B00.0] Approved TTDDRUID D09WEJ DRUGNAME Bromopride INDICATI Dyspepsia [ICD-11: MD92] Approved TTDDRUID D09WFI DRUGNAME Tetramethylpyrazine INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Phase 2 TTDDRUID D09WFL DRUGNAME MP-12 INDICATI Rift valley fever [ICD-11: 1D44] Phase 2 TTDDRUID D09WGH DRUGNAME Ropidoxuridine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Gastrointestinal cancer [ICD-11: 2C11] Phase 1 TTDDRUID D09WGU DRUGNAME PEG-VM-501 INDICATI Thrombocytopenia [ICD-11: 3B64] Investigative TTDDRUID D09WHM DRUGNAME DU-29894 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1 TTDDRUID D09WIM DRUGNAME AviFluCide-I INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D09WIR DRUGNAME CC-90009 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D09WJT DRUGNAME Toleragens INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D09WKB DRUGNAME Anisindione INDICATI Coagulation defect [ICD-11: 3B10.0] Approved TTDDRUID D09WKH DRUGNAME Zosyn/Tazocin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D09WKM DRUGNAME BI-836826 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D09WKT DRUGNAME ARD-412 INDICATI Premature ejaculation [ICD-11: HA03.0Z] Investigative TTDDRUID D09WMV DRUGNAME BMS-753951 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D09WND DRUGNAME TETRAPLATIN TETRANITRATE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D09WNK DRUGNAME Fenfluramine INDICATI Dravet syndrome [ICD-11: 8A61.11] Phase 3 INDICATI LennoxGastaut syndrome [ICD-11: 8A62.1] Phase 3 INDICATI Obesity [ICD-11: 5B81] Withdrawn from market TTDDRUID D09WNQ DRUGNAME NCTX INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09WOI DRUGNAME NZ-39000 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D09WOY DRUGNAME SB-559457 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Investigative TTDDRUID D09WPI DRUGNAME GOVX-B11 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D09WPN DRUGNAME AP22408 INDICATI Osteoporosis [ICD-11: FB83.0] Terminated TTDDRUID D09WRG DRUGNAME CEP-41750 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D09WRI DRUGNAME ELINAFIDE MESILATE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D09WSR DRUGNAME PCA062 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Esophageal cancer [ICD-11: 2B70] Phase 1 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09WTQ DRUGNAME RC-8800 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D09WUY DRUGNAME TP-104 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D09WVR DRUGNAME FX-107 INDICATI Dengue fever [ICD-11: 1D2Z] Preclinical TTDDRUID D09WWB DRUGNAME MenABCWY INDICATI Meningococcal infection [ICD-11: 1C1C] Phase 2 TTDDRUID D09WXY DRUGNAME CDX-014 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1/2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D09WYC DRUGNAME Y-26611 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D09WYE DRUGNAME NST-001 INDICATI Tinnitus [ICD-11: MC41] Phase 1 TTDDRUID D09WYL DRUGNAME GSK-557296 INDICATI Premature ejaculation [ICD-11: HA03.0Z] Phase 2 TTDDRUID D09WYX DRUGNAME Deflazacort INDICATI Duchenne dystrophy [ICD-11: 8C70] Approved TTDDRUID D09WZG DRUGNAME Anascorp INDICATI Poison intoxication [ICD-11: NE6Z] Phase 3 TTDDRUID D09WZU DRUGNAME BCI-838 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 1 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1 TTDDRUID D09WZV DRUGNAME GMA-161 INDICATI Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Approved (orphan drug) TTDDRUID D09XCX DRUGNAME PIRINIXIC ACID INDICATI Pulmonary fibrosis [ICD-11: CB03.4] Preclinical TTDDRUID D09XDR DRUGNAME Granulosin INDICATI Chronic granulomatous disease [ICD-11: 4A00.0Y] Investigative TTDDRUID D09XEM DRUGNAME NGN-9080 INDICATI Spinal cord injury [ICD-11: ND51.2] Investigative TTDDRUID D09XGB DRUGNAME VER 50589 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D09XGK DRUGNAME Testetrol INDICATI Hypogonadism [ICD-11: 5A61.0] Investigative TTDDRUID D09XHI DRUGNAME AZD-6538 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 1 TTDDRUID D09XHQ DRUGNAME TA-CD INDICATI Cocaine addiction [ICD-11: 6C45.2] Phase 2 TTDDRUID D09XHU DRUGNAME HER-2 Protein AutoVac INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D09XIZ DRUGNAME JNJ-26481585 INDICATI Advanced stage follicular lymphoma [ICD-11: 2A80] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D09XJF DRUGNAME EPI 589 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D09XKO DRUGNAME KD-101 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1 TTDDRUID D09XKT DRUGNAME KI-1003 INDICATI Eating disorder [ICD-11: 6B82] Investigative TTDDRUID D09XKW DRUGNAME Castor oil INDICATI Constipation [ICD-11: DD91.1] Approved TTDDRUID D09XLS DRUGNAME FR139317 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 INDICATI Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1 TTDDRUID D09XMP DRUGNAME SC-114 INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D09XMX DRUGNAME SaxaDapa FDC INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 3 TTDDRUID D09XNZ DRUGNAME CT-2408R INDICATI Shock [ICD-11: MG40] Terminated TTDDRUID D09XOF DRUGNAME NY-ESO-1 vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09XOR DRUGNAME Palladium Pd 103 INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D09XPD DRUGNAME GivaRex INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09XPJ DRUGNAME Micacocidin A INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D09XQF DRUGNAME Isoniazid INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Approved TTDDRUID D09XQU DRUGNAME Tirapazamine INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 TTDDRUID D09XRD DRUGNAME Comvax INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D09XRQ DRUGNAME HCBE-11 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09XSH DRUGNAME Cytoreg INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09XTN DRUGNAME Emicizumab INDICATI Factor VIII deficiency [ICD-11: 3B10] Approved TTDDRUID D09XUB DRUGNAME Viramidine INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3 TTDDRUID D09XUH DRUGNAME GASTRAZOLE INDICATI Duodenal ulcer [ICD-11: DA63] Phase 3 TTDDRUID D09XUI DRUGNAME 1,5-diphenylpyrrolidin-2-one derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D09XUY DRUGNAME Icofungipen INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 2 TTDDRUID D09XVQ DRUGNAME PT-14 INDICATI Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2 TTDDRUID D09XVS DRUGNAME Tc-99m tilmanocept INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D09XWD DRUGNAME Teprenone INDICATI Peptic ulcer [ICD-11: DA61] Approved TTDDRUID D09XWT DRUGNAME AZP-03 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D09XXH DRUGNAME VCH-286 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D09XXW DRUGNAME Co-2-1068 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D09XYU DRUGNAME XR-12890 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D09XZB DRUGNAME Gefitinib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved INDICATI Head and neck cancer [ICD-11: 2D42] Phase 3 INDICATI Urethral cancer [ICD-11: 2C93] Phase 2 TTDDRUID D09XZL DRUGNAME LX-7101 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1/2 TTDDRUID D09YAS DRUGNAME CYT-013-IL1bQb INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D09YBF DRUGNAME Gamma-tocotrienol INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D09YBZ DRUGNAME CO-12 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D09YDM DRUGNAME Camptothecin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D09YDO DRUGNAME Quinotolast INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D09YDQ DRUGNAME STX-107 INDICATI Autism spectrum disorder [ICD-11: 6A02] Phase 2 TTDDRUID D09YEY DRUGNAME Botulinum toxin type F INDICATI Dystonia [ICD-11: 8A02] Approved TTDDRUID D09YGK DRUGNAME Ultragrivak INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D09YGZ DRUGNAME OCT-002 INDICATI Acute hyperammonaemia [ICD-11: 5C50.A] Phase 2 TTDDRUID D09YHI DRUGNAME SX5 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Investigative TTDDRUID D09YHJ DRUGNAME Ivermectin INDICATI Intestinal strongyloidiasis due to nematode parasite [ICD-11: 1F6B] Approved TTDDRUID D09YHL DRUGNAME MKG-02 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D09YJK DRUGNAME BMS-766 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D09YKI DRUGNAME Polyhydroxy benzamide derivative 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D09YNJ DRUGNAME IQP-0410 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D09YPJ DRUGNAME SM08502 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09YRA DRUGNAME SSTarbaclofen INDICATI Fragile X syndrome [ICD-11: LD55] Phase 2 INDICATI Autism spectrum disorder [ICD-11: 6A02] Phase 2 TTDDRUID D09YTH DRUGNAME CPU-228 INDICATI Cardiac failure [ICD-11: BD10-BD13] Investigative TTDDRUID D09YTY DRUGNAME Osutidine INDICATI Duodenal ulcer [ICD-11: DA63] Discontinued in Phase 3 TTDDRUID D09YUH DRUGNAME Anti-HIV peptides INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D09YUK DRUGNAME SS1(dsFv)-PE38 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D09YUQ DRUGNAME SR-11237 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D09YUS DRUGNAME KRG-3332 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Terminated TTDDRUID D09YVQ DRUGNAME Chondrogen INDICATI Arthritis [ICD-11: FA20] Phase 1/2 TTDDRUID D09YVX DRUGNAME Etofenamate INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D09YXN DRUGNAME CAR-T cells targeting Mesothelin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09YXS DRUGNAME GX-E2 INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D09YXT DRUGNAME LY3321367 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09YYQ DRUGNAME Aponidin INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D09ZAV DRUGNAME RG-8803 INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Terminated TTDDRUID D09ZBJ DRUGNAME RAGE-immunoglobulin fusion protein INDICATI Diabetic macular edema [ICD-11: 9B71.02] Investigative TTDDRUID D09ZCA DRUGNAME Biphenyl mannoside derivative 24 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D09ZCH DRUGNAME HRC-201 INDICATI Liver cancer [ICD-11: 2C12] Terminated TTDDRUID D09ZDY DRUGNAME CAR138 T Cells INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 1 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D09ZFF DRUGNAME HRC-101 INDICATI Blood transfusion [ICD-11: QB98] Terminated TTDDRUID D09ZFJ DRUGNAME AMG 529 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D09ZGK DRUGNAME BCMA-CART INDICATI Multiple myeloma [ICD-11: 2A83] Clinical trial TTDDRUID D09ZHZ DRUGNAME Mecobalamin INDICATI Anemia [ICD-11: 3A00-3A9Z] Approved TTDDRUID D09ZIO DRUGNAME Eptifibatide INDICATI Acute cardiac ischemic events [ICD-11: BA40.Z] Approved TTDDRUID D09ZIS DRUGNAME Zonisamide INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D09ZJQ DRUGNAME Seocalcitol INDICATI Rickets [ICD-11: 5B57] Phase 3 TTDDRUID D09ZKB DRUGNAME Ad35-GRIN/ENV INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D09ZKS DRUGNAME HP-228 INDICATI Postoperative pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D09ZKU DRUGNAME DISBA-01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09ZLZ DRUGNAME RAD-140 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D09ZMV DRUGNAME Votucalis INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D09ZNL DRUGNAME ChronSeal INDICATI Fibrosis [ICD-11: GA14-GC01] Phase 1/2 TTDDRUID D09ZNQ DRUGNAME Recombinant L-asparaginase INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Investigative TTDDRUID D09ZNS DRUGNAME Paramyxovirus therapy INDICATI Paramyxovirus infection [ICD-11: 1C8E.Y] Investigative TTDDRUID D09ZOQ DRUGNAME Incruse Ellipta INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D09ZPN DRUGNAME MK-6892 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D09ZPX DRUGNAME HSR-6071 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D09ZQN DRUGNAME Dienestrol INDICATI Atrophic vaginitis [ICD-11: GA30.2] Approved TTDDRUID D09ZQX DRUGNAME SL65.0155 INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2 TTDDRUID D09ZRB DRUGNAME PUR0200 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1 TTDDRUID D09ZSC DRUGNAME Everolimus INDICATI Advanced/metastatic breast cancer [ICD-11: 2C60] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D09ZSO DRUGNAME Alefacept INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D09ZSY DRUGNAME CI-1012 INDICATI Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 2 TTDDRUID D09ZUM DRUGNAME CR-4892 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D09ZVC DRUGNAME Begacestat INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D09ZVJ DRUGNAME R-954 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D09ZVR DRUGNAME MDL-43291 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D09ZWH DRUGNAME LX2931 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Hereditary acantholytic dermatoses [ICD-11: EC20.2] Phase 2 TTDDRUID D09ZWI DRUGNAME KUR-521 INDICATI Back pain [ICD-11: ME84.Z] Investigative TTDDRUID D09ZWU DRUGNAME PMID25666693-Compound-40 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammator